<SEC-DOCUMENT>0000950123-11-094900.txt : 20111103
<SEC-HEADER>0000950123-11-094900.hdr.sgml : 20111103
<ACCEPTANCE-DATETIME>20111103165825
ACCESSION NUMBER:		0000950123-11-094900
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20110930
FILED AS OF DATE:		20111103
DATE AS OF CHANGE:		20111103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50743
		FILM NUMBER:		111178362

	BUSINESS ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>b87804e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>e10vq</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 10-Q</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the quarterly period ended September&nbsp;30, 2011</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>OR</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Commission File Number 000-50743</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>ALNYLAM PHARMACEUTICALS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact Name of Registrant as Specified in Its Charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">77-0602661</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Incorporation or Organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">300 Third Street, Cambridge, MA
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">02142</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(617)&nbsp;551-8200<BR>
(Registrant&#146;s Telephone Number, Including Area Code)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed
by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or
for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to submit and post such files). Yes
<FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the
Exchange Act. (Check one):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Large accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Accelerated filer <FONT style="font-family: Wingdings">&#254;</FONT></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Non-accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">(do not check if smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of
the Exchange Act). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At October&nbsp;31, 2011, the registrant had 42,726,984 shares of Common Stock, $0.01 par value per
share, outstanding.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>









<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INDEX</B>
</DIV>


<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="B87804tocpage"></A>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>PAGE</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>NUMBER</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804101"><B>PART I. FINANCIAL INFORMATION</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><A href="#B87804102">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#B87804103">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF
SEPTEMBER 30, 2011 AND DECEMBER 31, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#B87804104">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS
ENDED SEPTEMBER 30, 2011 AND 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#B87804105">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2011 AND 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#B87804106">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804107">ITEM 2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804108">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804109">ITEM 4. CONTROLS AND PROCEDURES</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:0px; text-indent:-0px"><A href="#B87804110"><B>PART II. OTHER INFORMATION</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804111">ITEM 1. LEGAL PROCEEDINGS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804112">ITEM 1A. RISK FACTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804113">ITEM 6. EXHIBITS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#B87804114">SIGNATURES</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv10w1.htm">EX-10.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv12.htm">EX-12</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv31w1.htm">EX-31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv31w2.htm">EX-31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv32w1.htm">EX-32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="b87804exv32w2.htm">EX-32.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alny-20110930.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alny-20110930.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alny-20110930_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alny-20110930_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alny-20110930_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="B87804103"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ALNYLAM PHARMACEUTICALS, INC.</B>
</DIV>

<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In thousands, except share and per share amounts)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current assets:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">74,336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">74,599</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98,685</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">158,532</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration receivables</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,027</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,450</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Income taxes receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,669</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,909</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,889</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">179,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">254,139</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">113,218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">116,773</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,289</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investment in joint venture (Regulus Therapeutics Inc.)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,421</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,616</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">448</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">310,223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">393,265</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current liabilities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,486</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,312</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,116</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred rent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">484</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">484</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,727</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,134</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93,927</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">102,046</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred rent, net of current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,884</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,869</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred revenue, net of current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84,810</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">129,974</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">729</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">143</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">182,350</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">235,032</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies (Notes 4, 5 and 6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Stockholders&#146; equity:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Preferred stock, $0.01 par value, 5,000,000 shares
authorized and no shares issued and outstanding at
September&nbsp;30, 2011 and December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, $0.01 par value, 125,000,000 shares
authorized; 42,687,941 shares issued and outstanding
at September&nbsp;30, 2011; 42,343,423 shares issued and
outstanding at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">427</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">423</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">514,290</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">500,443</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated other comprehensive (loss)&nbsp;income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(151</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">714</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(386,693</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(343,347</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127,873</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">158,233</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">310,223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">393,265</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these condensed consolidated financial statements.
</DIV>
<!-- /xbrl,bs -->


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left">
<A name="B87804104"></A>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ALNYLAM PHARMACEUTICALS, INC.</B>
</DIV>

<!-- xbrl,op -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In thousands, except per share amounts)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>


    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net revenues from research collaborators</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,791</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">62,302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">78,849</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating expenses:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development<SUP style="FONT-size: 85%; vertical-align: text-top"> (1)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,274</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,468</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">80,304</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative <SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,955</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,928</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,205</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,229</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103,534</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">110,509</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,438</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,728</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(41,232</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(31,660</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Other income (expense):</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Equity in loss of joint venture (Regulus Therapeutics Inc.)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(467</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,226</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,551</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,723</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">265</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">602</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">969</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,833</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other (expense)&nbsp;income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(597</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(532</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(799</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(604</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,114</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,838</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,237</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,332</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(36,498</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Provision for income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(298</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(87</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(13,237</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,630</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,585</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per common share &#151; basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.31</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.23</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1.02</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.87</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average common shares used to compute basic and
diluted net loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,654</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,123</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,389</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41,989</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Comprehensive loss:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(13,237</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,630</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,585</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign currency translation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unrealized gain (loss)&nbsp;on marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(865</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Comprehensive loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(13,142</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,628</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(44,211</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,013</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</table>
</div>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 12pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1px">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">(1)&nbsp;Non-cash stock-based compensation expenses included in
operating expenses are as follows:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,789</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,725</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,284</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,200</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,469</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,786</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,706</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these condensed consolidated financial statements.
</DIV>
<!-- /xbrl,op -->


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left">
<A name="B87804105"></A>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ALNYLAM PHARMACEUTICALS, INC.</B>
</DIV>

<!-- xbrl,cf -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In thousands)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Nine Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from operating activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,585</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adjustments to reconcile net loss to net cash provided by
(used in) operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,888</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,650</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(133</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash stock-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,594</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,906</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Charge for 401(k) company stock match</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">402</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Equity in loss of joint venture (Regulus Therapeutics Inc.)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,551</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,723</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other than temporary impairment on equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Changes in operating assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration receivables</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,423</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,163</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Income taxes receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,980</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,281</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,826</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,928</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Income taxes payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,546</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,741</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">553</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(50,571</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(40,877</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(61,909</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(63,953</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from investing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(767</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,594</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(217,821</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(287,493</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Sales and maturities of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">279,763</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">261,346</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29,741</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from financing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from issuance of common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,143</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from issuance of shares to Novartis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">993</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,136</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Effect of exchange rate on cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net decrease in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(263</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(90,587</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Cash and cash equivalents, beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74,599</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">137,468</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Cash and cash equivalents, end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">74,336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these condensed consolidated financial statements.
</DIV>
<!-- /xbrl,cf -->



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl,ns -->

<DIV align="left">
<A name="B87804106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ALNYLAM PHARMACEUTICALS, INC.<BR>

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR>
(Unaudited)</B>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Basis of Presentation and Principles of Consolidation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc.
(the &#147;Company&#148; or &#147;Alnylam&#148;) are unaudited and have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#147;GAAP&#148;) applicable to interim
periods and, in the opinion of management, include all normal and recurring adjustments that are
necessary to state fairly the results of operations for the reported periods. The Company&#146;s
condensed consolidated financial statements have also been prepared on a basis substantially
consistent with, and should be read in conjunction with, the Company&#146;s audited consolidated
financial statements for the year ended December&nbsp;31, 2010, which were included in the Company&#146;s
Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
on February&nbsp;18, 2011. The year-end condensed balance sheet data was derived from audited financial
statements, but does not include all disclosures required by GAAP. The results of the Company&#146;s
operations for any interim period are not necessarily indicative of the results of the Company&#146;s
operations for any other interim period or for a full fiscal year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying condensed consolidated financial statements reflect the operations of the
Company and Alnylam U.S., Inc., Alnylam Europe AG (&#147;Alnylam Europe&#148;)
and Alnylam Securities Corporation, wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have
been eliminated. The Company uses the equity method of accounting to account for its investment in
Regulus Therapeutics Inc. (&#147;Regulus&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Use of Estimates</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Net Loss Per Common Share</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per common share is computed by dividing net loss attributable to common
stockholders by the weighted average number of common shares outstanding. Diluted net loss per
common share is computed by dividing net loss attributable to common stockholders by the weighted
average number of common shares and dilutive potential common share equivalents then outstanding.
Potential common shares consist of shares issuable upon the exercise of stock options (using the
treasury stock method) and unvested restricted stock awards. Because the inclusion of potential
common shares would be anti-dilutive for all periods presented, diluted net loss per common share
is the same as basic net loss per common share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth for the periods presented the potential common shares (prior to
consideration of the treasury stock method) excluded from the calculation of net loss per common
share because their inclusion would be anti-dilutive, in thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three and Nine Months  Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options to purchase common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,802</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,915</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unvested restricted common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">355</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,157</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,915</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Restricted Stock Awards</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of restricted stock awards granted to employees is based upon the quoted
closing market price per share on the date of grant, adjusted for assumed forfeitures. For
performance-based restricted stock awards, the value of the awards is measured when the Company
determines the achievement of such performance conditions is deemed probable. Expense is
recognized over the vesting period, commencing when the Company determines that it is probable that
the awards will vest. In May&nbsp;2011, the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">granted an aggregate of 229,806 shares of performance-based restricted stock awards to its
employees, excluding the Company&#146;s leadership team. These restricted stock awards were valued at
$2.3&nbsp;million on the grant date and have a term of five years. The vesting of these awards is
predicated on the Company&#146;s achievement of certain clinical development goals. For the three and
nine months ended September&nbsp;30, 2011, the Company recorded $0.4&nbsp;million and $0.7&nbsp;million,
respectively, of stock-based compensation expense related to these restricted stock awards.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Fair Value Measurements</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables present information about the Company&#146;s assets that are measured at fair
value on a recurring basis at September&nbsp;30, 2011 and December&nbsp;31, 2010, and indicate the fair value
hierarchy of the valuation techniques the Company utilized to determine such fair value. In
general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted)&nbsp;in active
markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data
points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair
values determined by Level 3 inputs utilize unobservable data points for the asset or liability,
and include situations where there is little, if any, market activity for the asset or liability.
Financial assets measured at fair value on a recurring basis are summarized as follows, in
thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>At</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Quoted Prices in</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Active Markets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Observable Inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unobservable Inputs</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 2)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 3)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">67,515</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">59,517</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities (fixed income)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Corporate notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">U.S. Government obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Commercial paper</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,197</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,197</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities (equity holdings)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">279,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">59,517</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">219,901</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>At</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Quoted Prices in</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><b>December 31, </b></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Active Markets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Observable Inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unobservable Inputs</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 2)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 3)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">59,702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,686</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">19,016</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities (fixed income)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Corporate notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">133,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">133,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">U.S. Government obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">122,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">122,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Commercial paper</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities (equity holdings)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,958</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,958</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">335,007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,686</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">294,321</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the nine months ended September&nbsp;30, 2011, there were no transfers between Level 1 and
Level 2 financial assets. The carrying amounts reflected in the Company&#146;s condensed consolidated
balance sheets for cash, collaboration receivables, other current assets, accounts payable and
accrued expenses approximate fair value due to their short-term maturities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Investments in Marketable Securities</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests its excess cash balances in short-term and long-term marketable debt and
equity securities. The Company classifies its investments in marketable debt securities as either
held-to-maturity or available-for-sale based on facts and circumstances present at the time it
purchased the securities. At each balance sheet date presented, the Company classified all of its
investments in debt and equity securities as available-for-sale. The Company reports
available-for-sale investments at fair value at each balance sheet date and includes any unrealized
holding gains and losses (the adjustment to fair value) in stockholders&#146; equity. Realized gains and
losses are determined using the specific identification method and are included in other income. If
any adjustment to fair value reflects a decline in the value of the investment, the Company
considers all available evidence to evaluate the extent to which the decline is &#147;other than
temporary&#148; and, if so, marks the investment to market through a charge to its condensed
consolidated statements of operations. The Company did not record any impairment charges related to
its fixed income marketable securities during the current period. During the three and nine months
ended September&nbsp;30, 2011, the Company recorded an impairment charge of $0.6&nbsp;million related to its
investment in equity securities of Tekmira Pharmaceuticals Corporation (&#147;Tekmira&#148;), as the
decrease in the fair
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">value of this investment was deemed to be other than temporary. The Company&#146;s marketable
securities are classified as cash equivalents if the original maturity, from the date of purchase,
is 90&nbsp;days or less, and as marketable securities if the original maturity, from the date of
purchase, is in excess of 90&nbsp;days. The Company&#146;s cash equivalents are composed of money market
funds, U.S. government obligations and commercial paper.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables summarize the Company&#146;s marketable securities at September&nbsp;30, 2011 and
December&nbsp;31, 2010, in thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Gains</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Losses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair Value</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commercial paper (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">21,198</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">21,197</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate notes (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52,183</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(26</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52,180</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate notes (Due after 1&nbsp;year through 2&nbsp;years)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,607</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(139</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,489</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,308</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due after 1&nbsp;year through 2&nbsp;years)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(37</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,979</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">212,054</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(205</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">211,903</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>December 31, 2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Gains</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Losses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair Value</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commercial paper (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">17,734</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">17,733</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate notes (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">116,385</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">204</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(23</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">116,566</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate notes (Due after 1&nbsp;year through 2&nbsp;years)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(25</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,775</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due within 1&nbsp;year)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,246</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,233</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due after 1&nbsp;year through 2&nbsp;years)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98,111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(93</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98,040</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,345</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,958</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">274,588</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(158</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">275,305</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Subsequent Events</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluated all events or transactions that occurred after September&nbsp;30, 2011
through the date these condensed consolidated financial statements were issued. During this period,
the Company did not have any material recognized or nonrecognized subsequent events.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Recent Accounting Pronouncements</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2011, the Company adopted new authoritative guidance on revenue recognition for
multiple element arrangements. The guidance, which applies to multiple element arrangements entered
into or materially modified on or after January&nbsp;1, 2011, amends the criteria for separating and
allocating consideration in a multiple element arrangement by modifying the fair value requirements
for revenue recognition and eliminating the use of the residual method. The fair value of
deliverables under the arrangement may be derived using a &#147;best estimate of selling price&#148; if
vendor specific objective evidence and third-party evidence is not available. Deliverables under
the arrangement will be separate units of accounting provided (i)&nbsp;a delivered item has value to the
customer on a standalone basis; and (ii)&nbsp;if the arrangement includes a general right of return
relative to the delivered item, delivery or performance of the undelivered item is considered
probable and substantially in the control of the vendor. The Company did not enter into any
significant multiple element arrangements or materially modify any existing multiple element
arrangements during the nine months ended September&nbsp;30, 2011. The Company&#146;s existing license and
collaboration agreements continue to be accounted for under previously issued revenue recognition
guidance for multiple element arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2011, the Company adopted new authoritative guidance on revenue recognition for
milestone payments related to arrangements under which the Company has continuing performance
obligations. Consideration for events that meet the definition of a milestone in accordance with
the accounting guidance for the milestone method of revenue recognition is recognized as revenue in
its entirety in the period in which the milestone is achieved only if all of the following
conditions are met: (i)&nbsp;the milestone is commensurate with either the Company&#146;s performance in
achieving the milestone or the enhancement of the value of the delivered item as a result of a
specific outcome resulting from the Company&#146;s performance in achieving the milestone; (ii)&nbsp;the
consideration relates solely to past performance; and (iii)&nbsp;the amount of the milestone
consideration is reasonable relative to all of the deliverables and payment terms, including other
potential milestone consideration, within the arrangement. Otherwise, the milestone payments are
not considered to be substantive and are deferred and recognized as revenue over the term
of the arrangement as the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">completes its performance obligations. The adoption of this guidance does not materially
change the Company&#146;s previous method of recognizing milestone payments. The Company will evaluate
all potential future milestones under existing arrangements with licensing partners, as specified
below, and any new arrangements with milestones, under the new revenue recognition guidance for
milestone payments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2011, the Financial Accounting Standards Board (&#147;FASB&#148;) issued a new accounting
standard that clarifies the application of certain existing fair value measurement guidance and
expands the disclosures for fair value measurements that are estimated using significant
unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and
interim reporting periods beginning on or after December&nbsp;15, 2011. The Company does not expect that
adoption of this new standard will have a material impact on its condensed consolidated financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2011, the FASB issued an amendment to the accounting guidance for presentation of
comprehensive income. Under the amended guidance, a company may present the total of comprehensive
income, the components of net income and the components of other comprehensive income either in a
single continuous statement of comprehensive income or in two separate but consecutive statements.
In either case, a company is required to present each component of net income along with total net
income, each component of other comprehensive income along with a total for other comprehensive
income and a total amount for comprehensive income.
For public companies, the amendment is effective for fiscal years, and interim periods within those
years, beginning after December&nbsp;15, 2011, and shall be applied retrospectively. Early adoption is
permitted. Other than a change in presentation, the adoption of this amendment is not expected to have
a material impact on the Company&#146;s condensed consolidated financial statements.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2. SIGNIFICANT AGREEMENTS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company&#146;s total consolidated net revenues from research
collaborators, for the periods indicated, in thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Roche</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">41,983</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">41,983</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Takeda</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,494</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,556</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,479</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Novartis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,984</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">133</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,957</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,133</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,431</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,430</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total net revenues from research collaborators</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,791</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">62,302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">78,849</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Platform Alliances</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Roche Alliance</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2007, the Company and, for limited purposes, Alnylam Europe, entered into a license
and collaboration agreement (the &#147;LCA&#148;) with F. Hoffmann-La Roche Ltd (&#147;Roche Basel&#148;) and
Hoffmann-La Roche Inc. (together with Roche Basel, &#147;Roche&#148;). Under the LCA, which became effective
in August&nbsp;2007, the Company granted Roche a non-exclusive license to the Company&#146;s intellectual
property, including delivery-related intellectual property existing as of the date of the LCA, to
develop and commercialize therapeutic products that function through RNA interference (&#147;RNAi&#148;),
subject to the Company&#146;s existing contractual obligations to third parties. The license is
initially limited to four therapeutic areas, and may be expanded to include up to 18 additional
therapeutic areas, comprising substantially all other fields of human disease, as identified and
agreed upon by the parties, upon payment to the Company by Roche of an additional $50.0&nbsp;million for
each additional therapeutic area, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration for the rights granted to Roche under the LCA, Roche paid the Company $273.5
million in upfront cash payments. In addition, in exchange for the Company&#146;s contributions under
the LCA, for each RNAi therapeutic product developed by Roche, its affiliates or sublicensees under
the LCA, the Company is entitled to receive milestone payments upon achievement of specified
development and sales events, totaling up to an aggregate of $100.0&nbsp;million per therapeutic target,
together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the
Company and Roche also established a discovery
collaboration in October&nbsp;2009 (&#147;Discovery Collaboration&#148;), subject to the Company&#146;s existing
contractual obligations to third parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2007, the Company executed a common stock purchase agreement (the &#147;Common Stock
Purchase Agreement&#148;) with Roche Finance Ltd, an affiliate of Roche. In connection with the
execution of the LCA and the Common Stock Purchase Agreement, the Company also executed a share
purchase agreement (the &#147;Alnylam Europe Purchase Agreement&#148;) with Alnylam Europe and Roche
Beteiligungs GmbH, an affiliate of Roche (&#147;Roche Germany&#148;). Under the terms of the Alnylam Europe
Purchase Agreement, the Company sold substantially all of the non-intellectual property assets of
Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In summary, the Company received upfront payments totaling $331.0&nbsp;million under the Roche
alliance, which include an upfront payment under the LCA of $273.5&nbsp;million, $42.5&nbsp;million under the
Common Stock Purchase Agreement and $15.0&nbsp;million under the Alnylam Europe Purchase Agreement. The
Company initially recorded $278.2&nbsp;million of these proceeds as deferred revenue in connection with
the Roche alliance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When evaluating multiple element arrangements, the Company considers whether the components of
the arrangement represent separate units of accounting. The accounting guidance specifically
requires that the delivered components must have value to the customer on a standalone basis and
that there is objective and reliable evidence of the fair value of the undelivered components.
Application of this standard requires subjective determinations and requires management to make
judgments about the value of each individual element and whether it is separable from the other
aspects of the contractual relationship. The Company has determined that the deliverables under
its agreements with Roche include the license, the Alnylam Europe assets and employees, the
steering committees (joint steering committee and future technology committee) and the services
under the Discovery Collaboration. The Company has determined that, pursuant to the accounting
guidance governing revenue recognition on multiple element arrangements, the license and assets of
Alnylam Europe are not separable from the undelivered services (i.e., the steering committees and
Discovery Collaboration) and, accordingly the license and the services are being treated as a
single unit of accounting. When multiple deliverables are accounted for as a single unit of
accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
Roche alliance, the steering committee services and the Discovery Collaboration services are the
final deliverables and all such services will end, contractually, five years from the effective
date of the LCA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is recognizing the Roche-related revenue on a straight-line basis over five years
because the Company cannot reasonably estimate the total level of effort required to complete its
service obligations under the LCA, and therefore, cannot utilize a proportional performance model.
As future substantive milestones are achieved, the Company will recognize as revenue a portion of
the milestone payment, equal to the percentage of the performance period completed when the
milestone is achieved, multiplied by the amount of the milestone payment. The Company will
recognize the remaining portion of the milestone over the remaining performance period on a
straight-line basis. The Company will continue to recognize the Roche-related revenue on a
straight-line basis over five years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November&nbsp;2010, Roche announced the discontinuation of certain activities in research and
early development, including its RNAi research efforts. The remaining deliverables under the LCA
currently remain in effect. In October&nbsp;2011, Arrowhead Research Corporation (&#147;Arrowhead&#148;) announced
its acquisition of RNA therapeutics assets from Roche, including the LCA. In the event Arrowhead terminates
the LCA or the Company and Arrowhead mutually agree to modify the LCA, the Company
will reassess its deliverables and the period over which it will complete its performance
obligations under the LCA. At September&nbsp;30, 2011, deferred revenue under the LCA was $51.3&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><I>Takeda Alliance</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2008, the Company entered into a license and collaboration agreement (the &#147;Takeda
Collaboration Agreement&#148;) with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) to pursue the
development and commercialization of RNAi therapeutics. Under the Takeda Collaboration Agreement,
the Company granted Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&#146;s
intellectual property, including delivery-related intellectual property, controlled by the Company
as of the date of the agreement or during the five years thereafter, to develop, manufacture, use
and commercialize RNAi therapeutics, subject to the Company&#146;s existing contractual obligations to
third parties. The license initially is limited to the fields of oncology and metabolic disease and
may be expanded at Takeda&#146;s option to include other therapeutic areas, subject to specified
conditions. Under the Takeda Collaboration Agreement, Takeda is the Company&#146;s exclusive platform
partner in the Asian territory, as defined in the Takeda Collaboration Agreement, through May&nbsp;2013.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration for the rights granted to Takeda under the Takeda Collaboration Agreement,
Takeda agreed to pay the
Company $150.0&nbsp;million in upfront and near-term technology transfer payments. In addition, the
Company has the option, exercisable until the start of Phase III development, to opt-in under a
50-50 profit sharing agreement to the development and commercialization in the United States of up
to four Takeda licensed products and would be entitled to opt-in rights for two additional products
for each additional field expansion, if any, elected by Takeda under the Takeda Collaboration
Agreement. In June&nbsp;2008, Takeda paid the Company an upfront payment of $100.0&nbsp;million and agreed to
pay an additional $50.0&nbsp;million to the Company upon achievement of specified technology transfer
milestones. Of this $50.0&nbsp;million, $20.0&nbsp;million was paid to the Company in October&nbsp;2008, $20.0
million was paid to the Company in March&nbsp;2010 and $10.0&nbsp;million was paid to the Company in March
2011 (collectively, &#147;Technology Transfer Milestones&#148;). If Takeda elects to expand its license to
additional therapeutic areas, Takeda will be required to pay the Company $50.0&nbsp;million for each of
up to approximately 20 total additional fields selected, if any, comprising substantially all other
fields of human disease, as identified and agreed upon by the parties. In addition, for each RNAi
therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled
to receive specified development and commercialization milestones, totaling up to $171.0&nbsp;million
per product, together with royalty payments based on worldwide annual net sales, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Takeda Collaboration Agreement, the Company and Takeda are also collaborating
on the research of RNAi therapeutics directed to one or two disease targets agreed to by the
parties (the &#147;Research Collaboration&#148;), subject to the Company&#146;s existing contractual obligations
with third parties. Takeda also has the option, subject to certain conditions, to collaborate with
the Company on the research and development of RNAi drug delivery technology for targets agreed to
by the parties. In addition, Takeda has a right of first negotiation for the development and
commercialization of the Company&#146;s RNAi therapeutic products in the Asian territory, excluding the
Company&#146;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a
similar right of first negotiation to participate with Takeda in the development and
commercialization in the United States of licensed products. The collaboration is governed by a
joint technology transfer committee (the &#147;JTTC&#148;), a joint research collaboration committee (the
&#147;JRCC&#148;) and a joint delivery collaboration committee (the &#147;JDCC&#148;), each of which is comprised of an
equal number of representatives from each party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has determined that the deliverables under the Takeda Collaboration Agreement
include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer
activities and the services that the Company will be obligated to perform under the Research
Collaboration. The Company has determined that, pursuant to the accounting guidance governing
revenue recognition on multiple element arrangements, the license and undelivered services (i.e.,
the joint committees and the Research Collaboration) are not separable and, accordingly, the
license and services are being treated as a single unit of accounting. When multiple deliverables
are accounted for as a single unit of accounting, the Company bases its revenue recognition pattern
on the final deliverable. Under the Takeda Collaboration Agreement, the last elements to be
delivered are the JDCC and JTTC services, each of which has a life of no more than seven years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is recognizing the upfront payment of $100.0&nbsp;million and the Technology Transfer
Milestones of $50.0&nbsp;million, the receipt of which the Company believed was probable at the
commencement of the collaboration, on a straight-line basis over seven years because the Company is
unable to reasonably estimate the level of effort to fulfill these obligations, primarily because
the effort required under the Research Collaboration is largely unknown, and therefore, cannot
utilize the proportional performance model. As future substantive milestones are achieved, the
Company will recognize as revenue a portion of the milestone payment equal to the percentage of the
performance period completed when the milestone is achieved, multiplied by the amount of the
milestone payment. The Company will recognize the remaining portion of the milestone over the
remaining performance period on a straight-line basis. At September&nbsp;30, 2011, deferred revenue
under the Takeda Collaboration Agreement was $80.3&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Discovery and Development Alliances</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><I>Novartis Broad Alliance</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the second half of 2005, the Company entered into a series of transactions with Novartis
Pharma AG and its affiliate, Novartis Institutes for BioMedical Research, Inc. (together,
&#147;Novartis&#148;), which included a stock purchase agreement, an investor rights agreement (the &#147;Investor
Rights Agreement&#148;), and a research collaboration and license agreement (the &#147;Collaboration and
License Agreement&#148;). The Collaboration and License Agreement had an initial research term of three
years, with an option for two additional one-year extensions at the election of Novartis. Novartis
elected to extend the term through October&nbsp;2010, the fifth and final planned year. In October&nbsp;2010,
the research program under the Collaboration and License Agreement was substantially completed in
accordance with the terms of the Collaboration and License Agreement, subject to certain surviving
rights and obligations of the parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Investor Rights Agreement provides Novartis with the right generally to maintain its
ownership percentage in the
Company until the earlier of any sale by Novartis of shares of the Company&#146;s common stock and
the expiration or termination of the Collaboration and License Agreement, subject to certain
exceptions. At September&nbsp;30, 2011, Novartis owned 13.1% of the Company&#146;s outstanding common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration for the rights granted to Novartis under the Collaboration and License
Agreement, Novartis made an upfront payment of $10.0&nbsp;million to the Company in October&nbsp;2005, partly
to reimburse prior costs incurred by the Company to develop <I>in vivo </I>RNAi technology. The Company
also received research funding and development milestone payments from Novartis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2010, Novartis exercised its right under the Collaboration and License Agreement
to select 31 designated gene targets, for which Novartis has exclusive rights to discover, develop
and commercialize RNAi therapeutic products using the Company&#146;s intellectual property and
technology, including delivery-related intellectual property and related technology. Under the
terms of the Collaboration and License Agreement, for any RNAi therapeutic products Novartis
develops against these targets, the Company is entitled to receive milestone payments upon
achievement of certain specified development and annual net sales events, up to an aggregate of
$75.0&nbsp;million per therapeutic product, as well as royalties on annual net sales of any such
product. Novartis&#146; right of first offer with respect to an exclusive license for additional
targets has terminated. In September&nbsp;2010, Novartis declined to exercise its non-exclusive option
to integrate into its operations the Company&#146;s fundamental and chemistry intellectual property
under the terms of the Collaboration and License Agreement. If Novartis had elected to exercise the
integration option, Novartis would have been required to make additional payments to the Company
totaling $100.0&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company believes the estimated period of performance under the Collaboration and License
Agreement is ten years, which includes the three-year initial term of the agreement, two one-year
extensions elected by Novartis and limited support as part of a technology transfer until 2015, the
fifth anniversary of the completion of the research term under the Collaboration and License
Agreement. The Company continues to use an expected term of ten years in its proportional
performance model. The Company reevaluates the expected term when new information is known that
could affect the Company&#146;s estimate. In the event the Company&#146;s period of performance is different
than estimated, the Company will adjust the amount of revenue recognized on a prospective basis. At
September&nbsp;30, 2011, deferred revenue under the Novartis Collaboration and License Agreement was
$0.2&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Product Alliances</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><I>Kyowa Hakko Kirin Alliance</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2008, the Company entered into a license and collaboration agreement (the &#147;Kyowa Hakko
Kirin Agreement&#148;) with Kyowa Hakko Kirin Co., Ltd. (&#147;Kyowa Hakko Kirin&#148;). Under the Kyowa Hakko
Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to its intellectual
property in Japan and other markets in Asia (the &#147;Licensed Territory&#148;) for the development and
commercialization of an RNAi therapeutic for the treatment of respiratory syncytial virus (&#147;RSV&#148;)
infection. The Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific
RNAi therapeutic compounds that comprise the ALN-RSV program (&#147;Additional Compounds&#148;). The Company
retains all development and commercialization rights worldwide outside of the Licensed Territory,
subject to its agreement with Cubist Pharmaceuticals, Inc. (&#147;Cubist&#148;) described below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Kyowa Hakko Kirin Agreement, in June&nbsp;2008, Kyowa Hakko Kirin paid the
Company an upfront cash payment of $15.0&nbsp;million. In addition, Kyowa Hakko Kirin is required to
make payments to the Company upon achievement of specified development and sales milestones
totaling up to $78.0&nbsp;million, and royalty payments based on annual net sales, if any, of RNAi
therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its affiliates and sublicensees in the
Licensed Territory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The collaboration between Kyowa Hakko Kirin and the Company is governed by a joint steering
committee that is comprised of an equal number of representatives from each party. Under the
agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to
the development activities to be undertaken in the Licensed Territory, with the initial focus on
Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the
development plan that are reasonably necessary for the regulatory approval and commercialization of
an RNAi therapeutic for the treatment of RSV in Japan and the rest of the Licensed Territory. The
Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement
unless Kyowa Hakko Kirin elects, prior to the first commercial sale of the product in the Licensed
Territory, to manufacture the product itself or arrange for a third party to manufacture the
product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has determined that the deliverables under the Kyowa Hakko Kirin Agreement include
the license, the joint steering committee, the manufacturing services and any Additional Compounds.
The Company has determined that, pursuant to the accounting guidance governing revenue recognition
on multiple element arrangements, the individual deliverables are not separable and, accordingly,
must be accounted for as a single unit of accounting. When multiple deliverables are accounted for
as a single unit
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of accounting, the Company bases its revenue recognition pattern on the final deliverable.
The Company is currently unable to reasonably estimate its period of performance under the Kyowa
Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the
fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The Company is
deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate
its period of performance. The Company will continue to reassess whether it can reasonably estimate
the period of performance to fulfill its obligations under the Kyowa Hakko Kirin Agreement. At
September&nbsp;30, 2011, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&nbsp;million.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><I>Cubist Alliance</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2009, the Company entered into a license and collaboration agreement with Cubist
(the &#147;Cubist Agreement&#148;) to develop and commercialize therapeutic products (&#147;Licensed Products&#148;)
based on certain of the Company&#146;s RNAi technology for the treatment of RSV infection. Licensed
Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV
inhibitors. In November&nbsp;2009, the Company and Cubist entered into an amendment to the Cubist
Agreement (the &#147;Amendment&#148;), which provides that the Company and Cubist would focus their
collaboration and joint development efforts on ALN-RSV02, a second-generation compound, intended
for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and
Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant
to the terms of the Amendment, the Company is continuing to develop ALN-RSV01 for adult transplant
patients at its sole discretion and expense. Cubist has the right to opt into collaborating with
the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time
following the completion of the Company&#146;s Phase IIb trial of ALN-RSV01, subject to the payment by
Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the
Company&#146;s development expenses for ALN-RSV01. In December&nbsp;2010, the Company and Cubist jointly made
a portfolio decision to put the development of ALN-RSV02 on hold.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration for the rights granted to Cubist under the Cubist Agreement, in January&nbsp;2009,
Cubist paid the Company an upfront cash payment of $20.0&nbsp;million. Cubist is also obligated under
the Cubist Agreement to pay the Company milestone payments, totaling up to an aggregate of $82.5
million, and has the right to convert the North American co-development and profit sharing
arrangement into a royalty-bearing license.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has determined that the deliverables under the Cubist Agreement include the
licenses, technology transfer related to the ALN-RSV program, the joint steering committee and the
development and manufacturing services that the Company is obligated to perform during the
development period. The Company also has determined that, pursuant to the accounting guidance
governing revenue recognition on multiple element arrangements, the licenses and undelivered
services are not separable and, accordingly, the licenses and services are being treated as a
single unit of accounting. When multiple deliverables are accounted for as a single unit of
accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
Cubist Agreement, the last element to be delivered is the development and manufacturing services,
which have an expected life of approximately eight years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is recognizing the upfront payment of $20.0&nbsp;million on a straight-line basis over
approximately eight years because the Company is unable to reasonably estimate the level of effort
to fulfill its performance obligations, and therefore, cannot utilize a proportional performance
model. As future substantive milestones are achieved, the Company will recognize as revenue a
portion of the milestone payment, equal to the percentage of the performance period completed when
the milestone is achieved, multiplied by the amount of the milestone payment. The Company will
recognize the remaining portion of the milestone over the remaining performance period on a
straight-line basis. At September&nbsp;30, 2011, deferred revenue under the Cubist Agreement was $13.2
million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for
developing Licensed Products in North America, and each bears one-half of the related development
costs, provided that under the terms of the Amendment, the Company is funding the advancement of
ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue
generating arrangements that involve cost sharing between the parties, the Company presents the
results of activities for which it acts as the principal on a gross basis and reports any payments
received from, or made to, other collaborators based on other applicable GAAP or, in the absence of
other applicable GAAP, analogy to authoritative accounting literature or a reasonable, rational and
consistently applied accounting policy election. As the Company is not considered the principal
under the Cubist Agreement, the Company records any amounts due from Cubist as a reduction of
research and development expense.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. INCOME TAXES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company expects to generate U.S. taxable losses during 2011 and has recorded no income tax
provision for the three or nine months ended September&nbsp;30, 2011. During the three and nine months
ended September&nbsp;30, 2010, the Company recorded a provision for income taxes of $0.3&nbsp;million and
$0.1&nbsp;million, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2009 and 2008, the Company utilized certain tax attributes, including net operating
loss and tax credit carryforwards as a result of the recognition of revenue for certain proceeds
received from strategic alliances. However, the Company also generated a deferred tax asset related
to the recognition of this revenue for tax purposes and recorded a net deferred tax asset to the
extent it was more likely than not that the asset would be realized. During 2010, the Company
generated sufficient net operating losses to carry back to 2009 and 2008 to obtain a refund of
taxes paid in those years, resulting in a realization of its net deferred tax asset. As a result,
during 2010, the Company reclassified $10.7&nbsp;million of its deferred tax asset to income taxes
receivable. The Company received this income tax refund during the three months ended March&nbsp;31,
2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2010, the Company had federal and state net operating loss carryforwards of
$27.5&nbsp;million and $101.6&nbsp;million, respectively, to reduce future taxable income that will expire at
various dates through 2030. Ownership changes, as defined in the Internal Revenue Code, including
those resulting from the issuance of common stock in connection with the Company&#146;s public
offerings, may limit the amount of net operating loss that can be utilized to offset future taxable
income or tax liability. The Company has determined that there is no limitation on the utilization
of net operating loss carryforwards in accordance with Section&nbsp;382 of the Internal Revenue Code.
In July&nbsp;2011, the Internal Revenue Service completed its audits of the Company&#146;s 2008 and 2009 tax
years. The Company did not record any tax expense related to these audits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company continues to recognize fully its tax benefits which are offset by a valuation
allowance to the extent that it is more likely than not that the deferred tax assets will not be
realized. At September&nbsp;30, 2011, the Company had $0.1&nbsp;million of total gross unrecognized tax
benefits that, if recognized, would favorably impact the Company&#146;s effective income tax rate in
future periods.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4. REGULUS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2007, the Company and Isis Pharmaceuticals, Inc. (&#147;Isis&#148;) established Regulus, a
company focused on the discovery, development and commercialization of microRNA therapeutics, a
potential new class of drugs to treat the pathways of human disease. Regulus, which initially was
established as a limited liability company, converted to a C corporation in January&nbsp;2009 and
changed its name to Regulus Therapeutics Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration for the Company&#146;s and Isis&#146; initial interests in Regulus, each party granted
Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic
applications as well as certain patents in the microRNA field. In addition, the Company made an
initial cash contribution to Regulus of $10.0&nbsp;million, resulting in the Company and Isis making
approximately equal aggregate initial capital contributions to Regulus. In March&nbsp;2009, the Company
and Isis each purchased $10.0&nbsp;million of Series&nbsp;A preferred stock of Regulus. In October&nbsp;2010, in
connection with its strategic alliance with Regulus formed in June&nbsp;2010, Sanofi made a $10.0
million equity investment in Regulus. As a result of this investment, the Company recognized a gain
of $4.4&nbsp;million due to the increase in valuation of Regulus. This amount was recorded as other
income in the Company&#146;s consolidated statements of operations for the year ended December&nbsp;31, 2010.
At September&nbsp;30, 2011, the Company, Isis and Sanofi owned approximately 45%, 46% and 9%,
respectively, of Regulus. Regulus continues to operate as an independent company with a separate
board of directors, scientific advisory board and management team, some of whom have options to
purchase common stock of Regulus. Members of the board of directors of Regulus who are the
Company&#146;s employees or Isis&#146; employees are not eligible to receive options to purchase Regulus
common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has reviewed the consolidation guidance that defines a variable interest entity
(&#147;VIE&#148;) and concluded that Regulus currently qualifies as a VIE. The Company does not consolidate
Regulus as the Company lacks the power to direct the activities that could significantly impact the
economic success of this entity. At September&nbsp;30, 2011, the total carrying value of the Company&#146;s
investment in Regulus in its condensed consolidated balance
sheets was $1.4&nbsp;million under the equity method. The Company&#146;s maximum exposure to loss related to
this VIE is limited to the carrying value of the Company&#146;s investment, as well the portion of
Regulus&#146; debt, including accrued interest, guaranteed by the Company which was $5.4&nbsp;million at
September&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for its investment in Regulus using the equity method of accounting.
Summary results of Regulus&#146; operations for the three and nine months ended September&nbsp;30, 2011 and
2010 and balance sheets at September&nbsp;30, 2011 and December&nbsp;31, 2010 are presented in the tables
below, in thousands (unaudited):
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Statement of Operations Data:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,426</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,804</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,783</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,743</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,688</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,182</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(974</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,434</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,262</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,378</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(67</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(48</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(322</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(132</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,041</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,482</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(5,584</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(13,510</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>December 31, 2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balance Sheet Data:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash, cash equivalents and marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">44,088</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">54,789</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Working capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,587</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,446</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48,810</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59,703</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Notes payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,270</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,964</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,996</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. COMMITMENTS AND CONTINGENCIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Litigation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><I>Tekmira Litigation</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;16, 2011, Tekmira and Protiva Biotherapeutics, Inc. filed a civil complaint against
the Company in the Business Litigation Section of the Suffolk County Superior Court, in Boston,
Massachusetts and on June&nbsp;3, 2011, the plaintiffs filed an amended complaint adding AlCana
Technologies, Inc. (&#147;AlCana&#148;), a research collaborator of the Company, as a defendant. The amended
complaint alleges misappropriation of the plaintiffs&#146; confidential and proprietary information and
trade secrets, civil conspiracy, and tortious interference with contractual relationships by the
Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of
good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive acts
and practices by the Company. The plaintiffs seek, among other relief, injunctive relief,
unspecified damages and the termination of licenses that the plaintiffs provided to the Company.
On April&nbsp;6, 2011, the Company timely served and filed an answer to the plaintiffs&#146; original
complaint denying the plaintiffs&#146; claims, together with counterclaims against the plaintiffs. On
June&nbsp;28, 2011, the Company timely served and filed an answer to the plaintiffs&#146; amended complaint
denying the plaintiffs&#146; claims and counterclaims against the plaintiffs asserting breach of
contract, defamation, breach of covenant not to sue, breach of patent prosecution and non-use
provisions, misappropriation of confidential and proprietary information and trade secrets, unjust
enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of
Massachusetts statutes. The Company is seeking damages and equitable relief on its counterclaims.
In September&nbsp;2011, the Court granted the plaintiffs&#146; motion to dismiss the Company&#146;s
counterclaim for defamation. The Company has a number of additional
counterclaims remaining against the plaintiffs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><I>University of Utah Litigation</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;22, 2011, The University of Utah (the &#147;University&#148;) filed a civil complaint in the
United States District Court for the District of Massachusetts against the Company, Max Planck
Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH (together, &#147;Max
Planck&#148;), the Whitehead Institute for Biomedical Research (&#147;Whitehead&#148;), the Massachusetts
Institute of Technology (&#147;MIT&#148;) and the University of Massachusetts (&#147;UMass&#148;), claiming a professor
at the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl
patents. The University did not serve the original complaint on the Company or the other
defendants. On July&nbsp;6, 2011, the University filed an amended complaint alleging substantially the
same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was
served on the Company on July&nbsp;14, 2011. The University is seeking changes to the inventorship of
the Tuschl patents, unspecified damages and other relief. On October&nbsp;31, 2011, the Company, Max
Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on
October&nbsp;31, 2011, UMass filed a motion to dismiss on separate
grounds, which the Company, Max Planck, Whitehead
and MIT have joined.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although the Company believes that it has meritorious defenses to each of the claims in the
lawsuits described above and intends to fully defend itself in these matters, litigation is subject
to inherent uncertainty and a court could ultimately rule against the Company in one or both of
these matters. In addition, the defense of litigation and related matters are costly and may divert
the attention of the Company&#146;s management and other resources that would otherwise be engaged in
running the Company&#146;s business. The Company has not recorded an estimate of the possible loss
associated with the legal proceedings described above due in each case to the uncertainties related
to both the likelihood and the amount of any possible loss or range of loss.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><I>Tuschl Settlement</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March&nbsp;2011, the Company, Max Planck, Whitehead and UMass entered into a global settlement
agreement (the &#147;Settlement Agreement&#148;) resolving their ongoing litigation regarding the Tuschl
patents. MIT, formerly a party to the litigation, also agreed to the terms of the Settlement
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The litigation was initiated in June&nbsp;2009 and scheduled for trial in March&nbsp;2011 in the United
States District Court for the District of Massachusetts, and related to, among other things, the
prosecution of the Tuschl I and Tuschl II patent applications. In the field of RNAi therapeutics,
the Company is the exclusive licensee of the Tuschl I patent applications from Max Planck, MIT and
Whitehead, and of the Tuschl II patent applications from Max Planck. The terms of the Settlement
Agreement included mutual releases and dismissal with prejudice of all claims and counterclaims in
the litigation between the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the Settlement Agreement, Max Planck, Whitehead, UMass and MIT agreed that future
prosecution of the Tuschl I and Tuschl II patent families in the United States should be
coordinated and led by a single party. Max Planck will assume that role, in addition to their
ongoing leadership in the continued prosecution of the Tuschl II patent family outside the United
States. UMass will lead future prosecution of the Tuschl I patent family outside the United
States. In addition, under the terms of the Settlement Agreement, the Company granted UMass the
right to sublicense the U.S. Tuschl II patent family to Merck &#038; Co., Inc., subject to certain
third-party obligations of the Company and other limitations, in exchange for a share of certain
future sublicense income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company incurred costs of $3.3&nbsp;million and $3.8&nbsp;million during the three months ended
March&nbsp;31, 2011 and 2010, respectively, in connection with this dispute. These costs were charged
to general and administrative expense. The Company does not expect to incur any additional
significant expenses related to this dispute.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6. RESTRUCTURING</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2010, as a result of the planned completion of the fifth and final year of the
research program under the Novartis Collaboration and License Agreement and the Company&#146;s reduced
need for service-based collaboration resources, the Company&#146;s Board of Directors approved and the
Company effected a corporate restructuring to focus the Company&#146;s resources on its most promising
programs and significantly reduce its cost structure. The corporate restructuring included a
reduction of the Company&#146;s overall workforce by approximately 25%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2010, the Company recorded $2.2&nbsp;million of
restructuring-related costs in operating expenses, including employee severance, benefits and
related costs. During the nine months ended September&nbsp;30, 2011, the Company did not record any
additional restructuring related costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the components of the Company&#146;s restructuring expenses recorded
in operating expenses and in current liabilities, in thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Original</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(Reversals) or</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amounts</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amounts</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Charges and Amounts</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Adjustments to</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Paid Through</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Accrued at</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Accrued</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Charges</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Employee severance, benefits and related costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,193</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(20</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,173</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,193</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(20</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,173</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the components of the Company&#146;s restructuring activities
for the nine months ended September&nbsp;30, 2011, in thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amounts </B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(Reversals) or</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amounts</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amounts</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Accrued at </B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Adjustments to</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Paid Through</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Accrued at</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>December 31, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Charges</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Employee severance, benefits and related costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- /xbrl,ns -->


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="B87804107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>This Quarterly Report on </I><I>Form 10-Q</I><I> contains forward-looking statements that involve risks and
uncertainties. The statements contained in this Quarterly Report on </I><I>Form 10-Q</I><I> that are not purely
historical are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act
of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Without limiting the foregoing, the
words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target,&#148; &#147;goal&#148; and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements
contain these words. All forward-looking statements included in this Quarterly Report on Form&nbsp;10-Q
are based on information available to us up to, and including, the date of this document, and we
assume no obligation to update any such forward-looking statements to reflect events or
circumstances that arise after the date hereof. Our actual results could differ materially from
those anticipated in these forward-looking statements as a result of certain important factors,
including those set forth below under this Item&nbsp;2 &#151; &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations,&#148; Part&nbsp;II, Item&nbsp;1A &#151; &#147;Risk Factors&#148; and elsewhere in
this Quarterly Report on </I><I>Form 10-Q</I><I>. You should carefully review those factors and also carefully
review the risks outlined in other documents that we file from time to time with the Securities and
Exchange Commission, or SEC.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company developing novel therapeutics based on RNA interference, or
RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and
regulating the expression of specific genes. Since many diseases are caused by the inappropriate
activity of specific genes, the ability to silence genes selectively through RNAi could provide a
new way to treat a wide range of human diseases. We believe that drugs that work through RNAi have
the potential to become a broad new class of drugs, like small molecule, protein and antibody
drugs. Using our intellectual property and the expertise we have built in RNAi, we are developing a
set of biological and chemical methods and know-how that we apply in a systematic way to develop
RNAi therapeutics for the treatment of a variety of diseases.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our core product strategy, which we refer to as &#147;Alnylam 5x15,&#148; is focused on the development
and commercialization of innovative RNAi therapeutics for the treatment of genetically defined
diseases. Under our core product strategy, we expect to progress five RNAi therapeutic programs
into advanced stages of clinical development by the end of 2015. As part of this strategy, our goal
is to develop product candidates with the following shared characteristics: a genetically defined
target and disease; the potential to have a significant impact in high unmet need patient
populations; the ability to leverage our existing RNAi delivery platform; the opportunity to
monitor an early biomarker in Phase I clinical trials for human proof of concept; and the existence
of clinically relevant endpoints for the filing of a new drug application, or NDA, with a focused
patient database and possible accelerated paths for commercialization. We intend to focus on
developing and commercializing certain products arising from this core product strategy on our own
in the United States and potentially certain other countries. We intend to enter into alliances to
develop and commercialize other core products both in the United States and in other global
territories. We currently have four core programs in clinical or pre-clinical development: ALN-TTR
for the treatment of transthyretin-mediated amyloidosis, or ATTR; ALN-PCS for the treatment of
severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia; and ALN-APC for the
treatment of hemophilia. As part of our core product strategy, at or around the end of 2011, we
expect to designate one additional RNAi therapeutic candidate targeting a genetically defined
disease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While focusing our efforts on our core product strategy, we also intend to continue to advance
additional development programs through existing or future alliances. We have three partner-based
programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of
respiratory syncytial virus, or RSV, infection, ALN-VSP for the treatment of liver cancers and
ALN-HTT for the treatment of Huntington&#146;s disease, or HD.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our most advanced core product development program, ALN-TTR, targets the transthyretin, or
TTR, gene, for the treatment of ATTR, a hereditary, systemic disease associated with severe
morbidity and mortality caused by a mutation in the TTR gene that leads to the extracellular
deposition of amyloid fibrils. In July&nbsp;2010, we initiated a Phase I clinical trial for ALN-TTR01, a
systemically delivered RNAi therapeutic. ALN-TTR01 employs a first-generation lipid nanoparticle,
or LNP, formulation. The Phase I clinical trial for ALN-TTR01 is being conducted in Portugal,
Sweden, the United Kingdom and France, and is a randomized, blinded, placebo-controlled dose
escalation study. As a result of favorable safety data to date, we received regulatory approval to
extend this Phase I clinical trial with additional dose cohorts up to 1.0 mg/kg, increasing
enrollment from 28 to up to 36 patients. The primary objective is to evaluate the safety and
tolerability of a single dose of intravenous ALN-TTR01. Secondary objectives include
characterization of plasma and urine pharmacokinetics of ALN-TTR01 and assessment of
pharmacodynamic activity based on
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">measurements of circulating TTR serum levels. In January&nbsp;2011, The Committee for Orphan
Medicinal Products of the European Medicines Agency adopted a positive opinion for ALN-TTR01
designation as an orphan medicinal product for the treatment of familial amyloidotic
polyneuropathy, one of the predominant forms of ATTR. In April&nbsp;2011, the European Commission
officially designated ALN-TTR01 as an orphan drug. In parallel with the development of ALN-TTR01,
we are also advancing ALN-TTR02 utilizing a proprietary second-generation LNP formulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our second core product development program is ALN-PCS. ALN-PCS employs a proprietary
second-generation LNP formulation, specifically using the MC3 lipid. We are developing ALN-PCS, a
systemically delivered RNAi therapeutic, for the treatment of severe hypercholesterolemia. ALN-PCS
targets a gene called proprotein convertase subtilisin/kexin type 9, or PCSK9, which is involved in
the regulation of LDL receptor levels on hepatocytes and the metabolism of LDL cholesterol, or
LDL-c, which is also commonly referred to as &#147;bad cholesterol.&#148; In September&nbsp;2011, we initiated a
Phase I clinical trial for ALN-PCS in the United Kingdom. The Phase I clinical trial is a
randomized, single-blind, placebo-controlled, single-ascending dose study, intended to enroll
approximately 32 healthy volunteer subjects with elevated baseline LDLc. The primary objective of
the clinical trial is to evaluate the safety and tolerability of a single dose of ALN-PCS, with
patients being enrolled into five sequential cohorts of increasing doses ranging from 0.015 to 0.25
mg/kg. Secondary objectives include characterization of plasma and urine pharmacokinetics of
ALN-PCS, and assessment of pharmacodynamic effects of the drug on plasma PCSK9 protein and LDLc
levels measured from serial blood samples prior to and following dosing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designated ALN-HPN as our third core product development program. ALN-HPN is a
systemically delivered RNAi therapeutic targeting the hepcidin pathway, a genetically validated
gene pathway in iron homeostasis, for the treatment of refractory anemia. Anemia of chronic
disease, or ACD, occurs in patients with end-stage renal disease, cancer and chronic inflammatory
disease. ACD patients who are refractory to erythropoiesis-stimulating agents and intravenous iron
define a condition of refractory anemia for which there is substantial unmet need. Pre-clinical
studies with a small interfering RNA, or siRNA, targeting hepcidin demonstrated the ability to
silence the gene and increase serum iron levels. ALN-HPN also employs a second-generation LNP
formulation. We are currently conducting additional pre-clinical studies of ALN-HPN.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designated ALN-APC as our fourth core product development program. ALN-APC is a
systemically delivered RNAi therapeutic targeting protein C, a genetically defined target, for the
treatment of hemophilia. Protein C is expressed exclusively in the liver, circulates in plasma and
defines a key natural anticoagulant pathway. Activated protein C (APC)&nbsp;inactivates factors Va and
VIIIa, both proteins in the blood coagulation pathway, resulting in reduced thrombin generation.
ALN-APC provides a pharmacologic strategy to reproduce the human genetics observed with
co-inheritance of prothrombotic factors in hemophilia. RNAi silencing of protein C is expected to
increase thrombin generation in hemophilia patients thereby reducing the frequency of bleeding.
Preclinical studies of an siRNA targeting protein C showed dose-dependent silencing of the protein
C mRNA. Further, administration of the siRNA resulted in marked reductions in protein C plasma
levels. We are currently conducting additional pre-clinical studies of ALN-APC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As noted above, while focusing our efforts on our core product strategy, we also intend to
continue to advance additional partner-based development programs, including ALN-RSV, ALN-VSP and
ALN-HTT, through existing or future alliances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February&nbsp;2010, we initiated a multi-center, global, randomized, double-blind,
placebo-controlled Phase IIb clinical trial to evaluate the clinical efficacy as well as safety of
aerosolized ALN-RSV01 in adult lung transplant patients naturally infected with RSV. Patients are
being randomized in a one-to-one drug to placebo ratio. The primary endpoint of this clinical trial
is a reduction in the incidence of new or progressive bronchiolitis obliterans syndrome, or BOS, a
potentially life-threatening complication in lung transplant patients. During 2010, we amended the
protocol of this clinical trial to perform an interim analysis, blinded to us and investigators,
which could expand enrollment from 76 to up to 120 patients. The interim analysis will be
performed when 75% of patients are evaluable for the BOS endpoint at six months. We have formed
collaborations with Cubist Pharmaceuticals, Inc., or Cubist, and Kyowa Hakko Kirin Co., Ltd., or
Kyowa Hakko Kirin, for the development and commercialization of RNAi products for the treatment of
RSV. Under our agreement with Cubist, we are developing ALN-RSV01 for adult transplant patients at
our sole discretion and expense and Cubist has the right to opt into collaborating with us on
ALN-RSV01 in the future. In December&nbsp;2010, we and Cubist jointly made a portfolio decision to put
the development of ALN-RSV02, a second-generation compound for the pediatric population, on hold.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August&nbsp;2011, we announced the completion of a Phase I clinical trial for ALN-VSP, which was
our first systemically delivered RNAi therapeutic to enter clinical development. ALN-VSP is
comprised of two siRNAs, one targeting vascular endothelial growth factor, or VEGF, and the other
targeting kinesin spindle protein, or KSP, and employs a first-generation LNP formulation. We are
developing ALN-VSP for the treatment of liver cancers, including both primary and secondary liver
cancers. This Phase I clinical
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">trial was a multi-center, open label, dose escalation study to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of intravenous ALN-VSP in patients with
advanced solid tumors with liver involvement. We completed enrollment in this clinical trial during
the first quarter of 2011 and reported study results in June&nbsp;2011. ALN-VSP was administered to 41
patients at doses ranging from 0.1 to 1.5 mg/kg and was generally well tolerated. As of November
2011, three patients with disease control were continuing to receive therapy in an extension study.
Results from pharmacodynamic measurements provide evidence of biological activity, and biopsy data
demonstrate both tissue levels of ALN-VSP and also human proof-of-concept for an RNAi mechanism of
action. We intend to partner our ALN-VSP program prior to initiating a Phase II clinical trial.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A third partner-based development program is ALN-HTT, an RNAi therapeutic candidate targeting
the huntingtin gene, for the treatment of HD, which we are developing in collaboration with
Medtronic, Inc., or Medtronic. In November&nbsp;2010, we and Medtronic entered into an agreement with
CHDI Foundation, Inc., or CHDI, under which CHDI has agreed to initially fund approximately 50% of
the costs of this program up to the point at which an investigational new drug application, or IND,
can be filed with the United States Food and Drug Administration, or FDA, or a comparable foreign
regulatory filing can be made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also continue to work internally and with third-party collaborators to develop new
technologies to deliver our RNAi therapeutics both directly to specific sites of disease, and
systemically by intravenous or subcutaneous administration. We have numerous RNAi therapeutic
delivery collaborations and intend to continue to collaborate with government, academic and
corporate third parties to evaluate different delivery options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the strength of our intellectual property portfolio relating to the
development and commercialization of siRNAs as therapeutics provides us a leading position with
respect to this therapeutic modality. This includes ownership of, or exclusive rights to, issued
patents and pending patent applications claiming fundamental features of siRNAs and RNAi
therapeutics as well as those claiming crucial chemical modifications and promising delivery
technologies. We believe that no other company possesses a portfolio of such broad and exclusive
rights to the patents and patent applications required for the commercialization of RNAi
therapeutics. Given the importance of our intellectual property portfolio to our business
operations, we intend to vigorously enforce our rights and defend against challenges that have
arisen or may arise in this area.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, our expertise in RNAi therapeutics and broad intellectual property portfolio have
allowed us to form alliances with leading companies, including Isis Pharmaceuticals, Inc., or Isis,
Medtronic, Novartis Pharma AG, or Novartis, Biogen Idec Inc., or Biogen Idec, F. Hoffmann-La Roche
Ltd, or Roche, Takeda Pharmaceutical Company Limited, or Takeda, Kyowa Hakko Kirin and Cubist. We
have also entered into contracts with government agencies, including the National Institute of
Allergy and Infectious Diseases, or NIAID, a component of the National Institutes of Health, or
NIH. We have established collaborations with and, in some instances, received funding and expertise
from, major medical and disease associations, including CHDI. Finally, to further enable the field
and monetize our intellectual property rights, we also grant licenses to biotechnology companies
for the development and commercialization of RNAi therapeutics for specified targets in which we
have no direct strategic interest, under our InterfeRx<SUP style="FONT-size: 85%; vertical-align: text-top">tm</SUP> program, and to research
companies that commercialize RNAi reagents or services under our research product licenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also seek to form or advance new ventures and opportunities in areas outside our primary
focus on RNAi therapeutics. For example, we have presented data regarding the application of RNAi
technology to improve the manufacturing processes for biologics, including recombinant proteins and
monoclonal antibodies. We are advancing these applications of RNAi technology in an internal effort
referred to as Alnylam Biotherapeutics. We have formed, and intend to form additional,
collaborations through this effort with third-party biopharmaceutical companies. In addition, we
recently announced our progress on VaxiRNA, an RNAi technology derived from our Alnylam
Biotherapeutics initiative, for the enhanced production of viruses used in the manufacture of
vaccine products. In October&nbsp;2011, we entered into a VaxiRNA collaboration with GlaxoSmithKline,
or GSK, for influenza vaccine production. Additionally, in 2007, we and Isis established Regulus
Therapeutics Inc., or Regulus, a company focused on the discovery, development and
commercialization of microRNA therapeutics. Because microRNAs are believed to regulate whole
networks of genes that can be involved in discrete disease processes, microRNA therapeutics
represent a possible new approach to target the pathways of human disease. Regulus has formed
collaborations with GSK, and Sanofi to advance its efforts. Given the broad applications for RNAi
technology, in addition to our efforts on Alnylam Biotherapeutics, VaxiRNA and Regulus, we believe
new ventures and opportunities will be available to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, a substantial portion of our total net revenues has been derived from collaboration
revenues from strategic alliances with Roche, Takeda, Cubist and Novartis, and from the United
States government in connection with our development of treatments for hemorrhagic fever viruses,
including Ebola. We expect our revenues to continue to be derived primarily from existing
alliances, new strategic alliances, new government and foundation funding and existing and new
license fee revenues.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred significant losses since we commenced operations in 2002 and expect such
losses to continue for the foreseeable future. Historically, we have generated losses principally
from costs associated with research and development activities, acquiring, filing and expanding
intellectual property rights and general administrative costs. As a result of planned expenditures
for research and development activities relating to our drug development programs, including the
development of drug delivery technologies and clinical trial costs, extension of the capabilities
of our technology platform, including through business initiatives, continued management and growth
of our patent portfolio, collaborations and general corporate activities, we expect to incur
additional operating losses for the foreseeable future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we currently have programs focused on a number of therapeutic areas, we are unable to
predict when, if ever, we will successfully develop or be able to commence sales of any product.
Our sources of potential funding for the next several years are expected to be derived primarily
from new and existing strategic alliances, which may include license and other fees, funded
research and development and milestone payments, government and foundation funding, and proceeds
from the sale of equity or debt. In July&nbsp;2011, we filed a shelf registration statement with the
SEC for an indeterminate number of shares of common stock and/or other securities, up to an
aggregate of $150.0&nbsp;million, for future issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We anticipate that our operating results will fluctuate for the foreseeable future and,
therefore, period-to-period comparisons should not be relied upon as predictive of the results of
future periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Research and Development</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have focused on drug discovery and development programs. Research and
development expenses represent a substantial percentage of our total operating expenses. Under our
core product strategy, we expect to progress five RNAi therapeutic programs into advanced stages of
clinical development by the end of 2015. While focusing our efforts on our core product strategy,
we also intend to continue to advance additional partner-based development programs through
existing or future alliances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, we continue to work internally and with third-party collaborators to develop new
technologies to deliver our RNAi therapeutics both directly to specific sites of disease, and
systemically by intravenous or subcutaneous administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is a risk that any drug discovery or development program may not produce revenue for a
variety of reasons, including the possibility that we will not be able to adequately demonstrate
the safety and efficacy of the product candidate. Moreover, there are uncertainties specific to any
new field of drug discovery, including RNAi. The successful development of any product candidate we
develop is highly uncertain. Due to the numerous risks associated with developing drugs, we cannot
reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to
complete the development of, or the period, if any, in which material net cash inflows will
commence from, any potential product candidate. These risks include the uncertainty of:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to discover new product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to progress product candidates into pre-clinical and clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and cost of our pre-clinical trials and other
research and development activities, including those related to developing safe and
effective ways of delivering siRNAs into cells and tissues;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and cost of any clinical trials we commence;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>clinical trial results;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of filing, prosecuting, defending and enforcing any patent claims and other
intellectual property rights;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms, timing and success of any collaboration, licensing and other arrangements that we
may establish;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost, timing and success of regulatory filings and approvals or potential
changes in regulations that govern our industry or the way in which they are interpreted
or enforced;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of establishing sufficient sales, marketing and distribution
capabilities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of establishing sufficient clinical and commercial supplies
for any product candidates and products that we may develop;
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limits on our ability to research, develop, or manufacture our product candidates
as a result of contractual obligations to third parties or intellectual property held by
third parties;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs associated with legal activities, including litigation, arising in the
course of our business activities and our ability to prevail in any such legal disputes;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of competing technological and market developments.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any failure to complete any stage of the development of any potential products in a timely
manner could have a material adverse effect on our operations, financial position and liquidity. A
discussion of some of the risks and uncertainties associated with completing our projects on
schedule, or at all, and the potential consequences of failing to do so, are set forth in Part&nbsp;II,
Item&nbsp;1A below under the heading &#147;Risk Factors.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Strategic Alliances</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant component of our business plan is to enter into strategic alliances and
collaborations with pharmaceutical and biotechnology companies, academic institutions, research
foundations and others, as appropriate, to gain access to funding, capabilities, technical
resources and intellectual property to further our development efforts and to generate revenues. We
also seek to form or advance new ventures and opportunities in areas outside our primary focus on
RNAi therapeutics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To generate revenues from our intellectual property rights, we also grant licenses to
biotechnology companies under our InterfeRx program for the development and commercialization of
RNAi therapeutics for specified targets in which we have no direct strategic interest. We also
license key aspects of our intellectual property to companies active in the research products and
services market, which includes the manufacture and sale of reagents. Our InterfeRx and research
product licenses aim to generate modest near-term revenues that we can re-invest in the development
of our proprietary RNAi therapeutics pipeline. At September&nbsp;30, 2011, we had granted such licenses,
on both an exclusive and non-exclusive basis, to approximately 20 companies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since delivery of RNAi therapeutics remains a major objective of our research activities, we
also look to form collaboration and licensing arrangements with other companies and academic
institutions to gain access to delivery technologies. For example, we have entered into agreements
with Tekmira Pharmaceuticals Corporation, or Tekmira, the Massachusetts Institute of Technology, or
MIT, The University of British Columbia, or UBC, and AlCana Technologies, Inc., or AlCana, among
others, to focus on various delivery strategies. We have also entered into license agreements with
Isis, Max Planck Innovation GmbH (formerly known as Garching Innovation GmbH), or Max Planck
Innovation, Tekmira, MIT, Cancer Research Technology Limited, or CRT, Whitehead Institute for
Biomedical Research, or Whitehead, Stanford University, or Stanford, The University of Texas
Southwestern Medical Center, or UTSW, as well as a number of other entities, to obtain rights to
intellectual property in the field of RNAi.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally, we seek funding for the development of our proprietary RNAi therapeutics pipeline
from the government and foundations. For example, in 2006, the NIAID awarded us a contract to
advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever
virus, including the Ebola virus, which contract ended in December&nbsp;2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Roche Collaboration Agreement. </B>In October&nbsp;2011, Arrowhead Research Corporation, or Arrowhead,
announced its acquisition of RNA therapeutics assets from Roche, including our license and
collaboration agreement with Roche.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>UBC/AlCana Delivery Collaboration. </B>Our research agreement with UBC and AlCana entered into in
July&nbsp;2009 is focused on the discovery of novel lipids, such as the MC3 lipid, employed in
second-generation LNP formulations for the systemic delivery of RNAi therapeutics. Pursuant to the
terms of the research agreement, we were funding collaborative research over an initial two-year
period, and in July&nbsp;2011, we exercised our right to extend the collaborative research and our
funding for a third year, through July&nbsp;2012. The collaborative research is being conducted by our
scientists, together with scientists at UBC and AlCana.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the research agreement, we have exclusive rights to all new inventions relating to the
delivery of oligonucleotides and other nucleic acid constructs, as well as sole rights to
sublicense any resulting intellectual property to our current and future collaborators. UBC and
AlCana are eligible to receive up to an aggregate of $1.3&nbsp;million in milestone payments from us for
each licensed product (as defined in the research agreement) directed to a particular target (as
defined in the research agreement), together with single-digit royalty payments on annual product
sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent with the execution of the research agreement, we also entered into a supplemental
agreement with Tekmira, Protiva Biotherapeutics Inc., a wholly-owned subsidiary of Tekmira, or
Protiva, UBC and AlCana, which contains additional terms regarding the intellectual property rights
arising out of the research agreement. Pursuant to the terms of the supplemental agreement,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">each of Tekmira and Protiva has the right to use new inventions under the research agreement
for its own RNAi therapeutic programs that are licensed under our InterfeRx program and would be
required to pay milestones and royalties to UBC and AlCana in connection with such use.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the terms of the supplemental agreement, each of Tekmira and Protiva waived all
prohibitions and restrictions on certain former Tekmira employees who are now working at UBC and
AlCana in connection with their performance of the collaborative research under the research
agreement and granted us, AlCana, UBC and such former Tekmira employees a covenant not to sue for
any cause of action relating to such activities that arose out of their former employment with
Tekmira.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The subject matter of these agreements is the subject of ongoing litigation between Tekmira
and Protiva, on the one hand, and us and AlCana, on the other hand, a description of which is set
forth below under Part&nbsp;II, Item&nbsp;1 &#151; Legal Proceedings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Takeda Alliance. </B>Under our collaboration agreement with Takeda, Takeda agreed to pay us $50.0
million upon achievement of specified technology transfer milestones. Of this $50.0&nbsp;million, $20.0
million was paid to us in October&nbsp;2008, $20.0&nbsp;million was paid to us in March&nbsp;2010 and the final
$10.0&nbsp;million was paid to us in March&nbsp;2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Alnylam Biotherapeutics</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since 2009, we have advanced our efforts regarding the application of RNAi technologies to
improve the manufacturing processes for biologics, including recombinant proteins and monoclonal
antibodies. These applications of RNAi technology, which we are advancing in an internal effort
referred to as Alnylam Biotherapeutics, have the potential to create new business opportunities. In
particular, we are advancing RNAi technologies to improve the quantity and quality of biologics
manufacturing processes using mammalian cell culture, such as Chinese hamster ovary, or CHO, cells.
This RNAi technology potentially could be applied to the improvement of manufacturing processes for
existing marketed drugs, new drugs in development and for the emerging biosimilars market. We have
developed proprietary delivery lipids that enable the efficient delivery of siRNAs into CHO cells
when grown in suspension culture, as well as other cell systems that are used for the manufacture
of biologics. Studies have demonstrated that silencing certain target genes involved in certain CHO
cell apoptotic and metabolic pathways resulted in improved cell viability as compared with
untreated cells. Additional studies demonstrated the ability to target a viral infection of CHO
cells and alter glycosylation pathways. During 2010, we established two Alnylam Biotherapeutics
collaborations with leading biotechnology and pharmaceutical companies. As we advance our Alnylam
Biotherapeutics technology, we plan to seek additional collaborations with established biologic
manufacturers, selling licenses, products and services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>VaxiRNA</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are also applying RNAi technology to improve the manufacturing processes for vaccines in an
effort called VaxiRNA. The VaxiRNA platform stems from work we have performed as part of our
Alnylam Biotherapeutics efforts. With VaxiRNA, we are using siRNAs that silence specific genes in
vaccine production systems, such as cells or chicken eggs, which limit or prevent the efficient
growth of viruses used in the manufacture of vaccine products. New innovations in vaccine
manufacturing are needed to enable the scale and speed of global immunization for a number of
pathogens. In October 2011, we formed a VaxiRNA collaboration with GSK for influenza vaccine production.
Under the terms of the agreement, GSK has agreed to provide research funding and certain
success-based milestone payments to us. If successfully applied in the manufacture of commercial
product, we will also have the right to receive payments on unit product sales, if any. In
addition, GSK has obtained an option for VaxiRNA applications toward two additional vaccine
products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>microRNA Therapeutics</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulus. </B>In September&nbsp;2007, we and Isis established Regulus, a company focused on the
discovery, development and commercialization of microRNA therapeutics. Regulus leverages our and
Isis&#146; technologies, know-how and intellectual property relating to microRNA therapeutics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulus, which initially was established as a limited liability company, converted to a C
corporation as of January&nbsp;2, 2009 and changed its name to Regulus Therapeutics Inc. In
consideration for our and Isis&#146; initial interests in Regulus, we and Isis each granted Regulus
exclusive licenses to our intellectual property for certain microRNA therapeutics as well as
certain patents in the microRNA field. At September&nbsp;30, 2011, we, Isis and Sanofi owned
approximately 45%, 46% and 9%, respectively, of Regulus. Regulus continues to operate as an
independent company with a separate board of directors, scientific advisory board and management
team, some of whom have options to purchase common stock of Regulus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulus is exploring therapeutic opportunities that arise from microRNA dysregulation. Since
microRNAs are believed to regulate broad networks of genes and biological pathways, microRNA
therapeutics define a new and potentially high-impact strategy to target multiple nodes on disease
pathways. microRNAs are small non-coding RNAs that regulate the expression of other genes. There
are approximately 700 microRNAs that have been identified in the human genome, and these are
believed to regulate the expression of up to 30% of all human genes. Since microRNAs may act as
master regulators of the genome and are often found to be dysregulated in disease, microRNAs
potentially represent an exciting new platform for drug discovery and development. Regulus is
advancing microRNA therapeutics in several areas including fibrosis, hepatitis C virus, or HCV,
infection, immuno-inflammatory diseases, metabolic and cardiovascular diseases, and oncology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2008, Regulus entered into a worldwide strategic alliance with GSK to discover,
develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as
rheumatoid arthritis and inflammatory bowel disease. In connection with this alliance, Regulus
received $20.0&nbsp;million in upfront payments from GSK, including a $15.0&nbsp;million option fee and a
loan of $5.0&nbsp;million (guaranteed by us and Isis) that will convert into Regulus common stock under
certain specified circumstances. Regulus is eligible to receive development, regulatory and sales
milestone payments for each of the four microRNA-targeted therapeutics discovered and developed as
part of the alliance, and would also receive royalty payments on worldwide sales of products
resulting from the alliance, if any. In May&nbsp;2009, Regulus achieved the first demonstration of a
pharmacological effect in immune cells by specific microRNA inhibition, the initial discovery
milestone under the GSK alliance, which triggered a payment under the agreement. In July&nbsp;2011,
Regulus and GSK identified a third microRNA target under this alliance triggering an additional
pre-clinical milestone payment from GSK.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February&nbsp;2010, Regulus and GSK established a new collaboration to develop and commercialize
microRNA therapeutics targeting miR-122 in all fields, with the treatment of HCV infection as the
lead indication. Under the terms of this collaboration, Regulus received $8.0&nbsp;million in upfront
payments from GSK, including a $3.0&nbsp;million license fee and a loan of $5.0&nbsp;million (guaranteed by
us and Isis) that will convert into Regulus common stock under certain specified circumstances.
Consistent with the original GSK alliance, Regulus is eligible to receive development, regulatory
and sales milestone payments, as well as royalty payments on worldwide sales of products resulting
from the alliance, if any, as Regulus and GSK advance microRNA therapeutics targeting miR-122.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2010, Regulus entered into a global, strategic alliance with Sanofi to discover,
develop and commercialize microRNA therapeutics on up to four microRNA targets. Under the terms of
this alliance, Regulus received $25.0&nbsp;million in upfront fees and is entitled to annual research
support for three years with the option to extend research support for two additional years. In
addition, Regulus is eligible to receive royalties on microRNA therapeutic products commercialized
by Sanofi, if any. Sanofi will support 100% of the costs of clinical development and
commercialization of each program. The alliance will initially focus on the therapeutic area of
fibrosis. Regulus and Sanofi will collaborate on up to four microRNA targets, including Regulus&#146;
lead fibrosis program targeting miR-21. Sanofi also received an option for a broader technology
alliance with Regulus that provides Regulus certain rights to participate in development and
commercialization of resulting products. If exercised, this option is worth up to an additional
$50.0&nbsp;million to Regulus. We and Isis are each eligible to receive 7.5% of all potential upfront
and milestone payments, in addition to single-digit royalties on product sales, if any. We received
$1.9&nbsp;million from Regulus in connection with this alliance, representing 7.5% of the $25.0&nbsp;million
upfront payment from Sanofi to Regulus. In addition, in October&nbsp;2010, Sanofi made a $10.0&nbsp;million
equity investment in Regulus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Intellectual Property</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The strength of our intellectual property portfolio relating to the development and
commercialization of siRNAs as therapeutics is essential to our business strategy. We own or
license issued patents and pending patent applications in the United States and in key markets
around the world claiming fundamental features of siRNAs and RNAi therapeutics as well as those
claiming crucial chemical modifications and promising delivery technologies. Specifically, we have
a portfolio of patents, patent applications and other intellectual property covering: fundamental
aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related
mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic uses;
siRNAs directed to specific targets as treatments for particular diseases; delivery technologies,
such as in the field of cationic liposomes; and all aspects of our specific development candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that no other company possesses a portfolio of such broad and exclusive rights to
the patents and patent applications required for the commercialization of RNAi therapeutics. Our
intellectual property portfolio for RNAi therapeutics includes over 1,800 active cases and over 700
granted or issued patents, of which over 300 are issued or granted in the United States, the
European Union and Japan. We continue to seek to grow our portfolio through the creation of new
technology in this field. In addition, we are very active in our evaluation of third-party technologies.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our expertise in RNAi therapeutics and broad intellectual property portfolio have allowed us
to form alliances with leading companies, including Isis, Medtronic, Novartis, Biogen, Roche,
Takeda, Kyowa Hakko Kirin and Cubist, as well as license agreements with other biotechnology
companies interested in developing RNAi therapeutic products and research companies that
commercialize RNAi reagents or services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given the importance of our intellectual property portfolio to our business operations, we
intend to vigorously enforce our rights and defend against challenges that have arisen or may arise
in this area.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Critical Accounting Policies and Estimates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><I>Revenue Recognition</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2011, we adopted new authoritative guidance on revenue recognition for multiple
element arrangements. The guidance, which applies to multiple element arrangements entered into or
materially modified on or after January&nbsp;1, 2011, amends the criteria for separating and allocating
consideration in a multiple element arrangement by modifying the fair value requirements for
revenue recognition and eliminating the use of the residual method. The fair value of deliverables
under the arrangement may be derived using a &#147;best estimate of selling price&#148; if vendor specific
objective evidence and third-party evidence is not available. Deliverables under the arrangement
will be separate units of accounting provided (i)&nbsp;a delivered item has value to the customer on a
standalone basis; and (ii)&nbsp;if the arrangement includes a general right of return relative to the
delivered item, delivery or performance of the undelivered item is considered probable and
substantially in the control of the vendor. We did not enter into any significant multiple element
arrangements or materially modify any of our existing multiple element arrangements during the nine
months ended September&nbsp;30, 2011. Our existing license and collaboration agreements continue to be
accounted for under previously issued revenue recognition guidance for multiple element
arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as noted above, there have been no significant changes to our critical accounting
policies since the beginning of this fiscal year. Our other critical accounting policies are
described in the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; section of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2010, which
we filed with the SEC on February&nbsp;18, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following data summarizes the results of our operations for the periods indicated, in
thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,791</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">62,302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">78,849</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,229</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103,534</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">110,509</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,438</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,728</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(41,232</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(31,660</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(13,237</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,630</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,585</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Net Revenues from Research Collaborators</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We generate revenues through research collaborations. The following table summarizes our
total consolidated net revenues from research collaborators, for the periods indicated, in
thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Roche</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">41,983</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">41,983</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Takeda</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,494</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,556</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,479</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Novartis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,984</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">133</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,957</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Government contract</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,095</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research collaborator</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">918</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,392</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,560</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,232</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">InterfeRx program, research reagent license and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">367</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">719</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total net revenues from research collaborators</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,791</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">62,302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">78,849</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The decrease in Novartis revenues for the three and nine months ended September&nbsp;30, 2011
as compared to the three and nine months ended September&nbsp;30, 2010 was due primarily to the planned
completion of the fifth and final year of the research program under the Novartis collaboration and
license agreement in October&nbsp;2010. The decrease in government contract revenues for the three and
nine months ended September&nbsp;30, 2011 as compared to the three and nine months ended September&nbsp;30,
2010 was primarily the result of the completion of our contract with the NIAID in December&nbsp;2010.
The decrease in other research collaborator revenues for the three months ended September&nbsp;30, 2011
as compared to the three months ended September&nbsp;30, 2010 was primarily due to our Alnylam
Biotherapeutics&#146; collaborations formed in 2010. The decrease in other research collaborator
revenues for the nine months ended September&nbsp;30, 2011 as compared to the nine months ended
September&nbsp;30, 2010 was primarily the result of the $1.9&nbsp;million sublicense fee recognized in
connection with Regulus&#146; June&nbsp;2010 alliance with Sanofi, representing 7.5% of the $25.0&nbsp;million
upfront payment from Sanofi to Regulus and our Alnylam Biotherapeutics&#146; collaborations formed in
2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred revenue of $160.5&nbsp;million at September&nbsp;30, 2011 consists of payments we have
received from collaborators, primarily Roche, Takeda, Kyowa Hakko Kirin and Cubist, but have not
yet recognized pursuant to our revenue recognition policies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the foreseeable future, we expect our revenues to continue to be derived primarily from
our alliances with Roche, Takeda and Cubist, and other strategic alliances, as well as new
collaborations, foundation funding, government contracts and licensing activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Operating expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables summarize our operating expenses for the periods indicated, in thousands
and as a percentage of total operating expenses, together with the changes, in thousands and
percentages:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of Total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of Total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Operating</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Operating</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Expenses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Expenses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">%</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">24,274</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">73</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,468</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">75</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,194</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and
administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,955</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">27</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,928</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">25</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">*</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">33,229</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">36,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,167</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Indicates less than 1%</TD>
</TR>

</TABLE>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of Total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of Total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Operating</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Operating</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Decrease</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Expenses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Expenses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">%</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">75,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">73</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">80,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">73</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,378</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and
administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">27</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,205</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">27</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,597</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">103,534</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">110,509</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6,975</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Research and development. </I></B>The following tables summarize the components of our research
and development expenses for the periods indicated, in thousands and as a percentage of total
research and development expenses, together with the changes, in thousands and percentages:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><b>Three Months </b></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30,</B> <B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30,</B> <B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Research and development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Clinical trial and manufacturing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,744</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">28</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,974</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">18</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,770</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">36</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation and related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,464</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">23</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,121</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">22</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(657</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(11</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Facilities-related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">13</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,049</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">11</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">External services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,392</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">20</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,394</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(44</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash stock-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,789</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">11</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,725</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">10</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Lab supplies and materials</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(264</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,863</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,863</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">License fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">716</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">734</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">695</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total research and development
expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">24,274</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,468</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,194</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses decreased during the three months ended September&nbsp;30,
2011 as compared to the three months ended September&nbsp;30, 2010 due primarily to lower external
services expense, including pre-clinical costs associated with our ALN-PCS program.
Lab supplies and materials and compensation and related expenses also decreased during the three
months ended September&nbsp;30, 2011 as compared to the three months ended September&nbsp;30, 2010 due
primarily to the reduction in workforce in connection with our September&nbsp;2010 corporate
restructuring. Partially offsetting these decreases was an increase in clinical trial and
manufacturing expenses primarily related to the advancement of our ALN-PCS program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to continue to devote a substantial portion of our resources to research and
development expenses as we continue development of our and our collaborators&#146; product candidates
and focus on continuing to develop drug delivery-related technologies, however, we expect that
research and development expenses will remain consistent for the remainder of 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of our research and development costs are not tracked by project as they
benefit multiple projects or our technology platform and because our most-advanced programs are in
the early stages of clinical development. However, our collaboration agreements contain
cost-sharing arrangements pursuant to which certain costs incurred under the project are
reimbursed. Costs reimbursed under the agreements typically include certain direct external costs
and a negotiated full-time equivalent labor rate for the actual time worked on the project. In
addition, we have been reimbursed under government contracts for certain allowable costs including
direct internal and external costs. As a result, although a significant portion of our research and
development expenses are not tracked on a project-by-project basis, we do track direct external
costs attributable to, and the actual time our employees worked on, our collaborations and
government contracts.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30,</B> <B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Research and development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Clinical trial and manufacturing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">19,504</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">26</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,249</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">19</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,255</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">28</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation and related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">23</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,439</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">23</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(772</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">External services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">16</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">20</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,461</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Facilities-related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,574</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">13</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,967</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">11</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">607</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash stock-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,284</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">11</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(916</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(10</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Lab supplies and materials</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,994</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">8</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,256</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(20</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,863</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,863</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">License fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,065</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,848</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(783</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,420</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,609</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(189</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total research and development expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">75,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">80,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,378</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses decreased during the nine months ended September&nbsp;30,
2011 as compared to the nine months ended September&nbsp;30, 2010 due primarily to lower external
services expense, including research funding paid to Isis in connection with our ssRNAi collaborative effort with Isis, which we terminated in November 2010.
Lab supplies and materials and compensation and related expenses also decreased during the nine
months ended September&nbsp;30, 2011 as compared to the nine months ended September&nbsp;30, 2010 due
primarily to the reduction in workforce in connection with our September&nbsp;2010 corporate
restructuring. Partially offsetting these decreases was an increase in clinical trial and
manufacturing expenses primarily related to the advancement of our ALN-PCS program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>General and administrative. </I></B>The following tables summarize the components of our general and
administrative expenses for the periods indicated, in thousands and as a percentage of total
general and administrative expenses, together with the changes, in thousands and percentages:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><b>% of</b></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>General and administrative</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Consulting and professional services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,776</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">53</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">46</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">16</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation and related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,646</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">18</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">17</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash stock-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,469</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">17</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,787</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">20</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(318</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Facilities-related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">518</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">609</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(91</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">330</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(330</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">546</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total general and administrative
expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,955</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,928</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">*</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Indicates less than 1%</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses remained consistent during the three months ended
September&nbsp;30, 2011 as compared to the three months ended September&nbsp;30, 2010. For the remainder of
2011, we expect that general and administrative expenses will remain consistent.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><b>% of</b></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nine Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>% of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>General and administrative</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Consulting and professional services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">52</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">52</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,305</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation and related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,408</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">20</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">16</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">641</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">13</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash stock-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">16</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,706</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">19</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,396</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(24</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Facilities-related</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,778</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(17</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">330</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(330</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,662</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,852</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(190</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(10</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total general and administrative
expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">30,205</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,597</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The decrease in general and administrative expenses during the nine months ended September&nbsp;30,
2011 as compared to the nine months ended September&nbsp;30, 2010 was due primarily to lower consulting
and professional services expenses related to business activities, primarily legal activities, a
description of which is set forth below under Part&nbsp;II, Item&nbsp;1 &#151; Legal Proceedings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Other income (expense)</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We incurred $0.5&nbsp;million and $2.6&nbsp;million of equity in loss of joint venture (Regulus
Therapeutics Inc.) for the three and nine months ended September&nbsp;30, 2011, respectively, as
compared to $1.2&nbsp;million and $6.7&nbsp;million for the three and nine months ended September&nbsp;30, 2010,
respectively, related to our share of the net losses incurred by Regulus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income was $0.3&nbsp;million and $1.0&nbsp;million for the three and nine months ended
September&nbsp;30, 2011, respectively, as compared to $0.6&nbsp;million and $1.8&nbsp;million for the three and nine months ended September&nbsp;30,
2010, respectively. The decrease was due primarily to lower average cash, cash equivalent and
marketable securities balances.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense was $0.6&nbsp;million and $0.5&nbsp;million for the three and nine months ended September
30, 2011, respectively, and was due primarily to an impairment charge of $0.6&nbsp;million related to
our investment in Tekmira equity securities, as the decrease in the fair value of this investment
was deemed to be other than temporary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Liquidity and Capital Resources</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our cash flow activities for the periods indicated, in
thousands:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Nine Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(43,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(36,585</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adjustments to reconcile net loss to net cash (used
in) provided by operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,021</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,548</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Changes in operating assets and liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38,584</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(52,916</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(61,909</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(63,953</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29,741</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,136</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Effect of exchange rate on cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net decrease in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(263</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(90,587</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents, beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74,599</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">137,468</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents, end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">74,336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since we commenced operations in 2002, we have generated significant losses. At September
30, 2011, we had an accumulated deficit of $386.7&nbsp;million. At September&nbsp;30, 2011, we had cash, cash
equivalents and marketable securities of $286.2&nbsp;million, compared to cash, cash equivalents and
marketable securities of $349.9&nbsp;million at December&nbsp;31, 2010. We invest primarily in cash
equivalents, U.S. government and municipal obligations, high-grade corporate notes and commercial
paper. Our investment objectives are, primarily, to assure liquidity and preservation of capital
and, secondarily, to obtain investment income. All of our investments in debt securities are
recorded at fair value and are available-for-sale. Fair value is determined based on quoted market
prices and models using observable data inputs. We have not recorded any impairment charges related
to our fixed income marketable securities at September&nbsp;30, 2011. For the three and nine months
ended September&nbsp;30, 2011, we recorded an impairment charge of $0.6&nbsp;million related to our
investment in Tekmira equity securities, as the decrease in the fair value of this investment was
deemed to be other than temporary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Operating activities</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have required significant amounts of cash to fund our operating activities as a result of
net losses since our inception. For the nine months ended September&nbsp;30, 2011, net cash used in
operating activities of $61.9&nbsp;million was due primarily to our net loss and a decrease in deferred
revenue of $50.6&nbsp;million. These amounts were partially offset by the receipt of our income tax
refund of $10.7&nbsp;million in March&nbsp;2011. In addition, net cash used in operating activities is
adjusted for non-cash items to reconcile net loss to net cash used in or provided by operating
activities. These non-cash adjustments consist primarily of stock-based compensation, equity in
loss of joint venture (Regulus Therapeutics Inc.), and depreciation and amortization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that we will require significant amounts of cash to fund our operating activities
for the foreseeable future as we continue to develop and advance our research and development
initiatives. The actual amount of overall expenditures will depend on numerous factors, including
the timing of expenses, the timing and terms of collaboration agreements or other strategic
transactions, if any, and the timing and progress of our research and development efforts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><B><I>Investing activities</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the nine months ended September&nbsp;30, 2011, net cash provided by investing activities of
$61.2&nbsp;million resulted primarily from net sales and maturities of marketable securities. For the
nine months ended September&nbsp;30, 2010, net cash used in investing activities of $29.7&nbsp;million
resulted primarily from net purchases of marketable securities of $26.1&nbsp;million and purchases of
property and equipment of $3.6&nbsp;million related to our Cambridge facility.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Financing activities</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the nine months ended September&nbsp;30, 2011, net cash of $0.5&nbsp;million provided by financing
activities was due to proceeds from the issuance of common stock in connection with stock option
exercises. For the nine months ended September&nbsp;30, 2010, net cash provided by financing activities
of $3.1&nbsp;million was due to proceeds of $1.0&nbsp;million from our issuance of common stock to Novartis
in April&nbsp;2010, as well as proceeds from the issuance of common stock in connection with stock
option exercises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Operating Capital Requirements</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not know when, if ever, we will successfully develop or be able to commence sales of any
product. Therefore, we anticipate that we will continue to generate significant losses for the
foreseeable future as a result of planned expenditures for research and development activities
relating to our drug development programs, including the development of drug delivery technologies
and clinical trial costs, extension of the capabilities of our technology platform, including
through business initiatives, continued management and growth of our patent portfolio,
collaborations and general corporate activities. Based on our current operating plan, we believe
that our existing cash, cash equivalents and fixed income marketable securities, for which we have
not recognized any impairment charges, together with the cash we expect to generate under our
current alliances, will be sufficient to fund our planned operations for at least the next several
years. For reasons discussed below, we may require significant additional funds earlier than we
currently expect in order to develop, conduct clinical trials for and commercialize any product
candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the future, we may seek additional funding through additional collaborative arrangements
and public or private financings. In July&nbsp;2011, we filed a shelf registration statement with the
SEC for an indeterminate number of shares of common stock and/or other securities, for up to an
aggregate of $150.0&nbsp;million, for future issuance. During the current downturn in global financial
markets, some companies have experienced difficulties accessing their cash equivalents and
investment securities and raising capital generally, which have had a material adverse impact on
their liquidity. The current economic downturn has diminished the availability of capital and may
limit our ability to access these markets to obtain financing in the future. As a result of these
and other factors, additional funding may not be available to us on acceptable terms or at all. In
addition, the terms of any financing may adversely affect the holdings or the rights of our
stockholders. For example, if we raise additional funds by issuing equity securities, further
dilution to our existing stockholders may result. In addition, as a condition to providing
additional funds to us, future investors may demand, and may be granted, rights superior to those
of existing stockholders. If we are unable to obtain funding on a timely basis, we may be required
to significantly delay or curtail one or more of our research or development programs. We also
could be required to seek funds through arrangements with collaborators or others that may require
us to relinquish rights to some of our technologies or product candidates that we would otherwise
pursue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we are able to raise additional funds in a timely manner, our future capital
requirements may vary from what we expect and will depend on many factors, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our progress in demonstrating that siRNAs can be active as drugs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to develop relatively standard procedures for selecting and modifying siRNA
product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>progress in our research and development programs, as well as the magnitude of these
programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of milestone and other payments, if any, from
present and future collaborators, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of funding under current and future government or foundation
contracts, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to maintain and establish additional collaborative arrangements and/or new
business initiatives;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the resources, time and costs required to successfully initiate and complete our
pre-clinical and clinical trials, obtain regulatory approvals, and obtain and maintain
licenses to third-party intellectual property;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to manufacture, or contract with third-parties for the manufacture
of, our product candidates for clinical testing and commercial sale;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the resources, time and cost required for the preparation, filing, prosecution,
maintenance and enforcement of patent
claims;</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to successfully manage the potential impact of our September&nbsp;2010
corporate restructuring and workforce reduction on our culture, collaborative
relationships and business operations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs associated with legal activities, including litigation, arising in the
course of our business activities and our ability to prevail in any such legal disputes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>progress in the research and development programs of Regulus; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of sales and royalties, if any, from our potential products.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Contractual Obligations and Commitments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure of our contractual obligations and commitments is set forth under the heading
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Contractual
Obligations and Commitments&#148; in our Annual Report on Form 10-K for the year ended December&nbsp;31,
2010. There have been no material changes in our contractual obligations and commitments since
December&nbsp;31, 2010. </DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Recent Accounting Pronouncements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2011, we adopted new authoritative guidance on revenue recognition for milestone
payments related to arrangements under which we have continuing performance obligations.
Consideration for events that meet the definition of a milestone in accordance with the accounting
guidance for the milestone method of revenue recognition is recognized as revenue in its entirety
in the period in which the milestone is achieved only if all of the following conditions are met:
(i)&nbsp;the milestone is commensurate with either our performance in achieving the milestone or the
enhancement of the value of the delivered item as a result of a specific outcome resulting from our
performance in achieving the milestone; (ii)&nbsp;the consideration relates solely to past performance;
and (iii)&nbsp;the amount of the milestone consideration is reasonable relative to all of the
deliverables and payment terms, including other potential milestone consideration, within the
arrangement. Otherwise, the milestone payments are not considered to be substantive and are
deferred and recognized as revenue over the term of the arrangement as we complete our
performance obligations. The adoption of this guidance does not materially change our previous
method of recognizing milestone payments. All potential future milestones under existing
arrangements with licensing partners, as specified above, and any new arrangements with milestones,
will be evaluated under the new revenue recognition guidance for milestone payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2011, the Financial Accounting Standards Board, or FASB, issued a new accounting
standard that clarifies the application of certain existing fair value measurement guidance and
expands the disclosures for fair value measurements that are estimated using significant
unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and
interim reporting periods beginning on or after December&nbsp;15, 2011. We do not expect that adoption
of this new standard will have a material impact on our condensed consolidated financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2011, the FASB issued an amendment to the accounting guidance for presentation of
comprehensive income. Under the amended guidance, a company may present the total of comprehensive
income, the components of net income and the components of other comprehensive income either in a
single continuous statement of comprehensive income or in two separate but consecutive statements.
In either case, a company is required to present each component of net income along with total net
income, each component of other comprehensive income along with a total for other comprehensive
income and a total amount for comprehensive income.
For public companies, the amendment is effective for fiscal years, and interim periods within those
years, beginning after December&nbsp;15, 2011, and shall be applied retrospectively. Early adoption is
permitted. Other than a change in presentation, the adoption of this amendment is not expected to have
a material impact on our condensed consolidated financial statements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="B87804108"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 3.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our investment portfolio, we own financial instruments that are sensitive to market
risks. The investment portfolio is used to preserve our capital until it is required to fund
operations, including our research and development activities. Our marketable securities consist of
U.S. government and municipal obligations, high-grade corporate notes and commercial paper. All of
our investments in debt securities are classified as available-for-sale and are recorded at fair
value. Our available-for-sale investments in debt securities are sensitive to changes in interest
rates and changes in the credit ratings of the issuers. Interest rate changes would result in a
change in the net fair value of these financial instruments due to the difference between the
market interest rate and the market interest rate at the date of purchase of the financial
instrument. If market interest rates were to increase immediately and uniformly by 50 basis
points, or one-half of a percentage point, from levels at September&nbsp;30, 2011, the net fair value of
our interest-sensitive financial instruments would have resulted in a hypothetical decline of $1.0
million. A downgrade in the credit rating of an issuer of a debt security or further deterioration
of the credit markets could result in a decline in the fair value of the debt instruments. Our
investment guidelines prohibit investment in auction rate securities and we do not believe we have
any direct exposure to losses relating from mortgage-based securities or derivatives related
thereto such as credit-default swaps. We have not recorded any impairment charges to our fixed
income marketable securities at September&nbsp;30, 2011.
</DIV>
<DIV align="left">
<A name="B87804109"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>CONTROLS AND PROCEDURES.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management, with the participation of our chief executive officer and vice president of
finance and treasurer, evaluated the effectiveness of our disclosure controls and procedures as of
September&nbsp;30, 2011. The term &#147;disclosure controls and procedures,&#148; as defined in Rules&nbsp;13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means
controls and other procedures of a company that are designed to ensure that information required to
be disclosed by a company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules
and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by a company in the reports that it
files or submits under the Exchange Act is accumulated and communicated to the company&#146;s
management, including its principal executive and principal financial officers, as appropriate to
allow timely decisions regarding required disclosure. Management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving their objectives and management necessarily applies its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. Based on the evaluation of our
disclosure controls and procedures as of September&nbsp;30, 2011, our chief executive officer and vice
president of finance and treasurer concluded that, as of such date, our disclosure controls and
procedures were effective at the reasonable assurance level.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No change in our internal control over financial reporting (as defined in Rules&nbsp;13a&#151;15(d) and
15d&#151;15(d) under the Exchange Act) occurred during the three months ended September&nbsp;30, 2011 that
has materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="B87804110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PART II. OTHER INFORMATION</B>
</DIV>

<DIV align="left">
<A name="B87804111"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>LEGAL PROCEEDINGS.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;<I>Tekmira Litigation</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;16, 2011, Tekmira and Protiva filed a civil complaint against us in the Business
Litigation Section of the Suffolk County Superior Court, in Boston, Massachusetts and on June&nbsp;3,
2011, the plaintiffs filed an amended complaint adding AlCana, a research collaborator of ours, as
a defendant. The amended complaint alleges misappropriation of the plaintiffs&#146; confidential and
proprietary information and trade secrets, civil conspiracy, and tortious interference with
contractual relationships by us and AlCana, and unjust enrichment, contractual breach, breach of
the implied covenant of good faith and fair dealing, unfair competition, false advertising, and
unfair and deceptive trade practices by us. The plaintiffs seek, among other relief, injunctive
relief, unspecified damages and the termination of licenses that the plaintiffs provided to us. On
April&nbsp;6, 2011, we timely served and filed an answer to the plaintiffs&#146; original complaint denying
the plaintiffs&#146; claims, together with counterclaims against the plaintiffs. On June&nbsp;28, 2011, we
timely served and filed an answer to the plaintiffs&#146; amended complaint denying the plaintiffs&#146;
claims and counterclaims against the plaintiffs asserting breach of contract, defamation, breach of
covenant not to sue, breach of patent prosecution and non-use provisions, misappropriation of
confidential and proprietary information and trade secrets, unjust enrichment, breach of the
implied covenant of good faith and fair dealing, as well as violations of Massachusetts statutes.
We are seeking the damages and equitable relief on our counterclaims. In September&nbsp;2011, the Court
granted the plaintiffs&#146; motion to dismiss our counterclaim for
defamation. We have a number of additional counterclaims remaining against the plaintiffs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;<I>University of Utah Litigation</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;22, 2011, The University of Utah, or the University, filed a civil complaint in the
United States District Court for the District of Massachusetts against us, Max Planck Gesellschaft
Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation, together, Max Planck, Whitehead,
MIT and the University of Massachusetts, or UMass, claiming a professor at the University is the
sole inventor, or in the alternative, a joint inventor, of the Tuschl patents. The University did
not serve the original complaint on us or the other defendants. On July&nbsp;6, 2011, the University
filed an amended complaint alleging substantially the same claims against us, Max Planck,
Whitehead, MIT and UMass. The amended complaint was served on us on July&nbsp;14, 2011. The University
is seeking changes to the inventorship of the Tuschl patents, unspecified damages and other relief.
On October&nbsp;31, 2011, we, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss.
Also on October&nbsp;31, 2011, UMass filed a motion to dismiss on
separate grounds, which we,
Max Planck, Whitehead and MIT have joined.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we believe we have meritorious defenses to each of the claims in the lawsuits
described above and intend to fully defend ourselves in these matters, litigation is subject to
inherent uncertainty and a court could ultimately rule against us in one or both of these matters.
In addition, the defense of litigation and related matters are costly and may divert the attention
of our management and other resources that would otherwise be engaged in running our business.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="B87804112"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1A.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>RISK FACTORS.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Our business is subject to numerous risks. We caution you that the following important
factors, among others, could cause our actual results to differ materially from those expressed in
forward-looking statements made by us or on our behalf in filings with the SEC, press releases,
communications with investors and oral statements. All statements other than statements relating to
historical matters should be considered forward-looking statements. When used in this report, the
words &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;may,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;will,&#148; &#147;plan,&#148; &#147;target,&#148; &#147;goal&#148;
and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these words. Any or all of our forward-looking statements in
this Quarterly Report on </I><I>Form 10-Q</I><I> and in any other public statements we make may turn out to be
wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks
and uncertainties. Many factors mentioned in the discussion below will be important in determining
future results. Consequently, no forward-looking statement can be guaranteed. Actual future results
may vary materially from those anticipated in forward-looking statements. We explicitly disclaim
any obligation to update any forward-looking statements to reflect events or circumstances that
arise after the date hereof. You are advised, however, to consult any further disclosure we make in
our reports filed with the SEC.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Risks Related to Our Business</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Being an Early Stage Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Because we have a short operating history, there is a limited amount of information about us
upon which you can evaluate our business and prospects.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations began in 2002 and we have only a limited operating history upon which you can
evaluate our business and prospects. In addition, as an early-stage company, we have limited
experience and have not yet demonstrated an ability to successfully overcome many of the risks and
uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
in the biopharmaceutical area. For example, to execute our business plan, we will need to
successfully:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>execute product development activities using unproven technologies related to
both RNAi and to the delivery of siRNAs to the relevant tissues and cells;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>build and maintain a strong intellectual property portfolio;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>gain regulatory acceptance for the development of our product candidates and
market success for any products we commercialize;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>develop and maintain successful strategic alliances; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>manage our spending as costs and expenses increase due to clinical trials,
regulatory approvals and commercialization.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are unsuccessful in accomplishing these objectives, we may not be able to develop
product candidates, commercialize products, raise capital, expand our business or continue our
operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>The approach we are taking to discover and develop novel RNAi therapeutics is unproven and may
never lead to marketable products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have concentrated our efforts and therapeutic product research on RNAi technology, and our
future success depends on the successful development of this technology and products based on it.
Neither we nor any other company has received regulatory approval to market therapeutics utilizing
siRNAs, the class of molecule we are trying to develop into drugs. The scientific discoveries that
form the basis for our efforts to discover and develop new drugs are relatively new. The scientific
evidence to support the feasibility of developing drugs based on these discoveries is both
preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics has been
expressed in scientific literature. For example, there are potential challenges to achieving safe
RNAi therapeutics based on the so-called off-target effects and activation of the interferon
response. In addition, decisions by other companies with respect to their RNAi development efforts
may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relatively few product candidates based on these discoveries have ever been tested in animals
or humans. siRNAs may not naturally possess the inherent properties typically required of drugs,
such as the ability to be stable in the body long enough to reach the tissues in which their
effects are required, nor the ability to enter cells within these tissues in order to exert their
effects. We currently have only limited data, and no conclusive evidence, to suggest that we can
introduce these drug-like properties into siRNAs. We may spend large amounts of money trying to
introduce these properties, and may never succeed in doing so. In addition, these compounds may not
demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory
studies, and they may interact with human biological systems in unforeseen, ineffective or harmful
ways. As a result, we may never succeed in developing a marketable product, we may not become
profitable and the value of our common stock will decline.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further, our focus solely on RNAi technology for developing drugs, as opposed to multiple,
more proven technologies for drug development, increases the risks associated with the ownership of
our common stock. If we are not successful in developing a product candidate using RNAi technology,
we may be required to change the scope and direction of our product development activities. In that
case, we may not be able to identify and implement successfully an alternative product development
strategy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Our Financial Results and Need for Financing</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We have a history of losses and may never become and remain consistently profitable.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have experienced significant operating losses since our inception. At September&nbsp;30, 2011,
we had an accumulated deficit of $386.7&nbsp;million. To date, we have not developed any products nor
generated any revenues from the sale of products. Further, we do not expect to generate any such
revenues in the foreseeable future. We expect to continue to incur annual net operating losses over
the next several years and will require substantial resources over the next several years as we
expand our efforts to discover, develop and commercialize RNAi therapeutics. We anticipate that the
majority of any revenue we generate over the next several years will be from alliances with
pharmaceutical and biotechnology companies or funding from contracts with the government or
foundations, but cannot be certain that we will be able to secure or maintain these alliances or
contracts, or meet the obligations or achieve any milestones that we may be required to meet or
achieve to receive payments. We anticipate that revenue derived from such sources will not be
sufficient to make us consistently profitable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that to become and remain consistently profitable, we must succeed in discovering,
developing and commercializing novel drugs with significant market potential. This will require us
to be successful in a range of challenging activities, including pre-clinical testing and clinical
trial stages of development, obtaining regulatory approval for these novel drugs and manufacturing,
marketing and selling them. We may never succeed in these activities, and may never generate
revenues that are significant enough to achieve profitability. Even if we do achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. If we
cannot become and remain consistently profitable, the market price of our common stock could
decline. In addition, we may be unable to raise capital, expand our business, diversify our product
offerings or continue our operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We will require substantial additional funds to complete our research and development activities
and if additional funds are not available, we may need to critically limit, significantly scale
back or cease our operations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have used substantial funds to develop our RNAi technologies and will require substantial
funds to conduct further research and development, including pre-clinical testing and clinical
trials of any product candidates, and to manufacture and market any products that are approved for
commercial sale. Because the successful development of our products is uncertain, we are unable to
estimate the actual funds we will require to develop and commercialize them.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future capital requirements and the period for which we expect our existing resources to
support our operations may vary from what we expect. We have based our expectations on a number of
factors, many of which are difficult to predict or are outside of our control, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our progress in demonstrating that siRNAs can be active as drugs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to develop relatively standard procedures for selecting and modifying siRNA
product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>progress in our research and development programs, as well as the magnitude of these
programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of milestone and other payments, if any, from present and
future collaborators, if
any;</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of funding under current and future government or
foundation contracts, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to maintain and establish additional collaborative arrangements and/or new
business initiatives;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the resources, time and costs required to initiate and complete our pre-clinical
and clinical trials, obtain regulatory approvals, and obtain and maintain licenses to
third-party intellectual property;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to manufacture, or contract with third-parties for the manufacture
of, our product candidates for clinical testing and commercial sale;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the resources, time and cost required for the preparation, filing, prosecution,
maintenance and enforcement of patent claims;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to successfully manage the potential impact of our September&nbsp;2010
corporate restructuring and workforce reduction on our culture, collaborative
relationships and business operations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs associated with legal activities, including litigation, arising in the
course of our business activities and our ability to prevail in any such legal disputes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>progress in the research and development programs of Regulus; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, receipt and amount of sales and royalties, if any, from our potential
products.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our estimates and predictions relating to these factors are incorrect, we may need to
modify our operating plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if our estimates are correct, we will be required to seek additional funding in the
future and intend to do so through either collaborative arrangements, public or private equity
offerings or debt financings, or a combination of one or more of these funding sources. Additional
funds may not be available to us on acceptable terms or at all.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the terms of any financing may adversely affect the holdings or the rights of our
stockholders. For example, if we raise additional funds by issuing equity securities, under our
shelf registration statement or otherwise, further dilution to our stockholders will result. In
addition, as a condition to providing additional funds to us, future investors may demand, and may
be granted, rights superior to those of existing stockholders. Moreover, our investor rights
agreement with Novartis provides Novartis with the right generally to maintain its ownership
percentage in us, subject to certain exceptions. These rights continue until the earlier of any
sale by Novartis of shares of our common stock and the expiration or termination of our license
agreement with Novartis, subject to certain exceptions. Pursuant to the terms of its investor
rights agreement with us, Novartis purchased an aggregate of 335,033 shares of our common stock,
resulting in aggregate payments to us of $7.6&nbsp;million. These purchases allowed Novartis to maintain
its ownership position of approximately 13.4% of our outstanding common stock. While the exercise
of these rights by Novartis has provided us with funding, and the exercise in the future by
Novartis may provide us with additional funding under some circumstances, these exercises have
caused, and any future exercise of these rights by Novartis will also cause further, dilution to
our stockholders. Debt financing, if available, may involve restrictive covenants that could limit
our flexibility in conducting future business activities and, in the event of insolvency, would be
paid before holders of equity securities received any distribution of corporate assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are unable to obtain funding on a timely basis, we may be required to significantly
delay or curtail one or more of our research or development programs or undergo additional
reductions in our workforce or other corporate restructuring activities. We also could be required
to seek funds through arrangements with collaborators or others that may require us to relinquish
rights to some of our technologies, product candidates or products that we would otherwise pursue
on our own.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>If the estimates we make, or the assumptions on which we rely, in preparing our condensed
consolidated financial statements prove inaccurate, our actual results may vary from those
reflected in our projections and accruals.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our condensed consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America. The preparation of these
condensed consolidated financial statements requires us to make
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">estimates and judgments that affect the reported amounts of our assets, liabilities, revenues
and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and
liabilities. We base our estimates on historical experience and on various other assumptions that
we believe to be reasonable under the circumstances. We cannot assure you, however, that our
estimates, or the assumptions underlying them, will be correct.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%">
<B><I>The investment of our cash, cash equivalents and marketable securities is subject to risks which
may cause losses and affect the liquidity of these investments.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At September&nbsp;30, 2011, we had $286.2&nbsp;million in cash, cash equivalents and marketable
securities. We historically have invested these amounts in corporate bonds, commercial paper,
securities issued by the U.S. government and municipal obligations, certificates of deposit and
money market funds meeting the criteria of our investment policy, which is focused on the
preservation of our capital. These investments are subject to general credit, liquidity, market and
interest rate risks, including the impact of U.S. sub-prime mortgage defaults that have affected
various sectors of the financial markets and caused credit and liquidity issues. We may realize
losses in the fair value of these investments or a complete loss of these investments, which would
have a negative effect on our condensed consolidated financial statements. In addition, should our
investments cease paying or reduce the amount of interest paid to us, our interest income would
suffer. The market risks associated with our investment portfolio may have an adverse effect on our
results of operations, liquidity and financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Our Dependence on Third Parties</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%">
<B><I>Our license and collaboration agreements with pharmaceutical companies are important to our
business. If these pharmaceutical companies do not successfully develop drugs pursuant to these
agreements or we develop drugs targeting the same diseases as our non-exclusive licensees, our
business could be adversely affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2007, we entered into a license and collaboration agreement with Roche. Under the
license and collaboration agreement we granted Roche a non-exclusive license to our intellectual
property to develop and commercialize therapeutic products that function through RNAi, subject to
our existing contractual obligations to third parties. The license is limited to the therapeutic
areas of oncology, respiratory diseases, metabolic diseases and certain liver diseases and may be
expanded to include up to 18 additional therapeutic areas, comprising substantially all other
fields of human disease, as identified and agreed upon by the parties, upon payment to us by Roche
of an additional $50.0&nbsp;million for each additional therapeutic area, if any. In addition, in
exchange for our contributions under the collaboration agreement, for each RNAi therapeutic product
developed by Roche, its affiliates, or sublicensees under the collaboration agreement, we are
entitled to receive milestone payments upon achievement of specified development and sales events,
totaling up to an aggregate of $100.0&nbsp;million per therapeutic target, together with royalty
payments based on worldwide annual net sales, if any. In November&nbsp;2010, Roche announced the
discontinuation of certain activities in research and early development, including their RNAi
research efforts. Our license and collaboration agreement with Roche currently remains in effect.
In October&nbsp;2011, Arrowhead announced its acquisition of RNA therapeutics assets from Roche,
including our license and collaboration agreement with Roche.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2008, we entered into a similar license and collaboration agreement with Takeda, which
is limited to the therapeutic areas of oncology and metabolic diseases, and which may be expanded
to include up to 20 additional therapeutic areas, comprising substantially all other fields of
human disease, as identified and agreed upon by the parties, upon payment to us by Takeda of an
additional $50.0&nbsp;million for each additional therapeutic area, if any. For each RNAi therapeutic
product developed by Takeda, its affiliates and sublicensees, we are entitled to receive specified
development and commercialization milestones, totaling up to $171.0&nbsp;million per product, together
with royalty payments based on worldwide annual net sales, if any. In addition, we agreed that we
will not grant any other party rights to develop RNAi therapeutics in the Asian territory through
May&nbsp;2013.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2010, Novartis exercised its right under our collaboration and license agreement
to select 31 designated gene targets, for which Novartis has exclusive rights to discover, develop
and commercialize RNAi therapeutic products using our intellectual property and technology. Under
the terms of the collaboration and license agreement, for any RNAi therapeutic products Novartis
develops against these targets, we are entitled to receive milestone payments upon achievement of
certain specified development and annual net sales events, up to an aggregate of $75.0&nbsp;million per
therapeutic product, as well as royalties on annual net sales of any such product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Takeda, Novartis or Arrowhead fails to successfully develop products using our technology, we may not
receive any milestone or royalty payments under these agreements. In addition, even if Takeda is
not successful in its efforts, we are limited in our ability to form alliances with other parties
in the Asia territory until 2013. We also have the option under the Takeda agreement, exercisable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">until the start of Phase III development, to opt-in under a 50-50 profit sharing agreement to
the development and commercialization in the United States of up to four Takeda licensed products,
and would be entitled to opt-in rights for two additional products for each additional field
expansion, if any, elected by Takeda under the collaboration agreement. If Takeda fails to
successfully develop products, we may not realize any economic benefit from these opt-in rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally, Takeda could become a competitor of ours in the development of RNAi-based drugs
targeting the same diseases that we choose to target. Takeda has significantly greater financial
resources than we do and far more experience in developing and marketing drugs, which could put us
at a competitive disadvantage if we were to compete with them in the development of RNAi-based
drugs targeting the same disease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%">
<B><I>We may not be able to execute our business strategy if we are unable to enter into alliances
with other companies that can provide business and scientific capabilities and funds for the
development and commercialization of our product candidates. If we are unsuccessful in forming
or maintaining these alliances on terms favorable to us, our business may not succeed.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any capability for sales, marketing or distribution and have limited
capabilities for drug development. In addition, we believe that other companies are expending
substantial resources in developing safe and effective means of delivering siRNAs to relevant cell
and tissue types. Accordingly, we have entered into alliances with other companies and
collaborators that we believe can provide such capabilities, and we intend to enter into such
additional alliances in the future. For example, we intend to enter into (1)&nbsp;non-exclusive platform
and/or multi-target discovery alliances which will enable our collaborators to develop RNAi
therapeutics and will bring in additional funding with which we can develop our RNAi therapeutics,
and (2)&nbsp;worldwide or specific geographic partnerships on select RNAi therapeutic programs. In such
alliances, we expect our current, and may expect our future, collaborators to provide substantial
capabilities in delivery of RNAi therapeutics to the relevant cell or tissue type, clinical
development, regulatory affairs, and/or marketing, sales and distribution. For example, under our
agreements with MIT, Tekmira, UBC and AlCana, among others, we have access to certain existing
delivery technologies and/or are developing additional delivery capabilities. In addition, under
our collaboration with Medtronic, we are jointly developing ALN-HTT, an RNAi therapeutic for HD,
which would be delivered using an implanted infusion device developed by Medtronic. The success of
this collaboration will depend, in part, on Medtronic&#146;s expertise in the area of delivery of drugs
by infusion device, something that they have never done before with our product candidates. In
other alliances, we may expect our collaborators to develop, market and sell certain of our product
candidates. We may have limited or no control over the development, sales, marketing and
distribution activities of these third parties. Our future revenues may depend heavily on the
success of the efforts of these third parties. For example, we will rely entirely on Kyowa Hakko
Kirin for development and commercialization of any RNAi products for the treatment of RSV in Asia.
If Kyowa Hakko Kirin is not successful in its commercialization efforts, our future revenues from
RNAi therapeutics for the treatment of RSV may be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not be successful in entering into such alliances on terms favorable to us due to
various factors, including our ability to successfully demonstrate proof of concept for our
technology in man, our ability to demonstrate the safety and efficacy of our specific drug
candidates, and the strength of our intellectual property. Even if we do succeed in securing any
such alliances, we may not be able to maintain them if, for example, development or approval of a
product candidate is delayed or sales of an approved drug are disappointing. Furthermore, any delay
in entering into collaboration agreements could delay the development and commercialization of our
product candidates and reduce their competitiveness even if they reach the market. Any such delay
related to our collaborations could adversely affect our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For certain product candidates that we may develop, we have formed collaborations to fund all
or part of the costs of drug development and commercialization, such as our collaborations with
Takeda, Cubist and Medtronic. We may not, however, be able to enter into additional collaborations,
and the terms of any collaboration agreement we do secure may not be favorable to us. If we are not
successful in our efforts to enter into future collaboration arrangements with respect to a
particular product candidate, we may not have sufficient funds to develop that or any other product
candidate internally, or to bring any product candidates to market. If we do not have sufficient
funds to develop and bring our product candidates to market, we will not be able to generate sales
revenues from these product candidates, and this will substantially harm our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%">
<B><I>If any collaborator terminates or fails to perform its obligations under agreements with us, the
development and commercialization of our product candidates could be delayed or terminated.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our dependence on collaborators for capabilities and funding means that our business could be
adversely affected if any collaborator terminates its collaboration agreement with us or fails to
perform its obligations under that agreement. Our current or future collaborations, if any, may not
be scientifically or commercially successful. Disputes may arise in the future with respect to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ownership of rights to technology or products developed with collaborators, which could have
an adverse effect on our ability to develop and commercialize any affected product candidate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our current collaborations allow, and we expect that any future collaborations will allow,
either party to terminate the collaboration for a material breach by the other party. Our agreement
with Kyowa Hakko Kirin for the development and commercialization of RSV therapeutics for the
treatment of RSV infection in Japan and other major markets in Asia may be terminated by Kyowa
Hakko Kirin without cause upon 180-days&#146; prior written notice to us, subject to certain conditions,
and our agreement with Cubist relating to the development and commercialization of certain RSV
therapeutics in territories outside of Asia may be terminated by Cubist at any time upon as little
as three months&#146; prior written notice, if such notice is given prior to the acceptance for filing
of the first application for regulatory approval of a licensed product. If we were to lose a
commercialization collaborator, we would have to attract a new collaborator or develop internal
sales, distribution and marketing capabilities, which would require us to invest significant
amounts of financial and management resources.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, if we have a dispute with a collaborator over the ownership of technology or
other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise,
or determines not to pursue the research and development of RNAi therapeutics, it would be
difficult for us to attract new collaborators and could adversely affect how we are perceived in
the business and financial communities. Moreover, a collaborator, or in the event of a change in
control of a collaborator or the assignment of a collaboration agreement to a third party, the
successor entity or assignee, could determine that it is in its interests to:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pursue alternative technologies or develop alternative products, either on its
own or jointly with others, that may be competitive with the products on which it is
collaborating with us or which could affect its commitment to the collaboration with us;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pursue higher-priority programs or change the focus of its development programs,
which could affect the collaborator&#146;s commitment to us; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if it has marketing rights, choose to devote fewer resources to the marketing of
our product candidates, if any are approved for marketing, than it does for product
candidates developed without us.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of these occur, the development and commercialization of one or more product candidates
could be delayed, curtailed or terminated because we may not have sufficient financial resources or
capabilities to continue such development and commercialization on our own.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%">
<B><I>Regulus is important to our business. If Regulus does not successfully develop drugs pursuant to
our license and collaboration agreement, our business could be adversely affected. In addition,
disagreements between us and Isis regarding the development of microRNA technology may cause
significant delays and other impediments in the development of this technology, which could
negatively affect the value of the technology and our investment in Regulus.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2007, we and Isis formed Regulus, of which we owned approximately 45% at
September&nbsp;30, 2011, to discover, develop and commercialize microRNA therapeutics. Regulus is
exploring therapeutic opportunities that arise from dysregulation of microRNAs. Neither Regulus nor
any other company has received regulatory approval to market therapeutics utilizing microRNA
technology. In connection with the establishment of Regulus, we exclusively licensed to Regulus our
intellectual property rights covering microRNA technology. Generally, we do not have rights to
pursue microRNA therapeutics independently of Regulus. If Regulus is unable to discover, develop
and commercialize microRNA therapeutics, our business could be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2008, Regulus formed a collaboration with GSK pursuant to which GSK provided Regulus
with loans totaling $5.4&nbsp;million, including accrued interest. These loans are guaranteed by us and
Isis. If Regulus is unable to repay GSK or convert the loans into Regulus common stock, we could be
liable for our share of these obligations, and our business could be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, Regulus operates as an independent company, governed by a board of directors. We
and Isis each can elect an equal number of directors to serve on the Regulus board. Regulus
researches and develops microRNA projects and programs pursuant to an operating plan that is
approved by its board. Any disagreements between Isis and us regarding a development decision or
any other decision submitted to Regulus&#146; board may cause significant delays in the development and
commercialization of microRNA technology and could negatively affect the value of our investment in
Regulus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We rely on third parties to conduct our clinical trials, and if they fail to fulfill their
obligations, our development plans may be adversely affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on independent clinical investigators, contract research organizations and other
third-party service providers to assist us in managing, monitoring and otherwise carrying out our
clinical trials. We have contracted, and we plan to continue to contract with certain third-parties
to provide certain services, including site selection, enrollment, monitoring and data management
services. Although we depend heavily on these parties, we do not control them and therefore, we
cannot be assured that these third-parties will adequately perform all of their contractual
obligations to us. If our third-party service providers cannot adequately and timely fulfill their
obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to
failure by such third-party to adhere to our protocols or regulatory requirements or if such
third-parties otherwise fail to meet deadlines, our development plans may be delayed or terminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We have very limited manufacturing experience or resources and we must incur significant costs
to develop this expertise or rely on third parties to manufacture our products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have very limited manufacturing experience. Our internal manufacturing capabilities are
limited to small-scale production of non-current good manufacturing practice, or cGMP, material for
use in <I>in vitro </I>and <I>in vivo </I>experiments. Some of our product candidates utilize specialized
formulations, such as liposomes or LNPs, whose scale-up and manufacturing could be very difficult.
We also have very limited experience in such scale-up and manufacturing, requiring us to depend on
a limited number of third parties, who might not be able to deliver in a timely manner, or at all.
In order to develop products, apply for regulatory approvals and commercialize our products, we
will need to develop, contract for, or otherwise arrange for the necessary manufacturing
capabilities. We may manufacture clinical trial materials ourselves or we may rely on others to
manufacture the materials we will require for any clinical trials that we initiate. There are a
limited number of manufacturers that supply synthetic siRNAs. We currently rely on several contract
manufacturers for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical
manufacturing that could affect the ability of our contract manufacturers to meet our delivery time
requirements or provide adequate amounts of material to meet our needs. Included in these risks are
synthesis and purification failures and contamination during the manufacturing process, which could
result in unusable product and cause delays in our development process, as well as additional
expense to us. To fulfill our siRNA requirements, we may also need to secure alternative suppliers
of synthetic siRNAs. In addition to the manufacture of the synthetic siRNAs, we may have additional
manufacturing requirements related to the technology required to deliver the siRNA to the relevant
cell or tissue type. In some cases, the delivery technology we utilize is highly specialized or
proprietary, and for technical and legal reasons, we may have access to only one or a limited
number of potential manufacturers for such delivery technology. For example, under our agreements
with Tekmira, we are obligated, subject to certain exceptions specified in our contract with
Tekmira, to utilize Tekmira for the manufacture of all LNP-formulated product candidates covered by
Tekmira&#146;s intellectual property beginning during pre-clinical development and continuing through
Phase II clinical trials. Failure by manufacturers to properly formulate our siRNAs for delivery
could result in unusable product. Furthermore, a breach by such manufacturers of their contractual
obligations or a dispute with such manufacturers would cause delays in our discovery and
development process, as well as additional expense to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The manufacturing process for any products that we may develop is subject to the FDA and
foreign regulatory authority approval process and we will need to contract with manufacturers who
can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. In
addition, if we receive the necessary regulatory approval for any product candidate, we also expect
to rely on third parties, including our commercial collaborators, to produce materials required for
commercial supply. We may experience difficulty in obtaining adequate manufacturing capacity for
our needs. If we are unable to obtain or maintain contract manufacturing for these product
candidates, or to do so on commercially reasonable terms, we may not be able to successfully
develop and commercialize our products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that we have existing, or enter into future, manufacturing arrangements with
third parties, we depend, and will depend in the future, on these third parties to perform their
obligations in a timely manner and consistent with contractual and regulatory requirements,
including those related to quality control and quality assurance. The failure of a third-party
manufacturer to perform its obligations as expected could adversely affect our business in a number
of ways, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may not be able to initiate or continue clinical trials of products that are under
development;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may be delayed in submitting regulatory applications, or receiving regulatory
approvals, for our product candidates;</TD>
</TR>




</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may lose the cooperation of our collaborators;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our products could be the subject of inspections by regulatory authorities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may be required to cease distribution or recall some or all batches of our products;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ultimately, we may not be able to meet commercial demands for our products.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any third-party manufacturer with whom we contract fails to perform its obligations, we may
be forced to manufacture the materials ourselves, for which we may not have the capabilities or
resources, or enter into an agreement with a different third-party manufacturer, which we may not
be able to do on reasonable terms, if at all. In some cases, the technical skills required to
manufacture our product may be unique to the original manufacturer and we may have difficulty
transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such
skills at all. In addition, if we are required to change manufacturers for any reason, we will be
required to verify that the new manufacturer maintains facilities and procedures that comply with
quality standards and with all applicable regulations and guidelines. The delays associated with
the verification of a new manufacturer could negatively affect our ability to develop product
candidates in a timely manner or within budget. Furthermore, a manufacturer may possess technology
related to the manufacture of our product candidate that such manufacturer owns independently. This
would increase our reliance on such manufacturer or require us to obtain a license from such
manufacturer in order to have another third party manufacture our products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We have no sales, marketing or distribution experience and would have to invest significant
financial and management resources to establish these capabilities.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have no sales, marketing or distribution experience. We currently expect to rely heavily on
third parties to launch and market certain of our product candidates, if approved. However, if we
elect to develop internal sales, distribution and marketing capabilities as part of our core
product strategy, we will need to invest significant financial and management resources. For core
products where we decide to perform sales, marketing and distribution functions ourselves, we could
face a number of additional risks, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may not be able to attract and build a significant marketing or sales force;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of establishing a marketing or sales force may not be justifiable in
light of the revenues generated by any particular product; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our direct sales and marketing efforts may not be successful.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are unable to develop our own sales, marketing and distribution capabilities, we will
not be able to successfully commercialize our core products without reliance on third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>The current credit and financial market conditions may exacerbate certain risks affecting our
business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due to the tightening of global credit, there may be a disruption or delay in the performance
of our third-party contractors, suppliers or collaborators. We rely on third parties for several
important aspects of our business, including significant portions of our manufacturing needs,
development of product candidates and conduct of clinical trials. If such third parties are unable
to satisfy their commitments to us, our business could be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Managing Our Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>If we are unable to attract and retain qualified key management and scientists, staff,
consultants and advisors, our ability to implement our business plan may be adversely affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent upon our senior management and scientific staff. The loss of the
service of any of the members of our senior management, including Dr.&nbsp;John Maraganore, our Chief
Executive Officer, may significantly delay or prevent the achievement of product development and
other business objectives. Our employment agreements with our key personnel are terminable without
notice. We do not carry key man life insurance on any of our employees.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face intense competition for qualified individuals from numerous pharmaceutical and
biotechnology companies, universities, governmental entities and other research institutions, many
of which have substantially greater resources with which to reward qualified individuals than we
do. In addition, as a result of our September&nbsp;2010 corporate restructuring and workforce reduction,
we may face additional challenges in retaining our existing employees and recruiting new employees
to join our company as our business needs change. We may be unable to attract and retain suitably
qualified individuals, and our failure to do so could have an adverse effect on our ability to
implement our future business plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We may have difficulty managing our growth and expanding our operations successfully as we seek
to evolve from a company primarily involved in discovery and pre-clinical testing into one that
develops and commercializes drugs.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since we commenced operations in 2002, we have grown substantially. At September&nbsp;30, 2011, we
had 171 employees in our facility in Cambridge, Massachusetts. We expect that as we seek to
increase the number of product candidates we are developing we will need to expand our operations
in the future. This growth may place a strain on our administrative and operational infrastructure.
If product candidates we develop enter and advance through clinical trials, we will need to expand
our development, regulatory, manufacturing, marketing and sales capabilities or contract with other
organizations to provide these capabilities for us. As our operations expand due to our development
progress, we expect that we will need to manage additional relationships with various
collaborators, suppliers and other organizations. Our ability to manage our operations and future
growth will require us to continue to improve our operational, financial and management controls,
reporting systems and procedures. We may not be able to implement improvements to our management
information and control systems in an efficient or timely manner and may discover deficiencies in
existing systems and controls.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Our business and operations could suffer in the event of system failures.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the implementation of security measures, our internal computer systems and those of
our contractors and consultants are vulnerable to damage from computer viruses, unauthorized
access, natural disasters, terrorism, war, and telecommunication and electrical failures. Such
events could cause interruption of our operations. For example, the loss of pre-clinical trial data
or data from completed or ongoing clinical trials for our product candidates could result in delays
in our regulatory filings and development efforts and significantly increase our costs. To the
extent that any disruption or security breach were to result in a loss of or damage to our data, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and
the development of our product candidates could be delayed.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Risks Related to Our Industry</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Any product candidates we develop may fail in development or be delayed to a point where they do
not become commercially viable.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining regulatory approval for the commercial distribution of our product
candidates, we must conduct, at our own expense, extensive pre-clinical tests and clinical trials
to demonstrate the safety and efficacy in humans of our product candidates. Pre-clinical and
clinical testing is expensive, difficult to design and implement, can take many years to complete
and is uncertain as to outcome, and the historical failure rate for product candidates is high. We
currently have several programs in clinical development. We are developing ALN-RSV01 for the
treatment of RSV infection. In February&nbsp;2010, we initiated a Phase IIb clinical trial to evaluate
the clinical efficacy endpoints as well as safety of aerosolized ALN-RSV01 in adult lung transplant
patients naturally infected with RSV. The objective of this Phase IIb clinical trial is to repeat
and extend the clinical results observed in a Phase IIa clinical trial. In addition, in March&nbsp;2009,
we initiated a Phase I clinical trial of ALN-VSP, our first systemically delivered RNAi
therapeutic. We are developing ALN-VSP for the treatment of primary and secondary liver cancer. In
July&nbsp;2010, we also initiated a Phase I clinical trial for ALN-TTR01, our second systemically
delivered RNAi therapeutic, which targets the TTR gene for the treatment of ATTR. In September
2011, we initiated a Phase I clinical trial of ALN-PCS for the treatment of severe
hypercholesteremia. However, we may not be able to further advance these or any other product
candidate through clinical trials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we enter into clinical trials, the results from pre-clinical testing or early clinical
trials of a product candidate may not predict the results that will be obtained in subsequent human
clinical trials of that product candidate or any other product candidate. For example, ALN-RSV01
may not demonstrate the same results in the Phase IIb clinical trial as it did in our Phase IIa
clinical trial. In addition, ALN-VSP, ALN-TTR01 and ALN-PCS employ novel delivery formulations that
have yet to be extensively evaluated in human clinical trials and proven safe and effective. We,
the FDA or other applicable regulatory authorities, or an institutional review
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">board, or IRB, or similar foreign review board or committee, may suspend clinical trials of a
product candidate at any time for various reasons, including if we or they believe the subjects or
patients participating in such trials are being exposed to unacceptable health risks. Among other
reasons, adverse side effects of a product candidate on subjects or patients in a clinical trial
could result in the FDA or foreign regulatory authorities suspending or terminating the trial and
refusing to approve a particular product candidate for any or all indications of use.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials of a new product candidate require the enrollment of a sufficient number of
patients, including patients who are suffering from the disease the product candidate is intended
to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many
factors, including the size of the patient population, the age and condition of the patients, the
stage and severity of disease, the nature of the protocol, the proximity of patients to clinical
sites, the availability of effective treatments for the relevant disease, the seasonality of
infections and the eligibility criteria for the clinical trial. In our ALN-VSP clinical trial, one
patient with advanced pancreatic neuroendocrine cancer with extensive involvement of the liver
developed hepatic failure five days following the second dose of ALN-VSP and subsequently died;
this was deemed possibly related to the study drug. Six additional patients treated at the same
dose did not exhibit any evidence of hepatotoxicity. In August
&nbsp;2011, we announced the completion of the ALN-VSP clinical trial. In addition, our ALN-TTR01 trial
targets a small population of patients suffering from ATTR. Delays or difficulties in patient
enrollment or difficulties retaining trial participants can result in increased costs, longer
development times or termination of a clinical trial.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials also require the review, oversight and approval of IRBs, which continually
review clinical investigations and protect the rights and welfare of human subjects. Inability to
obtain or delay in obtaining IRB approval can prevent or delay the initiation and completion of
clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data
or information derived from a clinical investigation not subject to initial and continuing IRB
review and approval in support of a marketing application.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our product candidates that we develop may encounter problems during clinical trials that will
cause us, an IRB or regulatory authorities to delay, suspend or terminate these trials, or that
will delay or confound the analysis of data from these trials. If we experience any such problems,
we may not have the financial resources to continue development of the product candidate that is
affected, or development of any of our other product candidates. We may also lose, or be unable to
enter into, collaborative arrangements for the affected product candidate and for other product
candidates we are developing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A failure of one of more of our clinical trials can occur at any stage of testing. We may
experience numerous unforeseen events during, or as a result of, pre-clinical testing and the
clinical trial process that could delay or prevent regulatory approval or our ability to
commercialize our product candidates, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our pre-clinical tests or clinical trials may produce negative or inconclusive
results, and we may decide, or regulators may require us, to conduct additional
pre-clinical testing or clinical trials, or we may abandon projects that we expect to be
promising;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delays in filing INDs or comparable foreign applications or delays or failure in
obtaining the necessary approvals from regulators or IRBs in order to commence a
clinical trial at a prospective trial site, or their suspension or termination of a
clinical trial once commenced;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conditions imposed on us by the FDA or comparable foreign authorities regarding
the scope or design of our clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>problems in engaging IRBs to oversee clinical trials or problems in obtaining or
maintaining IRB approval of trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delays in enrolling patients and volunteers into clinical trials, and variability
in the number and types of patients and volunteers available for clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>high drop-out rates for patients and volunteers in clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>negative or inconclusive results from our clinical trials or the clinical trials
of others for product candidates similar to ours;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inadequate supply or quality of product candidate materials or other materials
necessary for the conduct of our
clinical trials;</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>greater than anticipated clinical trial costs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>serious and unexpected drug-related side effects experienced by participants in
our clinical trials or by individuals using drugs similar to our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>poor effectiveness of our product candidates during clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unfavorable FDA or other regulatory agency inspection and review of a clinical
trial site or records of any clinical or pre-clinical investigation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>failure of our third-party contractors or investigators to comply with regulatory
requirements or otherwise meet their contractual obligations in a timely manner, or at
all;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>governmental or regulatory delays and changes in regulatory requirements, policy
and guidelines, including the imposition of additional regulatory oversight around
clinical testing generally or with respect to our technology in particular; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>varying interpretations of data by the FDA and similar foreign regulatory agencies.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we successfully complete clinical trials of our product candidates, any given product
candidate may not prove to be a safe and effective treatment for the diseases for which it was
being tested.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>The regulatory approval process may be delayed for any products we develop that require the use
of specialized drug delivery devices, which may require us to incur additional costs and delay
receipt of any potential product revenue.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some product candidates that we develop may need to be administered using specialized drug
delivery devices that deliver RNAi therapeutics directly to diseased parts of the body. For
example, we believe that product candidates we develop for HD or other central nervous system
diseases may need to be administered using such a device. For neurodegenerative diseases, we have
entered into a collaboration agreement with Medtronic to pursue potential development of
drug-device combinations incorporating RNAi therapeutics. We may not achieve successful development
results under this collaboration and may need to seek other collaborations to develop alternative
drug delivery systems, or utilize existing drug delivery systems, for the direct delivery of RNAi
therapeutics for these diseases. While we expect to rely on drug delivery systems that have been
approved by the FDA or other regulatory agencies to deliver drugs like ours to diseased parts of
the body, we, or our collaborator, may need to modify the design or labeling of such delivery
device for some products we may develop. In such an event, the FDA may regulate the product as a
combination product or require additional approvals or clearances for the modified delivery device.
Further, to the extent the specialized delivery device is owned by another company, we would need
that company&#146;s cooperation to implement the necessary changes to the device, or its labeling, and
to obtain any additional approvals or clearances. In cases where we do not have an ongoing
collaboration with the company that makes the device, obtaining such additional approvals or
clearances and the cooperation of such other company could significantly delay and increase the
cost of obtaining marketing approval, which could reduce the commercial viability of our product
candidate. In addition, the use of a specialized delivery system, even if previously approved,
could complicate the design or analysis of clinical trials for our RNAi therapeutics. In summary,
we may be unable to find, or experience delays in finding, suitable drug delivery systems to
administer RNAi therapeutics directly to diseased parts of the body, which could negatively affect
our ability to successfully commercialize these RNAi therapeutics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>We may be unable to obtain United States or foreign regulatory approval and, as a result, unable
to commercialize our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our product candidates are subject to extensive governmental regulations relating to, among
other things, research, testing, development, manufacturing, safety, efficacy, approval,
recordkeeping, reporting, labeling, storage, marketing and distribution of drugs. Rigorous
pre-clinical testing and clinical trials and an extensive regulatory approval process are required
to be successfully completed in the United States and in many foreign jurisdictions before a new
drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time
consuming, uncertain and subject to unanticipated delays. It is possible that none of the product
candidates we may develop will obtain the regulatory approvals necessary for us or our
collaborators to begin selling them.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have very limited experience in conducting and managing the clinical trials necessary to
obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and
other approvals is unpredictable but typically takes many years following the commencement of
clinical trials, depending upon the type, complexity and novelty of the product candidate. The
standards that the FDA and its foreign counterparts use when regulating us are not always applied
predictably or uniformly and can change. Any analysis we perform of data from pre-clinical and
clinical activities is subject to confirmation and interpretation by regulatory authorities, which
could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or
increased costs due to new government regulations, for example, from future legislation or
administrative action, or from changes in FDA policy during the period of product development,
clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes
will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be
changed, or what the impact of such changes, if any, may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because the drugs we are developing may represent a new class of drug, the FDA and its foreign
counterparts have not yet established any definitive policies, practices or guidelines in relation
to these drugs. While we believe the product candidates that we are currently developing are
regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to
regulate them or other products we may develop as biologics under the Public Health Service Act.
The lack of policies, practices or guidelines may hinder or slow review by the FDA of any
regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by
defining requirements we may not have anticipated. Such responses could lead to significant delays
in the clinical development of our product candidates. In addition, because there may be approved
treatments for some of the diseases for which we may seek approval, in order to receive regulatory
approval, we may need to demonstrate through clinical trials that the product candidates we develop
to treat these diseases, if any, are not only safe and effective, but safer or more effective than
existing products. Furthermore, in recent years, there has been increased public and political
pressure on the FDA with respect to the approval process for new drugs, and the number of approvals
to market new drugs has declined.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any delay or failure in obtaining required approvals could have a material adverse effect on
our ability to generate revenues from the particular product candidate for which we are seeking
approval. Furthermore, any regulatory approval to market a product may be subject to limitations on
the approved uses for which we may market the product or the labeling or other restrictions. In
addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategies, or
REMS, plan as part of an NDA or after approval, which may impose further requirements or
restrictions on the distribution or use of an approved drug or biologic, such as limiting
prescribing to certain physicians or medical centers that have undergone specialized training,
limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to
enroll in a registry. These limitations and restrictions may limit the size of the market for the
product and affect reimbursement by third-party payors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are also subject to numerous foreign regulatory requirements governing, among other things,
the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party
reimbursement. The foreign regulatory approval process varies among countries and includes all of
the risks associated with FDA approval described above as well as risks attributable to the
satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure
approval by regulatory authorities outside the United States and vice versa.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory
review. If we fail to comply with continuing U.S. and foreign requirements, our approvals could
be limited or withdrawn, we could be subject to other penalties, and our business would be
seriously harmed.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following any initial regulatory approval of any drugs we may develop, we will also be subject
to continuing regulatory review, including the review of adverse drug experiences and clinical
results that are reported after our drug products are made commercially available. This would
include results from any post-marketing tests or surveillance to monitor the safety and efficacy of
the drug product required as a condition of approval or agreed to by us. Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved uses
for which the product may be marketed. Other ongoing regulatory requirements include, among other
things, submissions of safety and other post-marketing information and reports, registration, as
well as continued compliance with cGMP requirements and good clinical practices for any clinical
trials that we conduct post-approval. In addition, we are conducting, and intend to continue to
conduct, clinical trials for our product candidates, and we intend to seek approval to market our
product candidates, in jurisdictions outside of the United States, and therefore will be subject
to, and must comply with, regulatory requirements in those jurisdictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has significant post-market authority, including, for example, the authority to
require labeling changes based on new safety information and to require post-market studies or
clinical trials to evaluate serious safety risks related to the use of a drug and to require
withdrawal of the product from the market. The FDA also has the authority to require a REMS plan
after approval,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which may impose further requirements or restrictions on the distribution or use of an
approved drug.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The manufacturer and manufacturing facilities we use to make any of our product candidates
will also be subject to periodic review and inspection by the FDA and other regulatory agencies.
The discovery of any new or previously unknown problems with our third-party manufacturers,
manufacturing processes or facilities, may result in restrictions on the drug or manufacturer or
facility, including withdrawal of the drug from the market. We do not have, and currently do not
intend to develop, the ability to manufacture material for our clinical trials or on a commercial
scale. We may manufacture clinical trial materials or we may contract a third party to manufacture
these materials for us. Reliance on third-party manufacturers entails risks to which we would not
be subject if we manufactured products ourselves, including reliance on the third-party
manufacturer for regulatory compliance. Our product promotion and advertising is also subject to
regulatory requirements and continuing regulatory review.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or our collaborators, manufacturers or service providers fail to comply with applicable
continuing regulatory requirements in the United States or foreign jurisdictions in which we may
seek to market our products, we or they may be subject to, among other things, fines, warning
letters, holds on clinical trials, refusal by the FDA to approve pending applications or
supplements to approved applications, suspension or withdrawal of regulatory approval, product
recalls and seizures, refusal to permit the import or export of products, operating restrictions,
injunction, civil penalties and criminal prosecution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Even if we receive regulatory approval to market our product candidates, the market may not be
receptive to our product candidates upon their commercial introduction, which will prevent us
from becoming profitable.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The product candidates that we are developing are based upon new technologies or therapeutic
approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors
and consumers, may not accept a product intended to improve therapeutic results based on RNAi
technology. As a result, it may be more difficult for us to convince the medical community and
third-party payors to accept and use our product, or to provide favorable reimbursement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other factors that we believe will materially affect market acceptance of our product
candidates include:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing of our receipt of any marketing approvals, the terms of any approvals
and the countries in which approvals are obtained;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the safety and efficacy of our product candidates, as demonstrated in clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>relative convenience and ease of administration of our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the willingness of patients to accept potentially new routes of administration;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the success of our physician education programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the availability of adequate government and third-party payor reimbursement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the pricing of our products, particularly as compared to alternative treatments; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>availability of alternative effective treatments for the diseases that product
candidates we develop are intended to treat and the relative risks, benefits and costs
of the treatments.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>If we or our collaborators, manufacturers or service providers fail to comply with healthcare
laws and regulations, we or they could be subject to enforcement actions, which could affect our
ability to develop, market and sell our products and may harm our reputation.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a manufacturer of pharmaceuticals, we are subject to federal, state, and foreign healthcare
laws and regulations pertaining to fraud and abuse and patients&#146; rights. These laws and regulations
include:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the U.S. federal healthcare program anti-kickback law, which prohibits, among
other things, persons from soliciting, receiving or providing remuneration, directly or
indirectly, to induce either the referral of an individual for a healthcare item or
service, or the purchasing or ordering of an item or service, for which payment may be
made under a federal healthcare program such as Medicare or Medicaid;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the U.S. federal false claims law, which prohibits, among other things,
individuals or entities from knowingly presenting or causing to be presented, claims for
payment by government funded programs such as Medicare or Medicaid that are false or
fraudulent, and which may apply to us by virtue of statements and representations made
to customers or third parties;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the U.S. federal Health Insurance Portability and Accountability Act, or HIPAA,
and Health Information Technology for Economic and Clinical Health, or HITECH, Act,
which prohibit executing a scheme to defraud healthcare programs; impose requirements
relating to the privacy, security, and transmission of individually identifiable health
information; and require notification to affected individuals and regulatory authorities
of certain breaches of security of individually identifiable health information; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>state laws comparable to each of the above federal laws, such as, for example,
anti-kickback and false claims laws applicable to commercial insurers and other
non-federal payors, requirements for mandatory corporate regulatory compliance programs,
and laws relating to patient data privacy and security.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our operations are found to be in violation of any such requirements, we may be subject to
penalties, including civil or criminal penalties, monetary damages, the curtailment or
restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion
from participation in government contracting or other government programs, including Medicare and
Medicaid, any of which could adversely our financial results. Although effective compliance
programs can mitigate the risk of investigation and prosecution for violations of these laws, these
risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation
could cause us to incur significant legal expenses and could divert our management&#146;s attention from
the operation of our business, even if our defense is successful. In addition, achieving and
sustaining compliance with applicable laws and regulations may be costly to us in terms of money,
time and resources.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or our collaborators, manufacturers or service providers fail to comply with applicable
federal, state or foreign laws or regulations, we could be subject to enforcement actions, which
could affect our ability to develop, market and sell our products successfully and could harm our
reputation and lead to reduced acceptance of our products by the market. These enforcement actions
include, among others:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>adverse regulatory inspection findings;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>warning letters;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>voluntary or mandatory product recalls or public notification or medical product
safety alerts to healthcare professionals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>restrictions on, or prohibitions against, marketing our products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>restrictions on, or prohibitions against, importation or exportation of our products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>suspension of review or refusal to approve pending applications or supplements to
approved applications;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exclusion from participation in government-funded healthcare programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exclusion from eligibility for the award of government contracts for our products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>suspension or withdrawal of product approvals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product seizures;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>injunctions; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>civil and criminal penalties and fines.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>Any drugs we develop may become subject to unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives, thereby harming our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary
widely from country to country. Some countries require approval of the sale price of a drug before
it can be marketed. In many countries, the pricing review period begins after marketing or product
licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. Although we
intend to monitor these regulations, our programs are currently in the early stages of development
and we will not be able to assess the impact of price regulations for a number of years. As a
result, we might obtain regulatory approval for a product in a particular country, but then be
subject to price regulations that delay our commercial launch of the product and negatively impact
the revenues we are able to generate from the sale of the product in that country.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to commercialize any products successfully also will depend in part on the extent
to which reimbursement for these products and related treatments will be available from government
health administration authorities, private health insurers and other organizations. Even if we
succeed in bringing one or more products to the market, these products may not be considered
cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell
our products on a competitive basis. Because our programs are in the early stages of development,
we are unable at this time to determine their cost effectiveness or the likely level or method of
reimbursement. Increasingly, the third-party payors who reimburse patients, such as government and
private insurance plans, are requiring that drug companies provide them with predetermined
discounts from list prices, and are seeking to reduce the prices charged for pharmaceutical
products. If the price we are able to charge for any products we develop is inadequate in light of
our development and other costs, our profitability could be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently expect that any drugs we develop may need to be administered under the
supervision of a physician. Under currently applicable U.S. law, drugs that are not usually
self-administered may be eligible for coverage by the Medicare program if:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>they are incident to a physician&#146;s services;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>they are &#147;reasonable and necessary&#148; for the diagnosis or treatment of the illness
or injury for which they are administered according to accepted standards of medical
practice;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>they are not excluded as immunizations; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>they have been approved by the FDA.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There may be significant delays in obtaining coverage for newly-approved drugs, and coverage
may be more limited than the purposes for which the drug is approved by the FDA. Moreover,
eligibility for coverage does not imply that any drug will be reimbursed in all cases or at a rate
that covers our costs, including research, development, manufacture, sale and distribution. Interim
payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be
made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are
already reimbursed, may be incorporated into existing payments for other services and may reflect
budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by
mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they
may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own reimbursement rates. Our inability to
promptly obtain coverage and profitable reimbursement rates from both government-funded and private
payors for new drugs that we develop and for which we obtain regulatory approval could have a
material adverse effect on our operating results, our ability to raise capital needed to
commercialize products, and our overall financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the efforts of governments and third-party payors to contain or reduce the
cost of healthcare and legislative and regulatory proposals to broaden the availability of
healthcare will continue to affect the business and financial condition of pharmaceutical and
biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare
system in the United States and other major healthcare markets have been proposed in recent years,
and such efforts have expanded substantially in recent years. These developments have included
prescription drug benefit legislation that was enacted and took effect in January&nbsp;2006, healthcare
reform legislation enacted by certain states, and major healthcare reform legislation that was
passed by Congress and enacted into law in the United States in 2010. These developments could,
directly or indirectly, affect our ability to sell our products, if approved, at a favorable price.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In particular, in March&nbsp;2010, the Patient Protection and Affordable Care Act, or PPACA, and a
related reconciliation bill were signed into law. This new legislation changes the current system
of healthcare insurance and benefits intended to broaden coverage and control costs. The new law
also contains provisions that will affect companies in the pharmaceutical industry and other
healthcare related industries by imposing additional costs and changes to business practices.
Provisions affecting pharmaceutical companies include the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mandatory rebates for drugs sold into the Medicaid program have been increased,
and the rebate requirement has been extended to drugs used in risk-based Medicaid
managed care plans.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The 340B Drug Pricing Program under the Public Health Services Act has been
extended to require mandatory discounts for drug products sold to certain critical
access hospitals, cancer hospitals and other covered entities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pharmaceutical companies are required to offer discounts on brand-name drugs to
patients who fall within the Medicare Part&nbsp;D coverage gap, commonly referred to as the
&#147;Donut Hole.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pharmaceutical companies are required to pay an annual non-tax deductible fee to
the federal government based on each company&#146;s market share of prior year total sales of
branded products to certain federal healthcare programs, such as Medicare, Medicaid,
Department of Veterans Affairs and Department of Defense. Since we expect our branded
pharmaceutical sales to constitute a small portion of the total federal health program
pharmaceutical market, we do not expect this annual assessment to have a material impact
on our financial condition.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The new law provides that biologic products may receive 12&nbsp;years of market
exclusivity, with a possible six-month extension for pediatric products. After this
exclusivity ends, generic manufacturers will be permitted to enter the market, which is
likely to reduce the pricing for such products and could affect the company&#146;s
profitability. In addition, generic manufacturers will be permitted to challenge one or
more of the patents for a branded drug after a product is marketed for four years.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The full effects of the U.S. healthcare reform legislation cannot be known until the new law
is implemented through regulations or guidance issued by the Centers for Medicare &#038; Medicaid
Services and other federal and state healthcare agencies. The financial impact of the U.S.
healthcare reform legislation over the next few years will depend on a number of factors, including
but not limited, to the policies reflected in implementing regulations and guidance, and changes in
sales volumes for products affected by the new system of rebates, discounts and fees. The new
legislation may also have a positive impact on our future net sales, if any, by increasing the
aggregate number of persons with healthcare coverage in the United States, but such increases are
unlikely to be realized until approximately 2014 at the earliest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover, we cannot predict what healthcare reform initiatives may be adopted in the future.
Further federal and state legislative and regulatory developments are likely, and we expect ongoing
initiatives in the United States to increase pressure on drug pricing. Such reforms could have an
adverse effect on anticipated revenues from product candidates that we may successfully develop and
for which we may obtain regulatory approval and may affect our overall financial condition and
ability to develop drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>There is a substantial risk of product liability claims in our business. If we are unable to
obtain sufficient insurance, a product liability claim against us could adversely affect our
business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business exposes us to significant potential product liability risks that are inherent in
the development, testing, manufacturing and marketing of human therapeutic products. Product
liability claims could delay or prevent completion of our clinical development programs. If we
succeed in marketing products, such claims could result in an FDA investigation of the safety and
effectiveness of our products, our manufacturing processes and facilities or our marketing
programs, and potentially a recall of our products or more serious enforcement action, limitations
on the approved indications for which they may be used, or suspension or withdrawal of approvals.
Regardless of the merits or eventual outcome, liability claims may also result in injury to our
reputation, costs to defend the related litigation, a diversion of management&#146;s time and our
resources, and substantial monetary awards to trial participants or patients. We currently have
product liability insurance that we believe is appropriate for our stage of development and may
need to obtain higher levels prior to marketing any of our product candidates. Any insurance we
have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore,
clinical trial and product liability insurance is becoming increasingly expensive. As a result, we
may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses
caused by product liability claims that could have a material adverse effect on our business.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>If we do not comply with laws regulating the protection of the environment and health and human
safety, our business could be adversely affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development involves the use of hazardous materials, chemicals and various
radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our
facilities in Cambridge that are required for our research and development activities. We are
subject to federal, state and local laws and regulations governing the use, manufacture, storage,
handling and disposal of these hazardous materials. We believe our procedures for storing, handling
and disposing these materials in our Cambridge facility comply with the relevant guidelines of the
City of Cambridge and the Commonwealth of Massachusetts. Although we believe that our safety
procedures for handling and disposing of these materials comply with the standards mandated by
applicable regulations, the risk of accidental contamination or injury from these materials cannot
be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be
substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and
the handling of biohazardous materials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may
incur due to injuries to our employees resulting from the use of these materials, this insurance
may not provide adequate coverage against potential liabilities. We do not maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of biological, hazardous or radioactive materials. Additional federal, state
and local laws and regulations affecting our operations may be adopted in the future. We may incur
substantial costs to comply with, and substantial fines or penalties if we violate, any of these
laws or regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Patents, Licenses and Trade Secrets</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin left=1%"><B><I>If we are not able to obtain and enforce patent protection for our discoveries, our ability to
develop and commercialize our product candidates will be harmed.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends, in part, on our ability to protect proprietary methods and technologies
that we develop under the patent and other intellectual property laws of the United States and
other countries, so that we can prevent others from unlawfully using our inventions and proprietary
information. However, we may not hold proprietary rights to some patents required for us to
commercialize our proposed products. Because certain U.S. patent applications are confidential
until the patents issue, such as applications filed prior to November&nbsp;29, 2000, or applications
filed after such date which will not be filed in foreign countries, third parties may have filed
patent applications for technology covered by our pending patent applications without our being
aware of those applications, and our patent applications may not have priority over those
applications. For this and other reasons, we may be unable to secure desired patent rights, thereby
losing desired exclusivity. Further, we may be required to obtain licenses under third-party
patents to market our proposed products or conduct our research and development or other
activities. If licenses are not available to us on acceptable terms, we will not be able to market
the affected products or conduct the desired activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy depends on our ability to rapidly identify and seek patent protection for our
discoveries. In addition, we may rely on third-party collaborators to file patent applications
relating to proprietary technology that we develop jointly during certain collaborations. The
process of obtaining patent protection is expensive and time-consuming. If our present or future
collaborators fail to file and prosecute all necessary and desirable patent applications at a
reasonable cost and in a timely manner, our business will be adversely affected. Despite our
efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized
parties may be able to obtain and use information that we regard as proprietary. While issued
patents are presumed valid, this does not guarantee that the patent will survive a validity
challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be
challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design
around our intellectual property. Moreover, third parties or the United States Patent and Trademark
Office, or USPTO, may commence interference proceedings involving our patents or patent
applications. For example, the USPTO has declared an interference between our issued patent
covering ALN-VSP, our RNAi therapeutic undergoing clinical testing for the treatment of liver
cancers, and a pending third-party application. Any challenge to, finding of unenforceability or
invalidation or circumvention of, our patents or patent applications, would be costly, would
require significant time and attention of our management and could have a material adverse effect
on our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pending patent applications may not result in issued patents. The patent position of
pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves
complex legal and factual considerations. The standards that the USPTO and its foreign counterparts
use to grant patents are not always applied predictably or uniformly and can change. Similarly, the
ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in
the United States and foreign countries, remains uncertain and is dependent upon the scope of the
protection decided upon by patent offices, courts and lawmakers.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Moreover, there are periodic discussions in the Congress of the United States and in
international jurisdictions about modifying various aspects of patent law. If any such changes are
enacted and do not provide adequate protection for discoveries, including our ability to pursue
infringers of our patents for substantial damages, our business could be adversely affected. There
is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or
allowable in pharmaceutical or biotechnology patents. Accordingly, we do not know the degree of
future protection for our proprietary rights or the breadth of claims that will be allowed in any
patents issued to us or to others.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also rely to a certain extent on trade secrets, know-how and technology, which are not
protected by patents, to maintain our competitive position. If any trade secret, know-how or other
technology not protected by a patent were to be disclosed to or independently developed by a
competitor, our business and financial condition could be materially adversely affected.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>We license patent rights from third-party owners. If such owners do not properly or successfully
obtain, maintain or enforce the patents underlying such licenses, our competitive position and
business prospects will be harmed.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to a number of licenses that give us rights to third-party intellectual
property that is necessary or useful for our business. In particular, we have obtained licenses
from, among others, CRT, Isis, MIT, Whitehead, Max Planck, Stanford, Tekmira and UTSW. We also
intend to enter into additional licenses to third-party intellectual property in the future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success will depend in part on the ability of our licensors to obtain, maintain and
enforce patent protection for our licensed intellectual property, in particular, those patents to
which we have secured exclusive rights. Our licensors may not successfully prosecute the patent
applications to which we are licensed. Even if patents issue in respect of these patent
applications, our licensors may fail to maintain these patents, may determine not to pursue
litigation against other companies that are infringing these patents, or may pursue such litigation
less aggressively than we would. Without protection for the intellectual property we license, other
companies might be able to offer substantially identical products for sale, which could adversely
affect our competitive business position and harm our business prospects. In addition, we
sublicense our rights under various third-party licenses to our collaborators. Any impairment of
these sublicensed rights could result in reduced revenues under our collaboration agreements or
result in termination of an agreement by one or more of our collaborators.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Other companies or organizations may challenge our patent rights or may assert patent rights
that prevent us from developing and commercializing our products.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RNAi is a relatively new scientific field, the commercial exploitation of which has resulted
in many different patents and patent applications from organizations and individuals seeking to
obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and
have licensed many of these patents from third parties on an exclusive basis. The issued patents
and pending patent applications in the United States and in key markets around the world that we
own or license claim many different methods, compositions and processes relating to the discovery,
development, manufacture and commercialization of RNAi therapeutics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically, we have a portfolio of patents, patent applications and other intellectual
property covering: fundamental aspects of the structure and uses of siRNAs, including their
manufacture and use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs
that improve their suitability for therapeutic uses; siRNAs directed to specific targets as
treatments for particular diseases; and delivery technologies, such as in the field of cationic
liposomes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As the field of RNAi therapeutics is maturing, patent applications are being fully processed
by national patent offices around the world. There is uncertainty about which patents will issue,
and, if they do, as to when, to whom, and with what claims. It is likely that there will be
significant litigation and other proceedings, such as interference, reexamination and opposition
proceedings, in various patent offices relating to patent rights in the RNAi field. For example,
various third parties have initiated oppositions to patents in our Kreutzer-Limmer and Tuschl II
series in the EPO and in other jurisdictions. We expect that additional oppositions will be filed
in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent
applications in our portfolio. In many cases, the possibility of appeal exists for either us or our
opponents, and it may be years before final, unappealable rulings are made with respect to these
patents in certain jurisdictions. The timing and outcome of these and other proceedings is
uncertain and may adversely affect our business if we are not successful in defending the
patentability and scope of our pending and issued patent claims. In addition, third parties may
attempt to invalidate our intellectual property rights. Even if our rights are not directly
challenged, disputes could lead to the weakening of our intellectual property rights. Our defense
against any attempt by third parties to circumvent or invalidate our intellectual property rights
could be costly to us, could require significant time and attention of our management and could
have a material adverse effect on our business and our ability to successfully compete in the field
of RNAi.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are many issued and pending patents that claim aspects of oligonucleotide chemistry that
we may need to apply to our siRNA therapeutic candidates. There are also many issued patents that
claim targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop.
Thus, it is possible that one or more organizations will hold patent rights to which we will need a
license. If those organizations refuse to grant us a license to such patent rights on reasonable
terms, we may not be able to market products or perform research and development or other
activities covered by these patents.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>If we become involved in patent litigation or other proceedings related to a determination of
rights, we could incur substantial costs and expenses, substantial liability for damages or be
required to stop our product development and commercialization efforts.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third parties may sue us for infringing their patent rights. Likewise, we may need to resort
to litigation to enforce a patent issued or licensed to us or to determine the scope and validity
of proprietary rights of others. In addition, a third party may claim that we have improperly
obtained or used its confidential or proprietary information. For example, in March&nbsp;2011, Tekmira
and Protiva filed a civil complaint against us in the Business Litigation Section of the Suffolk
County Superior Court, in Boston, Massachusetts and on June&nbsp;3, 2011, the plaintiffs filed an
amended complaint adding AlCana, a research collaborator of ours, as a defendant. The amended
complaint alleges misappropriation of the plaintiffs&#146; confidential and proprietary information and
trade secrets, civil conspiracy and tortious interference with contractual relationships by us and
AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and
fair dealing, unfair competition, false advertising, unfair and deceptive trade practices by us.
The plaintiffs seek, among other relief, injunctive relief, unspecified damages and the termination
of licenses that the plaintiffs provided to us. In April&nbsp;2011, we served and filed an answer to
the plaintiffs&#146; original complaint denying the plaintiffs&#146; claims, together with counterclaims against the plaintiffs. In June&nbsp;2011, we served and filed an answer to the plaintiffs&#146; amended
complaint denying the plaintiffs&#146; claims and counterclaims against the plaintiffs asserting breach
of contract, defamation, breach of covenant not to sue, breach of patent prosecution and non-use
provisions, misappropriation of confidential and proprietary information and trade secrets, unjust
enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of
Massachusetts statutes. We are seeking damages and equitable relief on our counterclaims. In
September&nbsp;2011, the Court granted the plaintiffs&#146; motion to
dismiss our counterclaim for defamation. We have a number of additional counterclaims remaining
against the plaintiffs. Although we believe we have meritorious defenses to each of the claims in
this lawsuit and intend to fully defend ourselves in this matter, litigation is subject to inherent
uncertainty and a court could ultimately rule against us and award substantial damages. In
addition, defense of litigation and related matters are costly and may divert the attention of our
management and other resources that would otherwise be engaged in running our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, third parties may challenge the inventorship of our patents or licensed patents.
For example, in March&nbsp;2011, the University of Utah filed a complaint in the United States District
Court for the District of Massachusetts against us, Max Planck, Whitehead, MIT and UMass, claiming
that a professor of the University is the sole inventor, or in the alternative, a joint inventor of
certain of our in-licensed patents. The original complaint was not served on any of the parties
and, in July&nbsp;2011, the University filed an amended complaint containing substantially the same
claims as the original complaint against us, Max Planck, Whitehead, MIT and UMass. The amended
complaint alleges the defendants have incorrectly determined inventorship of some of our
in-licensed patents and further claims unjust enrichment, unfair competition, false advertising and
seeks correction of inventorship, injunctive relief and unspecified
damages. On October&nbsp;31, 2011,
we, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss.
Also on October&nbsp;31, 2011, UMass filed a motion to dismiss on
separate grounds, which we, Max Planck,
Whitehead and MIT have joined. We believe we have meritorious defenses against each of the claims
in this lawsuit and intend to fully defend ourselves in this matter if the complaint is served.
However, litigation is subject to inherent uncertainty and a court could ultimately rule against
us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, in connection with a license agreement, we agreed to indemnify the licensor for
costs incurred in connection with litigation relating to intellectual property rights. The cost to
us of any litigation or other proceeding relating to intellectual property rights, even if resolved
in our favor, could be substantial, and the litigation would divert our management&#146;s efforts. Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. Uncertainties resulting from the
initiation and continuation of any litigation could delay our research and development efforts and
limit our ability to continue our operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any parties successfully claim that our creation or use of proprietary technologies
infringes upon their intellectual property rights, we might be forced to pay damages, potentially
including treble damages, if we are found to have willfully infringed on such parties&#146; patent
rights. In addition to any damages we might have to pay, a court could require us to stop the
infringing activity or obtain a license. Any license required under any patent may not be made
available on commercially acceptable terms, if at all. In addition, such licenses are likely to be
non-exclusive and, therefore, our competitors may have access to the same technology licensed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to us. If we fail to obtain a required license and are unable to design around a patent, we may be
unable to effectively market some of our technology and products, which could limit our ability to
generate revenues or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will
provide that royalties payable to us for licenses to our intellectual property may be offset by
amounts paid by our collaborators to third parties who have competing or superior intellectual
property positions in the relevant fields, which could result in significant reductions in our
revenues from products developed through collaborations.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>If we fail to comply with our obligations under any licenses or related agreements, we could
lose license rights that are necessary for developing and protecting our RNAi technology and any
related product candidates that we develop, or we could lose certain exclusive rights to grant
sublicenses.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our current licenses impose, and any future licenses we enter into are likely to impose,
various development, commercialization, funding, royalty, diligence, sublicensing, insurance and
other obligations on us. If we breach any of these obligations, the licensor may have the right to
terminate the license or render the license non-exclusive, which could result in us being unable to
develop, manufacture and sell products that are covered by the licensed technology or enable a
competitor to gain access to the licensed technology. In addition, while we cannot currently
determine the amount of the royalty obligations we will be required to pay on sales of future
products, if any, the amounts may be significant. The amount of our future royalty obligations will
depend on the technology and intellectual property we use in products that we successfully develop
and commercialize, if any. Therefore, even if we successfully develop and commercialize products,
we may be unable to achieve or maintain profitability.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Confidentiality agreements with employees and others may not adequately prevent disclosure of
trade secrets and other proprietary information.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to protect our proprietary technology and processes, we rely in part on
confidentiality agreements with our collaborators, employees, consultants, outside scientific
collaborators and sponsored researchers, and other advisors. These agreements may not effectively
prevent disclosure of confidential information and may not provide an adequate remedy in the event
of unauthorized disclosure of confidential information. In addition, others may independently
discover trade secrets and proprietary information, and in such cases we could not assert any trade
secret rights against such party. Costly and time-consuming litigation could be necessary to
enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade
secret protection could adversely affect our competitive business position.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Competition</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>The pharmaceutical market is intensely competitive. If we are unable to compete effectively with
existing drugs, new treatment methods and new technologies, we may be unable to commercialize
successfully any drugs that we develop.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pharmaceutical market is intensely competitive and rapidly changing. Many large
pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other
public and private research organizations are pursuing the development of novel drugs for the same
diseases that we are targeting or expect to target. Many of our competitors have:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>much greater financial, technical and human resources than we have at every stage
of the discovery, development, manufacture and commercialization of products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>more extensive experience in pre-clinical testing, conducting clinical trials,
obtaining regulatory approvals, and in manufacturing, marketing and selling
pharmaceutical products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product candidates that are based on previously tested or accepted technologies;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>products that have been approved or are in late stages of development; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>collaborative arrangements in our target markets with leading companies and research
institutions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will face intense competition from drugs that have already been approved and accepted by
the medical community for the treatment of the conditions for which we may develop drugs. We also
expect to face competition from new drugs that enter the market. We believe a significant number of
drugs are currently under development, and may become commercially available in the future, for the
treatment of conditions for which we may try to develop drugs. For instance, we are currently
evaluating RNAi therapeutics for ATTR, severe hypercholesterolemia, refractory anemia, hemophilia,
RSV, liver cancers and HD, and have a number
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of additional discovery programs targeting other diseases. These drugs may be more effective, safer, less expensive, or marketed and sold more
effectively, than any products we develop.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we successfully develop product candidates, and obtain approval for them, we will face
competition based on many different factors, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the safety and effectiveness of our products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the ease with which our products can be administered and the extent to which
patients accept relatively new routes of administration;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing and scope of regulatory approvals for these products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the availability and cost of manufacturing, marketing and sales capabilities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>price;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reimbursement coverage; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>patent position.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our competitors may develop or commercialize products with significant advantages over any
products we develop based on any of the factors listed above or on other factors. Our competitors
may therefore be more successful in commercializing their products than we are, which could
adversely affect our competitive position and business. Competitive products may make any products
we develop obsolete or noncompetitive before we can recover the expenses of developing and
commercializing our product candidates. Such competitors could also recruit our employees, which
could negatively impact our level of expertise and the ability to execute on our business plan.
Furthermore, we also face competition from existing and new treatment methods that reduce or
eliminate the need for drugs, such as the use of advanced medical devices. The development of new
medical devices or other treatment methods for the diseases we are targeting could make our product
candidates noncompetitive, obsolete or uneconomical.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>We face competition from other companies that are working to develop novel drugs and technology
platforms using technology similar to ours. If these companies develop drugs more rapidly than
we do or their technologies, including delivery technologies, are more effective, our ability to
successfully commercialize drugs may be adversely affected.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the competition we face from competing drugs in general, we also face
competition from other companies working to develop novel drugs using technology that competes more
directly with our own. We are aware of multiple companies that are working in the field of RNAi. In
addition, we granted licenses or options for licenses to Isis, GeneCare Research Institute Co.,
Ltd., Benitec Ltd., Calando Pharmaceuticals, Inc., Tekmira, Quark Biotech, Inc. and others under
which these companies may independently develop RNAi therapeutics against a limited number of
targets. Any of these companies may develop its RNAi technology more rapidly and more effectively
than us. Merck &#038; Co., Inc., or Merck, was one of our collaborators and a licensee under our
intellectual property for specified disease targets until September&nbsp;2007, at which time we and
Merck agreed to terminate our collaboration. As a result of its acquisition of Sirna Therapeutics,
Inc. in December&nbsp;2006, and in light of the mutual termination of our collaboration, Merck, which
has substantially more resources and experience in developing drugs than we do, may become a direct
competitor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, as a result of agreements that we have entered into, Arrowhead, as the assignee
of Roche, and Takeda have obtained non-exclusive licenses, and Novartis has obtained specific
exclusive licenses for 31 gene targets, to certain aspects of our technology that give them the
right to compete with us in certain circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also compete with companies working to develop antisense-based drugs. Like RNAi
therapeutics, antisense drugs target messenger RNAs, or mRNAs, in order to suppress the activity of
specific genes. Isis is currently marketing an antisense drug and has several antisense product
candidates in clinical trials. The development of antisense drugs is more advanced than that of
RNAi therapeutics, and antisense technology may become the preferred technology for drugs that
target mRNAs to silence specific genes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to competition with respect to RNAi and with respect to specific products, we face
substantial competition to discover and develop safe and effective means to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver siRNAs to the relevant cell and
tissue types may be developed by our competitors, and our ability to successfully commercialize a
competitive product would be adversely affected. In addition, substantial resources are being
expended by third parties in the effort to discover and develop a safe and effective means of
delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the
corporate sector. Some of our competitors have substantially greater resources than we do, and if
our competitors are able to negotiate exclusive access to those delivery solutions developed by
third parties, we may be unable to successfully commercialize our product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Alnylam Biotherapeutics efforts will also face competition from established companies
developing and commercializing technology applications to improve the manufacturing processes for
drugs. If these companies advance and market their technologies more rapidly than Alnylam
Biotherapeutics, we may be unable to establish collaborations for Alnylam Biotherapeutics with
established biologic manufacturers, selling licenses, products and services.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Risks Related to Our Common Stock</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has and may continue to fluctuate significantly in
response to factors that are beyond our control. The stock market in general has recently
experienced extreme price and volume fluctuations. The market prices of securities of
pharmaceutical and biotechnology companies have been extremely volatile, and have experienced
fluctuations that often have been unrelated or disproportionate to the operating performance of
these companies. These broad market fluctuations could result in extreme fluctuations in the price
of our common stock, which could cause purchasers of our common stock to incur substantial losses.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>We may incur significant costs from class action litigation due to our expected stock
volatility.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price may fluctuate for many reasons, including as a result of public announcements
regarding the progress of our development efforts or the development efforts of our collaborators
and/or competitors, the addition or departure of our key personnel, variations in our quarterly
operating results and changes in market valuations of pharmaceutical and biotechnology companies.
When the market price of a stock has been volatile as our stock price may be, holders of that stock
have occasionally brought securities class action litigation against the company that issued the
stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the
lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could
also divert the time and attention of our management.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Novartis&#146; ownership of our common stock could delay or prevent a change in corporate control.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At September&nbsp;30, 2011, Novartis held 13.1% of our outstanding common stock and has the right
to maintain its ownership percentage until the earlier of any sale by Novartis of shares of our
common stock and the expiration or termination of our collaboration and license agreement, subject
to certain exceptions. This concentration of ownership may harm the market price of our common
stock by:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delaying, deferring or preventing a change in control of our company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impeding a merger, consolidation, takeover or other business combination involving our
company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>discouraging a potential acquirer from making a tender offer or otherwise
attempting to obtain control of our company.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Sales of additional shares of our common stock could result in dilution to existing stockholders
and cause the price of our common stock to decline.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of substantial amounts of our common stock in the public market, or the availability of
such shares for sale, by us or others could adversely affect the price of our common stock.
Novartis has rights, subject to certain conditions, to require us to file registration statements
covering its shares or to include its shares in registration statements that we file. In addition,
if Novartis decides to sell a portion of its shares in a rapid or disorderly manner, our stock
price could be negatively impacted.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Anti-takeover provisions in our charter documents and under Delaware law and our stockholder
rights plan could make an acquisition of us, which may be beneficial to our stockholders, more
difficult and may prevent attempts by our stockholders to replace or remove our current
management.</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our certificate of incorporation and our bylaws may delay or prevent an
acquisition of us or a change in our management. In addition, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our board of directors. Because our board of
directors is responsible for appointing the members of our management team, these provisions could
in turn affect any attempt by our stockholders to replace current members of our management team.
These provisions include:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a classified board of directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a prohibition on actions by our stockholders by written consent;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limitations on the removal of directors; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>advance notice requirements for election to our board of directors and for
proposing matters that can be acted upon at stockholder meetings.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, our board of directors has adopted a stockholder rights plan, the provisions of
which could make it difficult for a potential acquirer of Alnylam to consummate an acquisition
transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover, because we are incorporated in Delaware, we are governed by the provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of
15% of our outstanding voting stock from merging or combining with us for a period of three years
after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. These provisions
would apply even if the proposed merger or acquisition could be considered beneficial by some
stockholders.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="B87804113"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 6. EXHIBITS.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1&#134;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;1, dated as of July&nbsp;27, 2011, to the Sponsored Research
Agreement dated as of July&nbsp;27, 2009 by and among the Company, The
University of British Columbia and AlCana Technologies, Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Computation of Consolidated Ratios of Earnings/Deficiencies to Fixed Charges</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(a)
promulgated under the Securities Exchange Act of 1934, as amended.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(a)
promulgated under the Securities Exchange Act of 1934, as amended.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(b)
promulgated under the Securities Exchange Act of 1934, as amended, and
Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(b)
promulgated under the Securities Exchange Act of 1934, as amended, and
Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">101&#043;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The following materials from Registrant&#146;s Quarterly Report on Form&nbsp;10-Q for
the quarter ended September&nbsp;30, 2011, formatted in XBRL (Extensible
Business Reporting Language): (i)&nbsp;the Condensed Consolidated Balance
Sheets, (ii)&nbsp;the Condensed Consolidated Statements of Operations and
Comprehensive Loss, (iii)&nbsp;the Condensed Consolidated Statements of Cash
Flows, and (iv)&nbsp;Notes to Condensed Consolidated Financial Statements,
tagged as blocks of text.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">&#134;</TD>
    <TD>&nbsp;</TD>
    <TD>Indicates confidential treatment requested as to certain portions,
which portions were omitted and filed separately with the Securities
and Exchange Commission pursuant to a Confidential Treatment Request.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">&#043;</TD>
    <TD>&nbsp;</TD>
    <TD>In accordance with Rule&nbsp;406T of Regulation&nbsp;S-T, the XBRL-related
information in Exhibit&nbsp;101 to this Quarterly Report on Form 10-Q shall
be deemed to be &#147;furnished&#148; and not &#147;filed.&#148;</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#B87804tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left">
<A name="B87804114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ALNYLAM PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Maraganore
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">John M. Maraganore, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Executive Officer<br>
(Principal Executive Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Michael P. Mason
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Michael P. Mason&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Vice President of Finance and Treasurer<br>
(Principal Financial and Accounting Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>b87804exv10w1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Confidential Materials omitted and filed separately with the<BR>
Securities and Exchange Commission. Asterisks denote omissions.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT </B>(this &#147;Amendment No.&nbsp;1&#148;) dated as of July
27, 2011 (the &#147;Effective Date&#148;) is by and among <B>Alnylam Pharmaceuticals, Inc.</B>, a Delaware
corporation with a principal office at 300 Third Street, Cambridge, MA 02142, USA
(&#147;<U>Alnylam</U>&#148;), <B>The University of British Columbia</B>, a corporation continued under the
University Act of British Columbia, Canada, with offices at 103-6190 Agronomy Road, Vancouver,
British Columbia, Canada (&#147;<U>UBC</U>&#148;) and <B>AlCana Technologies, Inc.</B>, a British Columbia
corporation with a principal business address at 2714 West 31st Avenue, Vancouver, British
Columbia, Canada V6L 2A1 (&#147;<U>AlCana</U>&#148;). Capitalized terms used but not defined herein shall
have the meanings ascribed to them in the Sponsored Research Agreement (as defined herein).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Alnylam, UBC, and AlCana are parties to a Sponsored Research Agreement dated as of
July&nbsp;27, 2009 (the &#147;Sponsored Research Agreement&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, Alnylam has provided the requisite written notice to each of UBC and AlCana of
Alnylam&#146;s election to extend the Initial Research Term for a period of one (1)&nbsp;Contract Year,
pursuant to Section&nbsp;3.5 of the Sponsored Research Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>the Parties now wish to amend the Sponsored Research Agreement to reflect such
extension of the Initial Research Term;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW THEREFORE, </B>in consideration of the mutual promises and covenants contained herein, the
parties hereto agree to the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Amendment to Research Plan. </B>The Research Program Workplan, as set forth in the
Sponsored Research Agreement, shall hereby be amended to include the workplan for the
additional Contract Year (the &#147;Year 3 Research Program Workplan&#148;) which is attached hereto as
Exhibit&nbsp;A-2 and incorporated herein by reference.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Amendment to Budget. </B>In consideration for the extension of the Initial Research Term, the
Budget shall hereby be amended to include the additional budget and payment schedule set forth
in Exhibit&nbsp;B-2 attached hereto and incorporated herein by reference.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Entire Agreement. </B>The Sponsored Research Agreement, as amended hereby, contains the entire
agreement among the parties with respect to the subject matter thereof and hereof and shall be
read and construed together as a single agreement. Except to the extent amended hereby, all
of the terms, provisions and conditions of the Sponsored Research Agreement are hereby
ratified and confirmed and shall remain in full force and effect as of the date specified
therein.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Counterparts. </B>This Amendment No.&nbsp;1 may be executed in any number of counterparts, each of
which will be deemed to be an original and all of which together will constitute one and the
same instrument.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;Signature page follows.&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> Page 1 of  2 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN WITNESS WHEREOF</B>, the parties have caused this Amendment No.&nbsp;1 to be executed by their duly
authorized representatives as of the date first written above.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>ALNYLAM PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Mason
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Michael Mason
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VP, Finance and Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>ALCANA TECHNOLOGIES, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ T.D. Madden
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Thomas Madden
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ J.P. Heale, PhD, MBA
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
J.P. Heale, PhD, MBA
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">University-Industry Liaison Office</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Mario A. Kasapi
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mario A. Kasapi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">University-Industry Liaison Office</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio --> Page 2 of  2 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;A-2</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Year 3 Research Program Workplan</U>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><IMG src="b87804b8780401.gif" alt="(ALNYLAM)">
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><IMG src="b87804b8780402.gif" alt="(ALNYLAM)">
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><IMG src="b87804b8780403.gif" alt="(ALNYLAM)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2011 RESEARCH PROGRAM</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>PROGRAM OBJECTIVES</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>2011 PLANS</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 1: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Hypotheses</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 2: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Hypotheses</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 3: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Hypotheses</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio --> Page 1of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 4: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Background</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 5: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Hypotheses</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 6: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Background</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Objective 7: &#091;**&#093;</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Work Plan</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio --> Page 2 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2. MAIN ACTIVITIES AND RESPONSIBILITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Objective 1: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 1. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Task</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Objective 2: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 2. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --> Page 3 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Objective 3: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 3. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Objective 4: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 4. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Objective 5: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 5. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --> Page 4 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Objective 6: &#091;**&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 6. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Objective 7: &#091;**&#093;</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 7. Tasks and Responsibilities</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Tasks</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --> Page 5 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. MAIN DELIVERABLES, TIMELINE AND COSTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 8. Key Individuals, Timelines and Costs.</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Activity/Deliverable</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timeline</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Cost ($US)</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>1</B></SUP></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --> Page 6 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Table 9. Key Individuals, Timelines and Costs Associated to Programs Led by UBC.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Activity/Deliverable</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Timeline</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Cost ($US)</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>2</B></SUP></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4. ADDITIONAL MATERIALS AND SUPPLIES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alnylam will supply the key research materials listed below (quantities to be mutually
agreed):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;**&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. KEY PERSONNEL</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Table 10. Key program personnel.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>AlCana</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>UBC</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Alnylam</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio --> Page 7 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. ALCANA/UBC BUDGET</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="5"><B>2011</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Percent</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Scientist</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Time (%)</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;**&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL FTE&#146;s</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FTE Rate<SUP style="FONT-size: 85%; vertical-align: text-top">1</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B><I>2011 BUDGET</I></B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q1</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q2</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q3</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>2</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q4</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>2</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>TOTAL</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Salaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preclinical studies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Rental Lab Space</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Materials and supplies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --> Page 8 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q1</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q2</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q3</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>2</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Q4</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>2</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>TOTAL</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ALCANA TOTAL</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">UBC Grant (PRC
laboratory)*</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Combined Totals</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">Note</TD>
    <TD>&nbsp;</TD>
    <TD> <SUP style="FONT-size: 85%; vertical-align: text-top"> 1</SUP> FTE rate &#091;**&#093;</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD><SUP style="FONT-size: 85%; vertical-align: text-top">2</SUP> Q3 and Q4 Costs do not include consumer price index adjustment</TD>
</TR>

</TABLE>



<P align="right" style="font-size: 10pt"><!-- Folio --> Page 9 of  9 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;B-2</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Year 3 Research Program Budget and Agreement Payments</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Budget.</U> The budget for the extension to the Research Term is included in the
Year 3 Research Program Workplan attached to this Amendment No.&nbsp;1 as <B>Exhibit&nbsp;A-2</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Payment Schedule</U>. In consideration for the extension to the Research Program,
Alnylam shall pay to UBC and AlCana (as set forth in Section&nbsp;8.4.4 of the Agreement) a
research payment as follows:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><b>Payment Due Date</b></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><b>UBC Share</b></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><b>AlCana Share</b></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><b>Total</b></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July 1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oct 1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Jan 1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> 2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April 1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> 2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July 1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> 2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;**&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Note:For the avoidance of doubt, the payments to UBC and AlCana in respect of July&nbsp;1, 2011
that are set forth on this Exhibit&nbsp;B-2 shall supercede, and are not in addition to, the
payments to UBC and AlCana in respect of July&nbsp;1, 2011 that are set forth in Exhibit&nbsp;B of the
original Sponsored Research Agreement.</TD>
</TR>

</TABLE>



<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Allocation of License Consideration to AlCana</U>. UBC, as Payee under this
Agreement and in consideration for the Field-Restricted Assignment, shall pay AlCana a
portion of all payments received by UBC in consideration for the Licenses as set forth in a
separate agreement between UBC and AlCana. The Parties acknowledge and agree that the
consideration for the Licenses and AlCana&#146;s portion thereof has been determined with
reference to the fair market value of the rights transferred pursuant to the
Field-Restricted Assignment and granted pursuant to the Licenses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Invoicing and Payments</U>. Invoices for all Research Program funding and
administration payments due AlCana from Alnylam under this Agreement will be provided to
Alnylam at the following address: ATTENTION: Accounts Payable, Alnylam Pharmaceuticals,
Inc., 300 Third Street, Cambridge, MA 02142,
<u>accountspayable@alnylam.com</u> and will reference
this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All payments under this Agreement shall be paid by bank wire transfer in immediately
available funds to such bank account as may be designated in writing by the payee thereof,
from time to time. Specifically, (a)&nbsp;all payments to Payee under this Agreement will be
made by wire transfer to UBC. Payment due to UBC:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>by cheque should be made payable to &#147;The University of British Columbia&#148;
delivered to UBC at the following address:</TD>
</TR>

</TABLE>
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">The Director<BR>
University &#151; Industry Liaison Office<BR>
University of British Columbia<BR>
#103 &#151; 6190 Agronomy Road
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Vancouver, British Columbia<BR>
V6T 1Z3<BR>
Telephone: (604) 822-8580<BR>
Fax: (604)&nbsp;822-8589
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>by wire transfer should be transferred in accordance with the instructions set
out below:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>For Canadian $ Deposits via wire (General)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>For US $ Deposits via wire:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;**&#093;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;**&#093;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;**&#093;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;**&#093;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;**&#093;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;**&#093;</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">; (b)&nbsp;all payments to AlCana under this Agreement will be made by wire transfer to
AlCana at: Bank of Montreal, 2102 41st Avenue West, Vancouver, British Columbia, Canada V6L
1Z2
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">; and (c)&nbsp;all payments to Alnylam under this Agreement will be made by wire transfer to
Alnylam at:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Bank Account Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alnylam Pharmaceuticals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Bank Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;**&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ABA Number:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;**&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Account Number:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;**&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp; <!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>3
<FILENAME>b87804exv12.htm
<DESCRIPTION>EX-12
<TEXT>
<HTML>
<HEAD>
<TITLE>exv12</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;12</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES TO FIXED CHARGES<BR>
(dollars in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="18">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="18" style="border-bottom: 1px solid #000000"><B>Fiscal Year Ended December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2007</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2006</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Earnings (loss):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-tax loss from continuing operations before adjustment for loss from equity investee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(40,795</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(12,770</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(35,362</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(42,098</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(16,240</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(79,146</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(34,608</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">add: Fixed charges (see below)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">905</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,532</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-tax income (loss)&nbsp;from continuing operations before adjustment for income/loss
from equity investees plus fixed charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(39,890</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(12,468</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(34,155</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(41,386</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(15,125</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(77,593</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(33,076</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Fixed charges:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest expense on indebtedness</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">872</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,083</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,029</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest expense on portion of rent expense representative of interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">905</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">470</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">503</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total fixed charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">905</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,532</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ratio of earnings to fixed charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficiency of earnings available to cover fixed charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(40,795</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(12,770</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(35,362</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(42,098</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(16,240</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(79,146</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(34,608</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>b87804exv31w1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>



<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, John M. Maraganore, Ph.D., certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material
information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in
which this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting,
or caused such internal control over financial reporting
to be designed under our supervision, to provide
reasonable assurance regarding the reliability of
financial reporting and the preparation of financial
statements for external purposes in accordance with
generally accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period
covered by this report based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s
internal control over financial reporting that occurred
during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to
record, process, summarize and report financial information; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that
involves management or other employees
who have a significant role in the
registrant&#146;s internal control over
financial reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Maraganore
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">John M. Maraganore, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>b87804exv31w2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>



<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, Michael P. Mason, certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material
information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in
which this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting,
or caused such internal control over financial reporting
to be designed under our supervision, to provide
reasonable assurance regarding the reliability of
financial reporting and the preparation of financial
statements for external purposes in accordance with
generally accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period
covered by this report based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s
internal control over financial reporting that occurred
during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in
the design or operation of internal control over
financial reporting which are reasonably likely to
adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves
management or other employees who have a significant
role in the registrant&#146;s internal control over
financial reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Michael P. Mason
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Michael P. Mason&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Vice President of Finance and Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>b87804exv32w1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT<BR>
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.
(the &#147;Company&#148;) for the quarter ended September&nbsp;30, 2011 as filed with the Securities and Exchange
Commission on the date hereof (the &#147;Report&#148;), the undersigned, John M. Maraganore, Ph.D., Chief
Executive Officer of the Company, hereby certifies, pursuant to Section&nbsp;1350 of Chapter&nbsp;63 of Title
18, United States Code, that to his knowledge:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Report fully complies with the
requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information contained in the Report
fairly presents, in all material
respects, the financial condition and
results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Maraganore
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">John M. Maraganore, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A signed original of this written statement required by Section&nbsp;906 has
been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon
request.
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>b87804exv32w2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">










<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT<BR>
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.
(the &#147;Company&#148;) for the quarter ended September&nbsp;30, 2011 as filed with the Securities and Exchange
Commission on the date hereof (the &#147;Report&#148;), the undersigned, Michael P. Mason, Vice President of
Finance and Treasurer of the Company, hereby certifies, pursuant to Section&nbsp;1350 of Chapter&nbsp;63 of
Title 18, United States Code, that to his knowledge:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the information contained in the Report fairly
presents, in all material respects, the financial
condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: November 3, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Michael P. Mason
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Michael P. Mason&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Vice President of Finance and Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A signed original of this written statement required by Section&nbsp;906 has been provided to the
Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>alny-20110930.xml
<DESCRIPTION>EX-101 INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:alny="http://alnylam.com/20110930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="alny-20110930.xsd" />
  <!-- Context Section -->
  <context id="BalanceAsOf_30Sep2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Oct2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2010-07-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="Jan-01-2011_Sep-30-2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
   &lt;div align="left" style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of Consolidation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc.
   (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Alnylam&amp;#8221;) are unaudited and have been prepared in accordance with accounting
   principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) applicable to interim
   periods and, in the opinion of management, include all normal and recurring adjustments that are
   necessary to state fairly the results of operations for the reported periods. The Company&amp;#8217;s
   condensed consolidated financial statements have also been prepared on a basis substantially
   consistent with, and should be read in conjunction with, the Company&amp;#8217;s audited consolidated
   financial statements for the year ended December&amp;#160;31, 2010, which were included in the Company&amp;#8217;s
   Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;)
   on February&amp;#160;18, 2011. The year-end condensed balance sheet data was derived from audited financial
   statements, but does not include all disclosures required by GAAP. The results of the Company&amp;#8217;s
   operations for any interim period are not necessarily indicative of the results of the Company&amp;#8217;s
   operations for any other interim period or for a full fiscal year.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The accompanying condensed consolidated financial statements reflect the operations of the
   Company and Alnylam U.S., Inc., Alnylam Europe AG (&amp;#8220;Alnylam Europe&amp;#8221;)
   and Alnylam Securities Corporation, wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have
   been eliminated. The Company uses the equity method of accounting to account for its investment in
   Regulus Therapeutics Inc. (&amp;#8220;Regulus&amp;#8221;).
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The preparation of financial statements in conformity with GAAP requires management to make
   estimates and assumptions that affect the reported amounts of assets and liabilities and the
   disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
   statements and the reported amounts of revenues and expenses during the reporting period. Actual
   results could differ from those estimates.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basic net loss per common share is computed by dividing net loss attributable to common
   stockholders by the weighted average number of common shares outstanding. Diluted net loss per
   common share is computed by dividing net loss attributable to common stockholders by the weighted
   average number of common shares and dilutive potential common share equivalents then outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options (using the
   treasury stock method) and unvested restricted stock awards. Because the inclusion of potential
   common shares would be anti-dilutive for all periods presented, diluted net loss per common share
   is the same as basic net loss per common share.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table sets forth for the periods presented the potential common shares (prior to
   consideration of the treasury stock method) excluded from the calculation of net loss per common
   share because their inclusion would be anti-dilutive, in thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three and Nine Months  Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options to purchase common stock
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,802&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,915&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Unvested restricted common stock
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;355&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,157&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,915&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The fair value of restricted stock awards granted to employees is based upon the quoted
   closing market price per share on the date of grant, adjusted for assumed forfeitures. For
   performance-based restricted stock awards, the value of the awards is measured when the Company
   determines the achievement of such performance conditions is deemed probable. Expense is
   recognized over the vesting period, commencing when the Company determines that it is probable that
   the awards will vest. In May&amp;#160;2011, the Company
   granted an aggregate of 229,806 shares of performance-based restricted stock awards to its
   employees, excluding the Company&amp;#8217;s leadership team. These restricted stock awards were valued at
   $2.3&amp;#160;million on the grant date and have a term of five years. The vesting of these awards is
   predicated on the Company&amp;#8217;s achievement of certain clinical development goals. For the three and
   nine months ended September&amp;#160;30, 2011, the Company recorded $0.4&amp;#160;million and $0.7&amp;#160;million,
   respectively, of stock-based compensation expense related to these restricted stock awards.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables present information about the Company&amp;#8217;s assets that are measured at fair
   value on a recurring basis at September&amp;#160;30, 2011 and December&amp;#160;31, 2010, and indicate the fair value
   hierarchy of the valuation techniques the Company utilized to determine such fair value. In
   general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted)&amp;#160;in active
   markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data
   points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair
   values determined by Level 3 inputs utilize unobservable data points for the asset or liability,
   and include situations where there is little, if any, market activity for the asset or liability.
   Financial assets measured at fair value on a recurring basis are summarized as follows, in
   thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;At&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Active Markets&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Observable Inputs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unobservable Inputs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;67,515&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;59,517&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,998&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Marketable securities (fixed income)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Corporate notes
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;108,669&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;108,669&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;U.S. Government obligations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;81,287&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;81,287&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Commercial paper
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21,197&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21,197&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Marketable securities (equity holdings)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;750&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;750&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;279,418&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;59,517&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;219,901&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;At&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Active Markets&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Observable Inputs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unobservable Inputs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;59,702&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;40,686&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;19,016&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Marketable securities (fixed income)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Corporate notes
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;133,341&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;133,341&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;U.S. Government obligations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;122,273&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;122,273&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Commercial paper
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17,733&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17,733&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Marketable securities (equity holdings)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,958&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,958&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;335,007&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;40,686&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;294,321&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the nine months ended September&amp;#160;30, 2011, there were no transfers between Level 1 and
   Level 2 financial assets. The carrying amounts reflected in the Company&amp;#8217;s condensed consolidated
   balance sheets for cash, collaboration receivables, other current assets, accounts payable and
   accrued expenses approximate fair value due to their short-term maturities.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Investments in Marketable Securities&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company invests its excess cash balances in short-term and long-term marketable debt and
   equity securities. The Company classifies its investments in marketable debt securities as either
   held-to-maturity or available-for-sale based on facts and circumstances present at the time it
   purchased the securities. At each balance sheet date presented, the Company classified all of its
   investments in debt and equity securities as available-for-sale. The Company reports
   available-for-sale investments at fair value at each balance sheet date and includes any unrealized
   holding gains and losses (the adjustment to fair value) in stockholders&amp;#8217; equity. Realized gains and
   losses are determined using the specific identification method and are included in other income. If
   any adjustment to fair value reflects a decline in the value of the investment, the Company
   considers all available evidence to evaluate the extent to which the decline is &amp;#8220;other than
   temporary&amp;#8221; and, if so, marks the investment to market through a charge to its condensed
   consolidated statements of operations. The Company did not record any impairment charges related to
   its fixed income marketable securities during the current period. During the three and nine months
   ended September&amp;#160;30, 2011, the Company recorded an impairment charge of $0.6&amp;#160;million related to its
   investment in equity securities of Tekmira Pharmaceuticals Corporation (&amp;#8220;Tekmira&amp;#8221;), as the
   decrease in the fair
   value of this investment was deemed to be other than temporary. The Company&amp;#8217;s marketable
   securities are classified as cash equivalents if the original maturity, from the date of purchase,
   is 90&amp;#160;days or less, and as marketable securities if the original maturity, from the date of
   purchase, is in excess of 90&amp;#160;days. The Company&amp;#8217;s cash equivalents are composed of money market
   funds, U.S. government obligations and commercial paper.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables summarize the Company&amp;#8217;s marketable securities at September&amp;#160;30, 2011 and
   December&amp;#160;31, 2010, in thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Commercial paper (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;21,198&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;21,197&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate notes (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;52,183&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;23&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(26&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;52,180&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate notes (Due after 1&amp;#160;year through 2&amp;#160;years)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56,607&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(139&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56,489&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S. Government obligations (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;25,304&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;25,308&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S. Government obligations (Due after 1&amp;#160;year through 2&amp;#160;years)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56,012&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(37&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;55,979&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Equity securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;750&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;750&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;212,054&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;54&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(205&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;211,903&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Commercial paper (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;17,734&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;17,733&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate notes (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;116,385&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;204&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(23&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;116,566&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate notes (Due after 1&amp;#160;year through 2&amp;#160;years)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16,767&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;33&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(25&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16,775&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S. Government obligations (Due within 1&amp;#160;year)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;24,246&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;24,233&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S. Government obligations (Due after 1&amp;#160;year through 2&amp;#160;years)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;98,111&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;22&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(93&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;98,040&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Equity securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,345&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;613&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,958&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;274,588&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;875&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(158&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;275,305&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company evaluated all events or transactions that occurred after September&amp;#160;30, 2011
   through the date these condensed consolidated financial statements were issued. During this period,
   the Company did not have any material recognized or nonrecognized subsequent events.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In January&amp;#160;2011, the Company adopted new authoritative guidance on revenue recognition for
   multiple element arrangements. The guidance, which applies to multiple element arrangements entered
   into or materially modified on or after January&amp;#160;1, 2011, amends the criteria for separating and
   allocating consideration in a multiple element arrangement by modifying the fair value requirements
   for revenue recognition and eliminating the use of the residual method. The fair value of
   deliverables under the arrangement may be derived using a &amp;#8220;best estimate of selling price&amp;#8221; if
   vendor specific objective evidence and third-party evidence is not available. Deliverables under
   the arrangement will be separate units of accounting provided (i)&amp;#160;a delivered item has value to the
   customer on a standalone basis; and (ii)&amp;#160;if the arrangement includes a general right of return
   relative to the delivered item, delivery or performance of the undelivered item is considered
   probable and substantially in the control of the vendor. The Company did not enter into any
   significant multiple element arrangements or materially modify any existing multiple element
   arrangements during the nine months ended September&amp;#160;30, 2011. The Company&amp;#8217;s existing license and
   collaboration agreements continue to be accounted for under previously issued revenue recognition
   guidance for multiple element arrangements.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In January&amp;#160;2011, the Company adopted new authoritative guidance on revenue recognition for
   milestone payments related to arrangements under which the Company has continuing performance
   obligations. Consideration for events that meet the definition of a milestone in accordance with
   the accounting guidance for the milestone method of revenue recognition is recognized as revenue in
   its entirety in the period in which the milestone is achieved only if all of the following
   conditions are met: (i)&amp;#160;the milestone is commensurate with either the Company&amp;#8217;s performance in
   achieving the milestone or the enhancement of the value of the delivered item as a result of a
   specific outcome resulting from the Company&amp;#8217;s performance in achieving the milestone; (ii)&amp;#160;the
   consideration relates solely to past performance; and (iii)&amp;#160;the amount of the milestone
   consideration is reasonable relative to all of the deliverables and payment terms, including other
   potential milestone consideration, within the arrangement. Otherwise, the milestone payments are
   not considered to be substantive and are deferred and recognized as revenue over the term
   of the arrangement as the Company
   completes its performance obligations. The adoption of this guidance does not materially
   change the Company&amp;#8217;s previous method of recognizing milestone payments. The Company will evaluate
   all potential future milestones under existing arrangements with licensing partners, as specified
   below, and any new arrangements with milestones, under the new revenue recognition guidance for
   milestone payments.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May&amp;#160;2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued a new accounting
   standard that clarifies the application of certain existing fair value measurement guidance and
   expands the disclosures for fair value measurements that are estimated using significant
   unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and
   interim reporting periods beginning on or after December&amp;#160;15, 2011. The Company does not expect that
   adoption of this new standard will have a material impact on its condensed consolidated financial
   statements.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In June&amp;#160;2011, the FASB issued an amendment to the accounting guidance for presentation of
   comprehensive income. Under the amended guidance, a company may present the total of comprehensive
   income, the components of net income and the components of other comprehensive income either in a
   single continuous statement of comprehensive income or in two separate but consecutive statements.
   In either case, a company is required to present each component of net income along with total net
   income, each component of other comprehensive income along with a total for other comprehensive
   income and a total amount for comprehensive income.
   For public companies, the amendment is effective for fiscal years, and interim periods within those
   years, beginning after December&amp;#160;15, 2011, and shall be applied retrospectively. Early adoption is
   permitted. Other than a change in presentation, the adoption of this amendment is not expected to have
   a material impact on the Company&amp;#8217;s condensed consolidated financial statements.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;div align="left" style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;2. SIGNIFICANT AGREEMENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table summarizes the Company&amp;#8217;s total consolidated net revenues from research
   collaborators, for the periods indicated, in thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Roche
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,995&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,995&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;41,983&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;41,983&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Takeda
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,494&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,556&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16,755&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16,479&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Novartis
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,984&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;133&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,957&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,287&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,133&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,431&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,430&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total net revenues from research collaborators
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;20,791&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;27,668&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;62,302&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;78,849&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Platform Alliances&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;i&gt;Roche Alliance&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In July&amp;#160;2007, the Company and, for limited purposes, Alnylam Europe, entered into a license
   and collaboration agreement (the &amp;#8220;LCA&amp;#8221;) with F. Hoffmann-La Roche Ltd (&amp;#8220;Roche Basel&amp;#8221;) and
   Hoffmann-La Roche Inc. (together with Roche Basel, &amp;#8220;Roche&amp;#8221;). Under the LCA, which became effective
   in August&amp;#160;2007, the Company granted Roche a non-exclusive license to the Company&amp;#8217;s intellectual
   property, including delivery-related intellectual property existing as of the date of the LCA, to
   develop and commercialize therapeutic products that function through RNA interference (&amp;#8220;RNAi&amp;#8221;),
   subject to the Company&amp;#8217;s existing contractual obligations to third parties. The license is
   initially limited to four therapeutic areas, and may be expanded to include up to 18 additional
   therapeutic areas, comprising substantially all other fields of human disease, as identified and
   agreed upon by the parties, upon payment to the Company by Roche of an additional $50.0&amp;#160;million for
   each additional therapeutic area, if any.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In consideration for the rights granted to Roche under the LCA, Roche paid the Company $273.5
   million in upfront cash payments. In addition, in exchange for the Company&amp;#8217;s contributions under
   the LCA, for each RNAi therapeutic product developed by Roche, its affiliates or sublicensees under
   the LCA, the Company is entitled to receive milestone payments upon achievement of specified
   development and sales events, totaling up to an aggregate of $100.0&amp;#160;million per therapeutic target,
   together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the
   Company and Roche also established a discovery
   collaboration in October&amp;#160;2009 (&amp;#8220;Discovery Collaboration&amp;#8221;), subject to the Company&amp;#8217;s existing
   contractual obligations to third parties.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In July&amp;#160;2007, the Company executed a common stock purchase agreement (the &amp;#8220;Common Stock
   Purchase Agreement&amp;#8221;) with Roche Finance Ltd, an affiliate of Roche. In connection with the
   execution of the LCA and the Common Stock Purchase Agreement, the Company also executed a share
   purchase agreement (the &amp;#8220;Alnylam Europe Purchase Agreement&amp;#8221;) with Alnylam Europe and Roche
   Beteiligungs GmbH, an affiliate of Roche (&amp;#8220;Roche Germany&amp;#8221;). Under the terms of the Alnylam Europe
   Purchase Agreement, the Company sold substantially all of the non-intellectual property assets of
   Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In summary, the Company received upfront payments totaling $331.0&amp;#160;million under the Roche
   alliance, which include an upfront payment under the LCA of $273.5&amp;#160;million, $42.5&amp;#160;million under the
   Common Stock Purchase Agreement and $15.0&amp;#160;million under the Alnylam Europe Purchase Agreement. The
   Company initially recorded $278.2&amp;#160;million of these proceeds as deferred revenue in connection with
   the Roche alliance.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;When evaluating multiple element arrangements, the Company considers whether the components of
   the arrangement represent separate units of accounting. The accounting guidance specifically
   requires that the delivered components must have value to the customer on a standalone basis and
   that there is objective and reliable evidence of the fair value of the undelivered components.
   Application of this standard requires subjective determinations and requires management to make
   judgments about the value of each individual element and whether it is separable from the other
   aspects of the contractual relationship. The Company has determined that the deliverables under
   its agreements with Roche include the license, the Alnylam Europe assets and employees, the
   steering committees (joint steering committee and future technology committee) and the services
   under the Discovery Collaboration. The Company has determined that, pursuant to the accounting
   guidance governing revenue recognition on multiple element arrangements, the license and assets of
   Alnylam Europe are not separable from the undelivered services (i.e., the steering committees and
   Discovery Collaboration) and, accordingly the license and the services are being treated as a
   single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
   Roche alliance, the steering committee services and the Discovery Collaboration services are the
   final deliverables and all such services will end, contractually, five years from the effective
   date of the LCA.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is recognizing the Roche-related revenue on a straight-line basis over five years
   because the Company cannot reasonably estimate the total level of effort required to complete its
   service obligations under the LCA, and therefore, cannot utilize a proportional performance model.
   As future substantive milestones are achieved, the Company will recognize as revenue a portion of
   the milestone payment, equal to the percentage of the performance period completed when the
   milestone is achieved, multiplied by the amount of the milestone payment. The Company will
   recognize the remaining portion of the milestone over the remaining performance period on a
   straight-line basis. The Company will continue to recognize the Roche-related revenue on a
   straight-line basis over five years.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In November&amp;#160;2010, Roche announced the discontinuation of certain activities in research and
   early development, including its RNAi research efforts. The remaining deliverables under the LCA
   currently remain in effect. In October&amp;#160;2011, Arrowhead Research Corporation (&amp;#8220;Arrowhead&amp;#8221;) announced
   its acquisition of RNA therapeutics assets from Roche, including the LCA. In the event Arrowhead terminates
   the LCA or the Company and Arrowhead mutually agree to modify the LCA, the Company
   will reassess its deliverables and the period over which it will complete its performance
   obligations under the LCA. At September&amp;#160;30, 2011, deferred revenue under the LCA was $51.3&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"&gt;&lt;i&gt;Takeda Alliance&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May&amp;#160;2008, the Company entered into a license and collaboration agreement (the &amp;#8220;Takeda
   Collaboration Agreement&amp;#8221;) with Takeda Pharmaceutical Company Limited (&amp;#8220;Takeda&amp;#8221;) to pursue the
   development and commercialization of RNAi therapeutics. Under the Takeda Collaboration Agreement,
   the Company granted Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&amp;#8217;s
   intellectual property, including delivery-related intellectual property, controlled by the Company
   as of the date of the agreement or during the five years thereafter, to develop, manufacture, use
   and commercialize RNAi therapeutics, subject to the Company&amp;#8217;s existing contractual obligations to
   third parties. The license initially is limited to the fields of oncology and metabolic disease and
   may be expanded at Takeda&amp;#8217;s option to include other therapeutic areas, subject to specified
   conditions. Under the Takeda Collaboration Agreement, Takeda is the Company&amp;#8217;s exclusive platform
   partner in the Asian territory, as defined in the Takeda Collaboration Agreement, through May&amp;#160;2013.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In consideration for the rights granted to Takeda under the Takeda Collaboration Agreement,
   Takeda agreed to pay the
   Company $150.0&amp;#160;million in upfront and near-term technology transfer payments. In addition, the
   Company has the option, exercisable until the start of Phase III development, to opt-in under a
   50-50 profit sharing agreement to the development and commercialization in the United States of up
   to four Takeda licensed products and would be entitled to opt-in rights for two additional products
   for each additional field expansion, if any, elected by Takeda under the Takeda Collaboration
   Agreement. In June&amp;#160;2008, Takeda paid the Company an upfront payment of $100.0&amp;#160;million and agreed to
   pay an additional $50.0&amp;#160;million to the Company upon achievement of specified technology transfer
   milestones. Of this $50.0&amp;#160;million, $20.0&amp;#160;million was paid to the Company in October&amp;#160;2008, $20.0
   million was paid to the Company in March&amp;#160;2010 and $10.0&amp;#160;million was paid to the Company in March
   2011 (collectively, &amp;#8220;Technology Transfer Milestones&amp;#8221;). If Takeda elects to expand its license to
   additional therapeutic areas, Takeda will be required to pay the Company $50.0&amp;#160;million for each of
   up to approximately 20 total additional fields selected, if any, comprising substantially all other
   fields of human disease, as identified and agreed upon by the parties. In addition, for each RNAi
   therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled
   to receive specified development and commercialization milestones, totaling up to $171.0&amp;#160;million
   per product, together with royalty payments based on worldwide annual net sales, if any.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Pursuant to the Takeda Collaboration Agreement, the Company and Takeda are also collaborating
   on the research of RNAi therapeutics directed to one or two disease targets agreed to by the
   parties (the &amp;#8220;Research Collaboration&amp;#8221;), subject to the Company&amp;#8217;s existing contractual obligations
   with third parties. Takeda also has the option, subject to certain conditions, to collaborate with
   the Company on the research and development of RNAi drug delivery technology for targets agreed to
   by the parties. In addition, Takeda has a right of first negotiation for the development and
   commercialization of the Company&amp;#8217;s RNAi therapeutic products in the Asian territory, excluding the
   Company&amp;#8217;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a
   similar right of first negotiation to participate with Takeda in the development and
   commercialization in the United States of licensed products. The collaboration is governed by a
   joint technology transfer committee (the &amp;#8220;JTTC&amp;#8221;), a joint research collaboration committee (the
   &amp;#8220;JRCC&amp;#8221;) and a joint delivery collaboration committee (the &amp;#8220;JDCC&amp;#8221;), each of which is comprised of an
   equal number of representatives from each party.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has determined that the deliverables under the Takeda Collaboration Agreement
   include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer
   activities and the services that the Company will be obligated to perform under the Research
   Collaboration. The Company has determined that, pursuant to the accounting guidance governing
   revenue recognition on multiple element arrangements, the license and undelivered services (i.e.,
   the joint committees and the Research Collaboration) are not separable and, accordingly, the
   license and services are being treated as a single unit of accounting. When multiple deliverables
   are accounted for as a single unit of accounting, the Company bases its revenue recognition pattern
   on the final deliverable. Under the Takeda Collaboration Agreement, the last elements to be
   delivered are the JDCC and JTTC services, each of which has a life of no more than seven years.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is recognizing the upfront payment of $100.0&amp;#160;million and the Technology Transfer
   Milestones of $50.0&amp;#160;million, the receipt of which the Company believed was probable at the
   commencement of the collaboration, on a straight-line basis over seven years because the Company is
   unable to reasonably estimate the level of effort to fulfill these obligations, primarily because
   the effort required under the Research Collaboration is largely unknown, and therefore, cannot
   utilize the proportional performance model. As future substantive milestones are achieved, the
   Company will recognize as revenue a portion of the milestone payment equal to the percentage of the
   performance period completed when the milestone is achieved, multiplied by the amount of the
   milestone payment. The Company will recognize the remaining portion of the milestone over the
   remaining performance period on a straight-line basis. At September&amp;#160;30, 2011, deferred revenue
   under the Takeda Collaboration Agreement was $80.3&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Discovery and Development Alliances&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"&gt;&lt;i&gt;Novartis Broad Alliance&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In the second half of 2005, the Company entered into a series of transactions with Novartis
   Pharma AG and its affiliate, Novartis Institutes for BioMedical Research, Inc. (together,
   &amp;#8220;Novartis&amp;#8221;), which included a stock purchase agreement, an investor rights agreement (the &amp;#8220;Investor
   Rights Agreement&amp;#8221;), and a research collaboration and license agreement (the &amp;#8220;Collaboration and
   License Agreement&amp;#8221;). The Collaboration and License Agreement had an initial research term of three
   years, with an option for two additional one-year extensions at the election of Novartis. Novartis
   elected to extend the term through October&amp;#160;2010, the fifth and final planned year. In October&amp;#160;2010,
   the research program under the Collaboration and License Agreement was substantially completed in
   accordance with the terms of the Collaboration and License Agreement, subject to certain surviving
   rights and obligations of the parties.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Investor Rights Agreement provides Novartis with the right generally to maintain its
   ownership percentage in the
   Company until the earlier of any sale by Novartis of shares of the Company&amp;#8217;s common stock and
   the expiration or termination of the Collaboration and License Agreement, subject to certain
   exceptions. At September&amp;#160;30, 2011, Novartis owned 13.1% of the Company&amp;#8217;s outstanding common stock.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In consideration for the rights granted to Novartis under the Collaboration and License
   Agreement, Novartis made an upfront payment of $10.0&amp;#160;million to the Company in October&amp;#160;2005, partly
   to reimburse prior costs incurred by the Company to develop &lt;i&gt;in vivo &lt;/i&gt;RNAi technology. The Company
   also received research funding and development milestone payments from Novartis.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In September&amp;#160;2010, Novartis exercised its right under the Collaboration and License Agreement
   to select 31 designated gene targets, for which Novartis has exclusive rights to discover, develop
   and commercialize RNAi therapeutic products using the Company&amp;#8217;s intellectual property and
   technology, including delivery-related intellectual property and related technology. Under the
   terms of the Collaboration and License Agreement, for any RNAi therapeutic products Novartis
   develops against these targets, the Company is entitled to receive milestone payments upon
   achievement of certain specified development and annual net sales events, up to an aggregate of
   $75.0&amp;#160;million per therapeutic product, as well as royalties on annual net sales of any such
   product. Novartis&amp;#8217; right of first offer with respect to an exclusive license for additional
   targets has terminated. In September&amp;#160;2010, Novartis declined to exercise its non-exclusive option
   to integrate into its operations the Company&amp;#8217;s fundamental and chemistry intellectual property
   under the terms of the Collaboration and License Agreement. If Novartis had elected to exercise the
   integration option, Novartis would have been required to make additional payments to the Company
   totaling $100.0&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company believes the estimated period of performance under the Collaboration and License
   Agreement is ten years, which includes the three-year initial term of the agreement, two one-year
   extensions elected by Novartis and limited support as part of a technology transfer until 2015, the
   fifth anniversary of the completion of the research term under the Collaboration and License
   Agreement. The Company continues to use an expected term of ten years in its proportional
   performance model. The Company reevaluates the expected term when new information is known that
   could affect the Company&amp;#8217;s estimate. In the event the Company&amp;#8217;s period of performance is different
   than estimated, the Company will adjust the amount of revenue recognized on a prospective basis. At
   September&amp;#160;30, 2011, deferred revenue under the Novartis Collaboration and License Agreement was
   $0.2&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Product Alliances&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"&gt;&lt;i&gt;Kyowa Hakko Kirin Alliance&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In June&amp;#160;2008, the Company entered into a license and collaboration agreement (the &amp;#8220;Kyowa Hakko
   Kirin Agreement&amp;#8221;) with Kyowa Hakko Kirin Co., Ltd. (&amp;#8220;Kyowa Hakko Kirin&amp;#8221;). Under the Kyowa Hakko
   Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to its intellectual
   property in Japan and other markets in Asia (the &amp;#8220;Licensed Territory&amp;#8221;) for the development and
   commercialization of an RNAi therapeutic for the treatment of respiratory syncytial virus (&amp;#8220;RSV&amp;#8221;)
   infection. The Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific
   RNAi therapeutic compounds that comprise the ALN-RSV program (&amp;#8220;Additional Compounds&amp;#8221;). The Company
   retains all development and commercialization rights worldwide outside of the Licensed Territory,
   subject to its agreement with Cubist Pharmaceuticals, Inc. (&amp;#8220;Cubist&amp;#8221;) described below.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Under the terms of the Kyowa Hakko Kirin Agreement, in June&amp;#160;2008, Kyowa Hakko Kirin paid the
   Company an upfront cash payment of $15.0&amp;#160;million. In addition, Kyowa Hakko Kirin is required to
   make payments to the Company upon achievement of specified development and sales milestones
   totaling up to $78.0&amp;#160;million, and royalty payments based on annual net sales, if any, of RNAi
   therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its affiliates and sublicensees in the
   Licensed Territory.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The collaboration between Kyowa Hakko Kirin and the Company is governed by a joint steering
   committee that is comprised of an equal number of representatives from each party. Under the
   agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to
   the development activities to be undertaken in the Licensed Territory, with the initial focus on
   Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the
   development plan that are reasonably necessary for the regulatory approval and commercialization of
   an RNAi therapeutic for the treatment of RSV in Japan and the rest of the Licensed Territory. The
   Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement
   unless Kyowa Hakko Kirin elects, prior to the first commercial sale of the product in the Licensed
   Territory, to manufacture the product itself or arrange for a third party to manufacture the
   product.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has determined that the deliverables under the Kyowa Hakko Kirin Agreement include
   the license, the joint steering committee, the manufacturing services and any Additional Compounds.
   The Company has determined that, pursuant to the accounting guidance governing revenue recognition
   on multiple element arrangements, the individual deliverables are not separable and, accordingly,
   must be accounted for as a single unit of accounting. When multiple deliverables are accounted for
   as a single unit
   of accounting, the Company bases its revenue recognition pattern on the final deliverable.
   The Company is currently unable to reasonably estimate its period of performance under the Kyowa
   Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the
   fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The Company is
   deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate
   its period of performance. The Company will continue to reassess whether it can reasonably estimate
   the period of performance to fulfill its obligations under the Kyowa Hakko Kirin Agreement. At
   September&amp;#160;30, 2011, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"&gt;&lt;i&gt;Cubist Alliance&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In January&amp;#160;2009, the Company entered into a license and collaboration agreement with Cubist
   (the &amp;#8220;Cubist Agreement&amp;#8221;) to develop and commercialize therapeutic products (&amp;#8220;Licensed Products&amp;#8221;)
   based on certain of the Company&amp;#8217;s RNAi technology for the treatment of RSV infection. Licensed
   Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV
   inhibitors. In November&amp;#160;2009, the Company and Cubist entered into an amendment to the Cubist
   Agreement (the &amp;#8220;Amendment&amp;#8221;), which provides that the Company and Cubist would focus their
   collaboration and joint development efforts on ALN-RSV02, a second-generation compound, intended
   for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and
   Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant
   to the terms of the Amendment, the Company is continuing to develop ALN-RSV01 for adult transplant
   patients at its sole discretion and expense. Cubist has the right to opt into collaborating with
   the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time
   following the completion of the Company&amp;#8217;s Phase IIb trial of ALN-RSV01, subject to the payment by
   Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the
   Company&amp;#8217;s development expenses for ALN-RSV01. In December&amp;#160;2010, the Company and Cubist jointly made
   a portfolio decision to put the development of ALN-RSV02 on hold.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In consideration for the rights granted to Cubist under the Cubist Agreement, in January&amp;#160;2009,
   Cubist paid the Company an upfront cash payment of $20.0&amp;#160;million. Cubist is also obligated under
   the Cubist Agreement to pay the Company milestone payments, totaling up to an aggregate of $82.5
   million, and has the right to convert the North American co-development and profit sharing
   arrangement into a royalty-bearing license.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has determined that the deliverables under the Cubist Agreement include the
   licenses, technology transfer related to the ALN-RSV program, the joint steering committee and the
   development and manufacturing services that the Company is obligated to perform during the
   development period. The Company also has determined that, pursuant to the accounting guidance
   governing revenue recognition on multiple element arrangements, the licenses and undelivered
   services are not separable and, accordingly, the licenses and services are being treated as a
   single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
   Cubist Agreement, the last element to be delivered is the development and manufacturing services,
   which have an expected life of approximately eight years.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is recognizing the upfront payment of $20.0&amp;#160;million on a straight-line basis over
   approximately eight years because the Company is unable to reasonably estimate the level of effort
   to fulfill its performance obligations, and therefore, cannot utilize a proportional performance
   model. As future substantive milestones are achieved, the Company will recognize as revenue a
   portion of the milestone payment, equal to the percentage of the performance period completed when
   the milestone is achieved, multiplied by the amount of the milestone payment. The Company will
   recognize the remaining portion of the milestone over the remaining performance period on a
   straight-line basis. At September&amp;#160;30, 2011, deferred revenue under the Cubist Agreement was $13.2
   million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for
   developing Licensed Products in North America, and each bears one-half of the related development
   costs, provided that under the terms of the Amendment, the Company is funding the advancement of
   ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue
   generating arrangements that involve cost sharing between the parties, the Company presents the
   results of activities for which it acts as the principal on a gross basis and reports any payments
   received from, or made to, other collaborators based on other applicable GAAP or, in the absence of
   other applicable GAAP, analogy to authoritative accounting literature or a reasonable, rational and
   consistently applied accounting policy election. As the Company is not considered the principal
   under the Cubist Agreement, the Company records any amounts due from Cubist as a reduction of
   research and development expense.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;3. INCOME TAXES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company expects to generate U.S. taxable losses during 2011 and has recorded no income tax
   provision for the three or nine months ended September&amp;#160;30, 2011. During the three and nine months
   ended September&amp;#160;30, 2010, the Company recorded a provision for income taxes of $0.3&amp;#160;million and
   $0.1&amp;#160;million, respectively.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During 2009 and 2008, the Company utilized certain tax attributes, including net operating
   loss and tax credit carryforwards as a result of the recognition of revenue for certain proceeds
   received from strategic alliances. However, the Company also generated a deferred tax asset related
   to the recognition of this revenue for tax purposes and recorded a net deferred tax asset to the
   extent it was more likely than not that the asset would be realized. During 2010, the Company
   generated sufficient net operating losses to carry back to 2009 and 2008 to obtain a refund of
   taxes paid in those years, resulting in a realization of its net deferred tax asset. As a result,
   during 2010, the Company reclassified $10.7&amp;#160;million of its deferred tax asset to income taxes
   receivable. The Company received this income tax refund during the three months ended March&amp;#160;31,
   2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2010, the Company had federal and state net operating loss carryforwards of
   $27.5&amp;#160;million and $101.6&amp;#160;million, respectively, to reduce future taxable income that will expire at
   various dates through 2030. Ownership changes, as defined in the Internal Revenue Code, including
   those resulting from the issuance of common stock in connection with the Company&amp;#8217;s public
   offerings, may limit the amount of net operating loss that can be utilized to offset future taxable
   income or tax liability. The Company has determined that there is no limitation on the utilization
   of net operating loss carryforwards in accordance with Section&amp;#160;382 of the Internal Revenue Code.
   In July&amp;#160;2011, the Internal Revenue Service completed its audits of the Company&amp;#8217;s 2008 and 2009 tax
   years. The Company did not record any tax expense related to these audits.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company continues to recognize fully its tax benefits which are offset by a valuation
   allowance to the extent that it is more likely than not that the deferred tax assets will not be
   realized. At September&amp;#160;30, 2011, the Company had $0.1&amp;#160;million of total gross unrecognized tax
   benefits that, if recognized, would favorably impact the Company&amp;#8217;s effective income tax rate in
   future periods.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;4. REGULUS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In September&amp;#160;2007, the Company and Isis Pharmaceuticals, Inc. (&amp;#8220;Isis&amp;#8221;) established Regulus, a
   company focused on the discovery, development and commercialization of microRNA therapeutics, a
   potential new class of drugs to treat the pathways of human disease. Regulus, which initially was
   established as a limited liability company, converted to a C corporation in January&amp;#160;2009 and
   changed its name to Regulus Therapeutics Inc.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In consideration for the Company&amp;#8217;s and Isis&amp;#8217; initial interests in Regulus, each party granted
   Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic
   applications as well as certain patents in the microRNA field. In addition, the Company made an
   initial cash contribution to Regulus of $10.0&amp;#160;million, resulting in the Company and Isis making
   approximately equal aggregate initial capital contributions to Regulus. In March&amp;#160;2009, the Company
   and Isis each purchased $10.0&amp;#160;million of Series&amp;#160;A preferred stock of Regulus. In October&amp;#160;2010, in
   connection with its strategic alliance with Regulus formed in June&amp;#160;2010, Sanofi made a $10.0
   million equity investment in Regulus. As a result of this investment, the Company recognized a gain
   of $4.4&amp;#160;million due to the increase in valuation of Regulus. This amount was recorded as other
   income in the Company&amp;#8217;s consolidated statements of operations for the year ended December&amp;#160;31, 2010.
   At September&amp;#160;30, 2011, the Company, Isis and Sanofi owned approximately 45%, 46% and 9%,
   respectively, of Regulus. Regulus continues to operate as an independent company with a separate
   board of directors, scientific advisory board and management team, some of whom have options to
   purchase common stock of Regulus. Members of the board of directors of Regulus who are the
   Company&amp;#8217;s employees or Isis&amp;#8217; employees are not eligible to receive options to purchase Regulus
   common stock.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has reviewed the consolidation guidance that defines a variable interest entity
   (&amp;#8220;VIE&amp;#8221;) and concluded that Regulus currently qualifies as a VIE. The Company does not consolidate
   Regulus as the Company lacks the power to direct the activities that could significantly impact the
   economic success of this entity. At September&amp;#160;30, 2011, the total carrying value of the Company&amp;#8217;s
   investment in Regulus in its condensed consolidated balance
   sheets was $1.4&amp;#160;million under the equity method. The Company&amp;#8217;s maximum exposure to loss related to
   this VIE is limited to the carrying value of the Company&amp;#8217;s investment, as well the portion of
   Regulus&amp;#8217; debt, including accrued interest, guaranteed by the Company which was $5.4&amp;#160;million at
   September&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company accounts for its investment in Regulus using the equity method of accounting.
   Summary results of Regulus&amp;#8217; operations for the three and nine months ended September&amp;#160;30, 2011 and
   2010 and balance sheets at September&amp;#160;30, 2011 and December&amp;#160;31, 2010 are presented in the tables
   below, in thousands (unaudited):
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Statement of Operations Data:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net revenues
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,809&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,309&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;10,426&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,804&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Operating expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,783&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,743&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15,688&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17,182&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Loss from operations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(974&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2,434&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(5,262&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(13,378&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other expense
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(67&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(48&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(322&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(132&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net loss
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(1,041&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(2,482&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(5,584&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(13,510&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance Sheet Data:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash, cash equivalents and marketable securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;44,088&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;54,789&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Working capital
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;29,587&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;40,446&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total assets
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;48,810&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;59,703&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Notes payable
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,262&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,270&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total stockholders&amp;#8217; equity
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,964&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,996&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;5. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"&gt;&lt;i&gt;Tekmira Litigation&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On March&amp;#160;16, 2011, Tekmira and Protiva Biotherapeutics, Inc. filed a civil complaint against
   the Company in the Business Litigation Section of the Suffolk County Superior Court, in Boston,
   Massachusetts and on June&amp;#160;3, 2011, the plaintiffs filed an amended complaint adding AlCana
   Technologies, Inc. (&amp;#8220;AlCana&amp;#8221;), a research collaborator of the Company, as a defendant. The amended
   complaint alleges misappropriation of the plaintiffs&amp;#8217; confidential and proprietary information and
   trade secrets, civil conspiracy, and tortious interference with contractual relationships by the
   Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of
   good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive acts
   and practices by the Company. The plaintiffs seek, among other relief, injunctive relief,
   unspecified damages and the termination of licenses that the plaintiffs provided to the Company.
   On April&amp;#160;6, 2011, the Company timely served and filed an answer to the plaintiffs&amp;#8217; original
   complaint denying the plaintiffs&amp;#8217; claims, together with counterclaims against the plaintiffs. On
   June&amp;#160;28, 2011, the Company timely served and filed an answer to the plaintiffs&amp;#8217; amended complaint
   denying the plaintiffs&amp;#8217; claims and counterclaims against the plaintiffs asserting breach of
   contract, defamation, breach of covenant not to sue, breach of patent prosecution and non-use
   provisions, misappropriation of confidential and proprietary information and trade secrets, unjust
   enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of
   Massachusetts statutes. The Company is seeking damages and equitable relief on its counterclaims.
   In September&amp;#160;2011, the Court granted the plaintiffs&amp;#8217; motion to dismiss the Company&amp;#8217;s
   counterclaim for defamation. The Company has a number of additional
   counterclaims remaining against the plaintiffs.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"&gt;&lt;i&gt;University of Utah Litigation&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On March&amp;#160;22, 2011, The University of Utah (the &amp;#8220;University&amp;#8221;) filed a civil complaint in the
   United States District Court for the District of Massachusetts against the Company, Max Planck
   Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH (together, &amp;#8220;Max
   Planck&amp;#8221;), the Whitehead Institute for Biomedical Research (&amp;#8220;Whitehead&amp;#8221;), the Massachusetts
   Institute of Technology (&amp;#8220;MIT&amp;#8221;) and the University of Massachusetts (&amp;#8220;UMass&amp;#8221;), claiming a professor
   at the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl
   patents. The University did not serve the original complaint on the Company or the other
   defendants. On July&amp;#160;6, 2011, the University filed an amended complaint alleging substantially the
   same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was
   served on the Company on July&amp;#160;14, 2011. The University is seeking changes to the inventorship of
   the Tuschl patents, unspecified damages and other relief. On October&amp;#160;31, 2011, the Company, Max
   Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on
   October&amp;#160;31, 2011, UMass filed a motion to dismiss on separate grounds, which the Company, Max Planck, Whitehead
   and MIT have joined.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Although the Company believes that it has meritorious defenses to each of the claims in the
   lawsuits described above and intends to fully defend itself in these matters, litigation is subject
   to inherent uncertainty and a court could ultimately rule against the Company in one or both of
   these matters. In addition, the defense of litigation and related matters are costly and may divert
   the attention of the Company&amp;#8217;s management and other resources that would otherwise be engaged in
   running the Company&amp;#8217;s business. The Company has not recorded an estimate of the possible loss
   associated with the legal proceedings described above due in each case to the uncertainties related
   to both the likelihood and the amount of any possible loss or range of loss.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"&gt;&lt;i&gt;Tuschl Settlement&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In March&amp;#160;2011, the Company, Max Planck, Whitehead and UMass entered into a global settlement
   agreement (the &amp;#8220;Settlement Agreement&amp;#8221;) resolving their ongoing litigation regarding the Tuschl
   patents. MIT, formerly a party to the litigation, also agreed to the terms of the Settlement
   Agreement.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The litigation was initiated in June&amp;#160;2009 and scheduled for trial in March&amp;#160;2011 in the United
   States District Court for the District of Massachusetts, and related to, among other things, the
   prosecution of the Tuschl I and Tuschl II patent applications. In the field of RNAi therapeutics,
   the Company is the exclusive licensee of the Tuschl I patent applications from Max Planck, MIT and
   Whitehead, and of the Tuschl II patent applications from Max Planck. The terms of the Settlement
   Agreement included mutual releases and dismissal with prejudice of all claims and counterclaims in
   the litigation between the parties.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As part of the Settlement Agreement, Max Planck, Whitehead, UMass and MIT agreed that future
   prosecution of the Tuschl I and Tuschl II patent families in the United States should be
   coordinated and led by a single party. Max Planck will assume that role, in addition to their
   ongoing leadership in the continued prosecution of the Tuschl II patent family outside the United
   States. UMass will lead future prosecution of the Tuschl I patent family outside the United
   States. In addition, under the terms of the Settlement Agreement, the Company granted UMass the
   right to sublicense the U.S. Tuschl II patent family to Merck &amp;#038; Co., Inc., subject to certain
   third-party obligations of the Company and other limitations, in exchange for a share of certain
   future sublicense income.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company incurred costs of $3.3&amp;#160;million and $3.8&amp;#160;million during the three months ended
   March&amp;#160;31, 2011 and 2010, respectively, in connection with this dispute. These costs were charged
   to general and administrative expense. The Company does not expect to incur any additional
   significant expenses related to this dispute.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="Jan-01-2011_Sep-30-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;6. RESTRUCTURING&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In September&amp;#160;2010, as a result of the planned completion of the fifth and final year of the
   research program under the Novartis Collaboration and License Agreement and the Company&amp;#8217;s reduced
   need for service-based collaboration resources, the Company&amp;#8217;s Board of Directors approved and the
   Company effected a corporate restructuring to focus the Company&amp;#8217;s resources on its most promising
   programs and significantly reduce its cost structure. The corporate restructuring included a
   reduction of the Company&amp;#8217;s overall workforce by approximately 25%.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the year ended December&amp;#160;31, 2010, the Company recorded $2.2&amp;#160;million of
   restructuring-related costs in operating expenses, including employee severance, benefits and
   related costs. During the nine months ended September&amp;#160;30, 2011, the Company did not record any
   additional restructuring related costs.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table summarizes the components of the Company&amp;#8217;s restructuring expenses recorded
   in operating expenses and in current liabilities, in thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Original&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Reversals) or&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Charges and Amounts&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Adjustments to&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Paid Through&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Accrued at&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Charges&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Employee severance, benefits and related costs
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,193&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(20&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,173&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,193&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(20&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,173&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following table summarizes the components of the Company&amp;#8217;s restructuring activities
   for the nine months ended September&amp;#160;30, 2011, in thousands:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amounts &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Reversals) or&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Accrued at &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Adjustments to&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Paid Through&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Accrued at&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Charges&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Employee severance, benefits and related costs
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;977&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;977&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;977&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;977&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <alny:DeferredIncomeTaxes contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-133000</alny:DeferredIncomeTaxes>
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">5706000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1786000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">4310000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">1469000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">9200000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2725000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">8284000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2789000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare contextRef="NineMonthsEnded_30Sep2010" unitRef="Shares" decimals="-3">41989000</alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare>
  <alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare contextRef="ThreeMonthsEnded_30Sep2010" unitRef="Shares" decimals="-3">42123000</alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare>
  <alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare contextRef="Jan-01-2011_Sep-30-2011" unitRef="Shares" decimals="-3">42389000</alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare>
  <alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="-3">42654000</alny:WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare>
  <dei:AmendmentFlag contextRef="Jan-01-2011_Sep-30-2011">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Jan-01-2011_Sep-30-2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Jan-01-2011_Sep-30-2011">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Jan-01-2011_Sep-30-2011">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Jan-01-2011_Sep-30-2011">2011-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Jan-01-2011_Sep-30-2011">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Jan-01-2011_Sep-30-2011">0001178670</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_31Oct2011" unitRef="Shares" decimals="INF">42726984</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Jan-01-2011_Sep-30-2011">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Jan-01-2011_Sep-30-2011">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2010" unitRef="USD" decimals="0">446579243</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Jan-01-2011_Sep-30-2011">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Jan-01-2011_Sep-30-2011">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Jan-01-2011_Sep-30-2011">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">9312000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">5486000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">11116000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">12230000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">-151000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">500443000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">514290000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">393265000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">310223000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">254139000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">179957000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">158532000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">98685000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">116773000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">113218000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">137468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2010" unitRef="USD" decimals="-3">46881000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">74599000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">74336000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-90587000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-263000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_30Sep2011" unitRef="USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2011" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">42343423</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">42687941</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">42343423</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">42687941</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">423000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">427000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-36013000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-9628000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-44211000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-13142000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DeferredRentCreditCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">484000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">484000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2869000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">2884000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">81134000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">75727000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">129974000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">84810000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3650000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">3888000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-01-2011_Sep-30-2011" unitRef="USDEPS" decimals="2">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-29000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">448000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">318000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-05" contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">30205000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-01" contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">8928000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-08" contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">27608000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-04" contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">8955000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-36498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-9332000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-43346000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-13237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-6723000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-1226000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-2551000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-467000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxesReceivable contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">10669000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:IncomeTaxesReceivable contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesReceivable>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">87000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">298000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-5928000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-3826000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-5546000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-40877000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-50571000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-10669000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">553000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">1741000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2281000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-1980000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-1163000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-1423000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:InvestmentIncomeInterest contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1833000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">602000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">969000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">265000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">3616000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1421000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">235032000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">182350000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">393265000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">310223000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">102046000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">93927000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LicenseAndServicesRevenue contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">78849000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">27668000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">62302000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">20791000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3136000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">471000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-29741000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">61175000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-63953000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-61909000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-36585000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-9630000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-43346000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-13237000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-4838000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-604000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-2114000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-799000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">110509000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">36396000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">103534000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">33229000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-31660000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-8728000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-41232000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-12438000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">601000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-865000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">95000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">143000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">729000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">52000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">20000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-532000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-597000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-402000</us-gaap:OtherPostretirementBenefitsPayments>
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">-393000</us-gaap:OtherPostretirementBenefitsPayments>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">595000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">287493000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">217821000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3594000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">767000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2011" unitRef="USDEPS" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" />
  <us-gaap:PreferredStockSharesIssued xsi:nil="true" contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" />
  <us-gaap:PreferredStockSharesOutstanding xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" />
  <us-gaap:PreferredStockSharesOutstanding xsi:nil="true" contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" unitRef="USD" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_30Sep2011" unitRef="USD" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6889000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">4909000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">993000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2143000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">471000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">261346000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">279763000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">18289000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">15309000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">3450000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">2027000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-07" contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">80304000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-06" contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">27468000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-02" contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">75926000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-03" contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">24274000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-343347000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">-386693000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensation contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">14906000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-01-2011_Sep-30-2011" unitRef="USD" decimals="-3">12594000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">158233000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">127873000</us-gaap:StockholdersEquity>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-05" xlink:label="Item-05_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-01" xlink:label="Item-01_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-08" xlink:label="Item-08_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-04" xlink:label="Item-04_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-07" xlink:label="Item-07_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-06" xlink:label="Item-06_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-02" xlink:label="Item-02_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-03" xlink:label="Item-03_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-05_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-01_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-08_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-04_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-07_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-06_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-02_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-03_lbl" xlink:to="Footnote-01" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Non-cash stock-based compensation expenses included in operating expenses are as follows: </link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>alny-20110930.xsd
<DESCRIPTION>EX-101 SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Bowne Tagger. XBRL Parser version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://alnylam.com/20110930" xmlns:alny="http://alnylam.com/20110930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://alnylam.com/role/Restructuring" id="Restructuring">
        <link:definition>0206 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0205 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/Regulus" id="Regulus">
        <link:definition>0204 - Disclosure - Regulus</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0203 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/SignificantAgreements" id="SignificantAgreements">
        <link:definition>0202 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20110930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20110930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20110930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <element id="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" name="NonCashStockBasedCompensationExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" name="NonCashStockBasedCompensationExpensesGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" name="NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="alny_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="alny_DeferredIncomeTaxes" name="DeferredIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" name="WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>alny-20110930_cal.xml
<DESCRIPTION>EX-101 CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--XBRL document created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#BalanceSheets" roleURI="http://alnylam.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#BalanceSheetsParenthetical" roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#StatementsOfCashFlows" roleURI="http://alnylam.com/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#SignificantAgreements" roleURI="http://alnylam.com/role/SignificantAgreements" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#IncomeTaxes" roleURI="http://alnylam.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#DocumentAndEntityInformation" roleURI="http://alnylam.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#Regulus" roleURI="http://alnylam.com/role/Regulus" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#CommitmentsAndContingencies" roleURI="http://alnylam.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#Restructuring" roleURI="http://alnylam.com/role/Restructuring" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredRevenueNoncurrent" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredRentCreditNoncurrent" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_DeferredRentCreditCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRentCreditCurrent" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_ReceivablesNetCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_ReceivablesNetCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="70" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_AvailableForSaleSecuritiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent" order="50" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="140" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_IncomeTaxesReceivable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_IncomeTaxesReceivable" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_OtherLiabilitiesNoncurrent" order="80" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="100" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTax" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTax" xlink:to="loc_NetIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_NonoperatingIncomeExpense" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_OtherNonoperatingIncomeExpense" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_InvestmentIncomeInterest" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_OperatingIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_OperatingExpenses" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTax" xlink:to="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_LicenseAndServicesRevenue" order="10" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="260" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="240" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="220" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="120" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_IncreaseDecreaseInReceivables" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInReceivables" order="200" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="180" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInOtherAccruedLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInOtherAccruedLiabilities" order="250" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities" order="30" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="90" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_DeferredIncomeTaxes" xlink:label="alny_DeferredIncomeTaxes" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="alny_DeferredIncomeTaxes" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_IncreaseDecreaseInIncomeTaxesReceivable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInIncomeTaxesReceivable" order="210" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="loc_OtherPostretirementBenefitsPayments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OtherPostretirementBenefitsPayments" order="160" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="0.01953125" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="90" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0201 - Disclosure - Summary of Significant Accounting Policies" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SignificantAgreements" xlink:title="0202 - Disclosure - Significant Agreements" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/IncomeTaxes" xlink:title="0203 - Disclosure - Income Taxes" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Regulus" xlink:title="0204 - Disclosure - Regulus" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/CommitmentsAndContingencies" xlink:title="0205 - Disclosure - Commitments and Contingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Restructuring" xlink:title="0206 - Disclosure - Restructuring" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>alny-20110930_lab.xml
<DESCRIPTION>EX-101 LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--Extended XBRL Label Linkbase created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedTotal" roleURI="http://xbrl.us/us-gaap/role/label/negatedTotal" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 125,000,000 shares authorized; 42,687,941 shares issued and outstanding at September 30, 2011; 42,343,423 shares issued and outstanding at December 31, 2010</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive Income, Net of Tax, Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negatedTotal" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income, Net of Tax, Attributable to Parent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income taxes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Income Taxes Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investments Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:to="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based employee remuneration classified as research and development expenses.</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:to="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses General And Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based employee remuneration classified as general and administrative expenses.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Collaboration receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Collaboration receivables</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Collaboration receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Included In Operating Expenses Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non-cash stock-based compensation expenses included in operating expenses are as follows:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Included In Operating Expenses.</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="alny_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="lab_DocumentFiscalYearFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="lab_DocumentFiscalPeriodFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_IncreaseDecreaseInOtherAccruedLiabilities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:to="lab_AvailableForSaleSecuritiesNoncurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesNoncurrent" xml:lang="en-US">Available-for-sale Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesNoncurrent" xml:lang="en-US">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="lab_PaymentsToAcquireAvailableForSaleSecurities" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_DepreciationDepletionAndAmortization" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_DeferredIncomeTaxes" xlink:label="alny_DeferredIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_DeferredIncomeTaxes" xlink:to="alny_DeferredIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_DeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_DeferredIncomeTaxes_lbl" xml:lang="en-US">The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations and the portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_DeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="lab_IncomeTaxesReceivable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_OtherLiabilitiesNoncurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_IncreaseDecreaseInIncomeTaxesReceivable" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_ProceedsFromIssuanceOfCommonStock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of shares to Novartis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of exchange rate on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="lab_CommitmentsAndContingencies" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Notes 4, 5 and 6)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lab_AccountingPoliciesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_IncomeTaxDisclosureAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EquityMethodInvestmentsAndJointVenturesAbstract" xml:lang="en-US">Regulus [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_RestructuringAndRelatedActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_EarningsPerShareBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Sales and maturities of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid, Deferred Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_CollaborativeArrangementDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="lab_LicenseAndServicesRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">Net revenues from research collaborators</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="us-gaap_OtherPostretirementBenefitsPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPostretirementBenefitsPayments" xlink:to="lab_OtherPostretirementBenefitsPayments" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherPostretirementBenefitsPayments" xml:lang="en-US">Other Postretirement Benefits Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_OtherPostretirementBenefitsPayments" xml:lang="en-US">Charge for 401(k) company stock match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity in loss of joint venture (Regulus Therapeutics Inc.)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity in loss of joint venture (Regulus Therapeutics Inc.)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in joint venture (Regulus Therapeutics Inc.)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2011 and December 31, 2010</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" xlink:label="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" xlink:to="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare_lbl" xml:lang="en-US">Weighted Average Common Shares Used To Compute Basic And Diluted Net Loss Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare_lbl" xml:lang="en-US">Weighted average common shares used to compute basic and diluted net loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare_lbl" xml:lang="en-US">The average number of shares issued and outstanding that are used in calculating basic and diluted earnings per share, determined based on the timing of issuance of shares in the period.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xml:lang="en-US">Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xml:lang="en-US">Other than temporary impairment on equity securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income, Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gain (loss) on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">SIGNIFICANT AGREEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">REGULUS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">RESTRUCTURING</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Significant Agreements [Abstract]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>alny-20110930_pre.xml
<DESCRIPTION>EX-101 PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--XBRL document created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#BalanceSheets" roleURI="http://alnylam.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#BalanceSheetsParenthetical" roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#StatementsOfCashFlows" roleURI="http://alnylam.com/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#SignificantAgreements" roleURI="http://alnylam.com/role/SignificantAgreements" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#IncomeTaxes" roleURI="http://alnylam.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#DocumentAndEntityInformation" roleURI="http://alnylam.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#Regulus" roleURI="http://alnylam.com/role/Regulus" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#CommitmentsAndContingencies" roleURI="http://alnylam.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="alny-20110930.xsd#Restructuring" roleURI="http://alnylam.com/role/Restructuring" />
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_ReceivablesNetCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_ReceivablesNetCurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_DeferredRentCreditCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRentCreditCurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRentCreditNoncurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_AvailableForSaleSecuritiesNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_IncomeTaxesReceivable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_IncomeTaxesReceivable" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OtherLiabilitiesNoncurrent" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_StockholdersEquityAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesIssued" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesIssued" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_OperatingExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_OperatingExpensesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_OperatingExpenses" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_OperatingIncomeLoss" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_NonoperatingIncomeExpenseAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_NonoperatingIncomeExpenseAbstract" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_InvestmentIncomeInterest" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_NonoperatingIncomeExpense" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_IncomeTaxExpenseBenefit" order="120" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_NetIncomeLoss" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_ComprehensiveIncomeNetOfTaxAbstract" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_ComprehensiveIncomeNetOfTax" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_LicenseAndServicesRevenue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" xlink:label="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_IncreaseDecreaseInReceivables" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInReceivables" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInOtherAccruedLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInOtherAccruedLiabilities" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_DeferredIncomeTaxes" xlink:label="alny_DeferredIncomeTaxes" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alny_DeferredIncomeTaxes" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_IncreaseDecreaseInIncomeTaxesReceivable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInIncomeTaxesReceivable" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="loc_OtherPostretirementBenefitsPayments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OtherPostretirementBenefitsPayments" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_SignificantAccountingPoliciesTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SignificantAgreements" xlink:title="0202 - Disclosure - Significant Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/IncomeTaxes" xlink:title="0203 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_IncomeTaxDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeTaxDisclosureAbstract" xlink:to="loc_IncomeTaxDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="alny-20110930.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityRegistrantName" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityCentralIndexKey" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentType" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentPeriodEndDate" order="80" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_AmendmentFlag" order="100" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentFiscalYearFocus" order="120" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentFiscalPeriodFocus" order="140" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_CurrentFiscalYearEndDate" order="160" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_EntityWellKnownSeasonedIssuer" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityWellKnownSeasonedIssuer" order="180" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_EntityVoluntaryFilers" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityVoluntaryFilers" order="200" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_EntityCurrentReportingStatus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityCurrentReportingStatus" order="220" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityFilerCategory" order="240" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_EntityPublicFloat" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityPublicFloat" order="260" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityCommonStockSharesOutstanding" order="280" use="optional" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Regulus" xlink:title="0204 - Disclosure - Regulus">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_EquityMethodInvestmentsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_EquityMethodInvestmentsDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/CommitmentsAndContingencies" xlink:title="0205 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Restructuring" xlink:title="0206 - Disclosure - Restructuring">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RestructuringAndRelatedActivitiesAbstract" xlink:to="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>b87804b8780401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b87804b8780401.gif
M1TE&.#EAQ0`]`.8``,C9Z%MDA>ON\9.:K=35W$M8>:FMO6%JB<;)TKW2Y+W`
MRZK'W<C,U9RALS=$;"0Q7/7V]H6+HB\Z8ZNPOXN2I_/V^)6YUGN"FZ2JN>3E
MZ%.-P.SR]OKZ^O#Q\JZRP.'CYKF^R>GJ[+6YQ;&UPW-[E@P:2WBFS,'$S<_2
MVFF<Q][@Y/#T]_CX^.WN[]#AZ\+&T8JRTN?HZO+R].CHZM_>Y49VJ_S\^_;X
M^5%:?;>[R!4A46UUD9F>L5R2PKB[QM;8W41/<VAPC1HF4]C:X-[I\-W>X:"E
MMH^6JOGZ_!PI5MO=XI>=K];:X/[]_?W^_5&*OOCZ^H&(H,S/UQ\X;`\=3OK\
M_.GL[@@61R`K6`@51S]);Q,@3P<72/[^_OW]_?W]_/[^_?[___[__OCX^OS\
M_`<61_S]_/_^_OW\_/W]_O___OW^_OO\^_S]_?[]_OGY^;_#SZ^SP)_`V?S\
M_?O[^]KG[=G9X/?W]^SL[O/T]//S]%5??_GZ^3ECFOO[^O___R'Y!```````
M+`````#%`#T```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2P7;>UN;J=76@A(`U2'+O$Q9)>2CLZ5U<E
M1\;0T8@0.UO,UU@0TMO1''$7UM?-!MSEQ&!?#$+BS!?F[[5=$'M7#R1+6,Q!
M\/RV?B0Z*+00-*),F7W]$JXR<T0+`2]B!*$H<X6$PHNG[F"X$*++H"Y'FAD)
M`ZG)%X\84S;JH@!#GD)>@%S9HB+2AP$L%B$P0":4"@P?(JH4U:4("CJ&0BQS
M@-)1DP%4##0]=$#'F%`3KG@@.713&*Z"6(3P8JA+A':1OFBYHF6JH:I7_T%E
M]=#U4I<;&Y"$D0<6ER$]#ZX(D8+(C)I#"+A0V4+@3"*X6+76K;3&2H($`%9T
M@8)449<)7*X$X6-(S(8-;O]X*8"%`I<@/1%!EBO9U!<(=U+/0N+B<@(B7<P(
MT"U(C`R95^"`*>NB@MLN&;8<"`$DB0KBLS_--06&0)PX'XC#@M+[,O`N=:`D
M`N.#2QD@-@R%60$@-1@*5^)X\7#%"%FJ5D5&5RDMG$!!%'$,HTL7`EP&@'-_
MK."";EWD$4`S4BQ72!H+""#41W@(\0`+:H3P@`,SZ);='!R8T843=ZC`1`QD
M-.4%!W102`8'9&WW$1TQH(!"!CD6LN,M9%C!A/\*=VCX!QAO?,"$%37^$0,"
M1AP!0DZ[W+4"$BA]`4,%AW1AP#('*%B(%7+8U\`5#7B41A1E2`5@7'^,@(4(
M>ESP@`Y4"*&%""B%@(,$>J3&P0X/9/"'CW^P88`#0E!1@@Y:*%#(`8B"`(00
M6^@@`05LJ$:!!(`*`00"Z""``0\_B+>@'`NT88@,!0BF1&IT6$#$(2U0&H(@
M7:B0!`X#O16@(`9<00$0#QPP0`,[))'$@%X,<,41S[V@0YJ/UO9'!#KL,8`(
M(UR01*.$%"`$!5@`$4$#%TA`100M!)!$``/P$(`.#Q#0!0<==/`?-RZD\&LA
M!E!1T1?,F9`:2UP$@(;_(&=X@8,0FBJ+9[-)2*``CV"0T8`.#FCS1PA8)!'#
M5'>0L(44CD$:A1$0+->%#5$XT^ZE''GAQ1<*/""$OB.\X807>D1QQ0%.OK.!
M!C"L00@$#EPA00?R;6`"`&`-<D<05-A!2!=Q;!%$?)LN^P?(X5U]`!4H#(+!
M%1$<_,<)1_\'Z2$H1/MAKA?$)H@79Y7`P)H2;'''.[=TX8(&&B2`DIEE4('!
M(6G(8<(-B,7[1N1(:H%%!FYEURP/S_%0YR`=&+WKX4%P/,C?AGP@00'MZM#1
MV0J4@8,?,!U0`A/FG%'!`@ND0'D*J/VAAP19D/!2(9+WL,#$)'#AP`[@A[^#
M_P1X6TV(ZE>0@[T(5PSP$09<1*`@"D<3+PCN70S-@@HC/,#[(.Z2`?;L4((`
M/"<"BGM'&Q)`N0;"X`9>6(+69G>V%9C`!!LX1`CLA84.>K"#2:#"`][0MH^E
MKRP*:-\@Q*`'!SR`,#:H5@X(\3<Z$.`(`9#``[!0@O\)(H"&H`$5#&B(`23P
M'4BP0`,IEP`52*`$&-#;'\0`!25NKRQ&*$$0",#%+G(1!4'@@@*F@C[U`4^%
M'VD`%4B`A@SLBVNW$Q<'>""!)`#A9@WP7[N$(,!"")&(A3#BXMY!124VL`<'
MX,(>BD0(-C`P!2LXA`WJB`!$=.$$5`""&<[GMF:9<?^%*70?(>[@`.M<H`1C
MI&%MP+"$$@#A!7YHPA]TY\,_`-&/0TR-(/G1!3_`H($UH$(24`<3!FJ@/H=@
MP--(B`@.:*$$`AM$&4L3RD*`@0<%S"0+PN:C%E!!`K\3!"WWV$="_%&71X1'
M&-ZP`,I-H01]L,`&TD"L"LBA!U2SE2',4(`2@$`\71!!&0HGS4Z>L!!BJ"8A
MSM""`I3!GU$+UX!".95Q`I"/0<QE$=,)CRY4(0$U*($#GJ"!%,"`>19P7DDC
M618F?#,/LF+!`R3P@X*:\)/%42@AO)`5!XRN$#X2:)P^@@#_=>$DML0H+@%)
MB%TJ1`8.F$(-EDC5%$SH$%[_N,`5>!#1LISR&8*8)O9T.@@R'($+<9`E4&LS
M!"X4``].Z,(;<J`%+@`A!$=XW"W-J=%`<A0>^Z$"")I'50WT``8+*XN)M@#'
M1<P`4PH2*R$2BD9"J,`!$MBD(7STA0!P00L4&,`>J%"`!XAP#]K8ZR#.N=%!
M]D,)6&B`%^[B@@58P`)R`(``O."80X!!"@<8*B.^0($@*$$0U%(3`P[`@.?\
MX``@P-X%J.`#W0"7,(*XPQ*T,-,`O.`-IR)!L@:P@\<5`@]!8)TA%'"`FO2#
M!20(``N:DC\O=+4L7G"#7Q@A-`WECQ!@&)I;Q"`T+_1E@T!0F2&^X(4F?.@+
M>K!"_PLXX)$WM(`.7,G?Q.Q;)J3R(PPY`,('.GH$'1C!(R01PX?^\!5(J($K
MAVDQB\,6B=X2@PXX$`$\C".!NWH!#B^`0`=BL#(K5*@%7>C`"1A`!CW4Q`D_
M:$(7XO8&*8!@"%Y`P`DRT`((=*$%+9""`A2`@CP@N05CABF8_P"!@10E!\G:
M!7$;8+AR=.%-4G%"%`C@`12,X`\B^.>KND"`%R!``4/8H@AVT(0.!"$&3C#"
M"?"``AM@H`,<>$%0$,"`/!`@!Q#X``-N$H,,Q(`.#2!'"%[P!Q9$(09X($88
M5'`!MKU#!C/%@QC`$(0C+/D"(H@"J(_0@`P0(`HDR(`2,/\0`0,,P`T@4$`#
MT&"`B_V!#`CZP`M4(`9._T$%K!8U'"HIB`Q,8`D0L`*KO7`$`R@X'BP80&/-
MX82[8<`C8(A"!\"``@P(P``Y>,$$)@`"%)Q`!`Q0@@?T$.\[-``.$0B!$3IP
M&S88H05W0`$"."`"Y(%[E@Q@P`3HP($W3``#&&#`JF<+`03$81=>^(%[X?&&
M/3@`#QYQ0IRZ,`0X_,'0'AB:#PCP`Q9,0`4^_X(!?H"`*0^!`08(-!V6H(`/
MZ&$)!C`""8,4!F/K801@5X$"[O`&#(3@X1#P``:PFPL@J14>7V@"&RYG@UM\
MH2?VA=C.;"#++Z#C239``UGRAXY++YS$\&3Y@AD@]J0NA,'P74`'&L"`AEOX
MP0:0MX$-I#B+O4SF\Z`/O>A'3_K2F_[TJ$^]ZE?/^M:[_O6PC[WL9T_[VMO^
(]KB/1"```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>b87804b8780402.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b87804b8780402.gif
M1TE&.#EA4`!D`.8``/S[Y/W]^*FXRB0Q;V9TD7."J]#:XNS/5`P<:MKCZNKS
M]8N7K-NG!_+HD.W6;/7Z^M>T-=C=WU9FC>*J`\W3W?K]^>JE`A<D4.+HZT51
M=>"Z1/GWV+C'TO[^_OW]];7%R_K\_!8D9^C$./#:C^.D`S1!;O/Y]'"`CYZO
MR4U;B*:QO?S]_`P:7/W[^)JFM.*O)?CZ^OGTNO[^^]BG%>NI`N7M\>[U]</,
MU/OWR_[\_-_,;_WY^^J?`OW][_3JIN7;I?C\]>.I&HR=Q]_$4!\J7//V^.CR
MZ_WZ]/GT].+/J7)]G?W^^X"-I/&B`?CY]NGIHO7CLOW^_O?[^^3BNO;IQM:S
M'/G\\.6\'=C;S_GTH3I*@-OBV./IV.#5BOWX\.&B!_[]_2HZ>OO]_>"N!,O6
MP^/=Q=BA"_SW^MBO"OCYZ]2K(++#U[W!N._?>M&F#.JD">"G#.VS%L/1V=OI
MO;.^S0P82LJC+;[$SN:I"=/1Q[W.WN[P]/SJX>[OL>>H`____R'Y!```````
M+`````!0`&0```?_@&!_'7^%AH>'A(B+B1V*C(8RDH@=,H^0?U&.'5$Y47\[
M'1X!A#(!,F";CF!@.3F"BY(R8AVLKCF.4;I1LK(>/1ZRE0&CAY*UK)Q`+3MG
M#V<@G0$5%;0Y`:[4U%+<W"";@[M1*Q7$'N?3U$OK2V+N[S*(XHZ]\<,RZ&!2
M1]0R0`H1#$082+"@P8,($RI<R-"`P(`1BJQ;`>3#`")$+F#<R+&CQX\@0XH<
MB?'"A1(&:%5X0.=""B4P"\B<2;.FS9LX<^K4"5/+``/?Q+"\(.3!$BEB5HBY
MM8-5*DHR6@28"J0JD`I+3)T#X8[:BBA>*\F:VL+5JEL@0.#JL.*!6R4#_RA8
MRB'C`U$PP,P%DT$MBABNC5:0<_0G[2=D`8"=&S5M22%92RI\%=--"E<Q4?3V
MD-'#RHFXIXC9%2+&0P6U7%>`^:J)GJ(.,-R!<.+E2``02M_AEI&CV8Y;KDQ-
M/?V@6]JT8(@!6X$J`!"X%/8&&!W%](X]`E"H4"'`!M(5'5XYHGQ#A8L$%9S<
M$,"^O7L.!FK`2!M<QI(54A[4,"!`").93*`@1P)&P,";!YZ!9LD*HXD1P`H[
M)%#"1B4D@-0WR;`E!0$9"0!"$1)L=)&(&)4@@1Q%/+`"")(L`8(-=!`P80@(
ML&`C"QAI40`&'N3@`1"?47!*+0VNMD("`["``/\"%<KP22).2F`C"OY(L"0"
M`Q!P`@%:T'BE%BIX!P(Q3AA00!@W#B`!$RXLH$0)-(:QA0<KY`!#D&N!4:1@
M2%[9Y).&5!*%E"R@L(,45BX9A@$/P/"`"@-<B2,=:N50Q`U$U&%C'01@T`T0
M#RBPP`49[!%`)W?&E>>>1R:YY)]0#5HC"OHDRL*B8WJQ!Q-*+LG""3"<400=
M)?3*@A(8J#45/RO8H`(3HZ"*YRJL]OEJ`D[&2B@*`3P@98UA1-!""_P(X&6-
M!,"`!`4I2"I!`C"\`H8LJR&QAX/2JDHM46(8B62OL$(YZ)0Y`&&EC>'FX$4+
M0*#0ZY),[%"$$N>6<$/_$2NRIEH'`;2@3KX4K,JOOY%>FZW`V^;@K:_A>G"$
M%Q@0<&4($ABP`@;%7EF`#6!$$5EN8BQ!3`!BQ`-&JB'O2QK)`&,+:"&"'HQ"
M!XBRS*@413!Q`0)U7+!`#6FDP<'#(=`1#(M+/"U<T7\</2V1(_-9,I-.:SNE
M#`^D8".6$A#`90@A:,&$'#:`@*`+#Q,1@6U/JF*(7T8C+?+2<C=]<J!13ME!
MWC4NF=$%-`:>@@L4V&""$[Q>.4`-'K3@\R#@^.5.Y&_K&7>K5X:10"ORRO!5
MVE++((7>BJ*@QQHH2.`E$24P@0$03%R))096N)Z5/((QUS;2X,%->:M-^_:;
M_VE<[2"U<\3?FA(89R30[LQ,`('XS#>D0<HQX!S#R_9!$N)]OW+S4P*.@(Y?
M>&`)X4F4H4#P/@0LJA4[\``=7%4C(B2``@]C@0M,\)5"C`,K1NL9[>+B/]M]
M+P%H6M(`(J"4;@2#=X320P5,0"CUK<!%5DA`!FJD)!:LH089>%@*$G`]L%2@
M*J>PQ/[<1L)!F!"`N//<&KA"Q:F@H@AH&H`"EN"M7BW*%5'(81!GIH<B+.!<
M(5B`"4C!EA5,A3FY&"$%2LBJ&N2L1DJP`0RD0B[3/.H"+"!`$3S6P$6UX!Q.
MX,#<6+`Z&$2@@4RB`Q!X0Q=7@($K>S!0>)!VF"BP2O\*2GC8!3A@`R_4IC-&
M^$`)ZE`"/3Q@!R!(E`,CT`,`I*$&O#*6$F"P`QAP0`N2TH(<G-#'(QQ!#`JX
MP0(P,!=.AH-5S8*+Z@B@`@H8X`,+D%(=4L`!(/0@`#1DF1R,4(,/*,]7(4#6
M#CA3`0I(`)`URA(=$J``(\@AFT0HU6WL%*1.LBH'+2B""^#$PQ"$(0Q)JD,(
M,F``&!RA!P^P@=YZE8$4I"!)-CH)$VJ`A!:LX!PRJ,$"X)2F%$A``L5B00B$
MX,9-]O.9MUO-$6'DIA24`*$F8@(=:B`%8@(!!&EP`4S^HX03**$`2F#"`@20
M`""8X#05,$6=SE`#`2R``#;_+4$),B`!)2Q@#0J`XPZ<\%).C$8U@M''$@QH
M@OT<;PUZ2(`-W%&G6_3`"46P@0T4H->^>J=.1[@*""1SJM[D(#_[D8,>]&``
M>CHA+6[DC3,',9JVJ>9HF3$F/QQ5A,Y>B$4`S8$V@&`%T\"@LYU]`#6P`8:_
M6`8$.XAM!?)C@ST4(3;9N\5'SX$TQU"6*)9MQ1'&)04;*),`)STI`99:@QR\
MS`L@;=8]D6O1OBW@`SR5`A`Z5A8Q&'<!)TBN=07@*8?B9RH!Z"W4*KN:2]8@
M`C$BJ?30200"H,``&'@O'=X$3TG9*`1JNB\&N+"%^(8@@S,CPNCD$)%QX"=(
M3^D`_WM54P.4#N#`\\TP([60@0R4(%(/R["O!K!5#V-4Q-+#T58IP!4P%"%(
MEOBM$()KK?G>*,0H3G$/.Z=C#=]8Q"&X`5?X&9<82QBX[:TQ`D)`A#!P50(9
M\`F.YPM@)Y_4IAFQ\=Y4.H`P:$$"%O5)?Y=,`7<P42[^FS`8_E6'.F3`!9YJ
MK2[TLX9W:JJ'FM(""C#P`+]81@HUH$,*QEPC4KF@!@_XRU^*$.AW_O<&/3NS
MD=6L`"8PH9J(3DL'/+H:H2B`/PN0R5(IP.>U/K0'2X!!?O9@`#J$N@!+Q6^B
M8[L#P03@**QV-1.P=0HI!`F!,@XN"!1@`LL\``-R^$!V4/\@@`_<8`M%$$I>
M^?H`IV*``LXVW1WH(`<,8`QK>S#=59QP;66C@-G.CL@*8."$3**#K''Q[9%G
MG`/<K,`$)@B5H"_0YC:SP"1O5D"CSM"Q4)F3WQ+@`A<RT+44H"#39T`"#$R@
M`#J$J-_])I40:E`$)\``!HN!-P4:5]EZKV`/+CA!!OB]-RUW+0,+`$(>E)"!
M3-V(`#]X0@T1D$\"W.`,+JAY?V_$PXSF%`,Y6`*11YYFX)H\`3:?LHC=+(4[
MW,A++"C`#QIP`K*UF0Y[6+E*<^RKC(X\"F<&3["?/K>9=1FAYU*A#9P`3%]A
MR05=<,`"*+BD%-@`9U0^*-QY[#G_%H-`'S!N.KVY\B\5EF"Y`KC#!US-)1!?
MP`@Q8`*-F+=<+.C@`!$0@HPNG$8C1(`(GGO\4CFP[:MFX,)*(@*+E^+K(M=B
MWG]XNH<E4(`?(@4,L/R1$Y)9@!1D@`LZ(`,!E$`'(WAG`T,000!,9X,/,$$)
M>4A"'DJ0@MXCFAMB^`-E0J4')DA`"R68HUIJ/\?P_($#3L<-#!)0`^]THPA[
MJ`'UTF`:((#!"6"C`T^0!K-A!0]0!!N@`5>0!@+G5'/7`#J`!!BP1DX@!>RF
M'WM`;6[Q`":P!PG@!+YS-`00%YJ0`^\7?W42#`^"`2X`95IE,46P!0O`!:51
M2UTP!!MP_P8LV#=3``%7@`4GM0`)8`+0UP:1`0P8L`!;L`(<\()<Q004\`!@
M4!;K%`"]-(),9X+PMW@KX`04<`<NP`09$`)U<"5UP`0Q&&5*X`)LL`5],`-0
MH`*#A@`9\`1J\`)8L$H(`"9/``$-@&W/TF%E8`-,H"E%5P)>I0(WL`<=L`3Z
M@(6.H(4HB`&OAWHBE@)8,`5LL#47D"4;8`8.H`*&F`)/,`-!L`5:T$,NX`!V
MT``2<!$XH@(_4`9C9&-,EGZM92>0N!H=L(7AH1J-AV)$P`9=T`>$LH=&,`8:
M,`>62`!/8`9OL`7$,P!EH`$0T`=W)`%3H`-L0`0MEV$70`$PP/\<3H"%IT`+
M6Q@%M=8!2K9D7:8%7J8"-Y@'F>)`&(`&9C`",G,!!3`"9A`$9<`A@00%0;",
M.4,$9*`#.C!0!_5A('8EL@<$'P4$YC@+O4@4Z@@>2*(I68("I*8`G;4'2)`%
M=O`$FH<C<G`%7S`$6X`"-U`#(_`%</`#]J0"$3`$*\D&9)A&3V`'/F`$((D$
M17!M`G`F&74#`0`&1V`%%8F.&+F.-6!4"W`'A=,;#^4%V(`#"C@%0G4"-_D%
M:I`%0"`%*^``;X`';9`&4F`%,1`$7Z`#,W<""_`$52`"```#/=`#/@(,0+`'
M-Y!R)Y``#W($Y:@@3BD$&>D(^/93P&'_"F?0`S"0!B/```ZP`>UF`CKP!91I
MF4?@`!8`!PY`@`"@`WA``B-@!29@!!MP`&YP`+.U%14P"KT101'U`$D9`(5)
M`5G1+ULH!K6F";')1@$``#U`A:/@!5`P!D'0`````B8P`D$P`2(0`QV0!@?@
M!U]P``#@`5I)`A,P`C*`F@WP`B_0`*<Q%6)`6DB`!+]A'Y1Q/S"`A>#1+W?`
M+TVA"4%C"9SQ`WT``$@`!N=P!#A0!20P!#$@D5#P`B2PG#F0!D-``F\@`AO0
M`PV@!A,P!C[`''R@`68``0?*'&[4`U20!"V0"JOP48ZP(5_$"1V`*06@CK@`
M)12J`_TI!1%4_P&C20)HT`:E104O8`%O,`0[`'T,8`$2B@-#X`9C<`4Q4`$M
MD`1!,`8'T`-U$EM'X`,Z\`,>D`G(\`<>H`F($BZL@'9R\'@P^AKT8`4XH`,0
MD`4`<`8YD)Y3,`%^$)8]D(!-P`-!$`-]``$TX`=7@`-98*$3X*$]T)83,`,-
M<`2M<`8`X`,0H`,;X`5SD41TXA=1MCN"D`,&8"(V"AY@05="XP4C8`<BX`-E
M<41I@`9-D)T;```BP`.MV@;CV00D<`54X``,0`-?H`$XL`$Z8`$6X*%>``96
MX`4^(`)5T``;4(4K$E54&@4/4%%(%Z<MH$-:8`._T5H220ZD<`30Y_\&&A`#
MD!F;L6H!B@H`.-D$#"`";1`$MGH%(Z`!<&`!##`$.`"=-,`#./A8;*D!;F"@
M7D`7#Y(6^)"4=B0!-=`*#W`$-2`C&+"M%9`&R4$,5MD`,\`#&@`%'N`$`?"N
M%K"D,:"K-$`"8R`"\&H!:("R?N`':*`#6:`!/&"O;0``#^`%5*`!#(`&S%DG
M*W(&'@L&0-`C4'<"<R6M'E`$!4`$!O`;HC6I2E%7'I"`?G"O,>`!9]`'"CH!
M;N``#F`&?D`##."6PHH&:$`"-""V#G``9L`#$U`%66`%%>`#'-JN.'`$U]`C
M0YJ#4G`*'$`$3)!H5-,#%2`$=<`!8F$%/Z#_`^1Z0#E`G%`P`RKKH4,Z!`QP
MH2\@`GB0M@QPN300LA-@`4W0!'"`LB2@LOCJ`50@`G!``S/0!IMQ%16`G#K0
M!8]U!"N@`A?@`D"@"R#P36M0!RX0-!21@$/0!N2Z`WD)?3Q``F8P!#X``&V@
M!F,@MG&PN31PH70Z`0S@!Z/KMG'P!A9``F[0!8\Z!.)+`B*``RT``J2U`6V@
M`1K0!W12`5ES`3=@!0@D!M^4`'6@!*J5=%;@`&XP`P<0`Z55`5;PC!9``V8P
MG3TY`=E[NA;@!Q?:LF-0I*-KP47*`W7J`UF0I$V`KK!;;SV``PX0!%V[`72"
M3(.6`*A6&*AF`Q^F_P!1)10Q(`([JP$^8)E``*MOT`0T,`9#T``B\`5"[`?"
MVK)TZ@=C0*?"JKU++`(-,`15,`&M.JY#"P!/P*%^,)WKI!0)X!(V0*4=8#AX
M<P)U0`&2$05CX@!HP+TS,`(;8`4YD,*CZ\`B<``DD,0M^\<5_,1*;,$30*>\
M*@(BH*2RR@`CX#$;X`!J@,1OX```(`51P1)GB,9_(!GUI@(LL``/@`]4&@.6
M^\1FH`%ML`$QH`%(_+EC,`9]_*>%7,C"6L%_;,$D\,=OX)89;,'3N0$C``%P
MX+U-H`%U#*TV0`"C]%&H()%C%0$#D`(80`S'1*HST+E^L,L'\,@SH,0C3/_+
MA'S!M2RZ?]JRMBRL36#!9I#!R.L`+_`%HON9#<!_I]`#G5HA<,06X>$$-'0!
M=(`$LGD&2'JV2HRN0^``(F`&?6S+?SS+!5W+MVS+GUO!WCD!5W``5LP`WXL'
MZ[M=HV`%NDL`-N`*7V&"E9"[_VL#1]`)(/"H5PS+#6P&+W`%ESO(MWS3.(W3
MG]NR)/`%<1`'7Y#!LFH!Y3D+Q"`#>_!.4_0;(/08`:``'Z8'G^`.'C":<:S$
M)1O43US..=W5.GW3/7VA8\`#8GL`.!`%0)`5'B``^60#D@`&:=,#F($/%5``
M%R#2/;!=`)4&5RRL'JR]8<O57CW8L]S$MWRA:##_KH=5`:Y@`\KC`D[P39CQ
M!W+M(+_0J4S;`]'0"@$P`B\0MC/;P+D\V*3-Q(5-`A0\OB9;!2,``*?A1BVP
M!H&3`+]0`;M`-$DA`U[P``60=87#"G4"K&8PT:'-T*7=U85-IZG=O&B`@PQ3
M`<T`(BP0/^>`G[Q@9@!5`7KP84)&$55*M[LZSA-MW,?=T`[=LN/=KCYP5Z/0
M#"VA!09@`G12";C1B`C$/AY@`RA0!UJP!X+5&P#0`%7PQ+4\WN1=WN%<V&'[
M!<L*`,()`CC#`G10;=4P+YQL'ZMP!%*P!WJS``K0+V=<U2-0!9Y[SAN,X!%]
MV(5,`B_0!AXP)DFY`D:@_P2<4@3_J0N%@$!KP1:MT#,8D(H+<`8><WA`Y=F7
M.]JBF\XH#LB"/0$+ZN(K@10RD#5NE@#J>'CQ4#26H`JKT`%B8'5A(``P<"I_
M4>00H,%I6\BF[=!I"\@1W<"J[9UN``&M/5MBP`\/(``#<`%Z(`5.$2B7P`@P
ML``880"#U`+S(06/RJ&U_`6&G=R%_,2&;<ZH#=&GS)RH&0`$9`,<$`(7H`)2
M@`FBS@D8H#7<9$Q.H%I+``!0H`%!$+9^,-IM3LBO_,IJ;MZAF[9!<*H`8`42
M>01I8`(<4'-,8`0!(.J8T%H>@`%JK`48$%#ET"^'RK9?4-#HK>(\[9VU/@%P
MH/_<07#`LS#7A-FI9Z@`OX#LD'#&3V4#S;X&11`<1W3G/S`$,X"V2TS(0#JZ
MZ1SIAIR]B0T%7K`#JK4"AU0$`E`"%W`")M`#1Q#HZ`XU[0!0>T``_-WG%OC:
MOSNR=O`%:<O5J)W:'\\#L@J6.H`#Y!,-TV`"`A`&=;`SI15C#P\5$'0$.S!0
M_&@A==*^8F`%`!`#\7O-)8O:A9RVM=S3!>D`;DHT[NLB4I``REP"*/``[MO4
M,8\(<Q%;0HD"Q5(S1;`#V``"W)`8/N``$*"@&.SD%C"S"QJI4```C*H4L0D$
M-B`'!,`"&:`")M`4EG$]50_HG/`7'EL$%%`L)4`'"G#_>&>P`Y2!%&>P`5T`
M`6C``'#P!90/!S,``0Y@\B"@(A_5#E*@``?/`O`-!/;36ICA\`]?"^+'%1VP
M`U)A`WO'`A)`2@S/#%YO!59`\%1P@VI0!4-`QRWP&E6-#<UR!WI3`@M@`[%9
M`3#@I3*0%GT/Z.&@"I)0`73`<"M5`T[P,JX`2W]1`;6T`3A`G))Q>*TP+E%0
M!`E`Z&Y&`5+0&HJ@1$\3_9`PA3M@`WH0(D3`?!P$"&!@'2M+44N(*SE@.2TR
M,BT[,$5T!$1$!'(V,"!_GI^@H:*CI)]@.Z@P&"X91`-,=#4/,`&/2Q45*XPY
M*[A.-71*`T09*#5.%1XRI<S-_J6,.SD>0"`U*I9$$@LW#V(!'N`Y,KP@-G),
M*:XG*K+>'@`>SO+S'2!144#Y42LP=P0E%THP$1#!AI0'4<H94%%@0$`"'![D
M\]`A&J1Y&)EUJ-5AGY@H8/ZL,(%!S@*`1$H06+/FWX4+&5Q0J"'%P[TEWSSH
MBI*QIR@9RF1TC-*A:)0`%4`\2*!"22LB%X@-3/!@18L``0;MJQ``T3*?8/]L
M7%:T@R="*\:MX*<@@1P!`N1@*`*"D:,<BV1XQ.DA0%BP'4**+?IIR<>B6+%6
M,%'A$59&@D#D^"-C"1B>,GKT^.NSPR.SH3+W"+!"C!AHT7(0LH<97&!!GJ)\
%#!L(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>b87804b8780403.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b87804b8780403.gif
M1TE&.#EA@@!'`.8``'QW=-ODQF5F6CHW,ZNGI()[=E142IN6E.WKZO7T\D-"
M/.'JS'-L:>CQTZ&;EBDF)+S#JIN3C;2[H]+9OHZ&@!83$LS3N,3+L4Q+0^7C
MX;"KIDE$0FIJ8?KY^<S*R<*]N:VSG'E];<7!OF);6,G&Q(J->]W<VM;3T8&$
M=(R$?E)-2M;=P&UF8I"(@MC5TXR*B5M;4=#-RYR@C'IR;;FVLXJ"?%I64L3#
MPI*5@T`].9J=B6YL:?W]_>_N[9"-C+F_IS4Q+JBCGH6#@\''KI68A:6JE7%S
M9;V[NN#>W'-T:XA_>C`L*LW)Q:&FD=/0S:2?G.?EY+ZXM$U)2+6SLE913Y6-
MAN/AW[6OK'V`<=O8U49"0.KHYW9Y:I.*A!\<&U];6O'P[F=A7HV0?OGX][BR
MKB0A'Z^UGH:)>*FOF(%^?6UO8H2'=H^3@,C/M*BLEK*WH).1D)^DCXN(AOO[
M^H^'@92+A9>;AU]@5>7NT/?W]OS\^XN#?4]01DA(0.OUUO___R'Y!```````
M+`````""`$<```?_@'^"@X2%AH>(B8=0C%`)BI"1DI.4DVE2F)E2)X@TFIB<
MAR147AA8*`)E6B25K:ZOE5L*$C^UM6HBB#LRMC\/3H9;81A-`7['?@T@.0>P
MSL_/!2C(R"4'+H</"]1>3%:$65I8V]3(`4LWT.KKD4MMY7XR5"F&"&74`644
M-(,F.3+PRKV1TH.=P8-_G!@(**^&(1)]J/U0D8+)("UL`L)3X!"AQV<JS#"T
MT<+0`374B+!H@400`RX:X6'9@.VCS5A>\#"44F-.(0``D:D!$`'!GQ,#C,6D
M9F9)D)M0)04QHG%9C4>$J"@]]B!%$#U_M(!86L["@#H=HJH]-&?)"HUO_W*D
MP"H(2D1S%:I$^4,""+P&%V2\:0"O3Y<M:Q,/^I`C9MRKA&Y@D+BD"RLM%\HU
MZ.-%Q1(MA*GQ:1%*\=H=.I!-H(KLS8`6=/^<3)DC@@D/?LL-F->"P@`[Y6#,
M^%#(20$;F*CL>$H)3!HJ4F;$-G0#`'0IR@FH<Z&`&H[NR'X`J0&&4!(QU(S8
MZ-(#`'IJ9W+4V!,%C(<[U%;P8:#]3X<G.=A0`@BUO$&$&CDP-P@+.6#@8`XJ
M\`!'#BB8(0$*.9A@R!@^Y'!'"6;48L:!.5SQS`LH'=.``>`=\\,2-10T"!4B
M(6-``55LL0$YQP3@10$ID,&#(),U\`,7`P"AQ/]3":2AP`\:3?"`!X2H``$R
M17P!AP(34%/"#CX-D@`+!KP3$`0Y4`F+%A(@`X$76D@$1`KE#=)'ESWFT`(9
M&MA0CAT;M/`$75KHL$09*E#00A?:S;#04FC80%<?/*+PP!*A43-`?W_,P8``
M9.%@`UBND/#H,5@\<-<Q$#Q0@U&"C#%9>$NTP,0.&5%31@$4E/9'#FD<D`(%
M%`21A1Y'8,!C3`,T\X<)?B(#@Q=;46-`&"W]\<2L2YFE8"4V-$&-`BJLZL<%
M#[0`ZQ]!)$$-&SET@01FU`RA3P1A$J*!`R?0M42;9/F!P0Y9_`$'%IH"%Q`'
M(YCXQP``D]4'!74VIPW_,FT`P8*YZ+XZ"`,X4*.&"BVXP$>F?HBA0$6'5"S(
M#:<>,T$<)4!I+0MD_!%&'-1`H%-`7-C@@&PIJB:#&&8BPX<2%E5RP#3(<$#%
MQM1TO*X4$?O!1QA5'``3-7>PD`)BD:@P5G@##+"!%W@>8P`+VBEP9<!^"#!"
M%0_;?$P1:6OQ0-M^&*!$SI64`7@9`)!)C05>I/"-(&6\A<P`,SSQA;C(X*%`
M%WA'DD`%U.#Q``.*:H'Y,7RP\%0%R_JQ@`29E7-M%0@L@<\2#/0VP.D"I^#P
M)"0,4/6<BB.S@A<U/#[&/<@TL(3O.<1^S!"U?IN("UYXH4`(/V"A0@TE[W#V
M_S%]J(Y`;LA8``00%60M\`X1Q%"!]FM```,5X"-AP_A^]*'$$Y4(PQNH`8.5
M4"!FQVO!XV+`FF/(0`LM($$%4-:$U[!B$@E0P@A44`8EV`I[0]!4`31`@A"4
M@P\VH`,#3"A"YF0``".0P@,\>`(2>"&$,AL`!7X7"1,\(%,+J(`2ZA`$!%:@
M!MGR@<*.H89Y9$%XU$!!H,@V"21XX`,$J$(8;*"%(E!C`7.Z`@!X!P$EI>`)
M+%31\_K3`20P(0H:H$,8J,"'`;9&2<29!!PX0`T0C$<#!(`!-1IPQ(+]00IZ
MZQ\+NA`#=U&#`R090RMX$(,7Y(`/=FA=$>3R`2W@\/\8=[!!"C3@`82U1BY[
M&<0<;B"$2\H`97Z`EQ(T)(D$;*!:=YA!"DY``%!1HP(I,"2U=%6`)QRA!"=D
M000*(00;/&Y#!$A2$JJ5'BI0``FLH\8#```;)5(C!(DR9`^>\(`<8(&:R##"
M/%RF"`WP`1\5B&<\?8F,0O[A<X,$)AD<P#N!,0"`A"A#"<J0AGP)(@9>$`#@
M`H*!,-!A"U[`1^.>LH&YH2X,%!C2$<J@!G26`P,LH``EOA`4NOFA`J3Y@P=:
MY(<A0)`$/G!?#@K`0Q?8+@`A*`.GIE`&"P2$"#\[QJX<0()W(D,"4F@!<;RP
MK"4`8&@'`()/X5&"H/IA``7_&)HD=.31F!P1&$%8`S7$(,HL""&1?IAI*EW"
MLV-<H`]#\\`2J+D"-B@@F\?`0^/V%3*AC&"78(AH\RJP!P+(E9H3*,$`\.JZ
MYVG`$J8TZ4EK``P`6%1@+*C#%H3PR6/D``!Y_`,2'F!5#J0!`3L+'1O2]@7!
MNG4`*?A`$CJ;`P9H-@:-2=^</)$U/)PA;6%PK1_BP,E)/&"JD@4F,):PK!\]
M80Z<_2@#<O$''NS@#/E4`@M8N@`8*(D"5,.2-9U0!JL*,0AS(,#7]I:H%N3V
M&`M(FQ+`RRT_-)$"&9!$#`0IV6,<D0D]$"X>*D"!G,D!K5C(02I]8"X_-(4"
M"D`F_S+6`%L*1(`%CCP&"E82`^8=8P7Z_,-9K>50*I34#R%(:@H.P`#>E:\.
MD]""'?N+4B:0@*5#2)=%X%`C<_`!6%K@@^20H8`9M&`)TM-<"UH0!01L8,AI
M58(#CF`N\43P#T!8U@,*4`<H]J@"7>B""`*\K`X"%!)0*`,LZ?;?)]`S'AN@
M0,&FD*LO%D$,;["J'R30P3U@(%-M&$`5(M`!'_`WKT>\PFR0P08G)D"XA$S!
M#.K;JA8$H="']H->?2<)-`XR!*`.-:@O>]("D"`-?445"VJ`&"<4+6`-N,,(
ME*"$-V>L"A^X@@*DU](RU.`#`$A-U!@P-B>\UP]M:%P8WO]LKQ9DX0D*@/(0
M8$M=173@`=5ZPQ)LP.UN`P&[Q!2!5D38!9^,0;AD:<(#PIR"R![#!ANP@53+
MP;<4N(`*5FU<"W@02&J@04\C<+<?@*`"*>0`N7NS0:\B00.6^D$!8HN``Y[@
M``>8N!Q;UL`&0@?,QPIB`)V-20.`$(867`$.4$/&ZR"P9A3PQ`GF.MX>'BL$
M"6LX#"E@0,KA*X&0W[P*4(A$&+R(%PM34<0G]L,,Y5#?'%]9$&D0N$8,(`4*
M5&$,3U@O/(;P'B:*[0/UE<`2]F`1&P!.`0"@P`NT7HXAV-P/PGE"6A3A@CA1
M0P8;J(&0",$`_BD=AGQ$1AQ@:\C_/X`A!TD+2`.X8,88_*$'?P[("H"`'V3<
MX:F+/H88M+`'$_1`"AS?PY3K.[S*<V5PD4!1.8I<@YHLB-24T\+;O9>"=8G8
M`&N&;ZJ`I($A_:$/,S9>#LJ@=<%I``!O-\((]M`##]3W`F78PYCO!`\+*(#X
MVE1":!.1`QST0@=>4$(-\E`(%A"A%^)AP!)J9HL^S&`/OA<$#X10!E(/MYS$
M(@#Y!1'-(>-!!A7``C;`![VP'R*@`NQ7"SE``?1P`!C0"VLP'IQ``%F6.3@0
M@%1@`+VP3=66"#X@!S.P`2*X`;.V5H-P!'(```H@@BL(`#.0@AL@!2)H88<0
M`VNC`'SP_V,54%LMH'?3<01>,`!]L%@;H$LS``!"$(,B"%H$`()*6'7+Y`%R
M(`<R*((LH`1DHP$[.(05L`$%H`0S(`1"4(52```=J`@D<``1L(9JF%^'D`%K
MR(81D`M(('%KZ``F2`AS0`,S$`8LL&K#$@0G$'^$\!\LP`!*4`4I0`!6P`,\
M8(<2ET=.`(D.4&T=$(=Q.'?^X0"'"#XMP(A_H`<.<(<1H":>`P:HB(H]0"J&
MT`$(@(JOB`"/,`>IB(J2E`@(X`0B$`4?(`)9L'^(H`<N\`%1(`(NH(FU"`98
MD0?)J(EZD(SLI`=.0(PB8`+`6(L(`(RFL8W<V(W>^(W@&([B2/\(4_`%.W".
MZ)B.5$!+KY`!RK$#5&![Z]`![_@%G.(,YK@#7^`#ZX`:*_"/`!F0%2`CKS`%
M&+`";:``'H$4_V@`%^0,8%`!_\@!<*`.8+!Q,<$XO@@+:8!,$J``(N`KZN``
MV!4`.2`"CN<,(O!.FT$&(D"(K@!V2]$$6E`##]D*5+`-9Z`%%'"3ZD`%/@4"
M2T`!9]@*/O``"C``,[1,S^`#VJ,`"D!T7`"5"O``JR8"<,`".P`'[/0',9`&
M&*95"7$7!F`#5!`&!1!T?^`"!-"6+@`%:;`#SD*.,\`"0L".CX8J&Y`"&I(!
M+\`"`,`/A4`"29`$-P`%;4D`V!`$!5#_`%+``@7`#UMP`.?H`T<G6D+PAP#@
MDSUP`DXP`V5@1U[``*3)``4P`-MC!W80`CG@<7]P@`9P!C*``T8P`)S@`+[T
M``^@!CJPD_DU`&K`FDLP`&N@`W?P!?)W!3D@`&*@`VN@`$(@"%1V#`U%!T@0
M!EJ``CJ``W<@!=EB`E]@`&SP'4M@`"&@`&F`!&4`:DM0`"*0`0R@`%Q`!#J0
M8`!E!2R``<4I`R70!W)@"'H@`A5@#"!&!P<@`F3P`%Q0+1])?AZ0`TMT#&Z0
M`]85,N>`!M)R`&,P08&3`Y*S`%Z`&-"6-0$`!%3B`U\#!`!`!^:T%0T@!BH@
M"#9@!*$A`5[P_Q9W<`!%=`Q:<`5(0`4<(&TY4!!?H`9X$`!M0!@!,)"&D`6S
M@@:O\0$\$`8(LP(<L`08Z@<<,`/VT"8-8`9H0`X5$`2>%!`A0`5=`!Y$@'$4
M$`4#X%,K$`=X\@9?@`!?X%,_,`![\!O)\`9G0T@B\`*^A`<7T```XU08D0PP
MD@-\%`!)L`3"%@(L\`0P`!CS$P(+D#$SP$YPL*9^P`4L0`=9,`50U`=24`"@
MXP<EL`%\JCE+L`0T:@&XTP>$,7DW=`PP8)8*XP85@"G)0&!>`"5#4`%:``1O
M,0%``&%,I`(CT!VQ]@!ET%8&,`->X%,3,$^(1@=`H!,ZD`,L8#N!X_^%J;JJ
M#]`F*$`%2A!/7H!'A3``L1-^=)``-A!"9E`&(S`"J8H"6E`!.I%@=$`!\90#
M5*`"7S,`&\1"M?4W+=6>99`9]L("ON147;`$4(*L(_`H`_"M/L4&0-`%,\!"
M!C`"@0=Q=#`K;U"$X,%M`X"A%^`%W):J9R`%$ND'*\`%#P`G!;!DA",(GT,8
M;5`&7K%2QR`!H2966IH#*&&2*2!]KT@'VNI%4K('6@`<8%0`@I4$/)%-=J"4
M5_(&75$%(.=@*B![OQH&=X$!(]`"`&"T90`$8\$X>U`#LV(#6Q1X#Q`&4`0!
MH69*:C`"]9<?1%`&2)``A"BT\0!;3.``@=?_!A?0N(T[!`J0`U?2%'6`+X+@
M!.K9)45@`S50@7:@!69+/H#)/'W+KWZP!E*0`E'0!\9P!V&P!`-T`0,@!05;
M`!'P!6[@!]<ZLT4`!'L0!BGR(Q#J!SXR`I7'N([;N`I0`%30!\5`0$<`DYW*
M1'\%EQ)6`;J9O>4TKEI0!2<P?%J"!.!J!*0)'B$K!2P$(R,`*@N`=N#*`2$U
M`S`Q8#6@`-O0MP/@J;Y+`-FT6JF*`SF@!,&JNP0&!"$$`C%HM-BKO0^@0QI`
M`RI0`08`,!OF>H*0`UV"!SR9`GK``@`11)+F!4OPF.GJ0!W+`+AW`15`DK]*
M`520FS-@K'XPH2F@_P57(G8S`![@1*UOL;40RQ4Q7"/;I`#3$`!8E:H3X`45
MH#";I`2SLC4;<+U*``!>\`!:\(=+\`#S0P`SD*I\,`-B^0<0Y2)#"4#N<0Q`
M<+--<"2_D*IX$`(5D`3;D&`YT"9#X`5TD+_$ZP4SD%MV`["$L9,"+#-\@`$^
MU;+U:Z$5P**Y4@)`D"MW$&<#:@X`0[Y4\#45``!2`#77YP5K;"D[<`<6$&LL
MH`4H8:-=$,8T,"L[20$600"/L@`_\!:M(@=,,`+"YB5`@*K;`,!'EAENH`(V
MP%]`,`,,`$4PL'Q`0&IYBG-E0*^U,@-&E3D<@%4I\`580!@2\`#(U`#A!_\$
M7L0X8'@7>``!7=(&,.(#LQ(`.-`$A.JM%+!]+P`#M8"V%&`4/4`%9S#*"W`!
M8O``?]4%-/``3?`6LBP`0,``U%H+,!`&2@`Q/P!2"B``M>`%%&`##YBG1"$"
M*QL`@'$&0*!P*5`!;_`#:D`2,0"\H[P":,`'UAP$/;`!!F``2T#2?@"W7L`+
M:Z`%2B`"7Q`"2=K/;+`$\_#01##*#=`&1+`;-=`%MG<`F#"<.#((6\`"91!/
MY00^5>!X)D`*6$T%2^:84K`^%*#)4C``,`(=&T#4>\`"4;T!A?6:,EL!JJ`$
M75`'(H`):%T`79``<P``6EP!&E,'79"N6B`':<#_U]DD`\D:@SFP!#-``5``
M!CL0V.OZA3UIIU<]/\5<`TJ0DH60`0Q(`??X!U"PM'L0MQ%P=$Q`!W4P'XNX
M?Q&0`MI77;/=`H^%!"V0`G0`#&#`VW1`77KP`72P!\4=`6[X!QI``07`*3T0
M`4I0W'3P`0YP!ROP`SG@`&&P$`VP'WL0=%$@?GL0)CW0`DI`VS40`6KIE5U0
M`Q10`RD0`<]4"'.0`/9]BWJ8`59@!5WI'U"`!!D0&_;MU]4UX)I82_O=`X28
M!_9]X',`!5:0`3YQ`"PD`5@@!CKAR'50!6`Q!O:MC7H`X1G0E7D`X?P-D^.H
M%@VG&6)0S+&5XC!>"?)Z,P<X8`8@(`9\`-GQ?>`QWN.*,`4;L#Y:P`#S407)
8[>-(G@A@H`%5T`461@+:F.12'HZ!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EADAE"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td><td class="nump">$ 0.01<span /></td><td class="nump">$ 0.01<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td><td class="nump">5,000,000<span /></td><td class="nump">5,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td><td class="nump">$ 0.01<span /></td><td class="nump">$ 0.01<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td><td class="nump">125,000,000<span /></td><td class="nump">125,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td><td class="nump">42,687,941<span /></td><td class="nump">42,343,423<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td><td class="nump">42,687,941<span /></td><td class="nump">42,343,423<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EKDBG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)<br />In Thousands, except Per Share data</strong></div></th><th class="th" colspan="4">3 Months Ended</th><th class="th" colspan="4">9 Months Ended</th></tr><tr><th class="th" colspan="2"><div>Sep. 30, 2011</div></th><th class="th" colspan="2"><div>Sep. 30, 2010</div></th><th class="th" colspan="2"><div>Sep. 30, 2011</div></th><th class="th" colspan="2"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Net revenues from research collaborators</a></td><td class="nump">$ 20,791<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 27,668<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 62,302<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 78,849<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td><td class="nump">24,274<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">27,468<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">75,926<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">80,304<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td><td class="nump">8,955<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">8,928<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">27,608<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td><td class="nump">30,205<span /></td><td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td><td class="nump">33,229<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">36,396<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">103,534<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">110,509<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td><td class="num">(12,438)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(8,728)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(41,232)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(31,660)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of joint venture (Regulus Therapeutics Inc.)</a></td><td class="num">(467)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(1,226)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(2,551)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(6,723)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td><td class="nump">265<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">602<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">969<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">1,833<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td><td class="num">(597)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">20<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(532)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">52<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td><td class="num">(799)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(604)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(2,114)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(4,838)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td><td class="num">(13,237)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(9,332)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(43,346)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(36,498)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(298)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(87)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td><td class="num">(13,237)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(9,630)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(43,346)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(36,585)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td><td class="num">$ (0.31)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">$ (0.23)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">$ (1.02)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">$ (0.87)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare', window );">Weighted average common shares used to compute basic and diluted net loss per common share</a></td><td class="nump">42,654<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">42,123<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">42,389<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">41,989<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td><td class="num">(13,237)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(9,630)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(43,346)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(36,585)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Foreign currency translation</a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(29)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td><td class="nump">95<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">2<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(865)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">601<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td><td class="num">(13,142)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(9,628)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(44,211)<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="num">(36,013)<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract', window );"><strong>Non-cash stock-based compensation expenses included in operating expenses are as follows:</strong></a></td><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="text">&#xA0;<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment', window );">Research and development</a></td><td class="nump">2,789<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">2,725<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">8,284<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">9,200<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative', window );">General and administrative</a></td><td class="nump">$ 1,469<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 1,786<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 4,310<span /></td><td class="fn" style="border-bottom: 0px;" /><td class="nump">$ 5,706<span /></td><td class="fn" style="border-bottom: 0px;" /></tr><tr><td colspan="9" /></tr><tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote"><td style="vertical-align: top;" valign="top">[1]</td><td style="vertical-align: top;" valign="top">Non-cash stock-based compensation expenses included in operating expenses are as follows: </td></tr></table></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration classified as general and administrative expenses.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Stock Based Compensation Expenses Included In Operating Expenses.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration classified as research and development expenses.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares issued and outstanding that are used in calculating basic and diluted earnings per share, determined based on the timing of issuance of shares in the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_WeightedAverageCommonSharesUsedToComputeBasicAndDilutedNetLossPerCommonShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A5<br /><br /> -Appendix A<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(3)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 8, 9, 10, 11, 12, 13, 14<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ComprehensiveIncomeNetOfTaxAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Subparagraph 1(i)<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h)(1)(i))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 323<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 18<br /><br /> -Paragraph 19<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 18<br /><br /> -Paragraph 6<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 11<br /><br /> -Article 7<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 9<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.12)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Income Tax Expense (or Benefit)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 45<br /><br /> -Subparagraph a, b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 7<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 14<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.7(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 1<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.1(d),(e))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 7<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.7)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingExpenses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 830<br /><br /> -SubTopic 30<br /><br /> -Section 45<br /><br /> -Paragraph 20<br /><br /> -Subparagraph (b),(c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 24<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(3)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 14, 17, 19, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 52<br /><br /> -Paragraph 13, 20, 31<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 24<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 17, 22<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(3)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 9<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.9)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 985<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 730<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51<br /><br /> -Subparagraph g<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 2<br /><br /> -Paragraph 12, 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 86<br /><br /> -Paragraph 11, 12<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EAWAE"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information (USD $)<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1" /><th class="th" colspan="1" /></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Oct. 31, 2011</div></th><th class="th"><div>Jun. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td><td class="text">ALNYLAM PHARMACEUTICALS, INC.<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td><td class="text">0001178670<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td><td class="text">10-Q<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td><td class="text">Sep. 30,
         2011<span /></td><td class="text"><span /></td><td class="text"><span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td><td class="text">false<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td><td class="text">2011<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td><td class="text">Q3<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td><td class="text">--12-31<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td><td class="text">Yes<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td><td class="text">Accelerated Filer<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 446,579,243<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td><td class="text">&#xA0;<span /></td><td class="nump">42,726,984<span /></td><td class="text">&#xA0;<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DocumentAndEntityInformationAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_DocumentAndEntityInformationAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_AmendmentFlag</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:booleanItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_CurrentFiscalYearEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gMonthDayItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:fiscalPeriodItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalYearFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gYearItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentPeriodEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:dateItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentType</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:submissionTypeItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCentralIndexKey</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:centralIndexKeyItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCurrentReportingStatus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityFilerCategory</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:filerCategoryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityPublicFloat</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityRegistrantName</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityVoluntaryFilers</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:IncomeTaxDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>3. INCOME TAXES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company expects to generate U.S. taxable losses during 2011 and has recorded no income tax
   provision for the three or nine months ended September&#160;30, 2011. During the three and nine months
   ended September&#160;30, 2010, the Company recorded a provision for income taxes of $0.3&#160;million and
   $0.1&#160;million, respectively.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During 2009 and 2008, the Company utilized certain tax attributes, including net operating
   loss and tax credit carryforwards as a result of the recognition of revenue for certain proceeds
   received from strategic alliances. However, the Company also generated a deferred tax asset related
   to the recognition of this revenue for tax purposes and recorded a net deferred tax asset to the
   extent it was more likely than not that the asset would be realized. During 2010, the Company
   generated sufficient net operating losses to carry back to 2009 and 2008 to obtain a refund of
   taxes paid in those years, resulting in a realization of its net deferred tax asset. As a result,
   during 2010, the Company reclassified $10.7&#160;million of its deferred tax asset to income taxes
   receivable. The Company received this income tax refund during the three months ended March&#160;31,
   2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2010, the Company had federal and state net operating loss carryforwards of
   $27.5&#160;million and $101.6&#160;million, respectively, to reduce future taxable income that will expire at
   various dates through 2030. Ownership changes, as defined in the Internal Revenue Code, including
   those resulting from the issuance of common stock in connection with the Company&#8217;s public
   offerings, may limit the amount of net operating loss that can be utilized to offset future taxable
   income or tax liability. The Company has determined that there is no limitation on the utilization
   of net operating loss carryforwards in accordance with Section&#160;382 of the Internal Revenue Code.
   In July&#160;2011, the Internal Revenue Service completed its audits of the Company&#8217;s 2008 and 2009 tax
   years. The Company did not record any tax expense related to these audits.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company continues to recognize fully its tax benefits which are offset by a valuation
   allowance to the extent that it is more likely than not that the deferred tax assets will not be
   realized. At September&#160;30, 2011, the Company had $0.1&#160;million of total gross unrecognized tax
   benefits that, if recognized, would favorably impact the Company&#8217;s effective income tax rate in
   future periods.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 136, 172<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 43, 44, 45, 46, 47, 48, 49<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock-->
   <div align="left" style="font-family: 'Times New Roman',Times,serif">
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <div align="left">
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt"><b><i>Basis of Presentation and Principles of Consolidation</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc.
   (the &#8220;Company&#8221; or &#8220;Alnylam&#8221;) are unaudited and have been prepared in accordance with accounting
   principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable to interim
   periods and, in the opinion of management, include all normal and recurring adjustments that are
   necessary to state fairly the results of operations for the reported periods. The Company&#8217;s
   condensed consolidated financial statements have also been prepared on a basis substantially
   consistent with, and should be read in conjunction with, the Company&#8217;s audited consolidated
   financial statements for the year ended December&#160;31, 2010, which were included in the Company&#8217;s
   Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
   on February&#160;18, 2011. The year-end condensed balance sheet data was derived from audited financial
   statements, but does not include all disclosures required by GAAP. The results of the Company&#8217;s
   operations for any interim period are not necessarily indicative of the results of the Company&#8217;s
   operations for any other interim period or for a full fiscal year.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The accompanying condensed consolidated financial statements reflect the operations of the
   Company and Alnylam U.S., Inc., Alnylam Europe AG (&#8220;Alnylam Europe&#8221;)
   and Alnylam Securities Corporation, wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have
   been eliminated. The Company uses the equity method of accounting to account for its investment in
   Regulus Therapeutics Inc. (&#8220;Regulus&#8221;).
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Use of Estimates</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with GAAP requires management to make
   estimates and assumptions that affect the reported amounts of assets and liabilities and the
   disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
   statements and the reported amounts of revenues and expenses during the reporting period. Actual
   results could differ from those estimates.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Net Loss Per Common Share</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Basic net loss per common share is computed by dividing net loss attributable to common
   stockholders by the weighted average number of common shares outstanding. Diluted net loss per
   common share is computed by dividing net loss attributable to common stockholders by the weighted
   average number of common shares and dilutive potential common share equivalents then outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options (using the
   treasury stock method) and unvested restricted stock awards. Because the inclusion of potential
   common shares would be anti-dilutive for all periods presented, diluted net loss per common share
   is the same as basic net loss per common share.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table sets forth for the periods presented the potential common shares (prior to
   consideration of the treasury stock method) excluded from the calculation of net loss per common
   share because their inclusion would be anti-dilutive, in thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="76%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three and Nine Months  Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Options to purchase common stock
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">8,802</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7,915</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Unvested restricted common stock
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">355</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">9,157</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7,915</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Restricted Stock Awards</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of restricted stock awards granted to employees is based upon the quoted
   closing market price per share on the date of grant, adjusted for assumed forfeitures. For
   performance-based restricted stock awards, the value of the awards is measured when the Company
   determines the achievement of such performance conditions is deemed probable. Expense is
   recognized over the vesting period, commencing when the Company determines that it is probable that
   the awards will vest. In May&#160;2011, the Company
   granted an aggregate of 229,806 shares of performance-based restricted stock awards to its
   employees, excluding the Company&#8217;s leadership team. These restricted stock awards were valued at
   $2.3&#160;million on the grant date and have a term of five years. The vesting of these awards is
   predicated on the Company&#8217;s achievement of certain clinical development goals. For the three and
   nine months ended September&#160;30, 2011, the Company recorded $0.4&#160;million and $0.7&#160;million,
   respectively, of stock-based compensation expense related to these restricted stock awards.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Fair Value Measurements</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following tables present information about the Company&#8217;s assets that are measured at fair
   value on a recurring basis at September&#160;30, 2011 and December&#160;31, 2010, and indicate the fair value
   hierarchy of the valuation techniques the Company utilized to determine such fair value. In
   general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted)&#160;in active
   markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data
   points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair
   values determined by Level 3 inputs utilize unobservable data points for the asset or liability,
   and include situations where there is little, if any, market activity for the asset or liability.
   Financial assets measured at fair value on a recurring basis are summarized as follows, in
   thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>At</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Quoted Prices in</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Significant</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Significant</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Active Markets</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Observable Inputs</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unobservable Inputs</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Description</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 1)</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 2)</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 3)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash equivalents
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">67,515</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">59,517</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">7,998</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Marketable securities (fixed income)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Corporate notes
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">108,669</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">108,669</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">U.S. Government obligations
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">81,287</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">81,287</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Commercial paper
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">21,197</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">21,197</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Marketable securities (equity holdings)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">750</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">750</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">279,418</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">59,517</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">219,901</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>At</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Quoted Prices in</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Significant</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Significant</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>December 31, </b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Active Markets</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Observable Inputs</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unobservable Inputs</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Description</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 1)</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 2)</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>(Level 3)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash equivalents
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">59,702</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">40,686</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">19,016</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Marketable securities (fixed income)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Corporate notes
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">133,341</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">133,341</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">U.S. Government obligations
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">122,273</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">122,273</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Commercial paper
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">17,733</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">17,733</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Marketable securities (equity holdings)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,958</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,958</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">335,007</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">40,686</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">294,321</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the nine months ended September&#160;30, 2011, there were no transfers between Level 1 and
   Level 2 financial assets. The carrying amounts reflected in the Company&#8217;s condensed consolidated
   balance sheets for cash, collaboration receivables, other current assets, accounts payable and
   accrued expenses approximate fair value due to their short-term maturities.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Investments in Marketable Securities</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company invests its excess cash balances in short-term and long-term marketable debt and
   equity securities. The Company classifies its investments in marketable debt securities as either
   held-to-maturity or available-for-sale based on facts and circumstances present at the time it
   purchased the securities. At each balance sheet date presented, the Company classified all of its
   investments in debt and equity securities as available-for-sale. The Company reports
   available-for-sale investments at fair value at each balance sheet date and includes any unrealized
   holding gains and losses (the adjustment to fair value) in stockholders&#8217; equity. Realized gains and
   losses are determined using the specific identification method and are included in other income. If
   any adjustment to fair value reflects a decline in the value of the investment, the Company
   considers all available evidence to evaluate the extent to which the decline is &#8220;other than
   temporary&#8221; and, if so, marks the investment to market through a charge to its condensed
   consolidated statements of operations. The Company did not record any impairment charges related to
   its fixed income marketable securities during the current period. During the three and nine months
   ended September&#160;30, 2011, the Company recorded an impairment charge of $0.6&#160;million related to its
   investment in equity securities of Tekmira Pharmaceuticals Corporation (&#8220;Tekmira&#8221;), as the
   decrease in the fair
   value of this investment was deemed to be other than temporary. The Company&#8217;s marketable
   securities are classified as cash equivalents if the original maturity, from the date of purchase,
   is 90&#160;days or less, and as marketable securities if the original maturity, from the date of
   purchase, is in excess of 90&#160;days. The Company&#8217;s cash equivalents are composed of money market
   funds, U.S. government obligations and commercial paper.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following tables summarize the Company&#8217;s marketable securities at September&#160;30, 2011 and
   December&#160;31, 2010, in thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amortized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Cost</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Gains</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Losses</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Commercial paper (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">21,198</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(2</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">21,197</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate notes (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">52,183</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">23</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(26</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">52,180</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate notes (Due after 1&#160;year through 2&#160;years)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">56,607</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">21</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(139</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">56,489</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">25,304</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">5</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(1</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">25,308</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due after 1&#160;year through 2&#160;years)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">56,012</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(37</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">55,979</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Equity securities
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">750</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">750</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">212,054</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">54</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(205</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">211,903</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>December 31, 2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amortized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Cost</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Gains</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Losses</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Commercial paper (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">17,734</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(3</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">17,733</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate notes (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">116,385</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">204</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(23</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">116,566</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate notes (Due after 1&#160;year through 2&#160;years)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">16,767</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">33</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(25</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">16,775</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due within 1&#160;year)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">24,246</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(14</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">24,233</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">U.S. Government obligations (Due after 1&#160;year through 2&#160;years)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">98,111</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">22</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(93</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">98,040</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Equity securities
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,345</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">613</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,958</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">274,588</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">875</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(158</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">275,305</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Subsequent Events</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company evaluated all events or transactions that occurred after September&#160;30, 2011
   through the date these condensed consolidated financial statements were issued. During this period,
   the Company did not have any material recognized or nonrecognized subsequent events.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Recent Accounting Pronouncements</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2011, the Company adopted new authoritative guidance on revenue recognition for
   multiple element arrangements. The guidance, which applies to multiple element arrangements entered
   into or materially modified on or after January&#160;1, 2011, amends the criteria for separating and
   allocating consideration in a multiple element arrangement by modifying the fair value requirements
   for revenue recognition and eliminating the use of the residual method. The fair value of
   deliverables under the arrangement may be derived using a &#8220;best estimate of selling price&#8221; if
   vendor specific objective evidence and third-party evidence is not available. Deliverables under
   the arrangement will be separate units of accounting provided (i)&#160;a delivered item has value to the
   customer on a standalone basis; and (ii)&#160;if the arrangement includes a general right of return
   relative to the delivered item, delivery or performance of the undelivered item is considered
   probable and substantially in the control of the vendor. The Company did not enter into any
   significant multiple element arrangements or materially modify any existing multiple element
   arrangements during the nine months ended September&#160;30, 2011. The Company&#8217;s existing license and
   collaboration agreements continue to be accounted for under previously issued revenue recognition
   guidance for multiple element arrangements.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2011, the Company adopted new authoritative guidance on revenue recognition for
   milestone payments related to arrangements under which the Company has continuing performance
   obligations. Consideration for events that meet the definition of a milestone in accordance with
   the accounting guidance for the milestone method of revenue recognition is recognized as revenue in
   its entirety in the period in which the milestone is achieved only if all of the following
   conditions are met: (i)&#160;the milestone is commensurate with either the Company&#8217;s performance in
   achieving the milestone or the enhancement of the value of the delivered item as a result of a
   specific outcome resulting from the Company&#8217;s performance in achieving the milestone; (ii)&#160;the
   consideration relates solely to past performance; and (iii)&#160;the amount of the milestone
   consideration is reasonable relative to all of the deliverables and payment terms, including other
   potential milestone consideration, within the arrangement. Otherwise, the milestone payments are
   not considered to be substantive and are deferred and recognized as revenue over the term
   of the arrangement as the Company
   completes its performance obligations. The adoption of this guidance does not materially
   change the Company&#8217;s previous method of recognizing milestone payments. The Company will evaluate
   all potential future milestones under existing arrangements with licensing partners, as specified
   below, and any new arrangements with milestones, under the new revenue recognition guidance for
   milestone payments.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued a new accounting
   standard that clarifies the application of certain existing fair value measurement guidance and
   expands the disclosures for fair value measurements that are estimated using significant
   unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and
   interim reporting periods beginning on or after December&#160;15, 2011. The Company does not expect that
   adoption of this new standard will have a material impact on its condensed consolidated financial
   statements.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2011, the FASB issued an amendment to the accounting guidance for presentation of
   comprehensive income. Under the amended guidance, a company may present the total of comprehensive
   income, the components of net income and the components of other comprehensive income either in a
   single continuous statement of comprehensive income or in two separate but consecutive statements.
   In either case, a company is required to present each component of net income along with total net
   income, each component of other comprehensive income along with a total for other comprehensive
   income and a total amount for comprehensive income.
   For public companies, the amendment is effective for fiscal years, and interim periods within those
   years, beginning after December&#160;15, 2011, and shall be applied retrospectively. Early adoption is
   permitted. Other than a change in presentation, the adoption of this amendment is not expected to have
   a material impact on the Company&#8217;s condensed consolidated financial statements.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 22<br /><br /> -Paragraph 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regulus<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Regulus [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">REGULUS</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>4. REGULUS</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2007, the Company and Isis Pharmaceuticals, Inc. (&#8220;Isis&#8221;) established Regulus, a
   company focused on the discovery, development and commercialization of microRNA therapeutics, a
   potential new class of drugs to treat the pathways of human disease. Regulus, which initially was
   established as a limited liability company, converted to a C corporation in January&#160;2009 and
   changed its name to Regulus Therapeutics Inc.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consideration for the Company&#8217;s and Isis&#8217; initial interests in Regulus, each party granted
   Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic
   applications as well as certain patents in the microRNA field. In addition, the Company made an
   initial cash contribution to Regulus of $10.0&#160;million, resulting in the Company and Isis making
   approximately equal aggregate initial capital contributions to Regulus. In March&#160;2009, the Company
   and Isis each purchased $10.0&#160;million of Series&#160;A preferred stock of Regulus. In October&#160;2010, in
   connection with its strategic alliance with Regulus formed in June&#160;2010, Sanofi made a $10.0
   million equity investment in Regulus. As a result of this investment, the Company recognized a gain
   of $4.4&#160;million due to the increase in valuation of Regulus. This amount was recorded as other
   income in the Company&#8217;s consolidated statements of operations for the year ended December&#160;31, 2010.
   At September&#160;30, 2011, the Company, Isis and Sanofi owned approximately 45%, 46% and 9%,
   respectively, of Regulus. Regulus continues to operate as an independent company with a separate
   board of directors, scientific advisory board and management team, some of whom have options to
   purchase common stock of Regulus. Members of the board of directors of Regulus who are the
   Company&#8217;s employees or Isis&#8217; employees are not eligible to receive options to purchase Regulus
   common stock.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has reviewed the consolidation guidance that defines a variable interest entity
   (&#8220;VIE&#8221;) and concluded that Regulus currently qualifies as a VIE. The Company does not consolidate
   Regulus as the Company lacks the power to direct the activities that could significantly impact the
   economic success of this entity. At September&#160;30, 2011, the total carrying value of the Company&#8217;s
   investment in Regulus in its condensed consolidated balance
   sheets was $1.4&#160;million under the equity method. The Company&#8217;s maximum exposure to loss related to
   this VIE is limited to the carrying value of the Company&#8217;s investment, as well the portion of
   Regulus&#8217; debt, including accrued interest, guaranteed by the Company which was $5.4&#160;million at
   September&#160;30, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company accounts for its investment in Regulus using the equity method of accounting.
   Summary results of Regulus&#8217; operations for the three and nine months ended September&#160;30, 2011 and
   2010 and balance sheets at September&#160;30, 2011 and December&#160;31, 2010 are presented in the tables
   below, in thousands (unaudited):
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Nine Months Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Statement of Operations Data:</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Net revenues
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3,809</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,309</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">10,426</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3,804</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Operating expenses
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4,783</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4,743</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">15,688</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">17,182</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Loss from operations
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(974</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(2,434</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(5,262</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(13,378</td>
       <td nowrap="nowrap">)</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Other expense
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(67</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(48</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(322</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(132</td>
       <td nowrap="nowrap">)</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Net loss
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(1,041</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(2,482</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(5,584</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(13,510</td>
       <td nowrap="nowrap">)</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="76%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>December 31, 2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Balance Sheet Data:</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash, cash equivalents and marketable securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">44,088</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">54,789</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Working capital
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">29,587</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">40,446</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Total assets
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">48,810</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">59,703</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Notes payable
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">11,262</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">11,270</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Total stockholders&#8217; equity
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,964</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7,996</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity investment, or group of investments, for which combined disclosure is appropriate, including: (a) the name of each investee and percentage of ownership of common stock, (b) accounting policies for investments in common stock, (c) difference between the amount at which the investment is carried and the amount of underlying equity in net assets and the accounting treatment of the difference, (d) the total fair value of each identified investment for which a market value is available, (e) summarized information as to assets, liabilities, and results of operations of the investees (for investments in unconsolidated subsidiaries, common stock of joint ventures, or other investments using the equity method), and (f) material effects of possible conversions, exercises, or contingent issuances of the investee. Other disclosures include (a) the names of any investee in which the investor owns 20 percent or more of the voting stock and investment is not accounted for using the equity method, and the reasons why not, and (b) the names of any investee in which the investor owns less than 20 percent of the voting stock and the investment is accounted for using the equity method, and the reasons why it is.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 323<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 323<br /><br /> -SubTopic 10<br /><br /> -Section 35<br /><br /> -Paragraph 32<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6903645&amp;loc=d3e32787-111569<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 18<br /><br /> -Paragraph 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.12)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 323<br /><br /> -SubTopic 10<br /><br /> -Section 35<br /><br /> -Paragraph 35<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6903645&amp;loc=d3e32847-111569<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EquityMethodInvestmentsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>5. COMMITMENTS AND CONTINGENCIES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt"><b><i>Litigation</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><i>Tekmira Litigation</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;On March&#160;16, 2011, Tekmira and Protiva Biotherapeutics, Inc. filed a civil complaint against
   the Company in the Business Litigation Section of the Suffolk County Superior Court, in Boston,
   Massachusetts and on June&#160;3, 2011, the plaintiffs filed an amended complaint adding AlCana
   Technologies, Inc. (&#8220;AlCana&#8221;), a research collaborator of the Company, as a defendant. The amended
   complaint alleges misappropriation of the plaintiffs&#8217; confidential and proprietary information and
   trade secrets, civil conspiracy, and tortious interference with contractual relationships by the
   Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of
   good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive acts
   and practices by the Company. The plaintiffs seek, among other relief, injunctive relief,
   unspecified damages and the termination of licenses that the plaintiffs provided to the Company.
   On April&#160;6, 2011, the Company timely served and filed an answer to the plaintiffs&#8217; original
   complaint denying the plaintiffs&#8217; claims, together with counterclaims against the plaintiffs. On
   June&#160;28, 2011, the Company timely served and filed an answer to the plaintiffs&#8217; amended complaint
   denying the plaintiffs&#8217; claims and counterclaims against the plaintiffs asserting breach of
   contract, defamation, breach of covenant not to sue, breach of patent prosecution and non-use
   provisions, misappropriation of confidential and proprietary information and trade secrets, unjust
   enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of
   Massachusetts statutes. The Company is seeking damages and equitable relief on its counterclaims.
   In September&#160;2011, the Court granted the plaintiffs&#8217; motion to dismiss the Company&#8217;s
   counterclaim for defamation. The Company has a number of additional
   counterclaims remaining against the plaintiffs.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><i>University of Utah Litigation</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;On March&#160;22, 2011, The University of Utah (the &#8220;University&#8221;) filed a civil complaint in the
   United States District Court for the District of Massachusetts against the Company, Max Planck
   Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH (together, &#8220;Max
   Planck&#8221;), the Whitehead Institute for Biomedical Research (&#8220;Whitehead&#8221;), the Massachusetts
   Institute of Technology (&#8220;MIT&#8221;) and the University of Massachusetts (&#8220;UMass&#8221;), claiming a professor
   at the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl
   patents. The University did not serve the original complaint on the Company or the other
   defendants. On July&#160;6, 2011, the University filed an amended complaint alleging substantially the
   same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was
   served on the Company on July&#160;14, 2011. The University is seeking changes to the inventorship of
   the Tuschl patents, unspecified damages and other relief. On October&#160;31, 2011, the Company, Max
   Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on
   October&#160;31, 2011, UMass filed a motion to dismiss on separate grounds, which the Company, Max Planck, Whitehead
   and MIT have joined.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Although the Company believes that it has meritorious defenses to each of the claims in the
   lawsuits described above and intends to fully defend itself in these matters, litigation is subject
   to inherent uncertainty and a court could ultimately rule against the Company in one or both of
   these matters. In addition, the defense of litigation and related matters are costly and may divert
   the attention of the Company&#8217;s management and other resources that would otherwise be engaged in
   running the Company&#8217;s business. The Company has not recorded an estimate of the possible loss
   associated with the legal proceedings described above due in each case to the uncertainties related
   to both the likelihood and the amount of any possible loss or range of loss.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><i>Tuschl Settlement</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2011, the Company, Max Planck, Whitehead and UMass entered into a global settlement
   agreement (the &#8220;Settlement Agreement&#8221;) resolving their ongoing litigation regarding the Tuschl
   patents. MIT, formerly a party to the litigation, also agreed to the terms of the Settlement
   Agreement.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The litigation was initiated in June&#160;2009 and scheduled for trial in March&#160;2011 in the United
   States District Court for the District of Massachusetts, and related to, among other things, the
   prosecution of the Tuschl I and Tuschl II patent applications. In the field of RNAi therapeutics,
   the Company is the exclusive licensee of the Tuschl I patent applications from Max Planck, MIT and
   Whitehead, and of the Tuschl II patent applications from Max Planck. The terms of the Settlement
   Agreement included mutual releases and dismissal with prejudice of all claims and counterclaims in
   the litigation between the parties.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As part of the Settlement Agreement, Max Planck, Whitehead, UMass and MIT agreed that future
   prosecution of the Tuschl I and Tuschl II patent families in the United States should be
   coordinated and led by a single party. Max Planck will assume that role, in addition to their
   ongoing leadership in the continued prosecution of the Tuschl II patent family outside the United
   States. UMass will lead future prosecution of the Tuschl I patent family outside the United
   States. In addition, under the terms of the Settlement Agreement, the Company granted UMass the
   right to sublicense the U.S. Tuschl II patent family to Merck &#038; Co., Inc., subject to certain
   third-party obligations of the Company and other limitations, in exchange for a share of certain
   future sublicense income.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company incurred costs of $3.3&#160;million and $3.8&#160;million during the three months ended
   March&#160;31, 2011 and 2010, respectively, in connection with this dispute. These costs were charged
   to general and administrative expense. The Company does not expect to incur any additional
   significant expenses related to this dispute.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 450<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 460<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Interpretation (FIN)<br /><br /> -Number 14<br /><br /> -Paragraph 3<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 440<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 5<br /><br /> -Paragraph 9, 10, 11, 12<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>6. RESTRUCTURING</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2010, as a result of the planned completion of the fifth and final year of the
   research program under the Novartis Collaboration and License Agreement and the Company&#8217;s reduced
   need for service-based collaboration resources, the Company&#8217;s Board of Directors approved and the
   Company effected a corporate restructuring to focus the Company&#8217;s resources on its most promising
   programs and significantly reduce its cost structure. The corporate restructuring included a
   reduction of the Company&#8217;s overall workforce by approximately 25%.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2010, the Company recorded $2.2&#160;million of
   restructuring-related costs in operating expenses, including employee severance, benefits and
   related costs. During the nine months ended September&#160;30, 2011, the Company did not record any
   additional restructuring related costs.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the components of the Company&#8217;s restructuring expenses recorded
   in operating expenses and in current liabilities, in thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Original</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>(Reversals) or</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amounts</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amounts</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Charges and Amounts</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Adjustments to</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Paid Through</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Accrued at</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Accrued</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Charges</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Employee severance, benefits and related costs
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,193</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(20</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,173</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,193</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(20</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,173</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the components of the Company&#8217;s restructuring activities
   for the nine months ended September&#160;30, 2011, in thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amounts </b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>(Reversals) or</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amounts</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amounts</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Accrued at </b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Adjustments to</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Paid Through</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Accrued at</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>December 31, 2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Charges</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Employee severance, benefits and related costs
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">977</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">977</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">977</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">977</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 420<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SAB TOPIC 5.P.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 420<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 146<br /><br /> -Paragraph 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 5<br /><br /> -Section P<br /><br /> -Subsection 3, 4<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 420<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SAB TOPIC 5.P.3)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EDPAG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br />In Thousands</strong></div></th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td><td class="num">$ (43,346)<span /></td><td class="num">$ (36,585)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td><td class="nump">3,888<span /></td><td class="nump">3,650<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DeferredIncomeTaxes', window );">Deferred income taxes</a></td><td class="text">&#xA0;<span /></td><td class="num">(133)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td><td class="nump">12,594<span /></td><td class="nump">14,906<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementBenefitsPayments', window );">Charge for 401(k) company stock match</a></td><td class="nump">393<span /></td><td class="nump">402<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of joint venture (Regulus Therapeutics Inc.)</a></td><td class="nump">2,551<span /></td><td class="nump">6,723<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet', window );">Other than temporary impairment on equity securities</a></td><td class="nump">595<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Collaboration receivables</a></td><td class="nump">1,423<span /></td><td class="nump">1,163<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable</a></td><td class="nump">10,669<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td><td class="nump">1,980<span /></td><td class="num">(2,281)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td><td class="num">(3,826)<span /></td><td class="num">(5,928)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td><td class="text">&#xA0;<span /></td><td class="num">(5,546)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other</a></td><td class="nump">1,741<span /></td><td class="nump">553<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td><td class="num">(50,571)<span /></td><td class="num">(40,877)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td><td class="num">(61,909)<span /></td><td class="num">(63,953)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td><td class="num">(767)<span /></td><td class="num">(3,594)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td><td class="num">(217,821)<span /></td><td class="num">(287,493)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td><td class="nump">279,763<span /></td><td class="nump">261,346<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td><td class="nump">61,175<span /></td><td class="num">(29,741)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock</a></td><td class="nump">471<span /></td><td class="nump">2,143<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares to Novartis</a></td><td class="text">&#xA0;<span /></td><td class="nump">993<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td><td class="nump">471<span /></td><td class="nump">3,136<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash</a></td><td class="text">&#xA0;<span /></td><td class="num">(29)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td><td class="num">(263)<span /></td><td class="num">(90,587)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td><td class="nump">74,599<span /></td><td class="nump">137,468<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td><td class="nump">$ 74,336<span /></td><td class="nump">$ 46,881<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DeferredIncomeTaxes"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations and the portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alny_DeferredIncomeTaxes</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alny</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 1<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7<br /><br /> -Footnote 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 8, 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash Equivalents<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances held in foreign currencies.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 25<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 830<br /><br /> -SubTopic 230<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 323<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 18<br /><br /> -Paragraph 19<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 18<br /><br /> -Paragraph 6<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 11<br /><br /> -Article 7<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 9<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.12)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from financing activity for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from investing activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementBenefitsPayments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund non-pension postretirement benefits.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (g)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherPostretirementBenefitsPayments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Staff Position (FSP)<br /><br /> -Number FAS115-1/124-1<br /><br /> -Paragraph 16B<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Staff Position (FSP)<br /><br /> -Number FAS115-1/124-1<br /><br /> -Paragraph 7<br /><br /> -Footnote 2<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Staff Position (FSP)<br /><br /> -Number FAS115-1/124-1<br /><br /> -Paragraph 15C<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Staff Position (FSP)<br /><br /> -Number FAS115-1/124-1<br /><br /> -Paragraph 15D<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireAvailableForSaleSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph A240<br /><br /> -Subparagraph i<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ShareBasedCompensation</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Significant Agreements [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <div align="left" style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>2. SIGNIFICANT AGREEMENTS</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the Company&#8217;s total consolidated net revenues from research
   collaborators, for the periods indicated, in thousands:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="52%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Nine Months Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 8pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Roche
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">13,995</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">13,995</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">41,983</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">41,983</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Takeda
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">5,494</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">5,556</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">16,755</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">16,479</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Novartis
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">15</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3,984</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">133</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">8,957</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Other
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,287</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4,133</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3,431</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">11,430</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total net revenues from research collaborators
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">20,791</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">27,668</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">62,302</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">78,849</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Platform Alliances</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt"><i>Roche Alliance</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2007, the Company and, for limited purposes, Alnylam Europe, entered into a license
   and collaboration agreement (the &#8220;LCA&#8221;) with F. Hoffmann-La Roche Ltd (&#8220;Roche Basel&#8221;) and
   Hoffmann-La Roche Inc. (together with Roche Basel, &#8220;Roche&#8221;). Under the LCA, which became effective
   in August&#160;2007, the Company granted Roche a non-exclusive license to the Company&#8217;s intellectual
   property, including delivery-related intellectual property existing as of the date of the LCA, to
   develop and commercialize therapeutic products that function through RNA interference (&#8220;RNAi&#8221;),
   subject to the Company&#8217;s existing contractual obligations to third parties. The license is
   initially limited to four therapeutic areas, and may be expanded to include up to 18 additional
   therapeutic areas, comprising substantially all other fields of human disease, as identified and
   agreed upon by the parties, upon payment to the Company by Roche of an additional $50.0&#160;million for
   each additional therapeutic area, if any.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consideration for the rights granted to Roche under the LCA, Roche paid the Company $273.5
   million in upfront cash payments. In addition, in exchange for the Company&#8217;s contributions under
   the LCA, for each RNAi therapeutic product developed by Roche, its affiliates or sublicensees under
   the LCA, the Company is entitled to receive milestone payments upon achievement of specified
   development and sales events, totaling up to an aggregate of $100.0&#160;million per therapeutic target,
   together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the
   Company and Roche also established a discovery
   collaboration in October&#160;2009 (&#8220;Discovery Collaboration&#8221;), subject to the Company&#8217;s existing
   contractual obligations to third parties.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2007, the Company executed a common stock purchase agreement (the &#8220;Common Stock
   Purchase Agreement&#8221;) with Roche Finance Ltd, an affiliate of Roche. In connection with the
   execution of the LCA and the Common Stock Purchase Agreement, the Company also executed a share
   purchase agreement (the &#8220;Alnylam Europe Purchase Agreement&#8221;) with Alnylam Europe and Roche
   Beteiligungs GmbH, an affiliate of Roche (&#8220;Roche Germany&#8221;). Under the terms of the Alnylam Europe
   Purchase Agreement, the Company sold substantially all of the non-intellectual property assets of
   Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In summary, the Company received upfront payments totaling $331.0&#160;million under the Roche
   alliance, which include an upfront payment under the LCA of $273.5&#160;million, $42.5&#160;million under the
   Common Stock Purchase Agreement and $15.0&#160;million under the Alnylam Europe Purchase Agreement. The
   Company initially recorded $278.2&#160;million of these proceeds as deferred revenue in connection with
   the Roche alliance.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;When evaluating multiple element arrangements, the Company considers whether the components of
   the arrangement represent separate units of accounting. The accounting guidance specifically
   requires that the delivered components must have value to the customer on a standalone basis and
   that there is objective and reliable evidence of the fair value of the undelivered components.
   Application of this standard requires subjective determinations and requires management to make
   judgments about the value of each individual element and whether it is separable from the other
   aspects of the contractual relationship. The Company has determined that the deliverables under
   its agreements with Roche include the license, the Alnylam Europe assets and employees, the
   steering committees (joint steering committee and future technology committee) and the services
   under the Discovery Collaboration. The Company has determined that, pursuant to the accounting
   guidance governing revenue recognition on multiple element arrangements, the license and assets of
   Alnylam Europe are not separable from the undelivered services (i.e., the steering committees and
   Discovery Collaboration) and, accordingly the license and the services are being treated as a
   single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
   Roche alliance, the steering committee services and the Discovery Collaboration services are the
   final deliverables and all such services will end, contractually, five years from the effective
   date of the LCA.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is recognizing the Roche-related revenue on a straight-line basis over five years
   because the Company cannot reasonably estimate the total level of effort required to complete its
   service obligations under the LCA, and therefore, cannot utilize a proportional performance model.
   As future substantive milestones are achieved, the Company will recognize as revenue a portion of
   the milestone payment, equal to the percentage of the performance period completed when the
   milestone is achieved, multiplied by the amount of the milestone payment. The Company will
   recognize the remaining portion of the milestone over the remaining performance period on a
   straight-line basis. The Company will continue to recognize the Roche-related revenue on a
   straight-line basis over five years.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In November&#160;2010, Roche announced the discontinuation of certain activities in research and
   early development, including its RNAi research efforts. The remaining deliverables under the LCA
   currently remain in effect. In October&#160;2011, Arrowhead Research Corporation (&#8220;Arrowhead&#8221;) announced
   its acquisition of RNA therapeutics assets from Roche, including the LCA. In the event Arrowhead terminates
   the LCA or the Company and Arrowhead mutually agree to modify the LCA, the Company
   will reassess its deliverables and the period over which it will complete its performance
   obligations under the LCA. At September&#160;30, 2011, deferred revenue under the LCA was $51.3&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><i>Takeda Alliance</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2008, the Company entered into a license and collaboration agreement (the &#8220;Takeda
   Collaboration Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) to pursue the
   development and commercialization of RNAi therapeutics. Under the Takeda Collaboration Agreement,
   the Company granted Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&#8217;s
   intellectual property, including delivery-related intellectual property, controlled by the Company
   as of the date of the agreement or during the five years thereafter, to develop, manufacture, use
   and commercialize RNAi therapeutics, subject to the Company&#8217;s existing contractual obligations to
   third parties. The license initially is limited to the fields of oncology and metabolic disease and
   may be expanded at Takeda&#8217;s option to include other therapeutic areas, subject to specified
   conditions. Under the Takeda Collaboration Agreement, Takeda is the Company&#8217;s exclusive platform
   partner in the Asian territory, as defined in the Takeda Collaboration Agreement, through May&#160;2013.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consideration for the rights granted to Takeda under the Takeda Collaboration Agreement,
   Takeda agreed to pay the
   Company $150.0&#160;million in upfront and near-term technology transfer payments. In addition, the
   Company has the option, exercisable until the start of Phase III development, to opt-in under a
   50-50 profit sharing agreement to the development and commercialization in the United States of up
   to four Takeda licensed products and would be entitled to opt-in rights for two additional products
   for each additional field expansion, if any, elected by Takeda under the Takeda Collaboration
   Agreement. In June&#160;2008, Takeda paid the Company an upfront payment of $100.0&#160;million and agreed to
   pay an additional $50.0&#160;million to the Company upon achievement of specified technology transfer
   milestones. Of this $50.0&#160;million, $20.0&#160;million was paid to the Company in October&#160;2008, $20.0
   million was paid to the Company in March&#160;2010 and $10.0&#160;million was paid to the Company in March
   2011 (collectively, &#8220;Technology Transfer Milestones&#8221;). If Takeda elects to expand its license to
   additional therapeutic areas, Takeda will be required to pay the Company $50.0&#160;million for each of
   up to approximately 20 total additional fields selected, if any, comprising substantially all other
   fields of human disease, as identified and agreed upon by the parties. In addition, for each RNAi
   therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled
   to receive specified development and commercialization milestones, totaling up to $171.0&#160;million
   per product, together with royalty payments based on worldwide annual net sales, if any.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Pursuant to the Takeda Collaboration Agreement, the Company and Takeda are also collaborating
   on the research of RNAi therapeutics directed to one or two disease targets agreed to by the
   parties (the &#8220;Research Collaboration&#8221;), subject to the Company&#8217;s existing contractual obligations
   with third parties. Takeda also has the option, subject to certain conditions, to collaborate with
   the Company on the research and development of RNAi drug delivery technology for targets agreed to
   by the parties. In addition, Takeda has a right of first negotiation for the development and
   commercialization of the Company&#8217;s RNAi therapeutic products in the Asian territory, excluding the
   Company&#8217;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a
   similar right of first negotiation to participate with Takeda in the development and
   commercialization in the United States of licensed products. The collaboration is governed by a
   joint technology transfer committee (the &#8220;JTTC&#8221;), a joint research collaboration committee (the
   &#8220;JRCC&#8221;) and a joint delivery collaboration committee (the &#8220;JDCC&#8221;), each of which is comprised of an
   equal number of representatives from each party.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has determined that the deliverables under the Takeda Collaboration Agreement
   include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer
   activities and the services that the Company will be obligated to perform under the Research
   Collaboration. The Company has determined that, pursuant to the accounting guidance governing
   revenue recognition on multiple element arrangements, the license and undelivered services (i.e.,
   the joint committees and the Research Collaboration) are not separable and, accordingly, the
   license and services are being treated as a single unit of accounting. When multiple deliverables
   are accounted for as a single unit of accounting, the Company bases its revenue recognition pattern
   on the final deliverable. Under the Takeda Collaboration Agreement, the last elements to be
   delivered are the JDCC and JTTC services, each of which has a life of no more than seven years.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is recognizing the upfront payment of $100.0&#160;million and the Technology Transfer
   Milestones of $50.0&#160;million, the receipt of which the Company believed was probable at the
   commencement of the collaboration, on a straight-line basis over seven years because the Company is
   unable to reasonably estimate the level of effort to fulfill these obligations, primarily because
   the effort required under the Research Collaboration is largely unknown, and therefore, cannot
   utilize the proportional performance model. As future substantive milestones are achieved, the
   Company will recognize as revenue a portion of the milestone payment equal to the percentage of the
   performance period completed when the milestone is achieved, multiplied by the amount of the
   milestone payment. The Company will recognize the remaining portion of the milestone over the
   remaining performance period on a straight-line basis. At September&#160;30, 2011, deferred revenue
   under the Takeda Collaboration Agreement was $80.3&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Discovery and Development Alliances</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><i>Novartis Broad Alliance</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the second half of 2005, the Company entered into a series of transactions with Novartis
   Pharma AG and its affiliate, Novartis Institutes for BioMedical Research, Inc. (together,
   &#8220;Novartis&#8221;), which included a stock purchase agreement, an investor rights agreement (the &#8220;Investor
   Rights Agreement&#8221;), and a research collaboration and license agreement (the &#8220;Collaboration and
   License Agreement&#8221;). The Collaboration and License Agreement had an initial research term of three
   years, with an option for two additional one-year extensions at the election of Novartis. Novartis
   elected to extend the term through October&#160;2010, the fifth and final planned year. In October&#160;2010,
   the research program under the Collaboration and License Agreement was substantially completed in
   accordance with the terms of the Collaboration and License Agreement, subject to certain surviving
   rights and obligations of the parties.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Investor Rights Agreement provides Novartis with the right generally to maintain its
   ownership percentage in the
   Company until the earlier of any sale by Novartis of shares of the Company&#8217;s common stock and
   the expiration or termination of the Collaboration and License Agreement, subject to certain
   exceptions. At September&#160;30, 2011, Novartis owned 13.1% of the Company&#8217;s outstanding common stock.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consideration for the rights granted to Novartis under the Collaboration and License
   Agreement, Novartis made an upfront payment of $10.0&#160;million to the Company in October&#160;2005, partly
   to reimburse prior costs incurred by the Company to develop <i>in vivo </i>RNAi technology. The Company
   also received research funding and development milestone payments from Novartis.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2010, Novartis exercised its right under the Collaboration and License Agreement
   to select 31 designated gene targets, for which Novartis has exclusive rights to discover, develop
   and commercialize RNAi therapeutic products using the Company&#8217;s intellectual property and
   technology, including delivery-related intellectual property and related technology. Under the
   terms of the Collaboration and License Agreement, for any RNAi therapeutic products Novartis
   develops against these targets, the Company is entitled to receive milestone payments upon
   achievement of certain specified development and annual net sales events, up to an aggregate of
   $75.0&#160;million per therapeutic product, as well as royalties on annual net sales of any such
   product. Novartis&#8217; right of first offer with respect to an exclusive license for additional
   targets has terminated. In September&#160;2010, Novartis declined to exercise its non-exclusive option
   to integrate into its operations the Company&#8217;s fundamental and chemistry intellectual property
   under the terms of the Collaboration and License Agreement. If Novartis had elected to exercise the
   integration option, Novartis would have been required to make additional payments to the Company
   totaling $100.0&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company believes the estimated period of performance under the Collaboration and License
   Agreement is ten years, which includes the three-year initial term of the agreement, two one-year
   extensions elected by Novartis and limited support as part of a technology transfer until 2015, the
   fifth anniversary of the completion of the research term under the Collaboration and License
   Agreement. The Company continues to use an expected term of ten years in its proportional
   performance model. The Company reevaluates the expected term when new information is known that
   could affect the Company&#8217;s estimate. In the event the Company&#8217;s period of performance is different
   than estimated, the Company will adjust the amount of revenue recognized on a prospective basis. At
   September&#160;30, 2011, deferred revenue under the Novartis Collaboration and License Agreement was
   $0.2&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt"><b><i>Product Alliances</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%"><i>Kyowa Hakko Kirin Alliance</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2008, the Company entered into a license and collaboration agreement (the &#8220;Kyowa Hakko
   Kirin Agreement&#8221;) with Kyowa Hakko Kirin Co., Ltd. (&#8220;Kyowa Hakko Kirin&#8221;). Under the Kyowa Hakko
   Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to its intellectual
   property in Japan and other markets in Asia (the &#8220;Licensed Territory&#8221;) for the development and
   commercialization of an RNAi therapeutic for the treatment of respiratory syncytial virus (&#8220;RSV&#8221;)
   infection. The Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific
   RNAi therapeutic compounds that comprise the ALN-RSV program (&#8220;Additional Compounds&#8221;). The Company
   retains all development and commercialization rights worldwide outside of the Licensed Territory,
   subject to its agreement with Cubist Pharmaceuticals, Inc. (&#8220;Cubist&#8221;) described below.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Under the terms of the Kyowa Hakko Kirin Agreement, in June&#160;2008, Kyowa Hakko Kirin paid the
   Company an upfront cash payment of $15.0&#160;million. In addition, Kyowa Hakko Kirin is required to
   make payments to the Company upon achievement of specified development and sales milestones
   totaling up to $78.0&#160;million, and royalty payments based on annual net sales, if any, of RNAi
   therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its affiliates and sublicensees in the
   Licensed Territory.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The collaboration between Kyowa Hakko Kirin and the Company is governed by a joint steering
   committee that is comprised of an equal number of representatives from each party. Under the
   agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to
   the development activities to be undertaken in the Licensed Territory, with the initial focus on
   Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the
   development plan that are reasonably necessary for the regulatory approval and commercialization of
   an RNAi therapeutic for the treatment of RSV in Japan and the rest of the Licensed Territory. The
   Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement
   unless Kyowa Hakko Kirin elects, prior to the first commercial sale of the product in the Licensed
   Territory, to manufacture the product itself or arrange for a third party to manufacture the
   product.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has determined that the deliverables under the Kyowa Hakko Kirin Agreement include
   the license, the joint steering committee, the manufacturing services and any Additional Compounds.
   The Company has determined that, pursuant to the accounting guidance governing revenue recognition
   on multiple element arrangements, the individual deliverables are not separable and, accordingly,
   must be accounted for as a single unit of accounting. When multiple deliverables are accounted for
   as a single unit
   of accounting, the Company bases its revenue recognition pattern on the final deliverable.
   The Company is currently unable to reasonably estimate its period of performance under the Kyowa
   Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the
   fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The Company is
   deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate
   its period of performance. The Company will continue to reassess whether it can reasonably estimate
   the period of performance to fulfill its obligations under the Kyowa Hakko Kirin Agreement. At
   September&#160;30, 2011, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&#160;million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 1%"><i>Cubist Alliance</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2009, the Company entered into a license and collaboration agreement with Cubist
   (the &#8220;Cubist Agreement&#8221;) to develop and commercialize therapeutic products (&#8220;Licensed Products&#8221;)
   based on certain of the Company&#8217;s RNAi technology for the treatment of RSV infection. Licensed
   Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV
   inhibitors. In November&#160;2009, the Company and Cubist entered into an amendment to the Cubist
   Agreement (the &#8220;Amendment&#8221;), which provides that the Company and Cubist would focus their
   collaboration and joint development efforts on ALN-RSV02, a second-generation compound, intended
   for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and
   Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant
   to the terms of the Amendment, the Company is continuing to develop ALN-RSV01 for adult transplant
   patients at its sole discretion and expense. Cubist has the right to opt into collaborating with
   the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time
   following the completion of the Company&#8217;s Phase IIb trial of ALN-RSV01, subject to the payment by
   Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the
   Company&#8217;s development expenses for ALN-RSV01. In December&#160;2010, the Company and Cubist jointly made
   a portfolio decision to put the development of ALN-RSV02 on hold.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consideration for the rights granted to Cubist under the Cubist Agreement, in January&#160;2009,
   Cubist paid the Company an upfront cash payment of $20.0&#160;million. Cubist is also obligated under
   the Cubist Agreement to pay the Company milestone payments, totaling up to an aggregate of $82.5
   million, and has the right to convert the North American co-development and profit sharing
   arrangement into a royalty-bearing license.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has determined that the deliverables under the Cubist Agreement include the
   licenses, technology transfer related to the ALN-RSV program, the joint steering committee and the
   development and manufacturing services that the Company is obligated to perform during the
   development period. The Company also has determined that, pursuant to the accounting guidance
   governing revenue recognition on multiple element arrangements, the licenses and undelivered
   services are not separable and, accordingly, the licenses and services are being treated as a
   single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the
   Cubist Agreement, the last element to be delivered is the development and manufacturing services,
   which have an expected life of approximately eight years.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is recognizing the upfront payment of $20.0&#160;million on a straight-line basis over
   approximately eight years because the Company is unable to reasonably estimate the level of effort
   to fulfill its performance obligations, and therefore, cannot utilize a proportional performance
   model. As future substantive milestones are achieved, the Company will recognize as revenue a
   portion of the milestone payment, equal to the percentage of the performance period completed when
   the milestone is achieved, multiplied by the amount of the milestone payment. The Company will
   recognize the remaining portion of the milestone over the remaining performance period on a
   straight-line basis. At September&#160;30, 2011, deferred revenue under the Cubist Agreement was $13.2
   million.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for
   developing Licensed Products in North America, and each bears one-half of the related development
   costs, provided that under the terms of the Amendment, the Company is funding the advancement of
   ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue
   generating arrangements that involve cost sharing between the parties, the Company presents the
   results of activities for which it acts as the principal on a gross basis and reports any payments
   received from, or made to, other collaborators based on other applicable GAAP or, in the absence of
   other applicable GAAP, analogy to authoritative accounting literature or a reasonable, rational and
   consistently applied accounting policy election. As the Company is not considered the principal
   under the Cubist Agreement, the Company records any amounts due from Cubist as a reduction of
   research and development expense.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif">
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 07-1<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 808<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E6OAG"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br />In Thousands</strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td><td class="nump">$ 74,336<span /></td><td class="nump">$ 74,599<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td><td class="nump">98,685<span /></td><td class="nump">158,532<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Collaboration receivables</a></td><td class="nump">2,027<span /></td><td class="nump">3,450<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td><td class="nump">0<span /></td><td class="nump">10,669<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td><td class="nump">4,909<span /></td><td class="nump">6,889<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td><td class="nump">179,957<span /></td><td class="nump">254,139<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td><td class="nump">113,218<span /></td><td class="nump">116,773<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td><td class="nump">15,309<span /></td><td class="nump">18,289<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in joint venture (Regulus Therapeutics Inc.)</a></td><td class="nump">1,421<span /></td><td class="nump">3,616<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td><td class="nump">318<span /></td><td class="nump">448<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td><td class="nump">310,223<span /></td><td class="nump">393,265<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td><td class="nump">5,486<span /></td><td class="nump">9,312<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td><td class="nump">12,230<span /></td><td class="nump">11,116<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td><td class="nump">484<span /></td><td class="nump">484<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td><td class="nump">75,727<span /></td><td class="nump">81,134<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td><td class="nump">93,927<span /></td><td class="nump">102,046<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td><td class="nump">2,884<span /></td><td class="nump">2,869<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td><td class="nump">84,810<span /></td><td class="nump">129,974<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td><td class="nump">729<span /></td><td class="nump">143<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td><td class="nump">182,350<span /></td><td class="nump">235,032<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 4, 5 and 6)</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2011 and December 31, 2010</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 125,000,000 shares authorized; 42,687,941 shares issued and outstanding at September 30, 2011; 42,343,423 shares issued and outstanding at December 31, 2010</a></td><td class="nump">427<span /></td><td class="nump">423<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td><td class="nump">514,290<span /></td><td class="nump">500,443<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td><td class="num">(151)<span /></td><td class="nump">714<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td><td class="num">(386,693)<span /></td><td class="num">(343,347)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td><td class="nump">127,873<span /></td><td class="nump">158,233<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td><td class="nump">$ 310,223<span /></td><td class="nump">$ 393,265<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 130<br /><br /><br /><br /> -Paragraph 14, 17, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15D<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 11<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 14<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.30(a)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Concepts (CON)<br /><br /><br /><br /> -Number 6<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Assets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 133<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15E<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 16<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15D<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15C<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 13, 17<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4, 5<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6379932&amp;loc=d3e22054-111558<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15C<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15D<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Available-for-Sale Securities<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15E<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AvailableForSaleSecuritiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -Footnote 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash Equivalents<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-03.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-03.(a),19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 450<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 5<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 30<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Technical Bulletin (FTB)<br /><br /><br /><br /> -Number 85-3<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.26(c))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Technical Bulletin (FTB)<br /><br /><br /><br /> -Number 85-3<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 48<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph a(1)<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)(1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph c<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-03.10)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.3(a)(4))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 109<br /><br /><br /><br /> -Section Appendix E<br /><br /><br /><br /> -Paragraph 289<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-03.5(c))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxesReceivable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.12)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19-26)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Liabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 32<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.32)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 24<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.24)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 129<br /><br /><br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 505<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.3-04)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.13)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph b, c<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 360<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.3,4)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ReceivablesNetCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31(a)(3))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29, 30, 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 4<br /><br /><br /><br /> -Section E<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 310<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.15</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>10</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Regulus</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/Regulus</Role>
      <ShortName>Regulus</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0205 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0206 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>alny-20110930.xml</File>
    <File>alny-20110930.xsd</File>
    <File>alny-20110930_cal.xml</File>
    <File>alny-20110930_lab.xml</File>
    <File>alny-20110930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\V-C<Q-V9D-5]D-#`W7S1B-S%?.69C.%\S96(X
M83$U9C$W9#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V-C<Q-V9D-5]D-#`W7S1B-S%?.69C.%\S
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM
M87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3:6=N:69I8V%N=%]!9W)E96UE;G1S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A
M>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5G
M=6QU<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4F5S=')U8W1U<FEN9SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%
M>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K
M<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!
M8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0
M<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO
M>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL
M/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@
M<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0
M(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8V-S$W9F0U7V0T,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D
M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-C<Q-V9D-5]D-#`W
M7S1B-S%?.69C.%\S96(X83$U9C$W9#DO5V]R:W-H965T<R]3:&5E=#`Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%05=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U
M;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N("A54T0@)FYB<W`[)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3`\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!2
M96=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D%,3EE,04T@4$A!4DU!0T555$E#04Q3+"!)3D,N/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A
M;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P
M,#$Q-S@V-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R
M:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A
M<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.
M;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!297!O<G1I;F<@4W1A
M='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y997,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^06-C96QE<F%T960@1FEL97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!0=6)L:6,@1FQO870\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-#0V+#4W.2PR
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-S(V+#DX-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C8W,3=F9#5?
M9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q-68Q-V0Y#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S8V-S$W9F0U7V0T,#=?-&(W,5\Y9F,X7S-E8CAA,35F
M,3=D.2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V3T%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@
M0F%L86YC92!3:&5E=',@*%5N875D:71E9"D@*%531"`F;F)S<#LD*3QB<CY)
M;B!4:&]U<V%N9',\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B9N8G-P.R0@-S0L,S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`W-"PU.3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA<FME=&%B;&4@<V5C
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@L-C@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34X+#4S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!R96-E:79A8FQE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0U,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S
M(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DP.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W.2PY-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-30L,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87)K971A8FQE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,RPR,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L
M-S<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$U+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#(X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N="!I
M;B!J;VEN="!V96YT=7)E("A296=U;'5S(%1H97)A<&5U=&EC<R!);F,N*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT
M86YG:6)L92!A<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,3`L,C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS+#(V-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL,S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPR,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PQ,38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M9F5R<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S4L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#$L,3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L.3(W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R
M+#`T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@<F5N="P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU92P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0L.#$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y+#DW-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@R+#,U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S-2PP,S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE
M;G1S(&%N9"!C;VYT:6YG96YC:65S("A.;W1E<R`T+"`U(&%N9"`V*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("9N8G-P
M.R0P+C`Q('!A<B!V86QU92P@-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D
M(&%N9"!N;R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!397!T
M96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+"`R,#$P/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@)FYB<W`[)#`N,#$@<&%R('9A;'5E+"`Q,C4L,#`P+#`P,"!S:&%R
M97,@875T:&]R:7IE9#L@-#(L-C@W+#DT,2!S:&%R97,@:7-S=65D(&%N9"!O
M=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L(#(P,3$[(#0R+#,T,RPT,C,@
M<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L
M(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4Q-"PR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L-#0S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE
M<B!C;VUP<F5H96YS:79E("AL;W-S*2!I;F-O;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X-BPV.3,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0S+#,T
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(W+#@W,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U."PR,S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B
M:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,S$P+#(R,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,SDS
M+#(V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q-68Q-V0Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8V-S$W9F0U7V0T,#=?-&(W,5\Y9F,X
M7S-E8CAA,35F,3=D.2]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5!1$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A5;F%U
M9&ET960I("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R
M<R<@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#8X-RPY-#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPS-#,L-#(S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#(L-C@W+#DT,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#,T,RPT,C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8V-S$W9F0U7V0T
M,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D.0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V-C<Q-V9D-5]D-#`W7S1B-S%?.69C.%\S96(X83$U9C$W
M9#DO5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T1"1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T
M871E;65N=',@;V8@3W!E<F%T:6]N<R!A;F0@0V]M<')E:&5N<VEV92!,;W-S
M("A5;F%U9&ET960I("A54T0@)FYB<W`[)"D\8G(^26X@5&AO=7-A;F1S+"!E
M>&-E<'0@4&5R(%-H87)E(&1A=&$\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/E-E<"X@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^4V5P
M+B`S,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CY397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/E-E<"X@,S`L(#(P,3`\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N9&5N
M<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@86YD
M($-O;7!R96AE;G-I=F4@3&]S<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!R979E;G5E<R!F<F]M(')E<V5A<F-H(&-O;&QA
M8F]R871O<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@,C`L-SDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`R-RPV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD
M(#8R+#,P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M-S@L.#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-"PR-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(W+#0V.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L.3(V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PS,#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U
M<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#DR.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<L-C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,"PR,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,C(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,SDV/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`S+#4S-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q,"PU,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3(L-#,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L-S(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Q+#(S
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,2PV-C`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN8V]M
M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET
M>2!I;B!L;W-S(&]F(&IO:6YT('9E;G1U<F4@*%)E9W5L=7,@5&AE<F%P975T
M:6-S($EN8RXI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-C<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR,C8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPU-3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-BPW,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=&AE<B`H97AP96YS92D@:6YC;VUE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,S(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!I;F-O;64@*&5X<&5N<V4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L,3$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0L.#,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@
M8F5F;W)E(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3,L,C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL
M,S,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S+#,T-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPT.3@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,CDX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPR,S<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.2PV,S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#,L,S0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V
M+#4X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M('!E<B!C;VUM;VX@<VAA<F4@+2!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C,Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XR,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#$N,#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C@W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA
M<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S
M<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,BPV-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPQ
M,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPS.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,2PY.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M<')E:&5N<VEV92!L;W-S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3,L,C,W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#DL-C,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0S+#,T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPU
M.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N(&-U
M<G)E;F-Y('1R86YS;&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A
M;&EZ960@9V%I;B`H;&]S<RD@;VX@;6%R:V5T86)L92!S96-U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPQ-#(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PV,C@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#0L,C$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,V+#`Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3F]N+6-A<V@@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X
M<&5N<V5S(&EN8VQU9&5D(&EN(&]P97)A=&EN9R!E>'!E;G-E<R!A<F4@87,@
M9F]L;&]W<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#<X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,2PT-CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$L-S@V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`T+#,Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-2PW,#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$.3X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^
M#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@
M/'1D(&-O;'-P86X],T0X('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!S=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@97AP96YS97,@:6YC;'5D960@:6X@;W!E<F%T
M:6YG(&5X<&5N<V5S(&%R92!A<R!F;VQL;W=S.B`\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q-68Q
M-V0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8V-S$W9F0U7V0T
M,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D.2]7;W)K<VAE971S+U-H965T,#4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5$4$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S
M("A5;F%U9&ET960I("A54T0@)FYB<W`[)"D\8G(^26X@5&AO=7-A;F1S/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$P/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A
M<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H-#,L,S0V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB
M<W`[)"`H,S8L-3@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I
M;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@<')O=FED960@8GD@*'5S960@:6XI
M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!S=&]C:RUB87-E9"!C;VUP96YS
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#4Y-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0VAA<F=E(&9O<B`T,#$H:RD@8V]M<&%N>2!S=&]C:R!M871C:#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@
M:6X@;&]S<R!O9B!J;VEN="!V96YT=7)E("A296=U;'5S(%1H97)A<&5U=&EC
M<R!);F,N*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU-3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#<R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@=&AA;B!T96UP;W)A<GD@:6UP86ER;65N="!O;B!E<75I
M='D@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@
M;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@<F5C96EV86)L97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87AE
M<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY.#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#(X,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M.#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4L.3(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YC;VUE('1A>&5S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4L-30V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<R!A
M;F0@;W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U,"PU-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#`L.#<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8Q+#DP.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V,RPY-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!I
M;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<V-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#4Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!U<F-H87-E<R!O9B!M87)K971A8FQE('-E8W5R:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-RPX,C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@W+#0Y,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-A;&5S(&%N9"!M871U<FET:65S(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<Y+#<V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V,2PS
M-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@:6YV97-T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q
M+#$W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(Y+#<T,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN
M9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@<VAA<F5S('1O($YO=F%R=&ES
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C="!O9B!E>&-H
M86YG92!R871E(&]N(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!D96-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3`L
M-3@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@8F5G:6YN:6YG(&]F
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0L-3DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,W+#0V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@96YD(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`W
M-"PS,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XF;F)S<#LD(#0V+#@X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q
M-68Q-V0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8V-S$W9F0U
M7V0T,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D.2]7;W)K<VAE971S+U-H965T
M,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)
M15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C
M:R!486=G960@3F]T92`Q("T@=7,M9V%A<#I3:6=N:69I8V%N=$%C8V]U;G1I
M;F=0;VQI8VEE<U1E>'1";&]C:RTM/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S
M+'-E<FEF)SX-"B`@(#PA+2T@>&)R;"QN<R`M+3X-"B`@(#PA+2T@>&)R;"QN
M>"`M+3X-"B`@(#QD:78@86QI9VX],T1L969T/@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,'!T)SX\8CX-"B`@(#PO8CX-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,G!T)SX\8CXQ+B!354U-05)9($]&(%-)1TY)1DE#04Y4
M($%#0T]53E1)3D<@4$],24-)15,\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@-G!T)SX\8CX\:3Y"87-I<R!O9B!0<F5S96YT871I;VX@86YD(%!R
M:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO:3X\+V(^#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#M4:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L('-T871E;65N=',@;V8@06QN>6QA;2!0:&%R;6%C975T:6-A
M;',L($EN8RX-"B`@("AT:&4@)B,X,C(P.T-O;7!A;GDF(S@R,C$[(&]R("8C
M.#(R,#M!;&YY;&%M)B,X,C(Q.RD@87)E('5N875D:71E9"!A;F0@:&%V92!B
M965N('!R97!A<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG#0H@
M("!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D
M(%-T871E<R!O9B!!;65R:6-A("@F(S@R,C`[1T%!4"8C.#(R,3LI(&%P<&QI
M8V%B;&4@=&\@:6YT97)I;0T*("`@<&5R:6]D<R!A;F0L(&EN('1H92!O<&EN
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M>0T*("`@8V]N<VES=&5N="!W:71H+"!A;F0@<VAO=6QD(&)E(')E860@:6X@
M8V]N:G5N8W1I;VX@=VET:"P@=&AE($-O;7!A;GDF(S@R,3<[<R!A=61I=&5D
M(&-O;G-O;&ED871E9`T*("`@9FEN86YC:6%L('-T871E;65N=',@9F]R('1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`L('=H:6-H('=E
M<F4@:6YC;'5D960@:6X@=&AE($-O;7!A;GDF(S@R,3<[<PT*("`@06YN=6%L
M(%)E<&]R="!O;B!&;W)M(#$P+4L@=&AA="!W87,@9FEL960@=VET:"!T:&4@
M4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C.#(R
M,#M314,F(S@R,C$[*0T*("`@;VX@1F5B<G5A<GDF(S$V,#LQ."P@,C`Q,2X@
M5&AE('EE87(M96YD(&-O;F1E;G-E9"!B86QA;F-E('-H965T(&1A=&$@=V%S
M(&1E<FEV960@9G)O;2!A=61I=&5D(&9I;F%N8VEA;`T*("`@<W1A=&5M96YT
M<RP@8G5T(&1O97,@;F]T(&EN8VQU9&4@86QL(&1I<V-L;W-U<F5S(')E<75I
M<F5D(&)Y($=!05`N(%1H92!R97-U;'1S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,-"B`@(&]P97)A=&EO;G,@9F]R(&%N>2!I;G1E<FEM('!E<FEO9"!A<F4@
M;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@;V8@
M=&AE($-O;7!A;GDF(S@R,3<[<PT*("`@;W!E<F%T:6]N<R!F;W(@86YY(&]T
M:&5R(&EN=&5R:6T@<&5R:6]D(&]R(&9O<B!A(&9U;&P@9FES8V%L('EE87(N
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#M4:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C
M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@<F5F;&5C="!T:&4@
M;W!E<F%T:6]N<R!O9B!T:&4-"B`@($-O;7!A;GD@86YD($%L;GEL86T@52Y3
M+BP@26YC+BP@06QN>6QA;2!%=7)O<&4@04<@*"8C.#(R,#M!;&YY;&%M($5U
M<F]P928C.#(R,3LI#0H@("!A;F0@06QN>6QA;2!396-U<FET:65S($-O<G!O
M<F%T:6]N+"!W:&]L;'DM;W=N960@<W5B<VED:6%R:65S(&]F('1H92!#;VUP
M86YY+B!!;&P@<VEG;FEF:6-A;G0@:6YT97)C;VUP86YY(&%C8V]U;G1S(&%N
M9"!T<F%N<V%C=&EO;G,@:&%V90T*("`@8F5E;B!E;&EM:6YA=&5D+B!4:&4@
M0V]M<&%N>2!U<V5S('1H92!E<75I='D@;65T:&]D(&]F(&%C8V]U;G1I;F<@
M=&\@86-C;W5N="!F;W(@:71S(&EN=F5S=&UE;G0@:6X-"B`@(%)E9W5L=7,@
M5&AE<F%P975T:6-S($EN8RX@*"8C.#(R,#M296=U;'5S)B,X,C(Q.RDN#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3)P="<^/&(^/&D^57-E(&]F($5S
M=&EM871E<SPO:3X\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@<')E<&%R871I
M;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W:71H
M($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME#0H@("!E<W1I;6%T
M97,@86YD(&%S<W5M<'1I;VYS('1H870@869F96-T('1H92!R97!O<G1E9"!A
M;6]U;G1S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@86YD('1H90T*("`@
M9&ES8VQO<W5R92!O9B!C;VYT:6YG96YT(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@870@=&AE(&1A=&4@;V8@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L#0H@("!S=&%T96UE;G1S(&%N9"!T:&4@<F5P;W)T960@86UO
M=6YT<R!O9B!R979E;G5E<R!A;F0@97AP96YS97,@9'5R:6YG('1H92!R97!O
M<G1I;F<@<&5R:6]D+B!!8W1U86P-"B`@(')E<W5L=',@8V]U;&0@9&EF9F5R
M(&9R;VT@=&AO<V4@97-T:6UA=&5S+@T*("`@/"]D:78^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$R<'0G/CQB/CQI/DYE="!,;W-S(%!E<B!#;VUM;VX@4VAA<F4\+VD^
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0F%S:6,@;F5T(&QO<W,@<&5R(&-O;6UO
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M<'1I;VYS("AU<VEN9R!T:&4-"B`@('1R96%S=7)Y('-T;V-K(&UE=&AO9"D@
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M+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O
M<G1H(&9O<B!T:&4@<&5R:6]D<R!P<F5S96YT960@=&AE('!O=&5N=&EA;"!C
M;VUM;VX@<VAA<F5S("AP<FEO<B!T;PT*("`@8V]N<VED97)A=&EO;B!O9B!T
M:&4@=')E87-U<GD@<W1O8VL@;65T:&]D*2!E>&-L=61E9"!F<F]M('1H92!C
M86QC=6QA=&EO;B!O9B!N970@;&]S<R!P97(@8V]M;6]N#0H@("!S:&%R92!B
M96-A=7-E('1H96ER(&EN8VQU<VEO;B!W;W5L9"!B92!A;G1I+61I;'5T:79E
M+"!I;B!T:&]U<V%N9',Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C
M96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!4
M86)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@
M("`\=&0@=VED=&@],T0W-B4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX]
M,T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CY4:')E92!A;F0@3FEN92!-;VYT
M:',@($5N9&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI
M9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$P
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M3W!T:6]N<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL-"B`@(#PO9&EV/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^."PX,#(\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C<L.3$U/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/E5N=F5S=&5D(')E<W1R:6-T960@8V]M;6]N('-T;V-K#0H@
M("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C,U
M-3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A
M8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C
M,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XY+#$U-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-RPY,34\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@
M("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R
M+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$R<'0G/CQB/CQI/E)E<W1R:6-T960@4W1O8VL@07=A<F1S/"]I/CPO
M8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H92!F86ER('9A;'5E(&]F(')E<W1R:6-T
M960@<W1O8VL@87=A<F1S(&=R86YT960@=&\@96UP;&]Y965S(&ES(&)A<V5D
M('5P;VX@=&AE('%U;W1E9`T*("`@8VQO<VEN9R!M87)K970@<')I8V4@<&5R
M('-H87)E(&]N('1H92!D871E(&]F(&=R86YT+"!A9&IU<W1E9"!F;W(@87-S
M=6UE9"!F;W)F96ET=7)E<RX@1F]R#0H@("!P97)F;W)M86YC92UB87-E9"!R
M97-T<FEC=&5D('-T;V-K(&%W87)D<RP@=&AE('9A;'5E(&]F('1H92!A=V%R
M9',@:7,@;65A<W5R960@=VAE;B!T:&4@0V]M<&%N>0T*("`@9&5T97)M:6YE
M<R!T:&4@86-H:65V96UE;G0@;V8@<W5C:"!P97)F;W)M86YC92!C;VYD:71I
M;VYS(&ES(&1E96UE9"!P<F]B86)L92X@17AP96YS92!I<PT*("`@<F5C;V=N
M:7IE9"!O=F5R('1H92!V97-T:6YG('!E<FEO9"P@8V]M;65N8VEN9R!W:&5N
M('1H92!#;VUP86YY(&1E=&5R;6EN97,@=&AA="!I="!I<R!P<F]B86)L92!T
M:&%T#0H@("!T:&4@87=A<F1S('=I;&P@=F5S="X@26X@36%Y)B,Q-C`[,C`Q
M,2P@=&AE($-O;7!A;GD-"B`@(&=R86YT960@86X@86=G<F5G871E(&]F(#(R
M.2PX,#8@<VAA<F5S(&]F('!E<F9O<FUA;F-E+6)A<V5D(')E<W1R:6-T960@
M<W1O8VL@87=A<F1S('1O(&ET<PT*("`@96UP;&]Y965S+"!E>&-L=61I;F<@
M=&AE($-O;7!A;GDF(S@R,3<[<R!L96%D97)S:&EP('1E86TN(%1H97-E(')E
M<W1R:6-T960@<W1O8VL@87=A<F1S('=E<F4@=F%L=65D(&%T#0H@("`F;F)S
M<#LD,BXS)B,Q-C`[;6EL;&EO;B!O;B!T:&4@9W)A;G0@9&%T92!A;F0@:&%V
M92!A('1E<FT@;V8@9FEV92!Y96%R<RX@5&AE('9E<W1I;F<@;V8@=&AE<V4@
M87=A<F1S(&ES#0H@("!P<F5D:6-A=&5D(&]N('1H92!#;VUP86YY)B,X,C$W
M.W,@86-H:65V96UE;G0@;V8@8V5R=&%I;B!C;&EN:6-A;"!D979E;&]P;65N
M="!G;V%L<RX@1F]R('1H92!T:')E92!A;F0-"B`@(&YI;F4@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!R96-O
M<F1E9"`F;F)S<#LD,"XT)B,Q-C`[;6EL;&EO;B!A;F0@)FYB<W`[)#`N-R8C
M,38P.VUI;&QI;VXL#0H@("!R97-P96-T:79E;'DL(&]F('-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=&AE<V4@<F5S=')I
M8W1E9"!S=&]C:R!A=V%R9',N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3)P="<^/&(^/&D^1F%I<B!686QU92!-96%S=7)E;65N=',\+VD^/"]B/@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[5&AE(&9O;&QO=VEN9R!T86)L97,@<')E<V5N="!I
M;F9O<FUA=&EO;B!A8F]U="!T:&4@0V]M<&%N>28C.#(Q-SMS(&%S<V5T<R!T
M:&%T(&%R92!M96%S=7)E9"!A="!F86ER#0H@("!V86QU92!O;B!A(')E8W5R
M<FEN9R!B87-I<R!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,2!A;F0@1&5C
M96UB97(F(S$V,#LS,2P@,C`Q,"P@86YD(&EN9&EC871E('1H92!F86ER('9A
M;'5E#0H@("!H:65R87)C:'D@;V8@=&AE('9A;'5A=&EO;B!T96-H;FEQ=65S
M('1H92!#;VUP86YY('5T:6QI>F5D('1O(&1E=&5R;6EN92!S=6-H(&9A:7(@
M=F%L=64N($EN#0H@("!G96YE<F%L+"!F86ER('9A;'5E<R!D971E<FUI;F5D
M(&)Y($QE=F5L(#$@:6YP=71S('5T:6QI>F4@<75O=&5D('!R:6-E<R`H=6YA
M9&IU<W1E9"DF(S$V,#MI;B!A8W1I=F4-"B`@(&UA<FME=',@9F]R(&ED96YT
M:6-A;"!A<W-E=',@;W(@;&EA8FEL:71I97,N($9A:7(@=F%L=65S(&1E=&5R
M;6EN960@8GD@3&5V96P@,B!I;G!U=',@=71I;&EZ92!D871A#0H@("!P;VEN
M=',@=&AA="!A<F4@;V)S97)V86)L92P@<W5C:"!A<R!Q=6]T960@<')I8V5S
M("AA9&IU<W1E9"DL(&EN=&5R97-T(')A=&5S(&%N9"!Y:65L9"!C=7)V97,N
M($9A:7(-"B`@('9A;'5E<R!D971E<FUI;F5D(&)Y($QE=F5L(#,@:6YP=71S
M('5T:6QI>F4@=6YO8G-E<G9A8FQE(&1A=&$@<&]I;G1S(&9O<B!T:&4@87-S
M970@;W(@;&EA8FEL:71Y+`T*("`@86YD(&EN8VQU9&4@<VET=6%T:6]N<R!W
M:&5R92!T:&5R92!I<R!L:71T;&4L(&EF(&%N>2P@;6%R:V5T(&%C=&EV:71Y
M(&9O<B!T:&4@87-S970@;W(@;&EA8FEL:71Y+@T*("`@1FEN86YC:6%L(&%S
M<V5T<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A
M<VES(&%R92!S=6UM87)I>F5D(&%S(&9O;&QO=W,L(&EN#0H@("!T:&]U<V%N
M9',Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`\
M=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED=&@]
M,T0U,B4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#(^/&(^070\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQB/E%U;W1E9"!0<FEC97,@:6X\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQB/E-I9VYI9FEC86YT/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY3:6=N
M:69I8V%N=#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^4V5P=&5M8F5R(#,P+#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^06-T:79E($UA<FME=',\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQB/D]B<V5R=F%B;&4@26YP=71S/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY5;F]B<V5R=F%B;&4@26YP=71S/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D1E<V-R:7!T:6]N
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^
M,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/BA,979E;"`Q*3PO8CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O
M;&ED(",P,#`P,#`G/CQB/BA,979E;"`R*3PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/BA,979E;"`S*3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\
M(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT
M9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D-A<V@@97%U:79A;&5N=',-"B`@(#PO9&EV/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XV
M-RPU,34\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[
M)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-3DL-3$W/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C<L.3DX/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^36%R:V5T86)L92!S96-U<FET:65S("AF:7AE9"!I
M;F-O;64I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HS,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M0V]R<&]R871E(&YO=&5S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C$P."PV-CD\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C$P."PV-CD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HS,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^52Y3+B!'
M;W9E<FYM96YT(&]B;&EG871I;VYS#0H@("`\+V1I=CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C@Q+#(X-SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X
M,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^.#$L,C@W/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,S!P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-O;6UE<F-I86P@<&%P97(-
M"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,C$L,3DW/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR,2PQ
M.3<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^36%R:V5T86)L92!S96-U<FET:65S("AE
M<75I='D@:&]L9&EN9W,I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C<U,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^-S4P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P
M.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C,P<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY4;W1A;`T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C(W.2PT,3@\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^-3DL-3$W/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C(Q.2PY,#$\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB
M<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`\=&%B;&4@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL
M<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R
M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED=&@],T0U,B4^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(^/&(^070\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E%U
M;W1E9"!0<FEC97,@:6X\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E-I9VYI
M9FEC86YT/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY3:6=N:69I8V%N=#PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(^/&(^1&5C96UB97(@,S$L(#PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#(^/&(^06-T:79E($UA<FME=',\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQB/D]B<V5R=F%B;&4@26YP=71S/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\8CY5;F]B<V5R=F%B;&4@26YP=71S/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D1E<V-R:7!T:6]N/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/BA,979E;"`Q*3PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P
M,#`G/CQB/BA,979E;"`R*3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/BA,979E
M;"`S*3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD
M:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U
M<'@G/D-A<V@@97%U:79A;&5N=',-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S
M<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU.2PW,#(\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-#`L-C@V/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C$Y+#`Q-CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z
M+3$U<'@G/DUA<FME=&%B;&4@<V5C=7)I=&EE<R`H9FEX960@:6YC;VUE*0T*
M("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U
M;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,S!P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-O<G!O<F%T
M92!N;W1E<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XQ,S,L,S0Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XQ,S,L,S0Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,S!P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E4N4RX@1V]V97)N;65N
M="!O8FQI9V%T:6]N<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XQ,C(L,C<S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XQ,C(L,C<S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*
M("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,S!P
M>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-O;6UE<F-I86P@<&%P97(-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3<L-S,S
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ-RPW,S,\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^36%R:V5T86)L92!S96-U<FET:65S("AE<75I='D@
M:&]L9&EN9W,I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C$L.34X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XQ+#DU.#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-
M"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HS,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M5&]T86P-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XS,S4L,#`W/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C0P+#8X-CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR
M.30L,S(Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(F(S$V,#LS,"P@,C`Q,2P@=&AE<F4@=V5R92!N;R!T<F%N<V9E<G,@8F5T
M=V5E;B!,979E;"`Q(&%N9`T*("`@3&5V96P@,B!F:6YA;F-I86P@87-S971S
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M('1O('1H96ER('-H;W)T+71E<FT@;6%T=7)I=&EE<RX-"B`@(#PO9&EV/@T*
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,G!T)SX\8CX\:3Y);G9E<W1M96YT<R!I;B!-87)K
M971A8FQE(%-E8W5R:71I97,\+VD^/"]B/@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE
M($-O;7!A;GD@:6YV97-T<R!I=',@97AC97-S(&-A<V@@8F%L86YC97,@:6X@
M<VAO<G0M=&5R;2!A;F0@;&]N9RUT97)M(&UA<FME=&%B;&4@9&5B="!A;F0-
M"B`@(&5Q=6ET>2!S96-U<FET:65S+B!4:&4@0V]M<&%N>2!C;&%S<VEF:65S
M(&ET<R!I;G9E<W1M96YT<R!I;B!M87)K971A8FQE(&1E8G0@<V5C=7)I=&EE
M<R!A<R!E:71H97(-"B`@(&AE;&0M=&\M;6%T=7)I='D@;W(@879A:6QA8FQE
M+69O<BUS86QE(&)A<V5D(&]N(&9A8W1S(&%N9"!C:7)C=6US=&%N8V5S('!R
M97-E;G0@870@=&AE('1I;64@:70-"B`@('!U<F-H87-E9"!T:&4@<V5C=7)I
M=&EE<RX@070@96%C:"!B86QA;F-E('-H965T(&1A=&4@<')E<V5N=&5D+"!T
M:&4@0V]M<&%N>2!C;&%S<VEF:65D(&%L;"!O9B!I=',-"B`@(&EN=F5S=&UE
M;G1S(&EN(&1E8G0@86YD(&5Q=6ET>2!S96-U<FET:65S(&%S(&%V86EL86)L
M92UF;W(M<V%L92X@5&AE($-O;7!A;GD@<F5P;W)T<PT*("`@879A:6QA8FQE
M+69O<BUS86QE(&EN=F5S=&UE;G1S(&%T(&9A:7(@=F%L=64@870@96%C:"!B
M86QA;F-E('-H965T(&1A=&4@86YD(&EN8VQU9&5S(&%N>2!U;G)E86QI>F5D
M#0H@("!H;VQD:6YG(&=A:6YS(&%N9"!L;W-S97,@*'1H92!A9&IU<W1M96YT
M('1O(&9A:7(@=F%L=64I(&EN('-T;V-K:&]L9&5R<R8C.#(Q-SL@97%U:71Y
M+B!296%L:7IE9"!G86EN<R!A;F0-"B`@(&QO<W-E<R!A<F4@9&5T97)M:6YE
M9"!U<VEN9R!T:&4@<W!E8VEF:6,@:61E;G1I9FEC871I;VX@;65T:&]D(&%N
M9"!A<F4@:6YC;'5D960@:6X@;W1H97(@:6YC;VUE+B!)9@T*("`@86YY(&%D
M:G5S=&UE;G0@=&\@9F%I<B!V86QU92!R969L96-T<R!A(&1E8VQI;F4@:6X@
M=&AE('9A;'5E(&]F('1H92!I;G9E<W1M96YT+"!T:&4@0V]M<&%N>0T*("`@
M8V]N<VED97)S(&%L;"!A=F%I;&%B;&4@979I9&5N8V4@=&\@979A;'5A=&4@
M=&AE(&5X=&5N="!T;R!W:&EC:"!T:&4@9&5C;&EN92!I<R`F(S@R,C`[;W1H
M97(@=&AA;@T*("`@=&5M<&]R87)Y)B,X,C(Q.R!A;F0L(&EF('-O+"!M87)K
M<R!T:&4@:6YV97-T;65N="!T;R!M87)K970@=&AR;W5G:"!A(&-H87)G92!T
M;R!I=',@8V]N9&5N<V5D#0H@("!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O
M9B!O<&5R871I;VYS+B!4:&4@0V]M<&%N>2!D:60@;F]T(')E8V]R9"!A;GD@
M:6UP86ER;65N="!C:&%R9V5S(')E;&%T960@=&\-"B`@(&ET<R!F:7AE9"!I
M;F-O;64@;6%R:V5T86)L92!S96-U<FET:65S(&1U<FEN9R!T:&4@8W5R<F5N
M="!P97)I;V0N($1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS#0H@
M("!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@=&AE($-O;7!A;GD@
M<F5C;W)D960@86X@:6UP86ER;65N="!C:&%R9V4@;V8@)FYB<W`[)#`N-B8C
M,38P.VUI;&QI;VX@<F5L871E9"!T;R!I=',-"B`@(&EN=F5S=&UE;G0@:6X@
M97%U:71Y('-E8W5R:71I97,@;V8@5&5K;6ER82!0:&%R;6%C975T:6-A;',@
M0V]R<&]R871I;VX@*"8C.#(R,#M496MM:7)A)B,X,C(Q.RDL(&%S('1H90T*
M("`@9&5C<F5A<V4@:6X@=&AE(&9A:7(-"B`@('9A;'5E(&]F('1H:7,@:6YV
M97-T;65N="!W87,@9&5E;65D('1O(&)E(&]T:&5R('1H86X@=&5M<&]R87)Y
M+B!4:&4@0V]M<&%N>28C.#(Q-SMS(&UA<FME=&%B;&4-"B`@('-E8W5R:71I
M97,@87)E(&-L87-S:69I960@87,@8V%S:"!E<75I=F%L96YT<R!I9B!T:&4@
M;W)I9VEN86P@;6%T=7)I='DL(&9R;VT@=&AE(&1A=&4@;V8@<'5R8VAA<V4L
M#0H@("!I<R`Y,"8C,38P.V1A>7,@;W(@;&5S<RP@86YD(&%S(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<R!I9B!T:&4@;W)I9VEN86P@;6%T=7)I='DL(&9R;VT@
M=&AE(&1A=&4@;V8-"B`@('!U<F-H87-E+"!I<R!I;B!E>&-E<W,@;V8@.3`F
M(S$V,#MD87ES+B!4:&4@0V]M<&%N>28C.#(Q-SMS(&-A<V@@97%U:79A;&5N
M=',@87)E(&-O;7!O<V5D(&]F(&UO;F5Y(&UA<FME=`T*("`@9G5N9',L(%4N
M4RX@9V]V97)N;65N="!O8FQI9V%T:6]N<R!A;F0@8V]M;65R8VEA;"!P87!E
M<BX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H92!F;VQL;W=I;F<@=&%B;&5S('-U;6UA
M<FEZ92!T:&4@0V]M<&%N>28C.#(Q-SMS(&UA<FME=&%B;&4@<V5C=7)I=&EE
M<R!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,2!A;F0-"B`@($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3`L(&EN('1H;W5S86YD<SH-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$
M,"!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9"!W:61T:#TS1#4R)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,30@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/E-E<'1E;6)E<B`S,"P@,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^
M/&(^1W)O<W,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D=R;W-S/"]B/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^06UO<G1I
M>F5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY5;G)E86QI>F5D/"]B/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,CX\8CY5;G)E86QI>F5D/"]B/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D-O<W0\+V(^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C
M,#`P,#`P)SX\8CY'86EN<SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DQO<W-E
M<SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D9A:7(@5F%L=64\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#;VUM97)C:6%L
M('!A<&5R("A$=64@=VET:&EN(#$F(S$V,#MY96%R*0T*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C(Q+#$Y.#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S
M<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF;F)S
M<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XH,CPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(Q+#$Y-SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#;W)P;W)A=&4@
M;F]T97,@*$1U92!W:71H:6X@,28C,38P.WEE87(I#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4R+#$X,SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,C,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^*#(V/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4R+#$X,#PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-
M"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#;W)P;W)A=&4@;F]T97,@*$1U92!A
M9G1E<B`Q)B,Q-C`[>65A<B!T:')O=6=H(#(F(S$V,#MY96%R<RD-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-38L-C`W
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XR,3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XH,3,Y/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4V
M+#0X.3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY5+E,N($=O=F5R;FUE;G0@;V)L:6=A=&EO;G,@*$1U92!W:71H:6X@,28C
M,38P.WEE87(I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C(U+#,P-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-3PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XH,3PO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XR-2PS,#@\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M52Y3+B!';W9E<FYM96YT(&]B;&EG871I;VYS("A$=64@869T97(@,28C,38P
M.WEE87(@=&AR;W5G:"`R)B,Q-C`[>65A<G,I#0H@("`\+V1I=CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4V+#`Q,CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XH,S<\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-34L.3<Y/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5Q=6ET>2!S96-U
M<FET:65S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C<U,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^-S4P/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D
M:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O
M=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C,P<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY4;W1A;`T*
M("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C(Q,BPP-30\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^-30\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/B@R,#4\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XR,3$L.3`S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@
M(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!W:61T
M:#TS1#4R)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX]
M,T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D1E8V5M8F5R(#,Q+"`R,#$P/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY'<F]S<SPO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(^/&(^1W)O<W,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY!;6]R=&EZ960\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQB/E5N<F5A;&EZ960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E5N<F5A
M;&EZ960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M/&(^0V]S=#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D=A:6YS/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^/&(^3&]S<V5S/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^
M1F%I<B!686QU93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/D-O;6UE<F-I86P@<&%P97(@*$1U92!W:71H:6X@,28C,38P
M.WEE87(I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,3<L-S,T/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C(\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B@S/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,3<L-S,S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/D-O<G!O<F%T92!N;W1E<R`H1'5E('=I=&AI;B`Q)B,Q-C`[
M>65A<BD-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,3$V+#,X-3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,C`T/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@R,SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XQ,38L-38V/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/D-O<G!O<F%T92!N;W1E<R`H1'5E(&%F=&5R(#$F(S$V,#MY96%R('1H<F]U
M9V@@,B8C,38P.WEE87)S*0T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XQ-BPW-C<\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C,S/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@R-3PO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ-BPW-S4\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^52Y3+B!';W9E<FYM96YT(&]B;&EG
M871I;VYS("A$=64@=VET:&EN(#$F(S$V,#MY96%R*0T*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR-"PR-#8\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C$\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^*#$T/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(T+#(S,SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-
M"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY5+E,N($=O=F5R;FUE;G0@;V)L:6=A
M=&EO;G,@*$1U92!A9G1E<B`Q)B,Q-C`[>65A<B!T:')O=6=H(#(F(S$V,#MY
M96%R<RD-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^.3@L,3$Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR,CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XH.3,\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^.3@L,#0P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D5Q=6ET>2!S96-U<FET:65S#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L,S0U/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XV,3,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L
M.34X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@
M("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C,P<'@[('1E
M>'0M:6YD96YT.BTQ-7!X)SY4;W1A;`T*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(W-"PU.#@\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^.#<U/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XH,34X/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,C<U+#,P-3PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V
M,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI
M9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%
M;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3)P="<^/&(^/&D^4W5B<V5Q=65N="!%=F5N=',\+VD^
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@979A;'5A=&5D(&%L
M;"!E=F5N=',@;W(@=')A;G-A8W1I;VYS('1H870@;V-C=7)R960@869T97(@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$-"B`@('1H<F]U9V@@=&AE(&1A=&4@
M=&AE<V4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!W97)E(&ES<W5E9"X@1'5R:6YG('1H:7,@<&5R:6]D+`T*("`@=&AE
M($-O;7!A;GD@9&ED(&YO="!H879E(&%N>2!M871E<FEA;"!R96-O9VYI>F5D
M(&]R(&YO;G)E8V]G;FEZ960@<W5B<V5Q=65N="!E=F5N=',N(`T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$R<'0G/CQB/CQI/E)E8V5N="!!8V-O=6YT
M:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO8CX-"B`@(#PO9&EV/@T*("`@/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN
M($IA;G5A<GDF(S$V,#LR,#$Q+"!T:&4@0V]M<&%N>2!A9&]P=&5D(&YE=R!A
M=71H;W)I=&%T:79E(&=U:61A;F-E(&]N(')E=F5N=64@<F5C;V=N:71I;VX@
M9F]R#0H@("!M=6QT:7!L92!E;&5M96YT(&%R<F%N9V5M96YT<RX@5&AE(&=U
M:61A;F-E+"!W:&EC:"!A<'!L:65S('1O(&UU;'1I<&QE(&5L96UE;G0@87)R
M86YG96UE;G1S(&5N=&5R960-"B`@(&EN=&\@;W(@;6%T97)I86QL>2!M;V1I
M9FEE9"!O;B!O<B!A9G1E<B!*86YU87)Y)B,Q-C`[,2P@,C`Q,2P@86UE;F1S
M('1H92!C<FET97)I82!F;W(@<V5P87)A=&EN9R!A;F0-"B`@(&%L;&]C871I
M;F<@8V]N<VED97)A=&EO;B!I;B!A(&UU;'1I<&QE(&5L96UE;G0@87)R86YG
M96UE;G0@8GD@;6]D:69Y:6YG('1H92!F86ER('9A;'5E(')E<75I<F5M96YT
M<PT*("`@9F]R(')E=F5N=64@<F5C;V=N:71I;VX@86YD(&5L:6UI;F%T:6YG
M('1H92!U<V4@;V8@=&AE(')E<VED=6%L(&UE=&AO9"X@5&AE(&9A:7(@=F%L
M=64@;V8-"B`@(&1E;&EV97)A8FQE<R!U;F1E<B!T:&4@87)R86YG96UE;G0@
M;6%Y(&)E(&1E<FEV960@=7-I;F<@82`F(S@R,C`[8F5S="!E<W1I;6%T92!O
M9B!S96QL:6YG('!R:6-E)B,X,C(Q.R!I9@T*("`@=F5N9&]R('-P96-I9FEC
M(&]B:F5C=&EV92!E=FED96YC92!A;F0@=&AI<F0M<&%R='D@979I9&5N8V4@
M:7,@;F]T(&%V86EL86)L92X@1&5L:79E<F%B;&5S('5N9&5R#0H@("!T:&4@
M87)R86YG96UE;G0@=VEL;"!B92!S97!A<F%T92!U;FET<R!O9B!A8V-O=6YT
M:6YG('!R;W9I9&5D("AI*28C,38P.V$@9&5L:79E<F5D(&ET96T@:&%S('9A
M;'5E('1O('1H90T*("`@8W5S=&]M97(@;VX@82!S=&%N9&%L;VYE(&)A<VES
M.R!A;F0@*&EI*28C,38P.VEF('1H92!A<G)A;F=E;65N="!I;F-L=61E<R!A
M(&=E;F5R86P@<FEG:'0@;V8@<F5T=7)N#0H@("!R96QA=&EV92!T;R!T:&4@
M9&5L:79E<F5D(&ET96TL(&1E;&EV97)Y(&]R('!E<F9O<FUA;F-E(&]F('1H
M92!U;F1E;&EV97)E9"!I=&5M(&ES(&-O;G-I9&5R960-"B`@('!R;V)A8FQE
M(&%N9"!S=6)S=&%N=&EA;&QY(&EN('1H92!C;VYT<F]L(&]F('1H92!V96YD
M;W(N(%1H92!#;VUP86YY(&1I9"!N;W0@96YT97(@:6YT;R!A;GD-"B`@('-I
M9VYI9FEC86YT(&UU;'1I<&QE(&5L96UE;G0@87)R86YG96UE;G1S(&]R(&UA
M=&5R:6%L;'D@;6]D:69Y(&%N>2!E>&ES=&EN9R!M=6QT:7!L92!E;&5M96YT
M#0H@("!A<G)A;F=E;65N=',@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2X@5&AE($-O;7!A;GDF(S@R,3<[
M<R!E>&ES=&EN9R!L:6-E;G-E(&%N9`T*("`@8V]L;&%B;W)A=&EO;B!A9W)E
M96UE;G1S(&-O;G1I;G5E('1O(&)E(&%C8V]U;G1E9"!F;W(@=6YD97(@<')E
M=FEO=7-L>2!I<W-U960@<F5V96YU92!R96-O9VYI=&EO;@T*("`@9W5I9&%N
M8V4@9F]R(&UU;'1I<&QE(&5L96UE;G0@87)R86YG96UE;G1S+@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[26X@2F%N=6%R>28C,38P.S(P,3$L('1H92!#;VUP86YY(&%D
M;W!T960@;F5W(&%U=&AO<FET871I=F4@9W5I9&%N8V4@;VX@<F5V96YU92!R
M96-O9VYI=&EO;B!F;W(-"B`@(&UI;&5S=&]N92!P87EM96YT<R!R96QA=&5D
M('1O(&%R<F%N9V5M96YT<R!U;F1E<B!W:&EC:"!T:&4@0V]M<&%N>2!H87,@
M8V]N=&EN=6EN9R!P97)F;W)M86YC90T*("`@;V)L:6=A=&EO;G,N($-O;G-I
M9&5R871I;VX@9F]R(&5V96YT<R!T:&%T(&UE970@=&AE(&1E9FEN:71I;VX@
M;V8@82!M:6QE<W1O;F4@:6X@86-C;W)D86YC92!W:71H#0H@("!T:&4@86-C
M;W5N=&EN9R!G=6ED86YC92!F;W(@=&AE(&UI;&5S=&]N92!M971H;V0@;V8@
M<F5V96YU92!R96-O9VYI=&EO;B!I<R!R96-O9VYI>F5D(&%S(')E=F5N=64@
M:6X-"B`@(&ET<R!E;G1I<F5T>2!I;B!T:&4@<&5R:6]D(&EN('=H:6-H('1H
M92!M:6QE<W1O;F4@:7,@86-H:65V960@;VYL>2!I9B!A;&P@;V8@=&AE(&9O
M;&QO=VEN9PT*("`@8V]N9&ET:6]N<R!A<F4@;65T.B`H:2DF(S$V,#MT:&4@
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M:2DF(S$V,#MT:&4-"B`@(&-O;G-I9&5R871I;VX@<F5L871E<R!S;VQE;'D@
M=&\@<&%S="!P97)F;W)M86YC93L@86YD("AI:6DI)B,Q-C`[=&AE(&%M;W5N
M="!O9B!T:&4@;6EL97-T;VYE#0H@("!C;VYS:61E<F%T:6]N(&ES(')E87-O
M;F%B;&4@<F5L871I=F4@=&\@86QL(&]F('1H92!D96QI=F5R86)L97,@86YD
M('!A>6UE;G0@=&5R;7,L(&EN8VQU9&EN9R!O=&AE<@T*("`@<&]T96YT:6%L
M(&UI;&5S=&]N92!C;VYS:61E<F%T:6]N+"!W:71H:6X@=&AE(&%R<F%N9V5M
M96YT+B!/=&AE<G=I<V4L('1H92!M:6QE<W1O;F4@<&%Y;65N=',@87)E#0H@
M("!N;W0@8V]N<VED97)E9"!T;R!B92!S=6)S=&%N=&EV92!A;F0@87)E(&1E
M9F5R<F5D(&%N9"!R96-O9VYI>F5D(&%S(')E=F5N=64@;W9E<B!T:&4@=&5R
M;0T*("`@;V8@=&AE(&%R<F%N9V5M96YT(&%S('1H92!#;VUP86YY#0H@("!C
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M(&YE=R!R979E;G5E(')E8V]G;FET:6]N(&=U:61A;F-E(&9O<@T*("`@;6EL
M97-T;VYE('!A>6UE;G1S+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@36%Y)B,Q-C`[
M,C`Q,2P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R
M9"`H)B,X,C(P.T9!4T(F(S@R,C$[*2!I<W-U960@82!N97<@86-C;W5N=&EN
M9PT*("`@<W1A;F1A<F0@=&AA="!C;&%R:69I97,@=&AE(&%P<&QI8V%T:6]N
M(&]F(&-E<G1A:6X@97AI<W1I;F<@9F%I<B!V86QU92!M96%S=7)E;65N="!G
M=6ED86YC92!A;F0-"B`@(&5X<&%N9',@=&AE(&1I<V-L;W-U<F5S(&9O<B!F
M86ER('9A;'5E(&UE87-U<F5M96YT<R!T:&%T(&%R92!E<W1I;6%T960@=7-I
M;F<@<VEG;FEF:6-A;G0-"B`@('5N;V)S97)V86)L92`H3&5V96P@,RD@:6YP
M=71S+B!4:&ES(&YE=R!S=&%N9&%R9"!I<R!E9F9E8W1I=F4@;VX@82!P<F]S
M<&5C=&EV92!B87-I<R!F;W(@86YN=6%L(&%N9`T*("`@:6YT97)I;2!R97!O
M<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@;VX@;W(@869T97(@1&5C96UB97(F
M(S$V,#LQ-2P@,C`Q,2X@5&AE($-O;7!A;GD@9&]E<R!N;W0@97AP96-T('1H
M870-"B`@(&%D;W!T:6]N(&]F('1H:7,@;F5W('-T86YD87)D('=I;&P@:&%V
M92!A(&UA=&5R:6%L(&EM<&%C="!O;B!I=',@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P-"B`@('-T871E;65N=',N#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M);B!*=6YE)B,Q-C`[,C`Q,2P@=&AE($9!4T(@:7-S=65D(&%N(&%M96YD
M;65N="!T;R!T:&4@86-C;W5N=&EN9R!G=6ED86YC92!F;W(@<')E<V5N=&%T
M:6]N(&]F#0H@("!C;VUP<F5H96YS:79E(&EN8V]M92X@56YD97(@=&AE(&%M
M96YD960@9W5I9&%N8V4L(&$@8V]M<&%N>2!M87D@<')E<V5N="!T:&4@=&]T
M86P@;V8@8V]M<')E:&5N<VEV90T*("`@:6YC;VUE+"!T:&4@8V]M<&]N96YT
M<R!O9B!N970@:6YC;VUE(&%N9"!T:&4@8V]M<&]N96YT<R!O9B!O=&AE<B!C
M;VUP<F5H96YS:79E(&EN8V]M92!E:71H97(@:6X@80T*("`@<VEN9VQE(&-O
M;G1I;G5O=7,@<W1A=&5M96YT(&]F(&-O;7!R96AE;G-I=F4@:6YC;VUE(&]R
M(&EN('1W;R!S97!A<F%T92!B=70@8V]N<V5C=71I=F4@<W1A=&5M96YT<RX-
M"B`@($EN(&5I=&AE<B!C87-E+"!A(&-O;7!A;GD@:7,@<F5Q=6ER960@=&\@
M<')E<V5N="!E86-H(&-O;7!O;F5N="!O9B!N970@:6YC;VUE(&%L;VYG('=I
M=&@@=&]T86P@;F5T#0H@("!I;F-O;64L(&5A8V@@8V]M<&]N96YT(&]F(&]T
M:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE(&%L;VYG('=I=&@@82!T;W1A;"!F
M;W(@;W1H97(@8V]M<')E:&5N<VEV90T*("`@:6YC;VUE(&%N9"!A('1O=&%L
M(&%M;W5N="!F;W(@8V]M<')E:&5N<VEV92!I;F-O;64N(`T*("`@1F]R('!U
M8FQI8R!C;VUP86YI97,L('1H92!A;65N9&UE;G0@:7,@969F96-T:79E(&9O
M<B!F:7-C86P@>65A<G,L(&%N9"!I;G1E<FEM('!E<FEO9',@=VET:&EN('1H
M;W-E#0H@("!Y96%R<RP@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R)B,Q-C`[
M,34L(#(P,3$L(&%N9"!S:&%L;"!B92!A<'!L:65D(')E=')O<W!E8W1I=F5L
M>2X@16%R;'D@861O<'1I;VX@:7,-"B`@('!E<FUI='1E9"X@3W1H97(@=&AA
M;B!A(&-H86YG92!I;B!P<F5S96YT871I;VXL('1H92!A9&]P=&EO;B!O9B!T
M:&ES(&%M96YD;65N="!I<R!N;W0@97AP96-T960@=&\@:&%V90T*("`@82!M
M871E<FEA;"!I;7!A8W0@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VYD96YS
M960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+@T*("`@/"]D
M:78^#0H@("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q-68Q
M-V0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8V-S$W9F0U7V0T
M,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D.2]7;W)K<VAE971S+U-H965T,#<N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:6=N
M:69I8V%N="!!9W)E96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06=R965M96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-)1TY)1DE#04Y4($%'4D5%345.5%,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`R("T@
M=7,M9V%A<#I#;VQL86)O<F%T:79E07)R86YG96UE;G1$:7-C;&]S=7)E5&5X
M=$)L;V-K+2T^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68G/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,G!T)SX\8CXR+B!324=.249)0T%.5"!!1U)%14U%3E13
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM
M87)I>F5S('1H92!#;VUP86YY)B,X,C$W.W,@=&]T86P@8V]N<V]L:61A=&5D
M(&YE="!R979E;G5E<R!F<F]M(')E<V5A<F-H#0H@("!C;VQL86)O<F%T;W)S
M+"!F;W(@=&AE('!E<FEO9',@:6YD:6-A=&5D+"!I;B!T:&]U<V%N9',Z#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`\=&%B;&4@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C
M96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED=&@],T0U,B4^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W
M:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#8^/&(^5&AR964@36]N=&AS($5N9&5D/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$-CX\8CY.:6YE($UO;G1H<R!%;F1E9#PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P
M,#`G/CQB/E-E<'1E;6)E<B`S,"P\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY3
M97!T96UB97(@,S`L/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)R!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E)O8VAE#0H@("`\+V1I=CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,3,L.3DU/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$S+#DY-3PO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT,2PY.#,\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^-#$L.3@S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@
M=&5X="UI;F1E;G0Z+3$U<'@G/E1A:V5D80T*("`@/"]D:78^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU+#0Y-#PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M-2PU-38\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C$V+#<U-3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,38L-#<Y
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DYO=F%R=&ES#0H@("`\+V1I
M=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$U/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XS+#DX-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3,S/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XX
M+#DU-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY/=&AE<@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XQ+#(X-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-"PQ,S,\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C,L-#,Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ,2PT,S`\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\
M+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI
M9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG
M<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,S!P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E1O=&%L
M(&YE="!R979E;G5E<R!F<F]M(')E<V5A<F-H(&-O;&QA8F]R871O<G,-"B`@
M(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XR,"PW.3$\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,C<L-C8X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C8R+#,P,CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XW."PX-#D\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@
M("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R
M+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A
M8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$R<'0G/CQB/CQI/E!L871F;W)M($%L;&EA;F-E<SPO:3X\+V(^
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SX\:3Y2;V-H92!!;&QI
M86YC93PO:3X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN($IU;'DF(S$V,#LR,#`W+"!T
M:&4@0V]M<&%N>2!A;F0L(&9O<B!L:6UI=&5D('!U<G!O<V5S+"!!;&YY;&%M
M($5U<F]P92P@96YT97)E9"!I;G1O(&$@;&EC96YS90T*("`@86YD(&-O;&QA
M8F]R871I;VX@86=R965M96YT("AT:&4@)B,X,C(P.TQ#028C.#(R,3LI('=I
M=&@@1BX@2&]F9FUA;FXM3&$@4F]C:&4@3'1D("@F(S@R,C`[4F]C:&4@0F%S
M96PF(S@R,C$[*2!A;F0-"B`@($AO9F9M86YN+4QA(%)O8VAE($EN8RX@*'1O
M9V5T:&5R('=I=&@@4F]C:&4@0F%S96PL("8C.#(R,#M2;V-H928C.#(R,3LI
M+B!5;F1E<B!T:&4@3$-!+"!W:&EC:"!B96-A;64@969F96-T:79E#0H@("!I
M;B!!=6=U<W0F(S$V,#LR,#`W+"!T:&4@0V]M<&%N>2!G<F%N=&5D(%)O8VAE
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M;VX@=&AR;W5G:"!23D$@:6YT97)F97)E;F-E("@F(S@R,C`[4DY!:28C.#(R
M,3LI+`T*("`@<W5B:F5C="!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&5X:7-T
M:6YG(&-O;G1R86-T=6%L(&]B;&EG871I;VYS('1O('1H:7)D('!A<G1I97,N
M(%1H92!L:6-E;G-E(&ES#0H@("!I;FET:6%L;'D@;&EM:71E9"!T;R!F;W5R
M('1H97)A<&5U=&EC(&%R96%S+"!A;F0@;6%Y(&)E(&5X<&%N9&5D('1O(&EN
M8VQU9&4@=7`@=&\@,3@@861D:71I;VYA;`T*("`@=&AE<F%P975T:6,@87)E
M87,L(&-O;7!R:7-I;F<@<W5B<W1A;G1I86QL>2!A;&P@;W1H97(@9FEE;&1S
M(&]F(&AU;6%N(&1I<V5A<V4L(&%S(&ED96YT:69I960@86YD#0H@("!A9W)E
M960@=7!O;B!B>2!T:&4@<&%R=&EE<RP@=7!O;B!P87EM96YT('1O('1H92!#
M;VUP86YY(&)Y(%)O8VAE(&]F(&%N(&%D9&ET:6]N86P@)FYB<W`[)#4P+C`F
M(S$V,#MM:6QL:6]N(&9O<@T*("`@96%C:"!A9&1I=&EO;F%L('1H97)A<&5U
M=&EC(&%R96$L(&EF(&%N>2X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V
M<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN(&-O;G-I9&5R
M871I;VX@9F]R('1H92!R:6=H=',@9W)A;G1E9"!T;R!2;V-H92!U;F1E<B!T
M:&4@3$-!+"!2;V-H92!P86ED('1H92!#;VUP86YY("9N8G-P.R0R-S,N-0T*
M("`@;6EL;&EO;B!I;B!U<&9R;VYT(&-A<V@@<&%Y;65N=',N($EN(&%D9&ET
M:6]N+"!I;B!E>&-H86YG92!F;W(@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VYT
M<FEB=71I;VYS('5N9&5R#0H@("!T:&4@3$-!+"!F;W(@96%C:"!23D%I('1H
M97)A<&5U=&EC('!R;V1U8W0@9&5V96QO<&5D(&)Y(%)O8VAE+"!I=',@869F
M:6QI871E<R!O<B!S=6)L:6-E;G-E97,@=6YD97(-"B`@('1H92!,0T$L('1H
M92!#;VUP86YY(&ES(&5N=&ET;&5D('1O(')E8V5I=F4@;6EL97-T;VYE('!A
M>6UE;G1S('5P;VX@86-H:65V96UE;G0@;V8@<W!E8VEF:65D#0H@("!D979E
M;&]P;65N="!A;F0@<V%L97,@979E;G1S+"!T;W1A;&EN9R!U<"!T;R!A;B!A
M9V=R96=A=&4@;V8@)FYB<W`[)#$P,"XP)B,Q-C`[;6EL;&EO;B!P97(@=&AE
M<F%P975T:6,@=&%R9V5T+`T*("`@=&]G971H97(@=VET:"!R;WEA;'1Y('!A
M>6UE;G1S(&)A<V5D(&]N('=O<FQD=VED92!A;FYU86P@;F5T('-A;&5S+"!I
M9B!A;GDN(%5N9&5R('1H92!,0T$L('1H90T*("`@0V]M<&%N>2!A;F0@4F]C
M:&4@86QS;R!E<W1A8FQI<VAE9"!A(&1I<V-O=F5R>0T*("`@8V]L;&%B;W)A
M=&EO;B!I;B!/8W1O8F5R)B,Q-C`[,C`P.2`H)B,X,C(P.T1I<V-O=F5R>2!#
M;VQL86)O<F%T:6]N)B,X,C(Q.RDL('-U8FIE8W0@=&\@=&AE($-O;7!A;GDF
M(S@R,3<[<R!E>&ES=&EN9PT*("`@8V]N=')A8W1U86P@;V)L:6=A=&EO;G,@
M=&\@=&AI<F0@<&%R=&EE<RX-"B`@(#PO9&EV/@T*("`@/"$M+2!&;VQI;R`M
M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*("`@/"]D:78^#0H@("`\(2TM(%!!
M1T5"4D5!2R`M+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF)SX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);B!*=6QY)B,Q
M-C`[,C`P-RP@=&AE($-O;7!A;GD@97AE8W5T960@82!C;VUM;VX@<W1O8VL@
M<'5R8VAA<V4@86=R965M96YT("AT:&4@)B,X,C(P.T-O;6UO;B!3=&]C:PT*
M("`@4'5R8VAA<V4@06=R965M96YT)B,X,C(Q.RD@=VET:"!2;V-H92!&:6YA
M;F-E($QT9"P@86X@869F:6QI871E(&]F(%)O8VAE+B!);B!C;VYN96-T:6]N
M('=I=&@@=&AE#0H@("!E>&5C=71I;VX@;V8@=&AE($Q#02!A;F0@=&AE($-O
M;6UO;B!3=&]C:R!0=7)C:&%S92!!9W)E96UE;G0L('1H92!#;VUP86YY(&%L
M<V\@97AE8W5T960@82!S:&%R90T*("`@<'5R8VAA<V4@86=R965M96YT("AT
M:&4@)B,X,C(P.T%L;GEL86T@175R;W!E(%!U<F-H87-E($%G<F5E;65N="8C
M.#(R,3LI('=I=&@@06QN>6QA;2!%=7)O<&4@86YD(%)O8VAE#0H@("!"971E
M:6QI9W5N9W,@1VUB2"P@86X@869F:6QI871E(&]F(%)O8VAE("@F(S@R,C`[
M4F]C:&4@1V5R;6%N>28C.#(R,3LI+B!5;F1E<B!T:&4@=&5R;7,@;V8@=&AE
M($%L;GEL86T@175R;W!E#0H@("!0=7)C:&%S92!!9W)E96UE;G0L('1H92!#
M;VUP86YY('-O;&0@<W5B<W1A;G1I86QL>2!A;&P@;V8@=&AE(&YO;BUI;G1E
M;&QE8W1U86P@<')O<&5R='D@87-S971S(&]F#0H@("!!;&YY;&%M($5U<F]P
M92!T;R!2;V-H92!'97)M86YY(&9O<B!A;B!A9V=R96=A=&4@<'5R8VAA<V4@
M<')I8V4@;V8@)FYB<W`[)#$U+C`F(S$V,#MM:6QL:6]N+@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[26X@<W5M;6%R>2P@=&AE($-O;7!A;GD@<F5C96EV960@=7!F<F]N
M="!P87EM96YT<R!T;W1A;&EN9R`F;F)S<#LD,S,Q+C`F(S$V,#MM:6QL:6]N
M('5N9&5R('1H92!2;V-H90T*("`@86QL:6%N8V4L('=H:6-H(&EN8VQU9&4@
M86X@=7!F<F]N="!P87EM96YT('5N9&5R('1H92!,0T$@;V8@)FYB<W`[)#(W
M,RXU)B,Q-C`[;6EL;&EO;BP@)FYB<W`[)#0R+C4F(S$V,#MM:6QL:6]N('5N
M9&5R('1H90T*("`@0V]M;6]N(%-T;V-K(%!U<F-H87-E($%G<F5E;65N="!A
M;F0@)FYB<W`[)#$U+C`F(S$V,#MM:6QL:6]N('5N9&5R('1H92!!;&YY;&%M
M($5U<F]P92!0=7)C:&%S92!!9W)E96UE;G0N(%1H90T*("`@0V]M<&%N>2!I
M;FET:6%L;'D@<F5C;W)D960@)FYB<W`[)#(W."XR)B,Q-C`[;6EL;&EO;B!O
M9B!T:&5S92!P<F]C965D<R!A<R!D969E<G)E9"!R979E;G5E(&EN(&-O;FYE
M8W1I;VX@=VET:`T*("`@=&AE(%)O8VAE(&%L;&EA;F-E+@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[5VAE;B!E=F%L=6%T:6YG(&UU;'1I<&QE(&5L96UE;G0@87)R86YG
M96UE;G1S+"!T:&4@0V]M<&%N>2!C;VYS:61E<G,@=VAE=&AE<B!T:&4@8V]M
M<&]N96YT<R!O9@T*("`@=&AE(&%R<F%N9V5M96YT(')E<')E<V5N="!S97!A
M<F%T92!U;FET<R!O9B!A8V-O=6YT:6YG+B!4:&4@86-C;W5N=&EN9R!G=6ED
M86YC92!S<&5C:69I8V%L;'D-"B`@(')E<75I<F5S('1H870@=&AE(&1E;&EV
M97)E9"!C;VUP;VYE;G1S(&UU<W0@:&%V92!V86QU92!T;R!T:&4@8W5S=&]M
M97(@;VX@82!S=&%N9&%L;VYE(&)A<VES(&%N9`T*("`@=&AA="!T:&5R92!I
M<R!O8FIE8W1I=F4@86YD(')E;&EA8FQE(&5V:61E;F-E(&]F('1H92!F86ER
M('9A;'5E(&]F('1H92!U;F1E;&EV97)E9"!C;VUP;VYE;G1S+@T*("`@07!P
M;&EC871I;VX@;V8@=&AI<R!S=&%N9&%R9"!R97%U:7)E<R!S=6)J96-T:79E
M(&1E=&5R;6EN871I;VYS(&%N9"!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA
M:V4-"B`@(&IU9&=M96YT<R!A8F]U="!T:&4@=F%L=64@;V8@96%C:"!I;F1I
M=FED=6%L(&5L96UE;G0@86YD('=H971H97(@:70@:7,@<V5P87)A8FQE(&9R
M;VT@=&AE(&]T:&5R#0H@("!A<W!E8W1S(&]F('1H92!C;VYT<F%C='5A;"!R
M96QA=&EO;G-H:7`N(%1H92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870@
M=&AE(&1E;&EV97)A8FQE<R!U;F1E<@T*("`@:71S(&%G<F5E;65N=',@=VET
M:"!2;V-H92!I;F-L=61E('1H92!L:6-E;G-E+"!T:&4@06QN>6QA;2!%=7)O
M<&4@87-S971S(&%N9"!E;7!L;WEE97,L('1H90T*("`@<W1E97)I;F<@8V]M
M;6ET=&5E<R`H:F]I;G0@<W1E97)I;F<@8V]M;6ET=&5E(&%N9"!F=71U<F4@
M=&5C:&YO;&]G>2!C;VUM:71T964I(&%N9"!T:&4@<V5R=FEC97,-"B`@('5N
M9&5R('1H92!$:7-C;W9E<GD@0V]L;&%B;W)A=&EO;BX@5&AE($-O;7!A;GD@
M:&%S(&1E=&5R;6EN960@=&AA="P@<'5R<W5A;G0@=&\@=&AE(&%C8V]U;G1I
M;F<-"B`@(&=U:61A;F-E(&=O=F5R;FEN9R!R979E;G5E(')E8V]G;FET:6]N
M(&]N(&UU;'1I<&QE(&5L96UE;G0@87)R86YG96UE;G1S+"!T:&4@;&EC96YS
M92!A;F0@87-S971S(&]F#0H@("!!;&YY;&%M($5U<F]P92!A<F4@;F]T('-E
M<&%R86)L92!F<F]M('1H92!U;F1E;&EV97)E9"!S97)V:6-E<R`H:2YE+BP@
M=&AE('-T965R:6YG(&-O;6UI='1E97,@86YD#0H@("!$:7-C;W9E<GD@0V]L
M;&%B;W)A=&EO;BD@86YD+"!A8V-O<F1I;F=L>2!T:&4@;&EC96YS92!A;F0@
M=&AE('-E<G9I8V5S(&%R92!B96EN9R!T<F5A=&5D(&%S(&$-"B`@('-I;F=L
M92!U;FET(&]F(&%C8V]U;G1I;F<N(%=H96X@;75L=&EP;&4@9&5L:79E<F%B
M;&5S(&%R92!A8V-O=6YT960@9F]R(&%S(&$@<VEN9VQE('5N:70@;V8-"B`@
M(&%C8V]U;G1I;F<L('1H92!#;VUP86YY(&)A<V5S(&ET<R!R979E;G5E(')E
M8V]G;FET:6]N('!A='1E<FX@;VX@=&AE(&9I;F%L(&1E;&EV97)A8FQE+B!5
M;F1E<B!T:&4-"B`@(%)O8VAE(&%L;&EA;F-E+"!T:&4@<W1E97)I;F<@8V]M
M;6ET=&5E('-E<G9I8V5S(&%N9"!T:&4@1&ES8V]V97)Y($-O;&QA8F]R871I
M;VX@<V5R=FEC97,@87)E('1H90T*("`@9FEN86P@9&5L:79E<F%B;&5S(&%N
M9"!A;&P@<W5C:"!S97)V:6-E<R!W:6QL(&5N9"P@8V]N=')A8W1U86QL>2P@
M9FEV92!Y96%R<R!F<F]M('1H92!E9F9E8W1I=F4-"B`@(&1A=&4@;V8@=&AE
M($Q#02X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.U1H92!#;VUP86YY(&ES(')E8V]G;FEZ
M:6YG('1H92!2;V-H92UR96QA=&5D(')E=F5N=64@;VX@82!S=')A:6=H="UL
M:6YE(&)A<VES(&]V97(@9FEV92!Y96%R<PT*("`@8F5C875S92!T:&4@0V]M
M<&%N>2!C86YN;W0@<F5A<V]N86)L>2!E<W1I;6%T92!T:&4@=&]T86P@;&5V
M96P@;V8@969F;W)T(')E<75I<F5D('1O(&-O;7!L971E(&ET<PT*("`@<V5R
M=FEC92!O8FQI9V%T:6]N<R!U;F1E<B!T:&4@3$-!+"!A;F0@=&AE<F5F;W)E
M+"!C86YN;W0@=71I;&EZ92!A('!R;W!O<G1I;VYA;"!P97)F;W)M86YC92!M
M;V1E;"X-"B`@($%S(&9U='5R92!S=6)S=&%N=&EV92!M:6QE<W1O;F5S(&%R
M92!A8VAI979E9"P@=&AE($-O;7!A;GD@=VEL;"!R96-O9VYI>F4@87,@<F5V
M96YU92!A('!O<G1I;VX@;V8-"B`@('1H92!M:6QE<W1O;F4@<&%Y;65N="P@
M97%U86P@=&\@=&AE('!E<F-E;G1A9V4@;V8@=&AE('!E<F9O<FUA;F-E('!E
M<FEO9"!C;VUP;&5T960@=VAE;B!T:&4-"B`@(&UI;&5S=&]N92!I<R!A8VAI
M979E9"P@;75L=&EP;&EE9"!B>2!T:&4@86UO=6YT(&]F('1H92!M:6QE<W1O
M;F4@<&%Y;65N="X@5&AE($-O;7!A;GD@=VEL;`T*("`@<F5C;V=N:7IE('1H
M92!R96UA:6YI;F<@<&]R=&EO;B!O9B!T:&4@;6EL97-T;VYE(&]V97(@=&AE
M(')E;6%I;FEN9R!P97)F;W)M86YC92!P97)I;V0@;VX@80T*("`@<W1R86EG
M:'0M;&EN92!B87-I<RX@5&AE($-O;7!A;GD@=VEL;"!C;VYT:6YU92!T;R!R
M96-O9VYI>F4@=&AE(%)O8VAE+7)E;&%T960@<F5V96YU92!O;B!A#0H@("!S
M=')A:6=H="UL:6YE(&)A<VES(&]V97(@9FEV92!Y96%R<RX-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.TEN($YO=F5M8F5R)B,Q-C`[,C`Q,"P@4F]C:&4@86YN;W5N8V5D
M('1H92!D:7-C;VYT:6YU871I;VX@;V8@8V5R=&%I;B!A8W1I=FET:65S(&EN
M(')E<V5A<F-H(&%N9`T*("`@96%R;'D@9&5V96QO<&UE;G0L(&EN8VQU9&EN
M9R!I=',@4DY!:2!R97-E87)C:"!E9F9O<G1S+B!4:&4@<F5M86EN:6YG(&1E
M;&EV97)A8FQE<R!U;F1E<B!T:&4@3$-!#0H@("!C=7)R96YT;'D@<F5M86EN
M(&EN(&5F9F5C="X@26X@3V-T;V)E<B8C,38P.S(P,3$L($%R<F]W:&5A9"!2
M97-E87)C:"!#;W)P;W)A=&EO;B`H)B,X,C(P.T%R<F]W:&5A9"8C.#(R,3LI
M(&%N;F]U;F-E9`T*("`@:71S(&%C<75I<VET:6]N(&]F(%).02!T:&5R87!E
M=71I8W,@87-S971S(&9R;VT@4F]C:&4L(&EN8VQU9&EN9R!T:&4@3$-!+B!)
M;B!T:&4@979E;G0@07)R;W=H96%D('1E<FUI;F%T97,-"B`@('1H92!,0T$@
M;W(@=&AE($-O;7!A;GD@86YD($%R<F]W:&5A9"!M=71U86QL>2!A9W)E92!T
M;R!M;V1I9GD@=&AE($Q#02P@=&AE($-O;7!A;GD-"B`@('=I;&P@<F5A<W-E
M<W,@:71S(&1E;&EV97)A8FQE<R!A;F0@=&AE('!E<FEO9"!O=F5R('=H:6-H
M(&ET('=I;&P@8V]M<&QE=&4@:71S('!E<F9O<FUA;F-E#0H@("!O8FQI9V%T
M:6]N<R!U;F1E<B!T:&4@3$-!+B!!="!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,2P@9&5F97)R960@<F5V96YU92!U;F1E<B!T:&4@3$-!('=A<R`F;F)S<#LD
M-3$N,R8C,38P.VUI;&QI;VXN#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3)P=#L@;6%R9VEN+6QE9G0Z(#$E)SX\:3Y486ME9&$@06QL:6%N8V4\+VD^
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#M);B!-87DF(S$V,#LR,#`X+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!L:6-E;G-E(&%N9"!C;VQL86)O<F%T:6]N(&%G
M<F5E;65N="`H=&AE("8C.#(R,#M486ME9&$-"B`@($-O;&QA8F]R871I;VX@
M06=R965M96YT)B,X,C(Q.RD@=VET:"!486ME9&$@4&AA<FUA8V5U=&EC86P@
M0V]M<&%N>2!,:6UI=&5D("@F(S@R,C`[5&%K961A)B,X,C(Q.RD@=&\@<'5R
M<W5E('1H90T*("`@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N
M(&]F(%).06D@=&AE<F%P975T:6-S+B!5;F1E<B!T:&4@5&%K961A($-O;&QA
M8F]R871I;VX@06=R965M96YT+`T*("`@=&AE($-O;7!A;GD@9W)A;G1E9"!4
M86ME9&$@82!N;VXM97AC;'5S:79E+"!W;W)L9'=I9&4L(')O>6%L='DM8F5A
M<FEN9R!L:6-E;G-E('1O('1H92!#;VUP86YY)B,X,C$W.W,-"B`@(&EN=&5L
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M;F0-"B`@(&UA>2!B92!E>'!A;F1E9"!A="!486ME9&$F(S@R,3<[<R!O<'1I
M;VX@=&\@:6YC;'5D92!O=&AE<B!T:&5R87!E=71I8R!A<F5A<RP@<W5B:F5C
M="!T;R!S<&5C:69I960-"B`@(&-O;F1I=&EO;G,N(%5N9&5R('1H92!486ME
M9&$@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0L(%1A:V5D82!I<R!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&5X8VQU<VEV92!P;&%T9F]R;0T*("`@<&%R=&YE<B!I
M;B!T:&4@07-I86X@=&5R<FET;W)Y+"!A<R!D969I;F5D(&EN('1H92!486ME
M9&$@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0L('1H<F]U9V@@36%Y)B,Q-C`[
M,C`Q,RX-"B`@(#PO9&EV/@T*("`@/"$M+2!&;VQI;R`M+3X-"B`@(#PA+2T@
M+T9O;&EO("TM/@T*("`@/"]D:78^#0H@("`\(2TM(%!!1T5"4D5!2R`M+3X-
M"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+%1I;65S+'-E<FEF)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);B!C;VYS:61E<F%T:6]N(&9O<B!T
M:&4@<FEG:'1S(&=R86YT960@=&\@5&%K961A('5N9&5R('1H92!486ME9&$@
M0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0L#0H@("!486ME9&$@86=R965D('1O
M('!A>2!T:&4-"B`@($-O;7!A;GD@)FYB<W`[)#$U,"XP)B,Q-C`[;6EL;&EO
M;B!I;B!U<&9R;VYT(&%N9"!N96%R+71E<FT@=&5C:&YO;&]G>2!T<F%N<V9E
M<B!P87EM96YT<RX@26X@861D:71I;VXL('1H90T*("`@0V]M<&%N>2!H87,@
M=&AE(&]P=&EO;BP@97AE<F-I<V%B;&4@=6YT:6P@=&AE('-T87)T(&]F(%!H
M87-E($E)22!D979E;&]P;65N="P@=&\@;W!T+6EN('5N9&5R(&$-"B`@(#4P
M+34P('!R;V9I="!S:&%R:6YG(&%G<F5E;65N="!T;R!T:&4@9&5V96QO<&UE
M;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&EN('1H92!5;FET960@4W1A=&5S
M(&]F('5P#0H@("!T;R!F;W5R(%1A:V5D82!L:6-E;G-E9"!P<F]D=6-T<R!A
M;F0@=V]U;&0@8F4@96YT:71L960@=&\@;W!T+6EN(')I9VAT<R!F;W(@='=O
M(&%D9&ET:6]N86P@<')O9'5C=',-"B`@(&9O<B!E86-H(&%D9&ET:6]N86P@
M9FEE;&0@97AP86YS:6]N+"!I9B!A;GDL(&5L96-T960@8GD@5&%K961A('5N
M9&5R('1H92!486ME9&$@0V]L;&%B;W)A=&EO;@T*("`@06=R965M96YT+B!)
M;B!*=6YE)B,Q-C`[,C`P."P@5&%K961A('!A:60@=&AE($-O;7!A;GD@86X@
M=7!F<F]N="!P87EM96YT(&]F("9N8G-P.R0Q,#`N,"8C,38P.VUI;&QI;VX@
M86YD(&%G<F5E9"!T;PT*("`@<&%Y(&%N(&%D9&ET:6]N86P@)FYB<W`[)#4P
M+C`F(S$V,#MM:6QL:6]N('1O('1H92!#;VUP86YY('5P;VX@86-H:65V96UE
M;G0@;V8@<W!E8VEF:65D('1E8VAN;VQO9WD@=')A;G-F97(-"B`@(&UI;&5S
M=&]N97,N($]F('1H:7,@)FYB<W`[)#4P+C`F(S$V,#MM:6QL:6]N+"`F;F)S
M<#LD,C`N,"8C,38P.VUI;&QI;VX@=V%S('!A:60@=&\@=&AE($-O;7!A;GD@
M:6X@3V-T;V)E<B8C,38P.S(P,#@L("9N8G-P.R0R,"XP#0H@("!M:6QL:6]N
M('=A<R!P86ED('1O('1H92!#;VUP86YY(&EN($UA<F-H)B,Q-C`[,C`Q,"!A
M;F0@)FYB<W`[)#$P+C`F(S$V,#MM:6QL:6]N('=A<R!P86ED('1O('1H92!#
M;VUP86YY(&EN($UA<F-H#0H@("`R,#$Q("AC;VQL96-T:79E;'DL("8C.#(R
M,#M496-H;F]L;V=Y(%1R86YS9F5R($UI;&5S=&]N97,F(S@R,C$[*2X@268@
M5&%K961A(&5L96-T<R!T;R!E>'!A;F0@:71S(&QI8V5N<V4@=&\-"B`@(&%D
M9&ET:6]N86P@=&AE<F%P975T:6,@87)E87,L(%1A:V5D82!W:6QL(&)E(')E
M<75I<F5D('1O('!A>2!T:&4@0V]M<&%N>2`F;F)S<#LD-3`N,"8C,38P.VUI
M;&QI;VX@9F]R(&5A8V@@;V8-"B`@('5P('1O(&%P<')O>&EM871E;'D@,C`@
M=&]T86P@861D:71I;VYA;"!F:65L9',@<V5L96-T960L(&EF(&%N>2P@8V]M
M<')I<VEN9R!S=6)S=&%N=&EA;&QY(&%L;"!O=&AE<@T*("`@9FEE;&1S(&]F
M(&AU;6%N(&1I<V5A<V4L(&%S(&ED96YT:69I960@86YD(&%G<F5E9"!U<&]N
M(&)Y('1H92!P87)T:65S+B!);B!A9&1I=&EO;BP@9F]R(&5A8V@@4DY!:0T*
M("`@=&AE<F%P975T:6,@<')O9'5C="!D979E;&]P960@8GD@5&%K961A+"!I
M=',@869F:6QI871E<R!A;F0@<W5B;&EC96YS965S+"!T:&4@0V]M<&%N>2!I
M<R!E;G1I=&QE9`T*("`@=&\@<F5C96EV92!S<&5C:69I960@9&5V96QO<&UE
M;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&UI;&5S=&]N97,L('1O=&%L:6YG
M('5P('1O("9N8G-P.R0Q-S$N,"8C,38P.VUI;&QI;VX-"B`@('!E<B!P<F]D
M=6-T+"!T;V=E=&AE<B!W:71H(')O>6%L='D@<&%Y;65N=',@8F%S960@;VX@
M=V]R;&1W:61E(&%N;G5A;"!N970@<V%L97,L(&EF(&%N>2X-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.U!U<G-U86YT('1O('1H92!486ME9&$@0V]L;&%B;W)A=&EO;B!!
M9W)E96UE;G0L('1H92!#;VUP86YY(&%N9"!486ME9&$@87)E(&%L<V\@8V]L
M;&%B;W)A=&EN9PT*("`@;VX@=&AE(')E<V5A<F-H(&]F(%).06D@=&AE<F%P
M975T:6-S(&1I<F5C=&5D('1O(&]N92!O<B!T=V\@9&ES96%S92!T87)G971S
M(&%G<F5E9"!T;R!B>2!T:&4-"B`@('!A<G1I97,@*'1H92`F(S@R,C`[4F5S
M96%R8V@@0V]L;&%B;W)A=&EO;B8C.#(R,3LI+"!S=6)J96-T('1O('1H92!#
M;VUP86YY)B,X,C$W.W,@97AI<W1I;F<@8V]N=')A8W1U86P@;V)L:6=A=&EO
M;G,-"B`@('=I=&@@=&AI<F0@<&%R=&EE<RX@5&%K961A(&%L<V\@:&%S('1H
M92!O<'1I;VXL('-U8FIE8W0@=&\@8V5R=&%I;B!C;VYD:71I;VYS+"!T;R!C
M;VQL86)O<F%T92!W:71H#0H@("!T:&4@0V]M<&%N>2!O;B!T:&4@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&]F(%).06D@9')U9R!D96QI=F5R>2!T96-H
M;F]L;V=Y(&9O<B!T87)G971S(&%G<F5E9"!T;PT*("`@8GD@=&AE('!A<G1I
M97,N($EN(&%D9&ET:6]N+"!486ME9&$@:&%S(&$@<FEG:'0@;V8@9FER<W0@
M;F5G;W1I871I;VX@9F]R('1H92!D979E;&]P;65N="!A;F0-"B`@(&-O;6UE
M<F-I86QI>F%T:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@4DY!:2!T:&5R
M87!E=71I8R!P<F]D=6-T<R!I;B!T:&4@07-I86X@=&5R<FET;W)Y+"!E>&-L
M=61I;F<@=&AE#0H@("!#;VUP86YY)B,X,C$W.W,@04Q.+5)35B!P<F]G<F%M
M+B!);B!A9&1I=&EO;B!T;R!T:&4@-3`M-3`@<')O9FET('-H87)I;F<@;W!T
M:6]N+"!T:&4@0V]M<&%N>2!H87,@80T*("`@<VEM:6QA<B!R:6=H="!O9B!F
M:7)S="!N96=O=&EA=&EO;B!T;R!P87)T:6-I<&%T92!W:71H(%1A:V5D82!I
M;B!T:&4@9&5V96QO<&UE;G0@86YD#0H@("!C;VUM97)C:6%L:7IA=&EO;B!I
M;B!T:&4@56YI=&5D(%-T871E<R!O9B!L:6-E;G-E9"!P<F]D=6-T<RX@5&AE
M(&-O;&QA8F]R871I;VX@:7,@9V]V97)N960@8GD@80T*("`@:F]I;G0@=&5C
M:&YO;&]G>2!T<F%N<V9E<B!C;VUM:71T964@*'1H92`F(S@R,C`[2E140R8C
M.#(R,3LI+"!A(&IO:6YT(')E<V5A<F-H(&-O;&QA8F]R871I;VX@8V]M;6ET
M=&5E("AT:&4-"B`@("8C.#(R,#M*4D-#)B,X,C(Q.RD@86YD(&$@:F]I;G0@
M9&5L:79E<GD@8V]L;&%B;W)A=&EO;B!C;VUM:71T964@*'1H92`F(S@R,C`[
M2D1#0R8C.#(R,3LI+"!E86-H(&]F('=H:6-H(&ES(&-O;7!R:7-E9"!O9B!A
M;@T*("`@97%U86P@;G5M8F5R(&]F(')E<')E<V5N=&%T:79E<R!F<F]M(&5A
M8V@@<&%R='DN#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!H87,@9&5T
M97)M:6YE9"!T:&%T('1H92!D96QI=F5R86)L97,@=6YD97(@=&AE(%1A:V5D
M82!#;VQL86)O<F%T:6]N($%G<F5E;65N=`T*("`@:6YC;'5D92!T:&4@;&EC
M96YS92P@=&AE(&IO:6YT(&-O;6UI='1E97,@*'1H92!*5%1#+"!*4D-#(&%N
M9"!*1$-#*2P@=&AE('1E8VAN;VQO9WD@=')A;G-F97(-"B`@(&%C=&EV:71I
M97,@86YD('1H92!S97)V:6-E<R!T:&%T('1H92!#;VUP86YY('=I;&P@8F4@
M;V)L:6=A=&5D('1O('!E<F9O<FT@=6YD97(@=&AE(%)E<V5A<F-H#0H@("!#
M;VQL86)O<F%T:6]N+B!4:&4@0V]M<&%N>2!H87,@9&5T97)M:6YE9"!T:&%T
M+"!P=7)S=6%N="!T;R!T:&4@86-C;W5N=&EN9R!G=6ED86YC92!G;W9E<FYI
M;F<-"B`@(')E=F5N=64@<F5C;V=N:71I;VX@;VX@;75L=&EP;&4@96QE;65N
M="!A<G)A;F=E;65N=',L('1H92!L:6-E;G-E(&%N9"!U;F1E;&EV97)E9"!S
M97)V:6-E<R`H:2YE+BP-"B`@('1H92!J;VEN="!C;VUM:71T965S(&%N9"!T
M:&4@4F5S96%R8V@@0V]L;&%B;W)A=&EO;BD@87)E(&YO="!S97!A<F%B;&4@
M86YD+"!A8V-O<F1I;F=L>2P@=&AE#0H@("!L:6-E;G-E(&%N9"!S97)V:6-E
M<R!A<F4@8F5I;F<@=')E871E9"!A<R!A('-I;F=L92!U;FET(&]F(&%C8V]U
M;G1I;F<N(%=H96X@;75L=&EP;&4@9&5L:79E<F%B;&5S#0H@("!A<F4@86-C
M;W5N=&5D(&9O<B!A<R!A('-I;F=L92!U;FET(&]F(&%C8V]U;G1I;F<L('1H
M92!#;VUP86YY(&)A<V5S(&ET<R!R979E;G5E(')E8V]G;FET:6]N('!A='1E
M<FX-"B`@(&]N('1H92!F:6YA;"!D96QI=F5R86)L92X@56YD97(@=&AE(%1A
M:V5D82!#;VQL86)O<F%T:6]N($%G<F5E;65N="P@=&AE(&QA<W0@96QE;65N
M=',@=&\@8F4-"B`@(&1E;&EV97)E9"!A<F4@=&AE($I$0T,@86YD($I45$,@
M<V5R=FEC97,L(&5A8V@@;V8@=VAI8V@@:&%S(&$@;&EF92!O9B!N;R!M;W)E
M('1H86X@<V5V96X@>65A<G,N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@0V]M<&%N
M>2!I<R!R96-O9VYI>FEN9R!T:&4@=7!F<F]N="!P87EM96YT(&]F("9N8G-P
M.R0Q,#`N,"8C,38P.VUI;&QI;VX@86YD('1H92!496-H;F]L;V=Y(%1R86YS
M9F5R#0H@("!-:6QE<W1O;F5S(&]F("9N8G-P.R0U,"XP)B,Q-C`[;6EL;&EO
M;BP@=&AE(')E8V5I<'0@;V8@=VAI8V@@=&AE($-O;7!A;GD@8F5L:65V960@
M=V%S('!R;V)A8FQE(&%T('1H90T*("`@8V]M;65N8V5M96YT(&]F('1H92!C
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M="!E<75A;"!T;R!T:&4@<&5R8V5N=&%G92!O9B!T:&4-"B`@('!E<F9O<FUA
M;F-E('!E<FEO9"!C;VUP;&5T960@=VAE;B!T:&4@;6EL97-T;VYE(&ES(&%C
M:&EE=F5D+"!M=6QT:7!L:65D(&)Y('1H92!A;6]U;G0@;V8@=&AE#0H@("!M
M:6QE<W1O;F4@<&%Y;65N="X@5&AE($-O;7!A;GD@=VEL;"!R96-O9VYI>F4@
M=&AE(')E;6%I;FEN9R!P;W)T:6]N(&]F('1H92!M:6QE<W1O;F4@;W9E<B!T
M:&4-"B`@(')E;6%I;FEN9R!P97)F;W)M86YC92!P97)I;V0@;VX@82!S=')A
M:6=H="UL:6YE(&)A<VES+B!!="!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@
M9&5F97)R960@<F5V96YU90T*("`@=6YD97(@=&AE(%1A:V5D82!#;VQL86)O
M<F%T:6]N($%G<F5E;65N="!W87,@)FYB<W`[)#@P+C,F(S$V,#MM:6QL:6]N
M+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$R<'0G/CQB/CQI/D1I<V-O
M=F5R>2!A;F0@1&5V96QO<&UE;G0@06QL:6%N8V5S/"]I/CPO8CX-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0[(&UA<F=I;BUL969T.B`Q)2<^/&D^
M3F]V87)T:7,@0G)O860@06QL:6%N8V4\+VD^#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M)
M;B!T:&4@<V5C;VYD(&AA;&8@;V8@,C`P-2P@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&$@<V5R:65S(&]F('1R86YS86-T:6]N<R!W:71H($YO=F%R=&ES
M#0H@("!0:&%R;6$@04<@86YD(&ET<R!A9F9I;&EA=&4L($YO=F%R=&ES($EN
M<W1I='5T97,@9F]R($)I;TUE9&EC86P@4F5S96%R8V@L($EN8RX@*'1O9V5T
M:&5R+`T*("`@)B,X,C(P.TYO=F%R=&ES)B,X,C(Q.RDL('=H:6-H(&EN8VQU
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M(&EN:71I86P@<F5S96%R8V@@=&5R;2!O9B!T:')E90T*("`@>65A<G,L('=I
M=&@@86X@;W!T:6]N(&9O<B!T=V\@861D:71I;VYA;"!O;F4M>65A<B!E>'1E
M;G-I;VYS(&%T('1H92!E;&5C=&EO;B!O9B!.;W9A<G1I<RX@3F]V87)T:7,-
M"B`@(&5L96-T960@=&\@97AT96YD('1H92!T97)M('1H<F]U9V@@3V-T;V)E
M<B8C,38P.S(P,3`L('1H92!F:69T:"!A;F0@9FEN86P@<&QA;FYE9"!Y96%R
M+B!);B!/8W1O8F5R)B,Q-C`[,C`Q,"P-"B`@('1H92!R97-E87)C:"!P<F]G
M<F%M('5N9&5R('1H92!#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E
M;65N="!W87,@<W5B<W1A;G1I86QL>2!C;VUP;&5T960@:6X-"B`@(&%C8V]R
M9&%N8V4@=VET:"!T:&4@=&5R;7,@;V8@=&AE($-O;&QA8F]R871I;VX@86YD
M($QI8V5N<V4@06=R965M96YT+"!S=6)J96-T('1O(&-E<G1A:6X@<W5R=FEV
M:6YG#0H@("!R:6=H=',@86YD(&]B;&EG871I;VYS(&]F('1H92!P87)T:65S
M+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L
M:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@
M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M5&EM97,L<V5R:68G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H92!);G9E<W1O<B!2:6=H=',@06=R965M
M96YT('!R;W9I9&5S($YO=F%R=&ES('=I=&@@=&AE(')I9VAT(&=E;F5R86QL
M>2!T;R!M86EN=&%I;B!I=',-"B`@(&]W;F5R<VAI<"!P97)C96YT86=E(&EN
M('1H90T*("`@0V]M<&%N>2!U;G1I;"!T:&4@96%R;&EE<B!O9B!A;GD@<V%L
M92!B>2!.;W9A<G1I<R!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VL@86YD#0H@("!T:&4@97AP:7)A=&EO;B!O<B!T97)M
M:6YA=&EO;B!O9B!T:&4@0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E
M96UE;G0L('-U8FIE8W0@=&\@8V5R=&%I;@T*("`@97AC97!T:6]N<RX@070@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$L($YO=F%R=&ES(&]W;F5D(#$S+C$E
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;W5T<W1A;F1I;F<@8V]M;6]N('-T
M;V-K+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@8V]N<VED97)A=&EO;B!F;W(@=&AE
M(')I9VAT<R!G<F%N=&5D('1O($YO=F%R=&ES('5N9&5R('1H92!#;VQL86)O
M<F%T:6]N(&%N9"!,:6-E;G-E#0H@("!!9W)E96UE;G0L($YO=F%R=&ES(&UA
M9&4@86X@=7!F<F]N="!P87EM96YT(&]F("9N8G-P.R0Q,"XP)B,Q-C`[;6EL
M;&EO;B!T;R!T:&4@0V]M<&%N>2!I;B!/8W1O8F5R)B,Q-C`[,C`P-2P@<&%R
M=&QY#0H@("!T;R!R96EM8G5R<V4@<')I;W(@8V]S=',@:6YC=7)R960@8GD@
M=&AE($-O;7!A;GD@=&\@9&5V96QO<"`\:3YI;B!V:79O(#PO:3Y23D%I('1E
M8VAN;VQO9WDN(%1H92!#;VUP86YY#0H@("!A;'-O(')E8V5I=F5D(')E<V5A
M<F-H(&9U;F1I;F<@86YD(&1E=F5L;W!M96YT(&UI;&5S=&]N92!P87EM96YT
M<R!F<F]M($YO=F%R=&ES+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@4V5P=&5M8F5R
M)B,Q-C`[,C`Q,"P@3F]V87)T:7,@97AE<F-I<V5D(&ET<R!R:6=H="!U;F1E
M<B!T:&4@0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E96UE;G0-"B`@
M('1O('-E;&5C="`S,2!D97-I9VYA=&5D(&=E;F4@=&%R9V5T<RP@9F]R('=H
M:6-H($YO=F%R=&ES(&AA<R!E>&-L=7-I=F4@<FEG:'1S('1O(&1I<V-O=F5R
M+"!D979E;&]P#0H@("!A;F0@8V]M;65R8VEA;&EZ92!23D%I('1H97)A<&5U
M=&EC('!R;V1U8W1S('5S:6YG('1H92!#;VUP86YY)B,X,C$W.W,@:6YT96QL
M96-T=6%L('!R;W!E<G1Y(&%N9`T*("`@=&5C:&YO;&]G>2P@:6YC;'5D:6YG
M(&1E;&EV97)Y+7)E;&%T960@:6YT96QL96-T=6%L('!R;W!E<G1Y(&%N9"!R
M96QA=&5D('1E8VAN;VQO9WDN(%5N9&5R('1H90T*("`@=&5R;7,@;V8@=&AE
M($-O;&QA8F]R871I;VX@86YD($QI8V5N<V4@06=R965M96YT+"!F;W(@86YY
M(%).06D@=&AE<F%P975T:6,@<')O9'5C=',@3F]V87)T:7,-"B`@(&1E=F5L
M;W!S(&%G86EN<W0@=&AE<V4@=&%R9V5T<RP@=&AE($-O;7!A;GD@:7,@96YT
M:71L960@=&\@<F5C96EV92!M:6QE<W1O;F4@<&%Y;65N=',@=7!O;@T*("`@
M86-H:65V96UE;G0@;V8@8V5R=&%I;B!S<&5C:69I960@9&5V96QO<&UE;G0@
M86YD(&%N;G5A;"!N970@<V%L97,@979E;G1S+"!U<"!T;R!A;B!A9V=R96=A
M=&4@;V8-"B`@("9N8G-P.R0W-2XP)B,Q-C`[;6EL;&EO;B!P97(@=&AE<F%P
M975T:6,@<')O9'5C="P@87,@=V5L;"!A<R!R;WEA;'1I97,@;VX@86YN=6%L
M(&YE="!S86QE<R!O9B!A;GD@<W5C:`T*("`@<')O9'5C="X@3F]V87)T:7,F
M(S@R,3<[(')I9VAT(&]F(&9I<G-T(&]F9F5R('=I=&@@<F5S<&5C="!T;R!A
M;B!E>&-L=7-I=F4@;&EC96YS92!F;W(@861D:71I;VYA;`T*("`@=&%R9V5T
M<R!H87,@=&5R;6EN871E9"X@26X@4V5P=&5M8F5R)B,Q-C`[,C`Q,"P@3F]V
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M;W9A<G1I<R!H860@96QE8W1E9"!T;R!E>&5R8VES92!T:&4-"B`@(&EN=&5G
M<F%T:6]N(&]P=&EO;BP@3F]V87)T:7,@=V]U;&0@:&%V92!B965N(')E<75I
M<F5D('1O(&UA:V4@861D:71I;VYA;"!P87EM96YT<R!T;R!T:&4@0V]M<&%N
M>0T*("`@=&]T86QI;F<@)FYB<W`[)#$P,"XP)B,Q-C`[;6EL;&EO;BX-"B`@
M(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P
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M(&]F(&$@=&5C:&YO;&]G>2!T<F%N<V9E<B!U;G1I;"`R,#$U+"!T:&4-"B`@
M(&9I9G1H(&%N;FEV97)S87)Y(&]F('1H92!C;VUP;&5T:6]N(&]F('1H92!R
M97-E87)C:"!T97)M('5N9&5R('1H92!#;VQL86)O<F%T:6]N(&%N9"!,:6-E
M;G-E#0H@("!!9W)E96UE;G0N(%1H92!#;VUP86YY(&-O;G1I;G5E<R!T;R!U
M<V4@86X@97AP96-T960@=&5R;2!O9B!T96X@>65A<G,@:6X@:71S('!R;W!O
M<G1I;VYA;`T*("`@<&5R9F]R;6%N8V4@;6]D96PN(%1H92!#;VUP86YY(')E
M979A;'5A=&5S('1H92!E>'!E8W1E9"!T97)M('=H96X@;F5W(&EN9F]R;6%T
M:6]N(&ES(&MN;W=N('1H870-"B`@(&-O=6QD(&%F9F5C="!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&5S=&EM871E+B!);B!T:&4@979E;G0@=&AE($-O;7!A;GDF
M(S@R,3<[<R!P97)I;V0@;V8@<&5R9F]R;6%N8V4@:7,@9&EF9F5R96YT#0H@
M("!T:&%N(&5S=&EM871E9"P@=&AE($-O;7!A;GD@=VEL;"!A9&IU<W0@=&AE
M(&%M;W5N="!O9B!R979E;G5E(')E8V]G;FEZ960@;VX@82!P<F]S<&5C=&EV
M92!B87-I<RX@070-"B`@(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q+"!D969E
M<G)E9"!R979E;G5E('5N9&5R('1H92!.;W9A<G1I<R!#;VQL86)O<F%T:6]N
M(&%N9"!,:6-E;G-E($%G<F5E;65N="!W87,-"B`@("9N8G-P.R0P+C(F(S$V
M,#MM:6QL:6]N+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$R<'0G/CQB
M/CQI/E!R;V1U8W0@06QL:6%N8V5S/"]I/CPO8CX-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`V<'0[(&UA<F=I;BUL969T.B`Q)2<^/&D^2WEO=V$@2&%K
M:V\@2VER:6X@06QL:6%N8V4\+VD^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);B!*=6YE
M)B,Q-C`[,C`P."P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&EC96YS
M92!A;F0@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@*'1H92`F(S@R,C`[2WEO
M=V$@2&%K:V\-"B`@($MI<FEN($%G<F5E;65N="8C.#(R,3LI('=I=&@@2WEO
M=V$@2&%K:V\@2VER:6X@0V\N+"!,=&0N("@F(S@R,C`[2WEO=V$@2&%K:V\@
M2VER:6XF(S@R,C$[*2X@56YD97(@=&AE($MY;W=A($AA:VMO#0H@("!+:7)I
M;B!!9W)E96UE;G0L('1H92!#;VUP86YY(&=R86YT960@2WEO=V$@2&%K:V\@
M2VER:6X@86X@97AC;'5S:79E(&QI8V5N<V4@=&\@:71S(&EN=&5L;&5C='5A
M;`T*("`@<')O<&5R='D@:6X@2F%P86X@86YD(&]T:&5R(&UA<FME=',@:6X@
M07-I82`H=&AE("8C.#(R,#M,:6-E;G-E9"!497)R:71O<GDF(S@R,C$[*2!F
M;W(@=&AE(&1E=F5L;W!M96YT(&%N9`T*("`@8V]M;65R8VEA;&EZ871I;VX@
M;V8@86X@4DY!:2!T:&5R87!E=71I8R!F;W(@=&AE('1R96%T;65N="!O9B!R
M97-P:7)A=&]R>2!S>6YC>71I86P@=FER=7,@*"8C.#(R,#M24U8F(S@R,C$[
M*0T*("`@:6YF96-T:6]N+B!4:&4@2WEO=V$@2&%K:V\@2VER:6X@06=R965M
M96YT(&-O=F5R<R!!3$XM4E-6,#$L(&%S('=E;&P@87,@861D:71I;VYA;"!2
M4U8M<W!E8VEF:6,-"B`@(%).06D@=&AE<F%P975T:6,@8V]M<&]U;F1S('1H
M870@8V]M<')I<V4@=&AE($%,3BU24U8@<')O9W)A;2`H)B,X,C(P.T%D9&ET
M:6]N86P@0V]M<&]U;F1S)B,X,C(Q.RDN(%1H92!#;VUP86YY#0H@("!R971A
M:6YS(&%L;"!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@<FEG
M:'1S('=O<FQD=VED92!O=71S:61E(&]F('1H92!,:6-E;G-E9"!497)R:71O
M<GDL#0H@("!S=6)J96-T('1O(&ET<R!A9W)E96UE;G0@=VET:"!#=6)I<W0@
M4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[0W5B:7-T)B,X,C(Q.RD@
M9&5S8W)I8F5D(&)E;&]W+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[56YD97(@=&AE('1E
M<FUS(&]F('1H92!+>6]W82!(86MK;R!+:7)I;B!!9W)E96UE;G0L(&EN($IU
M;F4F(S$V,#LR,#`X+"!+>6]W82!(86MK;R!+:7)I;B!P86ED('1H90T*("`@
M0V]M<&%N>2!A;B!U<&9R;VYT(&-A<V@@<&%Y;65N="!O9B`F;F)S<#LD,34N
M,"8C,38P.VUI;&QI;VXN($EN(&%D9&ET:6]N+"!+>6]W82!(86MK;R!+:7)I
M;B!I<R!R97%U:7)E9"!T;PT*("`@;6%K92!P87EM96YT<R!T;R!T:&4@0V]M
M<&%N>2!U<&]N(&%C:&EE=F5M96YT(&]F('-P96-I9FEE9"!D979E;&]P;65N
M="!A;F0@<V%L97,@;6EL97-T;VYE<PT*("`@=&]T86QI;F<@=7`@=&\@)FYB
M<W`[)#<X+C`F(S$V,#MM:6QL:6]N+"!A;F0@<F]Y86QT>2!P87EM96YT<R!B
M87-E9"!O;B!A;FYU86P@;F5T('-A;&5S+"!I9B!A;GDL(&]F(%).06D-"B`@
M('1H97)A<&5U=&EC<R!F;W(@=&AE('1R96%T;65N="!O9B!24U8@8GD@2WEO
M=V$@2&%K:V\@2VER:6XL(&ET<R!A9F9I;&EA=&5S(&%N9"!S=6)L:6-E;G-E
M97,@:6X@=&AE#0H@("!,:6-E;G-E9"!497)R:71O<GDN#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
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M='DN(%5N9&5R('1H90T*("`@86=R965M96YT+"!+>6]W82!(86MK;R!+:7)I
M;B!I<R!E<W1A8FQI<VAI;F<@82!D979E;&]P;65N="!P;&%N(&9O<B!T:&4@
M04Q.+5)35B!P<F]G<F%M(')E;&%T:6YG('1O#0H@("!T:&4@9&5V96QO<&UE
M;G0@86-T:79I=&EE<R!T;R!B92!U;F1E<G1A:V5N(&EN('1H92!,:6-E;G-E
M9"!497)R:71O<GDL('=I=&@@=&AE(&EN:71I86P@9F]C=7,@;VX-"B`@($IA
M<&%N+B!+>6]W82!(86MK;R!+:7)I;B!I<R!R97-P;VYS:6)L92P@870@:71S
M(&5X<&5N<V4L(&9O<B!A;&P@9&5V96QO<&UE;G0@86-T:79I=&EE<R!U;F1E
M<B!T:&4-"B`@(&1E=F5L;W!M96YT('!L86X@=&AA="!A<F4@<F5A<V]N86)L
M>2!N96-E<W-A<GD@9F]R('1H92!R96=U;&%T;W)Y(&%P<')O=F%L(&%N9"!C
M;VUM97)C:6%L:7IA=&EO;B!O9@T*("`@86X@4DY!:2!T:&5R87!E=71I8R!F
M;W(@=&AE('1R96%T;65N="!O9B!24U8@:6X@2F%P86X@86YD('1H92!R97-T
M(&]F('1H92!,:6-E;G-E9"!497)R:71O<GDN(%1H90T*("`@0V]M<&%N>2!I
M<R!R97-P;VYS:6)L92!F;W(@<W5P<&QY(&]F('1H92!P<F]D=6-T('1O($MY
M;W=A($AA:VMO($MI<FEN('5N9&5R(&$@<W5P<&QY(&%G<F5E;65N=`T*("`@
M=6YL97-S($MY;W=A($AA:VMO($MI<FEN(&5L96-T<RP@<')I;W(@=&\@=&AE
M(&9I<G-T(&-O;6UE<F-I86P@<V%L92!O9B!T:&4@<')O9'5C="!I;B!T:&4@
M3&EC96YS960-"B`@(%1E<G)I=&]R>2P@=&\@;6%N=69A8W1U<F4@=&AE('!R
M;V1U8W0@:71S96QF(&]R(&%R<F%N9V4@9F]R(&$@=&AI<F0@<&%R='D@=&\@
M;6%N=69A8W1U<F4@=&AE#0H@("!P<F]D=6-T+@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M5&AE($-O;7!A;GD@:&%S(&1E=&5R;6EN960@=&AA="!T:&4@9&5L:79E<F%B
M;&5S('5N9&5R('1H92!+>6]W82!(86MK;R!+:7)I;B!!9W)E96UE;G0@:6YC
M;'5D90T*("`@=&AE(&QI8V5N<V4L('1H92!J;VEN="!S=&5E<FEN9R!C;VUM
M:71T964L('1H92!M86YU9F%C='5R:6YG('-E<G9I8V5S(&%N9"!A;GD@061D
M:71I;VYA;"!#;VUP;W5N9',N#0H@("!4:&4@0V]M<&%N>2!H87,@9&5T97)M
M:6YE9"!T:&%T+"!P=7)S=6%N="!T;R!T:&4@86-C;W5N=&EN9R!G=6ED86YC
M92!G;W9E<FYI;F<@<F5V96YU92!R96-O9VYI=&EO;@T*("`@;VX@;75L=&EP
M;&4@96QE;65N="!A<G)A;F=E;65N=',L('1H92!I;F1I=FED=6%L(&1E;&EV
M97)A8FQE<R!A<F4@;F]T('-E<&%R86)L92!A;F0L(&%C8V]R9&EN9VQY+`T*
M("`@;75S="!B92!A8V-O=6YT960@9F]R(&%S(&$@<VEN9VQE('5N:70@;V8@
M86-C;W5N=&EN9RX@5VAE;B!M=6QT:7!L92!D96QI=F5R86)L97,@87)E(&%C
M8V]U;G1E9"!F;W(-"B`@(&%S(&$@<VEN9VQE('5N:70-"B`@(&]F(&%C8V]U
M;G1I;F<L('1H92!#;VUP86YY(&)A<V5S(&ET<R!R979E;G5E(')E8V]G;FET
M:6]N('!A='1E<FX@;VX@=&AE(&9I;F%L(&1E;&EV97)A8FQE+@T*("`@5&AE
M($-O;7!A;GD@:7,@8W5R<F5N=&QY('5N86)L92!T;R!R96%S;VYA8FQY(&5S
M=&EM871E(&ET<R!P97)I;V0@;V8@<&5R9F]R;6%N8V4@=6YD97(@=&AE($MY
M;W=A#0H@("!(86MK;R!+:7)I;B!!9W)E96UE;G0L(&%S(&ET(&ES('5N86)L
M92!T;R!E<W1I;6%T92!T:&4@=&EM96QI;F4@;V8@:71S(&1E;&EV97)A8FQE
M<R!R96QA=&5D('1O('1H90T*("`@9FEX960M<')I8V4@;W!T:6]N(&=R86YT
M960@=&\@2WEO=V$@2&%K:V\@2VER:6X@9F]R(&%N>2!!9&1I=&EO;F%L($-O
M;7!O=6YD<RX@5&AE($-O;7!A;GD@:7,-"B`@(&1E9F5R<FEN9R!A;&P@<F5V
M96YU92!U;F1E<B!T:&4@2WEO=V$@2&%K:V\@2VER:6X@06=R965M96YT('5N
M=&EL(&ET(&ES(&%B;&4@=&\@<F5A<V]N86)L>2!E<W1I;6%T90T*("`@:71S
M('!E<FEO9"!O9B!P97)F;W)M86YC92X@5&AE($-O;7!A;GD@=VEL;"!C;VYT
M:6YU92!T;R!R96%S<V5S<R!W:&5T:&5R(&ET(&-A;B!R96%S;VYA8FQY(&5S
M=&EM871E#0H@("!T:&4@<&5R:6]D(&]F('!E<F9O<FUA;F-E('1O(&9U;&9I
M;&P@:71S(&]B;&EG871I;VYS('5N9&5R('1H92!+>6]W82!(86MK;R!+:7)I
M;B!!9W)E96UE;G0N($%T#0H@("!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@
M9&5F97)R960@<F5V96YU92!U;F1E<B!T:&4@2WEO=V$@2&%K:V\@2VER:6X@
M06=R965M96YT('=A<R`F;F)S<#LD,34N-28C,38P.VUI;&QI;VXN#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3)P=#L@;6%R9VEN+6QE9G0Z(#$E)SX\
M:3Y#=6)I<W0@06QL:6%N8V4\+VD^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);B!*86YU
M87)Y)B,Q-C`[,C`P.2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&EC
M96YS92!A;F0@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:"!#=6)I<W0-
M"B`@("AT:&4@)B,X,C(P.T-U8FES="!!9W)E96UE;G0F(S@R,C$[*2!T;R!D
M979E;&]P(&%N9"!C;VUM97)C:6%L:7IE('1H97)A<&5U=&EC('!R;V1U8W1S
M("@F(S@R,C`[3&EC96YS960@4')O9'5C=',F(S@R,C$[*0T*("`@8F%S960@
M;VX@8V5R=&%I;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(%).06D@=&5C:&YO
M;&]G>2!F;W(@=&AE('1R96%T;65N="!O9B!24U8@:6YF96-T:6]N+B!,:6-E
M;G-E9`T*("`@4')O9'5C=',@:6YI=&EA;&QY(&EN8VQU9&5D($%,3BU24U8P
M,2P@87,@=V5L;"!A<R!S979E<F%L(&]T:&5R('-E8V]N9"UG96YE<F%T:6]N
M(%).06DM8F%S960@4E-6#0H@("!I;FAI8FET;W)S+B!);B!.;W9E;6)E<B8C
M,38P.S(P,#DL('1H92!#;VUP86YY(&%N9"!#=6)I<W0@96YT97)E9"!I;G1O
M(&%N(&%M96YD;65N="!T;R!T:&4@0W5B:7-T#0H@("!!9W)E96UE;G0@*'1H
M92`F(S@R,C`[06UE;F1M96YT)B,X,C(Q.RDL('=H:6-H('!R;W9I9&5S('1H
M870@=&AE($-O;7!A;GD@86YD($-U8FES="!W;W5L9"!F;V-U<R!T:&5I<@T*
M("`@8V]L;&%B;W)A=&EO;B!A;F0@:F]I;G0@9&5V96QO<&UE;G0@969F;W)T
M<R!O;B!!3$XM4E-6,#(L(&$@<V5C;VYD+6=E;F5R871I;VX@8V]M<&]U;F0L
M(&EN=&5N9&5D#0H@("!F;W(@=7-E(&EN('!E9&EA=')I8R!P871I96YT<RX@
M0V]N<VES=&5N="!W:71H('1H92!O<FEG:6YA;"!#=6)I<W0@06=R965M96YT
M+"!T:&4@0V]M<&%N>2!A;F0-"B`@($-U8FES="!W97)E(&5A8V@@<F5S<&]N
M<VEB;&4@9F]R(&]N92UH86QF(&]F('1H92!R96QA=&5D(&1E=F5L;W!M96YT
M(&-O<W1S(&9O<B!!3$XM4E-6,#(N(%!U<G-U86YT#0H@("!T;R!T:&4@=&5R
M;7,@;V8@=&AE($%M96YD;65N="P@=&AE($-O;7!A;GD@:7,@8V]N=&EN=6EN
M9R!T;R!D979E;&]P($%,3BU24U8P,2!F;W(@861U;'0@=')A;G-P;&%N=`T*
M("`@<&%T:65N=',@870@:71S('-O;&4@9&ES8W)E=&EO;B!A;F0@97AP96YS
M92X@0W5B:7-T(&AA<R!T:&4@<FEG:'0@=&\@;W!T(&EN=&\@8V]L;&%B;W)A
M=&EN9R!W:71H#0H@("!T:&4@0V]M<&%N>2!O;B!!3$XM4E-6,#$@:6X@=&AE
M(&9U='5R92P@=VAI8V@@<FEG:'0@;6%Y(&)E(&5X97)C:7-E9"!F;W(@82!S
M<&5C:69I960@<&5R:6]D(&]F('1I;64-"B`@(&9O;&QO=VEN9R!T:&4@8V]M
M<&QE=&EO;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(%!H87-E($E)8B!T<FEA
M;"!O9B!!3$XM4E-6,#$L('-U8FIE8W0@=&\@=&AE('!A>6UE;G0@8GD-"B`@
M($-U8FES="!O9B!A;B!O<'0M:6X@9F5E(')E<')E<V5N=&EN9R!R96EM8G5R
M<V5M96YT(&]F(&%N(&%G<F5E9"!U<&]N('!E<F-E;G1A9V4@;V8@8V5R=&%I
M;B!O9B!T:&4-"B`@($-O;7!A;GDF(S@R,3<[<R!D979E;&]P;65N="!E>'!E
M;G-E<R!F;W(@04Q.+5)35C`Q+B!);B!$96-E;6)E<B8C,38P.S(P,3`L('1H
M92!#;VUP86YY(&%N9"!#=6)I<W0@:F]I;G1L>2!M861E#0H@("!A('!O<G1F
M;VQI;R!D96-I<VEO;B!T;R!P=70@=&AE(&1E=F5L;W!M96YT(&]F($%,3BU2
M4U8P,B!O;B!H;VQD+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@8V]N<VED97)A=&EO
M;B!F;W(@=&AE(')I9VAT<R!G<F%N=&5D('1O($-U8FES="!U;F1E<B!T:&4@
M0W5B:7-T($%G<F5E;65N="P@:6X@2F%N=6%R>28C,38P.S(P,#DL#0H@("!#
M=6)I<W0@<&%I9"!T:&4@0V]M<&%N>2!A;B!U<&9R;VYT(&-A<V@@<&%Y;65N
M="!O9B`F;F)S<#LD,C`N,"8C,38P.VUI;&QI;VXN($-U8FES="!I<R!A;'-O
M(&]B;&EG871E9"!U;F1E<@T*("`@=&AE($-U8FES="!!9W)E96UE;G0@=&\@
M<&%Y('1H92!#;VUP86YY(&UI;&5S=&]N92!P87EM96YT<RP@=&]T86QI;F<@
M=7`@=&\@86X@86=G<F5G871E(&]F("9N8G-P.R0X,BXU#0H@("!M:6QL:6]N
M+"!A;F0@:&%S('1H92!R:6=H="!T;R!C;VYV97)T('1H92!.;W)T:"!!;65R
M:6-A;B!C;RUD979E;&]P;65N="!A;F0@<')O9FET('-H87)I;F<-"B`@(&%R
M<F%N9V5M96YT(&EN=&\@82!R;WEA;'1Y+6)E87)I;F<@;&EC96YS92X-"B`@
M(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.U1H92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870@
M=&AE(&1E;&EV97)A8FQE<R!U;F1E<B!T:&4@0W5B:7-T($%G<F5E;65N="!I
M;F-L=61E('1H90T*("`@;&EC96YS97,L('1E8VAN;VQO9WD@=')A;G-F97(@
M<F5L871E9"!T;R!T:&4@04Q.+5)35B!P<F]G<F%M+"!T:&4@:F]I;G0@<W1E
M97)I;F<@8V]M;6ET=&5E(&%N9"!T:&4-"B`@(&1E=F5L;W!M96YT(&%N9"!M
M86YU9F%C='5R:6YG('-E<G9I8V5S('1H870@=&AE($-O;7!A;GD@:7,@;V)L
M:6=A=&5D('1O('!E<F9O<FT@9'5R:6YG('1H90T*("`@9&5V96QO<&UE;G0@
M<&5R:6]D+B!4:&4@0V]M<&%N>2!A;'-O(&AA<R!D971E<FUI;F5D('1H870L
M('!U<G-U86YT('1O('1H92!A8V-O=6YT:6YG(&=U:61A;F-E#0H@("!G;W9E
M<FYI;F<@<F5V96YU92!R96-O9VYI=&EO;B!O;B!M=6QT:7!L92!E;&5M96YT
M(&%R<F%N9V5M96YT<RP@=&AE(&QI8V5N<V5S(&%N9"!U;F1E;&EV97)E9`T*
M("`@<V5R=FEC97,@87)E(&YO="!S97!A<F%B;&4@86YD+"!A8V-O<F1I;F=L
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M="!Y96%R<RX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H92!#;VUP86YY(&ES(')E8V]G
M;FEZ:6YG('1H92!U<&9R;VYT('!A>6UE;G0@;V8@)FYB<W`[)#(P+C`F(S$V
M,#MM:6QL:6]N(&]N(&$@<W1R86EG:'0M;&EN92!B87-I<R!O=F5R#0H@("!A
M<'!R;WAI;6%T96QY(&5I9VAT('EE87)S(&)E8V%U<V4@=&AE($-O;7!A;GD@
M:7,@=6YA8FQE('1O(')E87-O;F%B;'D@97-T:6UA=&4@=&AE(&QE=F5L(&]F
M(&5F9F]R=`T*("`@=&\@9G5L9FEL;"!I=',@<&5R9F]R;6%N8V4@;V)L:6=A
M=&EO;G,L(&%N9"!T:&5R969O<F4L(&-A;FYO="!U=&EL:7IE(&$@<')O<&]R
M=&EO;F%L('!E<F9O<FUA;F-E#0H@("!M;V1E;"X@07,@9G5T=7)E('-U8G-T
M86YT:79E(&UI;&5S=&]N97,@87)E(&%C:&EE=F5D+"!T:&4@0V]M<&%N>2!W
M:6QL(')E8V]G;FEZ92!A<R!R979E;G5E(&$-"B`@('!O<G1I;VX@;V8@=&AE
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M97(F(S$V,#LS,"P@,C`Q,2P@9&5F97)R960@<F5V96YU92!U;F1E<B!T:&4@
M0W5B:7-T($%G<F5E;65N="!W87,@)FYB<W`[)#$S+C(-"B`@(&UI;&QI;VXN
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
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M($-O;7!A;GD@:7,@9G5N9&EN9R!T:&4@861V86YC96UE;G0@;V8-"B`@($%,
M3BU24U8P,2!F;W(@861U;'0@;'5N9R!T<F%N<W!L86YT('!A=&EE;G1S(&%N
M9"!#=6)I<W0@<F5T86EN<R!A;B!O<'0M:6X@<FEG:'0N($9O<B!R979E;G5E
M#0H@("!G96YE<F%T:6YG(&%R<F%N9V5M96YT<R!T:&%T(&EN=F]L=F4@8V]S
M="!S:&%R:6YG(&)E='=E96X@=&AE('!A<G1I97,L('1H92!#;VUP86YY('!R
M97-E;G1S('1H90T*("`@<F5S=6QT<R!O9B!A8W1I=FET:65S(&9O<B!W:&EC
M:"!I="!A8W1S(&%S('1H92!P<FEN8VEP86P@;VX@82!G<F]S<R!B87-I<R!A
M;F0@<F5P;W)T<R!A;GD@<&%Y;65N=',-"B`@(')E8V5I=F5D(&9R;VTL(&]R
M(&UA9&4@=&\L(&]T:&5R(&-O;&QA8F]R871O<G,@8F%S960@;VX@;W1H97(@
M87!P;&EC86)L92!'04%0(&]R+"!I;B!T:&4@86)S96YC92!O9@T*("`@;W1H
M97(@87!P;&EC86)L92!'04%0+"!A;F%L;V=Y('1O(&%U=&AO<FET871I=F4@
M86-C;W5N=&EN9R!L:71E<F%T=7)E(&]R(&$@<F5A<V]N86)L92P@<F%T:6]N
M86P@86YD#0H@("!C;VYS:7-T96YT;'D@87!P;&EE9"!A8V-O=6YT:6YG('!O
M;&EC>2!E;&5C=&EO;BX@07,@=&AE($-O;7!A;GD@:7,@;F]T(&-O;G-I9&5R
M960@=&AE('!R:6YC:7!A;`T*("`@=6YD97(@=&AE($-U8FES="!!9W)E96UE
M;G0L('1H92!#;VUP86YY(')E8V]R9',@86YY(&%M;W5N=',@9'5E(&9R;VT@
M0W5B:7-T(&%S(&$@<F5D=6-T:6]N(&]F#0H@("!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@97AP96YS92X-"B`@(#PO9&EV/@T*("`@/"$M+2!&;VQI;R`M
M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*("`@/"]D:78^#0H@("`\(2TM(%!!
M1T5"4D5!2R`M+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF)SX-"B`@(#PO9&EV/@T*/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-C<Q-V9D
M-5]D-#`W7S1B-S%?.69C.%\S96(X83$U9C$W9#D-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q
M-68Q-V0Y+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!4
M87AE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DE.0T]-12!405A%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#,@+2!U<RUG
M86%P.DEN8V]M951A>$1I<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S
M+'-E<FEF)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3)P="<^/&(^,RX@24Y#3TU%(%1!
M6$53/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P="<^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@97AP96-T<R!T
M;R!G96YE<F%T92!5+E,N('1A>&%B;&4@;&]S<V5S(&1U<FEN9R`R,#$Q(&%N
M9"!H87,@<F5C;W)D960@;F\@:6YC;VUE('1A>`T*("`@<')O=FES:6]N(&9O
M<B!T:&4@=&AR964@;W(@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q
M-C`[,S`L(#(P,3$N($1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS
M#0H@("!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,"P@=&AE($-O;7!A
M;GD@<F5C;W)D960@82!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<R!O9B`F
M;F)S<#LD,"XS)B,Q-C`[;6EL;&EO;B!A;F0-"B`@("9N8G-P.R0P+C$F(S$V
M,#MM:6QL:6]N+"!R97-P96-T:79E;'DN#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$=7)I
M;F<@,C`P.2!A;F0@,C`P."P@=&AE($-O;7!A;GD@=71I;&EZ960@8V5R=&%I
M;B!T87@@871T<FEB=71E<RP@:6YC;'5D:6YG(&YE="!O<&5R871I;F<-"B`@
M(&QO<W,@86YD('1A>"!C<F5D:70@8V%R<GEF;W)W87)D<R!A<R!A(')E<W5L
M="!O9B!T:&4@<F5C;V=N:71I;VX@;V8@<F5V96YU92!F;W(@8V5R=&%I;B!P
M<F]C965D<PT*("`@<F5C96EV960@9G)O;2!S=')A=&5G:6,@86QL:6%N8V5S
M+B!(;W=E=F5R+"!T:&4@0V]M<&%N>2!A;'-O(&=E;F5R871E9"!A(&1E9F5R
M<F5D('1A>"!A<W-E="!R96QA=&5D#0H@("!T;R!T:&4@<F5C;V=N:71I;VX@
M;V8@=&AI<R!R979E;G5E(&9O<B!T87@@<'5R<&]S97,@86YD(')E8V]R9&5D
M(&$@;F5T(&1E9F5R<F5D('1A>"!A<W-E="!T;R!T:&4-"B`@(&5X=&5N="!I
M="!W87,@;6]R92!L:6ME;'D@=&AA;B!N;W0@=&AA="!T:&4@87-S970@=V]U
M;&0@8F4@<F5A;&EZ960N($1U<FEN9R`R,#$P+"!T:&4@0V]M<&%N>0T*("`@
M9V5N97)A=&5D('-U9F9I8VEE;G0@;F5T(&]P97)A=&EN9R!L;W-S97,@=&\@
M8V%R<GD@8F%C:R!T;R`R,#`Y(&%N9"`R,#`X('1O(&]B=&%I;B!A(')E9G5N
M9"!O9@T*("`@=&%X97,@<&%I9"!I;B!T:&]S92!Y96%R<RP@<F5S=6QT:6YG
M(&EN(&$@<F5A;&EZ871I;VX@;V8@:71S(&YE="!D969E<G)E9"!T87@@87-S
M970N($%S(&$@<F5S=6QT+`T*("`@9'5R:6YG(#(P,3`L('1H92!#;VUP86YY
M(')E8VQA<W-I9FEE9"`F;F)S<#LD,3`N-R8C,38P.VUI;&QI;VX@;V8@:71S
M(&1E9F5R<F5D('1A>"!A<W-E="!T;R!I;F-O;64@=&%X97,-"B`@(')E8V5I
M=F%B;&4N(%1H92!#;VUP86YY(')E8V5I=F5D('1H:7,@:6YC;VUE('1A>"!R
M969U;F0@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V
M,#LS,2P-"B`@(#(P,3$N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M!="!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$P+"!T:&4@0V]M<&%N>2!H860@9F5D97)A;"!A;F0@<W1A
M=&4@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;V8-"B`@("9N
M8G-P.R0R-RXU)B,Q-C`[;6EL;&EO;B!A;F0@)FYB<W`[)#$P,2XV)B,Q-C`[
M;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!T;R!R961U8V4@9G5T=7)E('1A>&%B
M;&4@:6YC;VUE('1H870@=VEL;"!E>'!I<F4@870-"B`@('9A<FEO=7,@9&%T
M97,@=&AR;W5G:"`R,#,P+B!/=VYE<G-H:7`@8VAA;F=E<RP@87,@9&5F:6YE
M9"!I;B!T:&4@26YT97)N86P@4F5V96YU92!#;V1E+"!I;F-L=61I;F<-"B`@
M('1H;W-E(')E<W5L=&EN9R!F<F]M('1H92!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H('1H92!#;VUP86YY)B,X,C$W.W,@
M<'5B;&EC#0H@("!O9F9E<FEN9W,L(&UA>2!L:6UI="!T:&4@86UO=6YT(&]F
M(&YE="!O<&5R871I;F<@;&]S<R!T:&%T(&-A;B!B92!U=&EL:7IE9"!T;R!O
M9F9S970@9G5T=7)E('1A>&%B;&4-"B`@(&EN8V]M92!O<B!T87@@;&EA8FEL
M:71Y+B!4:&4@0V]M<&%N>2!H87,@9&5T97)M:6YE9"!T:&%T('1H97)E(&ES
M(&YO(&QI;6ET871I;VX@;VX@=&AE('5T:6QI>F%T:6]N#0H@("!O9B!N970@
M;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!I;B!A8V-O<F1A;F-E('=I
M=&@@4V5C=&EO;B8C,38P.S,X,B!O9B!T:&4@26YT97)N86P@4F5V96YU92!#
M;V1E+@T*("`@26X@2G5L>28C,38P.S(P,3$L('1H92!);G1E<FYA;"!2979E
M;G5E(%-E<G9I8V4@8V]M<&QE=&5D(&ET<R!A=61I=',@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R`R,#`X(&%N9"`R,#`Y('1A>`T*("`@>65A<G,N(%1H92!#
M;VUP86YY(&1I9"!N;W0@<F5C;W)D(&%N>2!T87@@97AP96YS92!R96QA=&5D
M('1O('1H97-E(&%U9&ET<RX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V
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M"B`@(')E86QI>F5D+B!!="!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@=&AE
M($-O;7!A;GD@:&%D("9N8G-P.R0P+C$F(S$V,#MM:6QL:6]N(&]F('1O=&%L
M(&=R;W-S('5N<F5C;V=N:7IE9"!T87@-"B`@(&)E;F5F:71S('1H870L(&EF
M(')E8V]G;FEZ960L('=O=6QD(&9A=F]R86)L>2!I;7!A8W0@=&AE($-O;7!A
M;GDF(S@R,3<[<R!E9F9E8W1I=F4@:6YC;VUE('1A>"!R871E(&EN#0H@("!F
M=71U<F4@<&5R:6]D<RX-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8V-S$W9F0U7V0T
M,#=?-&(W,5\Y9F,X7S-E8CAA,35F,3=D.0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V-C<Q-V9D-5]D-#`W7S1B-S%?.69C.%\S96(X83$U9C$W
M9#DO5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F5G=6QU<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E9W5L=7,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M14=53%53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#
M5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS
M:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$
M+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@
M0FQO8VL@5&%G9V5D($YO=&4@-"`M('5S+6=A87`Z17%U:71Y365T:&]D26YV
M97-T;65N='-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I
M9B<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$R<'0G/CQB/C0N(%)%1U5,55,\+V(^#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#M);B!397!T96UB97(F(S$V,#LR,#`W+"!T:&4@0V]M
M<&%N>2!A;F0@27-I<R!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M)
M<VES)B,X,C(Q.RD@97-T86)L:7-H960@4F5G=6QU<RP@80T*("`@8V]M<&%N
M>2!F;V-U<V5D(&]N('1H92!D:7-C;W9E<GDL(&1E=F5L;W!M96YT(&%N9"!C
M;VUM97)C:6%L:7IA=&EO;B!O9B!M:6-R;U).02!T:&5R87!E=71I8W,L(&$-
M"B`@('!O=&5N=&EA;"!N97<@8VQA<W,@;V8@9')U9W,@=&\@=')E870@=&AE
M('!A=&AW87ES(&]F(&AU;6%N(&1I<V5A<V4N(%)E9W5L=7,L('=H:6-H(&EN
M:71I86QL>2!W87,-"B`@(&5S=&%B;&ES:&5D(&%S(&$@;&EM:71E9"!L:6%B
M:6QI='D@8V]M<&%N>2P@8V]N=F5R=&5D('1O(&$@0R!C;W)P;W)A=&EO;B!I
M;B!*86YU87)Y)B,Q-C`[,C`P.2!A;F0-"B`@(&-H86YG960@:71S(&YA;64@
M=&\@4F5G=6QU<R!4:&5R87!E=71I8W,@26YC+@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
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M9&1I=&EO;BP@=&AE($-O;7!A;GD@;6%D92!A;@T*("`@:6YI=&EA;"!C87-H
M(&-O;G1R:6)U=&EO;B!T;R!296=U;'5S(&]F("9N8G-P.R0Q,"XP)B,Q-C`[
M;6EL;&EO;BP@<F5S=6QT:6YG(&EN('1H92!#;VUP86YY(&%N9"!)<VES(&UA
M:VEN9PT*("`@87!P<F]X:6UA=&5L>2!E<75A;"!A9V=R96=A=&4@:6YI=&EA
M;"!C87!I=&%L(&-O;G1R:6)U=&EO;G,@=&\@4F5G=6QU<RX@26X@36%R8V@F
M(S$V,#LR,#`Y+"!T:&4@0V]M<&%N>0T*("`@86YD($ES:7,@96%C:"!P=7)C
M:&%S960@)FYB<W`[)#$P+C`F(S$V,#MM:6QL:6]N(&]F(%-E<FEE<R8C,38P
M.T$@<')E9F5R<F5D('-T;V-K(&]F(%)E9W5L=7,N($EN($]C=&]B97(F(S$V
M,#LR,#$P+"!I;@T*("`@8V]N;F5C=&EO;B!W:71H(&ET<R!S=')A=&5G:6,@
M86QL:6%N8V4@=VET:"!296=U;'5S(&9O<FUE9"!I;B!*=6YE)B,Q-C`[,C`Q
M,"P@4V%N;V9I(&UA9&4@82`F;F)S<#LD,3`N,`T*("`@;6EL;&EO;B!E<75I
M='D@:6YV97-T;65N="!I;B!296=U;'5S+B!!<R!A(')E<W5L="!O9B!T:&ES
M(&EN=F5S=&UE;G0L('1H92!#;VUP86YY(')E8V]G;FEZ960@82!G86EN#0H@
M("!O9B`F;F)S<#LD-"XT)B,Q-C`[;6EL;&EO;B!D=64@=&\@=&AE(&EN8W)E
M87-E(&EN('9A;'5A=&EO;B!O9B!296=U;'5S+B!4:&ES(&%M;W5N="!W87,@
M<F5C;W)D960@87,@;W1H97(-"B`@(&EN8V]M92!I;B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@
M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`N#0H@
M("!!="!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@=&AE($-O;7!A;GDL($ES
M:7,@86YD(%-A;F]F:2!O=VYE9"!A<'!R;WAI;6%T96QY(#0U)2P@-#8E(&%N
M9"`Y)2P-"B`@(')E<W!E8W1I=F5L>2P@;V8@4F5G=6QU<RX@4F5G=6QU<R!C
M;VYT:6YU97,@=&\@;W!E<F%T92!A<R!A;B!I;F1E<&5N9&5N="!C;VUP86YY
M('=I=&@@82!S97!A<F%T90T*("`@8F]A<F0@;V8@9&ER96-T;W)S+"!S8VEE
M;G1I9FEC(&%D=FES;W)Y(&)O87)D(&%N9"!M86YA9V5M96YT('1E86TL('-O
M;64@;V8@=VAO;2!H879E(&]P=&EO;G,@=&\-"B`@('!U<F-H87-E(&-O;6UO
M;B!S=&]C:R!O9B!296=U;'5S+B!-96UB97)S(&]F('1H92!B;V%R9"!O9B!D
M:7)E8W1O<G,@;V8@4F5G=6QU<R!W:&\@87)E('1H90T*("`@0V]M<&%N>28C
M.#(Q-SMS(&5M<&QO>65E<R!O<B!)<VES)B,X,C$W.R!E;7!L;WEE97,@87)E
M(&YO="!E;&EG:6)L92!T;R!R96-E:79E(&]P=&EO;G,@=&\@<'5R8VAA<V4@
M4F5G=6QU<PT*("`@8V]M;6]N('-T;V-K+@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE
M($-O;7!A;GD@:&%S(')E=FEE=V5D('1H92!C;VYS;VQI9&%T:6]N(&=U:61A
M;F-E('1H870@9&5F:6YE<R!A('9A<FEA8FQE(&EN=&5R97-T(&5N=&ET>0T*
M("`@*"8C.#(R,#M6244F(S@R,C$[*2!A;F0@8V]N8VQU9&5D('1H870@4F5G
M=6QU<R!C=7)R96YT;'D@<75A;&EF:65S(&%S(&$@5DE%+B!4:&4@0V]M<&%N
M>2!D;V5S(&YO="!C;VYS;VQI9&%T90T*("`@4F5G=6QU<R!A<R!T:&4@0V]M
M<&%N>2!L86-K<R!T:&4@<&]W97(@=&\@9&ER96-T('1H92!A8W1I=FET:65S
M('1H870@8V]U;&0@<VEG;FEF:6-A;G1L>2!I;7!A8W0@=&AE#0H@("!E8V]N
M;VUI8R!S=6-C97-S(&]F('1H:7,@96YT:71Y+B!!="!397!T96UB97(F(S$V
M,#LS,"P@,C`Q,2P@=&AE('1O=&%L(&-A<G)Y:6YG('9A;'5E(&]F('1H92!#
M;VUP86YY)B,X,C$W.W,-"B`@(&EN=F5S=&UE;G0@:6X@4F5G=6QU<R!I;B!I
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M=F5S=&UE;G0L(&%S('=E;&P@=&AE('!O<G1I;VX@;V8-"B`@(%)E9W5L=7,F
M(S@R,3<[(&1E8G0L(&EN8VQU9&EN9R!A8V-R=65D(&EN=&5R97-T+"!G=6%R
M86YT965D(&)Y('1H92!#;VUP86YY('=H:6-H('=A<R`F;F)S<#LD-2XT)B,Q
M-C`[;6EL;&EO;B!A=`T*("`@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$N#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:71S(&EN
M=F5S=&UE;G0@:6X@4F5G=6QU<R!U<VEN9R!T:&4@97%U:71Y(&UE=&AO9"!O
M9B!A8V-O=6YT:6YG+@T*("`@4W5M;6%R>2!R97-U;'1S(&]F(%)E9W5L=7,F
M(S@R,3<[(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$@86YD#0H@("`R,#$P
M(&%N9"!B86QA;F-E('-H965T<R!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,2!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!A<F4@<')E<V5N=&5D(&EN
M('1H92!T86)L97,-"B`@(&)E;&]W+"!I;B!T:&]U<V%N9',@*'5N875D:71E
M9"DZ#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@("`\(2TM("]&
M;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M+2!004=%0E)%04L@+2T^#0H@
M("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RQ4:6UE<RQS97)I9B<^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@
M/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D('=I9'1H
M/3-$-3(E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0V/CQB/E1H<F5E($UO;G1H<R!%;F1E9#PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#8^/&(^3FEN92!-;VYT:',@16YD960\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI
M9"`C,#`P,#`P)SX\8CY397!T96UB97(@,S`L/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3$\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$P/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M/&(^,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SX\8CY3=&%T96UE
M;G0@;V8@3W!E<F%T:6]N<R!$871A.CPO8CX-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY.970@<F5V96YU
M97,-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XS+#@P.3PO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XR+#,P.3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF
M;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ,"PT,C8\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,RPX,#0\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^3W!E<F%T:6YG(&5X<&5N<V5S#0H@("`\+V1I=CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C0L-S@S/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XT+#<T,SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,34L-C@X/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XQ-RPQ.#(\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DQO<W,@9G)O
M;2!O<&5R871I;VYS#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L
M969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#DW
M-#PO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B@R+#0S-#PO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@U+#(V,CPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F
M=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@Q,RPS
M-S@\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K
M9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY/=&AE
M<B!E>'!E;G-E#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#8W/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^*#0X/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^*#,R,CPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@Q,S(\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3F5T(&QO<W,-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$L,#0Q/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@R+#0X
M,CPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XH-2PU.#0\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$S+#4Q,#PO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z
M+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@
M(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E
M;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!W:61T:#TS1#<V)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P
M)SX\8CY397!T96UB97(@,S`L(#(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CY$96-E;6)E<B`S,2P@,C`Q,#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@
M("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@
M=&5X="UI;F1E;G0Z+3$U<'@G/CQB/D)A;&%N8V4@4VAE970@1&%T83H\+V(^
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^0V%S
M:"P@8V%S:"!E<75I=F%L96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^-#0L,#@X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C4T+#<X.3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O
M=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY7;W)K:6YG
M(&-A<&ET86P-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^,CDL-3@W/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT,"PT-#8\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX]
M,T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^5&]T86P@87-S971S
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C0X+#@Q,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^-3DL-S`S/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/DYO=&5S('!A>6%B;&4-"B`@(#PO9&EV/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3$L,C8R/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ
M,2PR-S`\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^5&]T86P@<W1O8VMH;VQD97)S)B,X,C$W.R!E<75I='D-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPY-C0\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C<L.3DV/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8V-S$W9F0U7V0T,#=?-&(W,5\Y
M9F,X7S-E8CAA,35F,3=D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V-C<Q-V9D-5]D-#`W7S1B-S%?.69C.%\S96(X83$U9C$W9#DO5V]R:W-H
M965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13
M($%.1"!#3TY424Y'14Y#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A4
M34P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]4
M4B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@
M(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@-2`M('5S+6=A87`Z0V]M
M;6ET;65N='-!;F1#;VYT:6YG96YC:65S1&ES8VQO<W5R951E>'1";&]C:RTM
M/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L5&EM97,L<V5R:68G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,G!T)SX\8CXU
M+B!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO8CX-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`V<'0G/CQB/CQI/DQI=&EG871I;VX\+VD^/"]B
M/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#9P=#L@;6%R9VEN+6QE9G0Z
M(#$E)SX\:3Y496MM:7)A($QI=&EG871I;VX\+VD^#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M/;B!-87)C:"8C,38P.S$V+"`R,#$Q+"!496MM:7)A(&%N9"!0<F]T:79A
M($)I;W1H97)A<&5U=&EC<RP@26YC+B!F:6QE9"!A(&-I=FEL(&-O;7!L86EN
M="!A9V%I;G-T#0H@("!T:&4@0V]M<&%N>2!I;B!T:&4@0G5S:6YE<W,@3&ET
M:6=A=&EO;B!396-T:6]N(&]F('1H92!3=69F;VQK($-O=6YT>2!3=7!E<FEO
M<B!#;W5R="P@:6X@0F]S=&]N+`T*("`@36%S<V%C:'5S971T<R!A;F0@;VX@
M2G5N928C,38P.S,L(#(P,3$L('1H92!P;&%I;G1I9F9S(&9I;&5D(&%N(&%M
M96YD960@8V]M<&QA:6YT(&%D9&EN9R!!;$-A;F$-"B`@(%1E8VAN;VQO9VEE
M<RP@26YC+B`H)B,X,C(P.T%L0V%N828C.#(R,3LI+"!A(')E<V5A<F-H(&-O
M;&QA8F]R871O<B!O9B!T:&4@0V]M<&%N>2P@87,@82!D969E;F1A;G0N(%1H
M92!A;65N9&5D#0H@("!C;VUP;&%I;G0@86QL96=E<R!M:7-A<'!R;W!R:6%T
M:6]N(&]F('1H92!P;&%I;G1I9F9S)B,X,C$W.R!C;VYF:61E;G1I86P@86YD
M('!R;W!R:65T87)Y(&EN9F]R;6%T:6]N(&%N9`T*("`@=')A9&4@<V5C<F5T
M<RP@8VEV:6P@8V]N<W!I<F%C>2P@86YD('1O<G1I;W5S(&EN=&5R9F5R96YC
M92!W:71H(&-O;G1R86-T=6%L(')E;&%T:6]N<VAI<',@8GD@=&AE#0H@("!#
M;VUP86YY(&%N9"!!;$-A;F$L(&%N9"!U;FIU<W0@96YR:6-H;65N="P@8V]N
M=')A8W1U86P@8G)E86-H+"!B<F5A8V@@;V8@=&AE(&EM<&QI960@8V]V96YA
M;G0@;V8-"B`@(&=O;V0@9F%I=&@@86YD(&9A:7(@9&5A;&EN9RP@=6YF86ER
M(&-O;7!E=&ET:6]N+"!F86QS92!A9'9E<G1I<VEN9RP@86YD('5N9F%I<B!A
M;F0@9&5C97!T:79E(&%C=',-"B`@(&%N9"!P<F%C=&EC97,@8GD@=&AE($-O
M;7!A;GDN(%1H92!P;&%I;G1I9F9S('-E96LL(&%M;VYG(&]T:&5R(')E;&EE
M9BP@:6YJ=6YC=&EV92!R96QI968L#0H@("!U;G-P96-I9FEE9"!D86UA9V5S
M(&%N9"!T:&4@=&5R;6EN871I;VX@;V8@;&EC96YS97,@=&AA="!T:&4@<&QA
M:6YT:69F<R!P<F]V:61E9"!T;R!T:&4@0V]M<&%N>2X-"B`@($]N($%P<FEL
M)B,Q-C`[-BP@,C`Q,2P@=&AE($-O;7!A;GD@=&EM96QY('-E<G9E9"!A;F0@
M9FEL960@86X@86YS=V5R('1O('1H92!P;&%I;G1I9F9S)B,X,C$W.R!O<FEG
M:6YA;`T*("`@8V]M<&QA:6YT(&1E;GEI;F<@=&AE('!L86EN=&EF9G,F(S@R
M,3<[(&-L86EM<RP@=&]G971H97(@=VET:"!C;W5N=&5R8VQA:6US(&%G86EN
M<W0@=&AE('!L86EN=&EF9G,N($]N#0H@("!*=6YE)B,Q-C`[,C@L(#(P,3$L
M('1H92!#;VUP86YY('1I;65L>2!S97)V960@86YD(&9I;&5D(&%N(&%N<W=E
M<B!T;R!T:&4@<&QA:6YT:69F<R8C.#(Q-SL@86UE;F1E9"!C;VUP;&%I;G0-
M"B`@(&1E;GEI;F<@=&AE('!L86EN=&EF9G,F(S@R,3<[(&-L86EM<R!A;F0@
M8V]U;G1E<F-L86EM<R!A9V%I;G-T('1H92!P;&%I;G1I9F9S(&%S<V5R=&EN
M9R!B<F5A8V@@;V8-"B`@(&-O;G1R86-T+"!D969A;6%T:6]N+"!B<F5A8V@@
M;V8@8V]V96YA;G0@;F]T('1O('-U92P@8G)E86-H(&]F('!A=&5N="!P<F]S
M96-U=&EO;B!A;F0@;F]N+75S90T*("`@<')O=FES:6]N<RP@;6ES87!P<F]P
M<FEA=&EO;B!O9B!C;VYF:61E;G1I86P@86YD('!R;W!R:65T87)Y(&EN9F]R
M;6%T:6]N(&%N9"!T<F%D92!S96-R971S+"!U;FIU<W0-"B`@(&5N<FEC:&UE
M;G0L(&)R96%C:"!O9B!T:&4@:6UP;&EE9"!C;W9E;F%N="!O9B!G;V]D(&9A
M:71H(&%N9"!F86ER(&1E86QI;F<L(&%S('=E;&P@87,@=FEO;&%T:6]N<R!O
M9@T*("`@36%S<V%C:'5S971T<R!S=&%T=71E<RX@5&AE($-O;7!A;GD@:7,@
M<V5E:VEN9R!D86UA9V5S(&%N9"!E<75I=&%B;&4@<F5L:65F(&]N(&ET<R!C
M;W5N=&5R8VQA:6US+@T*("`@26X@4V5P=&5M8F5R)B,Q-C`[,C`Q,2P@=&AE
M($-O=7)T(&=R86YT960@=&AE('!L86EN=&EF9G,F(S@R,3<[(&UO=&EO;B!T
M;R!D:7-M:7-S('1H92!#;VUP86YY)B,X,C$W.W,-"B`@(&-O=6YT97)C;&%I
M;2!F;W(@9&5F86UA=&EO;BX@5&AE($-O;7!A;GD@:&%S(&$@;G5M8F5R(&]F
M(&%D9&ET:6]N86P-"B`@(&-O=6YT97)C;&%I;7,@<F5M86EN:6YG(&%G86EN
M<W0@=&AE('!L86EN=&EF9G,N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3)P=#L@;6%R9VEN+6QE9G0Z(#$E)SX\:3Y5;FEV97)S:71Y(&]F(%5T86@@
M3&ET:6=A=&EO;CPO:3X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T]N($UA<F-H)B,Q-C`[
M,C(L(#(P,3$L(%1H92!5;FEV97)S:71Y(&]F(%5T86@@*'1H92`F(S@R,C`[
M56YI=F5R<VET>28C.#(R,3LI(&9I;&5D(&$@8VEV:6P@8V]M<&QA:6YT(&EN
M('1H90T*("`@56YI=&5D(%-T871E<R!$:7-T<FEC="!#;W5R="!F;W(@=&AE
M($1I<W1R:6-T(&]F($UA<W-A8VAU<V5T=',@86=A:6YS="!T:&4@0V]M<&%N
M>2P@36%X(%!L86YC:PT*("`@1V5S96QL<V-H869T(%IU<B!&;W)D97)U;F<@
M1&5R(%=I<W-E;G-C:&%F=&5N($4N5BX@86YD($UA>"!0;&%N8VL@26YN;W9A
M=&EO;B!';6)(("AT;V=E=&AE<BP@)B,X,C(P.TUA>`T*("`@4&QA;F-K)B,X
M,C(Q.RDL('1H92!7:&ET96AE860@26YS=&ET=71E(&9O<B!":6]M961I8V%L
M(%)E<V5A<F-H("@F(S@R,C`[5VAI=&5H96%D)B,X,C(Q.RDL('1H92!-87-S
M86-H=7-E='1S#0H@("!);G-T:71U=&4@;V8@5&5C:&YO;&]G>2`H)B,X,C(P
M.TU)5"8C.#(R,3LI(&%N9"!T:&4@56YI=F5R<VET>2!O9B!-87-S86-H=7-E
M='1S("@F(S@R,C`[54UA<W,F(S@R,C$[*2P@8VQA:6UI;F<@82!P<F]F97-S
M;W(-"B`@(&%T('1H92!5;FEV97)S:71Y(&ES('1H92!S;VQE(&EN=F5N=&]R
M(&]R+"!I;B!T:&4@86QT97)N871I=F4L(&$@:F]I;G0@:6YV96YT;W(L(&]F
M('1H92!4=7-C:&P-"B`@('!A=&5N=',N(%1H92!5;FEV97)S:71Y(&1I9"!N
M;W0@<V5R=F4@=&AE(&]R:6=I;F%L(&-O;7!L86EN="!O;B!T:&4@0V]M<&%N
M>2!O<B!T:&4@;W1H97(-"B`@(&1E9F5N9&%N=',N($]N($IU;'DF(S$V,#LV
M+"`R,#$Q+"!T:&4@56YI=F5R<VET>2!F:6QE9"!A;B!A;65N9&5D(&-O;7!L
M86EN="!A;&QE9VEN9R!S=6)S=&%N=&EA;&QY('1H90T*("`@<V%M92!C;&%I
M;7,@86=A:6YS="!T:&4@0V]M<&%N>2P@36%X(%!L86YC:RP@5VAI=&5H96%D
M+"!-250@86YD(%5-87-S+B!4:&4@86UE;F1E9"!C;VUP;&%I;G0@=V%S#0H@
M("!S97)V960@;VX@=&AE($-O;7!A;GD@;VX@2G5L>28C,38P.S$T+"`R,#$Q
M+B!4:&4@56YI=F5R<VET>2!I<R!S965K:6YG(&-H86YG97,@=&\@=&AE(&EN
M=F5N=&]R<VAI<"!O9@T*("`@=&AE(%1U<V-H;"!P871E;G1S+"!U;G-P96-I
M9FEE9"!D86UA9V5S(&%N9"!O=&AE<B!R96QI968N($]N($]C=&]B97(F(S$V
M,#LS,2P@,C`Q,2P@=&AE($-O;7!A;GDL($UA>`T*("`@4&QA;F-K+"!7:&ET
M96AE860L($U)5"!A;F0@54UA<W,@9FEL960@82!M;W1I;VX@=&\@9&ES;6ES
M<RX@06QS;R!O;@T*("`@3V-T;V)E<B8C,38P.S,Q+"`R,#$Q+"!536%S<R!F
M:6QE9"!A(&UO=&EO;B!T;R!D:7-M:7-S(&]N('-E<&%R871E(&=R;W5N9',L
M('=H:6-H('1H92!#;VUP86YY+"!-87@@4&QA;F-K+"!7:&ET96AE860-"B`@
M(&%N9"!-250@:&%V92!J;VEN960N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L
M:6\@+2T^#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M
M+2!004=%0E)%04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9B<^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[06QT:&]U
M9V@@=&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!I="!H87,@;65R:71O<FEO
M=7,@9&5F96YS97,@=&\@96%C:"!O9B!T:&4@8VQA:6US(&EN('1H90T*("`@
M;&%W<W5I=',@9&5S8W)I8F5D(&%B;W9E(&%N9"!I;G1E;F1S('1O(&9U;&QY
M(&1E9F5N9"!I='-E;&8@:6X@=&AE<V4@;6%T=&5R<RP@;&ET:6=A=&EO;B!I
M<R!S=6)J96-T#0H@("!T;R!I;FAE<F5N="!U;F-E<G1A:6YT>2!A;F0@82!C
M;W5R="!C;W5L9"!U;'1I;6%T96QY(')U;&4@86=A:6YS="!T:&4@0V]M<&%N
M>2!I;B!O;F4@;W(@8F]T:"!O9@T*("`@=&AE<V4@;6%T=&5R<RX@26X@861D
M:71I;VXL('1H92!D969E;G-E(&]F(&QI=&EG871I;VX@86YD(')E;&%T960@
M;6%T=&5R<R!A<F4@8V]S=&QY(&%N9"!M87D@9&EV97)T#0H@("!T:&4@871T
M96YT:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;6%N86=E;65N="!A;F0@
M;W1H97(@<F5S;W5R8V5S('1H870@=V]U;&0@;W1H97)W:7-E(&)E(&5N9V%G
M960@:6X-"B`@(')U;FYI;F<@=&AE($-O;7!A;GDF(S@R,3<[<R!B=7-I;F5S
M<RX@5&AE($-O;7!A;GD@:&%S(&YO="!R96-O<F1E9"!A;B!E<W1I;6%T92!O
M9B!T:&4@<&]S<VEB;&4@;&]S<PT*("`@87-S;V-I871E9"!W:71H('1H92!L
M96=A;"!P<F]C965D:6YG<R!D97-C<FEB960@86)O=F4@9'5E(&EN(&5A8V@@
M8V%S92!T;R!T:&4@=6YC97)T86EN=&EE<R!R96QA=&5D#0H@("!T;R!B;W1H
M('1H92!L:6ME;&EH;V]D(&%N9"!T:&4@86UO=6YT(&]F(&%N>2!P;W-S:6)L
M92!L;W-S(&]R(')A;F=E(&]F(&QO<W,N#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3)P=#L@;6%R9VEN+6QE9G0Z(#$E)SX\:3Y4=7-C:&P@4V5T=&QE
M;65N=#PO:3X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN($UA<F-H)B,Q-C`[,C`Q,2P@
M=&AE($-O;7!A;GDL($UA>"!0;&%N8VLL(%=H:71E:&5A9"!A;F0@54UA<W,@
M96YT97)E9"!I;G1O(&$@9VQO8F%L('-E='1L96UE;G0-"B`@(&%G<F5E;65N
M="`H=&AE("8C.#(R,#M3971T;&5M96YT($%G<F5E;65N="8C.#(R,3LI(')E
M<V]L=FEN9R!T:&5I<B!O;F=O:6YG(&QI=&EG871I;VX@<F5G87)D:6YG('1H
M92!4=7-C:&P-"B`@('!A=&5N=',N($U)5"P@9F]R;65R;'D@82!P87)T>2!T
M;R!T:&4@;&ET:6=A=&EO;BP@86QS;R!A9W)E960@=&\@=&AE('1E<FUS(&]F
M('1H92!3971T;&5M96YT#0H@("!!9W)E96UE;G0N#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@-G!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M4:&4@;&ET:6=A=&EO;B!W87,@:6YI=&EA=&5D(&EN($IU;F4F(S$V,#LR
M,#`Y(&%N9"!S8VAE9'5L960@9F]R('1R:6%L(&EN($UA<F-H)B,Q-C`[,C`Q
M,2!I;B!T:&4@56YI=&5D#0H@("!3=&%T97,@1&ES=')I8W0@0V]U<G0@9F]R
M('1H92!$:7-T<FEC="!O9B!-87-S86-H=7-E='1S+"!A;F0@<F5L871E9"!T
M;RP@86UO;F<@;W1H97(@=&AI;F=S+"!T:&4-"B`@('!R;W-E8W5T:6]N(&]F
M('1H92!4=7-C:&P@22!A;F0@5'5S8VAL($E)('!A=&5N="!A<'!L:6-A=&EO
M;G,N($EN('1H92!F:65L9"!O9B!23D%I('1H97)A<&5U=&EC<RP-"B`@('1H
M92!#;VUP86YY(&ES('1H92!E>&-L=7-I=F4@;&EC96YS964@;V8@=&AE(%1U
M<V-H;"!)('!A=&5N="!A<'!L:6-A=&EO;G,@9G)O;2!-87@@4&QA;F-K+"!-
M250@86YD#0H@("!7:&ET96AE860L(&%N9"!O9B!T:&4@5'5S8VAL($E)('!A
M=&5N="!A<'!L:6-A=&EO;G,@9G)O;2!-87@@4&QA;F-K+B!4:&4@=&5R;7,@
M;V8@=&AE(%-E='1L96UE;G0-"B`@($%G<F5E;65N="!I;F-L=61E9"!M=71U
M86P@<F5L96%S97,@86YD(&1I<VUI<W-A;"!W:71H('!R96IU9&EC92!O9B!A
M;&P@8VQA:6US(&%N9"!C;W5N=&5R8VQA:6US(&EN#0H@("!T:&4@;&ET:6=A
M=&EO;B!B971W965N('1H92!P87)T:65S+@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[07,@
M<&%R="!O9B!T:&4@4V5T=&QE;65N="!!9W)E96UE;G0L($UA>"!0;&%N8VLL
M(%=H:71E:&5A9"P@54UA<W,@86YD($U)5"!A9W)E960@=&AA="!F=71U<F4-
M"B`@('!R;W-E8W5T:6]N(&]F('1H92!4=7-C:&P@22!A;F0@5'5S8VAL($E)
M('!A=&5N="!F86UI;&EE<R!I;B!T:&4@56YI=&5D(%-T871E<R!S:&]U;&0@
M8F4-"B`@(&-O;W)D:6YA=&5D(&%N9"!L960@8GD@82!S:6YG;&4@<&%R='DN
M($UA>"!0;&%N8VL@=VEL;"!A<W-U;64@=&AA="!R;VQE+"!I;B!A9&1I=&EO
M;B!T;R!T:&5I<@T*("`@;VYG;VEN9R!L96%D97)S:&EP(&EN('1H92!C;VYT
M:6YU960@<')O<V5C=71I;VX@;V8@=&AE(%1U<V-H;"!)22!P871E;G0@9F%M
M:6QY(&]U='-I9&4@=&AE(%5N:71E9`T*("`@4W1A=&5S+B!536%S<R!W:6QL
M(&QE860@9G5T=7)E('!R;W-E8W5T:6]N(&]F('1H92!4=7-C:&P@22!P871E
M;G0@9F%M:6QY(&]U='-I9&4@=&AE(%5N:71E9`T*("`@4W1A=&5S+B!);B!A
M9&1I=&EO;BP@=6YD97(@=&AE('1E<FUS(&]F('1H92!3971T;&5M96YT($%G
M<F5E;65N="P@=&AE($-O;7!A;GD@9W)A;G1E9"!536%S<R!T:&4-"B`@(')I
M9VAT('1O('-U8FQI8V5N<V4@=&AE(%4N4RX@5'5S8VAL($E)('!A=&5N="!F
M86UI;'D@=&\@365R8VL@)B,P,S@[($-O+BP@26YC+BP@<W5B:F5C="!T;R!C
M97)T86EN#0H@("!T:&ER9"UP87)T>2!O8FQI9V%T:6]N<R!O9B!T:&4@0V]M
M<&%N>2!A;F0@;W1H97(@;&EM:71A=&EO;G,L(&EN(&5X8VAA;F=E(&9O<B!A
M('-H87)E(&]F(&-E<G1A:6X-"B`@(&9U='5R92!S=6)L:6-E;G-E(&EN8V]M
M92X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H92!#;VUP86YY(&EN8W5R<F5D(&-O<W1S
M(&]F("9N8G-P.R0S+C,F(S$V,#MM:6QL:6]N(&%N9"`F;F)S<#LD,RXX)B,Q
M-C`[;6EL;&EO;B!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9`T*("`@
M36%R8V@F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"P@<F5S<&5C=&EV96QY+"!I
M;B!C;VYN96-T:6]N('=I=&@@=&AI<R!D:7-P=71E+B!4:&5S92!C;W-T<R!W
M97)E(&-H87)G960-"B`@('1O(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M(&5X<&5N<V4N(%1H92!#;VUP86YY(&1O97,@;F]T(&5X<&5C="!T;R!I;F-U
M<B!A;GD@861D:71I;VYA;`T*("`@<VEG;FEF:6-A;G0@97AP96YS97,@<F5L
M871E9"!T;R!T:&ES(&1I<W!U=&4N#0H@("`\+V1I=CX-"B`@(#PO9&EV/@T*
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-C<Q
M-V9D-5]D-#`W7S1B-S%?.69C.%\S96(X83$U9C$W9#D-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-C8W,3=F9#5?9#0P-U\T8C<Q7SEF8SA?,V5B
M.&$Q-68Q-V0Y+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E<W1R=6-T=7)I;F<\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T
M<G5C='5R:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4D535%)50U154DE.1SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#8@
M+2!U<RUG86%P.E)E<W1R=6-T=7)I;F=!;F1296QA=&5D06-T:79I=&EE<T1I
M<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF)SX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3)P="<^/&(^-BX@4D535%)50U154DE.1SPO8CX-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`V<'0G/B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.TEN(%-E<'1E;6)E<B8C,38P.S(P,3`L(&%S(&$@<F5S=6QT
M(&]F('1H92!P;&%N;F5D(&-O;7!L971I;VX@;V8@=&AE(&9I9G1H(&%N9"!F
M:6YA;"!Y96%R(&]F('1H90T*("`@<F5S96%R8V@@<')O9W)A;2!U;F1E<B!T
M:&4@3F]V87)T:7,@0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E96UE
M;G0@86YD('1H92!#;VUP86YY)B,X,C$W.W,@<F5D=6-E9`T*("`@;F5E9"!F
M;W(@<V5R=FEC92UB87-E9"!C;VQL86)O<F%T:6]N(')E<V]U<F-E<RP@=&AE
M($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E8W1O<G,@87!P<F]V960@
M86YD('1H90T*("`@0V]M<&%N>2!E9F9E8W1E9"!A(&-O<G!O<F%T92!R97-T
M<G5C='5R:6YG('1O(&9O8W5S('1H92!#;VUP86YY)B,X,C$W.W,@<F5S;W5R
M8V5S(&]N(&ET<R!M;W-T('!R;VUI<VEN9PT*("`@<')O9W)A;7,@86YD('-I
M9VYI9FEC86YT;'D@<F5D=6-E(&ET<R!C;W-T('-T<G5C='5R92X@5&AE(&-O
M<G!O<F%T92!R97-T<G5C='5R:6YG(&EN8VQU9&5D(&$-"B`@(')E9'5C=&EO
M;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&]V97)A;&P@=V]R:V9O<F-E(&)Y
M(&%P<')O>&EM871E;'D@,C4E+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z
M(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[1'5R:6YG('1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`L('1H92!#;VUP
M86YY(')E8V]R9&5D("9N8G-P.R0R+C(F(S$V,#MM:6QL:6]N(&]F#0H@("!R
M97-T<G5C='5R:6YG+7)E;&%T960@8V]S=',@:6X@;W!E<F%T:6YG(&5X<&5N
M<V5S+"!I;F-L=61I;F<@96UP;&]Y964@<V5V97)A;F-E+"!B96YE9FET<R!A
M;F0-"B`@(')E;&%T960@8V]S=',N($1U<FEN9R!T:&4@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$L('1H92!#;VUP86YY(&1I
M9"!N;W0@<F5C;W)D(&%N>0T*("`@861D:71I;VYA;"!R97-T<G5C='5R:6YG
M(')E;&%T960@8V]S=',N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L
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M:71I97,L(&EN('1H;W5S86YD<SH-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9"!W:61T:#TS1#4R)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY/<FEG
M:6YA;#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^*%)E=F5R<V%L<RD@;W(\
M+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%M;W5N=',\+V(^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O
M;'-P86X],T0R/CQB/D%M;W5N=',\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D-H87)G
M97,@86YD($%M;W5N=',\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%D:G5S
M=&UE;G1S('1O/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY086ED(%1H<F]U
M9V@\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%C8W)U960@870\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C
M,#`P,#`P)SX\8CY!8V-R=65D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^0VAA
M<F=E<SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P@,C`Q
M,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P@,C`Q,3PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D5M<&QO>65E('-E=F5R86YC92P@8F5N969I=',@86YD
M(')E;&%T960@8V]S=',-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#$Y,SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)FYB<W`[
M)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#(P/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPQ-S,\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HS,'!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^5&]T86P-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#$Y,SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)FYB<W`[
M)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#(P/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPQ-S,\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P
M.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R
M:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M
M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L
M:6\@+2T^#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M
M+2!004=%0E)%04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9B<^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#9P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(&9O
M;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!C;VUP;VYE;G1S(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@<F5S=')U8W1U<FEN9R!A8W1I=FET:65S#0H@
M("!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P
M+"`R,#$Q+"!I;B!T:&]U<V%N9',Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1C96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`@("`\=&0@=VED=&@],T0U,B4^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^06UO
M=6YT<R`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/BA2979E<G-A;',I(&]R
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!;6]U;G1S/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY!;6]U;G1S/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!8V-R
M=65D(&%T(#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^061J=7-T;65N=',@
M=&\\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E!A:60@5&AR;W5G:#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^06-C<G5E9"!A=#PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/D1E8V5M8F5R(#,Q+"`R,#$P/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^
M0VAA<F=E<SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P@
M,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P@,C`Q
M,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/D5M<&QO>65E('-E=F5R86YC92P@8F5N969I=',@
M86YD(')E;&%T960@8V]S=',-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XY-S<\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XY-S<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^
M)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M;&5F=#HS,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^5&]T86P-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XY-S<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB
M<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XY-S<\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X
M)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL
M93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M
M+3X-"B`@(#PO=&%B;&4^#0H@("`\+V1I=CX-"B`@(#PO9&EV/@T*/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-C<Q-V9D-5]D
M-#`W7S1B-S%?.69C.%\S96(X83$U9C$W9#D-"D-O;G1E;G0M3&]C871I;VXZ
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M.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,2YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?-C8W,3=F9#5?
?9#0P-U\T8C<Q7SEF8SA?,V5B.&$Q-68Q-V0Y+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0000950123-11-094900-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950123-11-094900-xbrl.zip
M4$L#!!0````(`%>'8S]C0T\/KE\``*@<`P`1`!P`86QN>2TR,#$Q,#DS,"YX
M;6Q55`D``X4`LTZ%`+-.=7@+``$$)0X```0Y`0``[#UK<]NXM=_OS/T/J'?;
M.C.4+$I^R4FVX]C>U-L\?&VG=_NI`Y&0A(8BN01I6_?7WW,.P(>><61))AUV
MIK,.">*\'P`.=-[\[6'DL3L1*1GX;W?L9FN'"=\)7.D/WNXDJL&5(^7.WW[Y
M[_]Z\Z=&@_W^[OH#>R]\$?%8N.Q>QD-Z]I%'7]E9$(XC.1C&;/?L%>N-V?4U
M.P]\7WB>&+-&(YWD'5?P;>#KV=I-V[Q[Z$4>`WQ\]79G&,?AR=[>_?U]$Q\W
M@VBPUVZU.GO25S'W';&C1YYXTO^Z9#B^[@&\=/C#S/C[#HVVN]WN'KU-AW+/
M'V<C\1\>'S6=8`03VW:KVVFE`Z4*]MOVT3*D]8CT`^#K@/,P^Z#/58\&FQ<$
MH=&R&QT[PQOFD]_!%GSKYA\4!Q_NZ9?94"7G,01&VGN_?_QPXPS%B#>F`;AB
M:G8EG.8@N-N#%T7\0;",O4&^GBB:Z5KT&?'Y)!Z'XNV.DJ/0PVGIV3`2_;<[
MR.U&RN;F@W)WV)Z>"/7G+/!C\1"S&^'$H+9:>^"=8YY+]^W..^XAMJ?J<__?
MG=:-"&&VED8&1@H_EO'8_`O^+5U\TI<B8H2DF&!(2MG9Y3]V?FD!6^RCX\.C
MUIN]_+-TXKV)F=^$(I*!6X!#3(Q_060:K6ZC@Y.89^D,A6_>[!F2OD&??2X<
M$%>W1/0!<78;Y+\6^HS\[!+1A_J]9OF533_7*+_?$K]\]+4.UR:_STY</OT$
M$E>7WRTX8O$1'@S5A>\*MT1&".1$\3GD'\8,CR#2O-G+GV8#A>\6AFEK39^M
MB1O/K](3W&@]CANMIW'CD_0KP@Q[\\SXC?L(!W7LW\`&F*E12BMY#"M6L!+(
MQ[[X,LO%TE0LP6?(GB\WYQ=7-QDW7'D'E.3`<=RG9(3+B2#*'L.+D>`JB<0O
M)G,^@7G>[*4/L\_WYG]/TYX+/QA)?]'$E%"?J"&/A%HT\^P4;_8*%.A!4P3?
MT(P9P=\&-W<6('=FBH6L*,Z`^?&%!VKES^;'M/82`^FS=U[@?&6W?#"`A=BG
M(!;9&+,".;F1`Q_4S8'(<>HX00*ZY@^N`D\Z4JA;$+^>PNC"-2;M"RWA+U[\
M&F"??SZ[_=?5!1O&L.2\^O+NP^49VVGL[?UOYVQO[_SVG/W^]]N/'QBL0=EM
MQ'TE$7GN[>U=?-IA<Q8HM]=[#SB7C1^;/QMQX<NF&\/"H='XRR!^3;PTB"QD
M`BQ$V?<Q8&IR4`[&/?CR[8XG^O$.4_'8`POO`YL:?3Z2WOB$_?56CH1BG\0]
MNPY&W/^K10\L!4;6WYE!%C7'\M4\.O2KA^E7TUA,O$0%7C3:`:T1T2362OZ?
M.&%V*XQ?LQ&/@'&-.`A/&#R@B7&*WB2$WJ,!SC)I$3B[/0W/;K*;+Q\_GE[_
MBWW^E=U<OO]T^>OEV>FG6W9Z=O;YRZ?;RT_OV=5GT+++BYN-X74XC1;^(?&/
M=UQ)Q8(^NP*3!\9RLD7NN_!`^HZ$12^]AM6L`K5RZ3TA)M-Y-HLQ'X6O?[(/
M6X_^ZW8H&`=;&(7<'X,UH/5#6,+-'"<C`O[1!Y<)!'(/\($'Z(N(TE.]A\*N
MP`N.N".2&,S+4Q:[])TF$;4;`P@-\+C=;KT^T["R)_9K%D3%`6;*PH!7#%PL
M2WR>N!*1088/^9U@/2%\%D8BA/<N`_M'4B(7LWB]C\4S,R=<PEQ*`]KP\KPQ
MCA%AK+]'7#'VP;]ND$Y-(\0BH(KM%I!\?WIZ-8EA&((?X3U/L#B`J<#HY$@#
MI4"K$&LKA1&$TD?5@=G!6_`!,13?.E[B@D0\C_D!,-0C6B/A)%&$TN'N?Q(5
M:^['0QXC8PB(+QRA%(_&")U$Q/I<1D`>@@-M33PML"#$P`JP%>L#W_7;,(B0
M9(-IDZ%63,G)/GJM"-+W*`@)"=0AF)(4&@WKD3&II$=K&8FR2`'`BQBC'<K0
M(A:H89!X+DP#V'(2%0S[3^+K:*C'Q?.Q9JG:%/$E2'-Q3KDR%CQB`I-A!DMY
M,>J)*#>;CFTQS#,M=C^4SI#="U!0([U,D19Q\-3W$X!Y36Q'7OP*H@:K;OQ#
MR_2>`Q;22_=B<:H;U``(@8+4B%T\.$/N#PC$2"K<Z)VQLYN+LZ*"$F2$)7I1
M`GJ2TV(?$RVV%CN2W0"R"W+NZ74QR$"(F`'[.*'H@K;<H>2C8)3Q.&,IP<O9
M:K%>`M\&0(`?Q!.*[DKE>`%F/@J$^T<B44-Z8X8FIG$JJ.\RODZI-@Q)[=!H
M-KD1!)]:"\1N&.*"W<9`2CK_ZN`"&!]-`X5W])[U$Z"V#]2"\)'-S9<1!2+1
M]R`K-7XMXXGF'E%D.$BJFP:,+\V;IHX25O;L(HE@`G;Z?L+53KZ=T>GBI`4S
M.0LB,"_"!8TT`._2".Y](`(]CG0E2%],R[@),P%M>9JH9>FD^.MHHFV0LE+N
M:&+1T1$VY.>$)VF)(=P)5PIYJ%`$#K4\'K.1B(>H(/U"G$+_;?Y%:B,!G/3O
MA/;Z\">!N1:#Q$L4SA[QD**N(F9.<,Z,*K)LW3HWF\-ER=(7119UH6(YPE!:
M^CQ(AR>=TP'B<Y5=!QX0S`@%2/X9_53JN%0AG*,D1_RKU@N1<H%TARN5C$*M
M.CJ,]_NI"671F(^TLJ%Z*"6,VGF2]Z27AX+4QG(OBA_@&@Z4";%8]*V&AG:=
M&L&WC'[*I:?@YV(<B3OA)P9'\1#BO!`R$LIB\H_P7]I-@NDY<6*`I![8H:#O
M2N!.I.,,&`RH5<;-+:KS)XA]'P*EV!7@@G$7M(0V!DJMU[AB<2#>Q<Q#W('7
MP%3"G?8MF$0FC\(DUC&7=D)0*-D7/(XC";$[S6SUUT858+4,GA42`84?HUCO
M!1X6HR[<@6>"#,5/,'/2.IG#!1U)8LS[$%B3G4N/,"CB:7+!I^.Z%$\=0KZ!
M*^JPBRABDA`&F)JB6YA`#NW_CGLF,X<@4"20H%S-_5"E^2Z"-4\@HTN(AB0,
M="HI'B`*2>U0B1R(M-I][";*F!0!B2/:1!J;43K"O"(*$HHB`I<3"OCDX)]Z
M%+_G$:;][X3#(4811,K0E'&%&<TS0E'L/DW,,8EO9&RBE`>":;KZ"?6*6<`:
MR)TC[8E)"8K4H5+Q$4RM:+6P1)'+E4OU(=T([DDN)$?RP,`1B!;I\F*&+_KI
M`AW9A94K?ACD*R17Y*$*/UT@>?%@%B7&?8*;YYZ3>-FW<UBJK9O4NI>KA(P*
M2C%?ZF9]&R0*%$Z=?,\&U<1KP[4%<L+=R09]?<*T1!WA>2KD#E6XM'98+XB`
M/?0GO@JYZZ:O[J4;#]_NV*W6GV?WY?0FXBU!_SNN,Z=VX>*(W1FT>T$<!Z-\
M"I8.<5,01X=_GE8A9$7L+OGFX/L_L6LHZX:B_QU-BWY6'X_!2SQ"(QZ+X*,)
M\8/["&N-]']WIO=ZG0"M`1X<3N8R=.1)L0"/^Y@^[V.,3OSRW&55_%X0UU*D
MM1]I:!S!_80/C/)B]E.+_C?)WAO<1J0,HM.R:GYF_&ROR$_<E'HZ&\M)6&LS
M^D%'A6#?BT/8=)A[%[CC;X>YC$[N?!U$L,IS3]A/CB-$O[](U29BO?G<9%@8
MM$_L@_#!Q'*)Z\[XI(&/:+K/Z=HX8&$2.4.NQ$0R/Y-8;%$Y#&.H*):0/;:.
M6^WM(;`ZHD=6USY8LS=ZG-MYBBY\F;-L*:TN=`Y69O`VT<SVLMN;CTZVD>.:
MU2+';`,*,!,!BBY_@IM3`4!O(LWW_L\A^5+2\3A7LN60LU%]6MU2NY9]<%0%
ME[*)X%)U9[(N0^R`(;I!@NG:\WF4TA/S[7QX7JZ[1WM-DX\V?91PG6<R-[19
M=TH;L`2[K`<)M*W));GI1.@CGKG;R&P0<;V?&3`Q"KU@+&A+&W=PX6FVI?U'
M$J3[[WAPA9NE@.E7$6.5CD,;I&8/TGR0'E71_)8IA<&-3=QIQ@,U_7=?R!AK
M"9I85D'3PTQX8(<U#`V-Q`+4=0E)1B#^P]`$Z)OJ3)?=X^Y^X=!8'[\)6!J.
MI&\.>+DSE.).'P/BEGWB#(MHT%&;U&L<B944`I$/HZ"'RMAD%_K`#-Z9XS`G
M&/@@4I<%=T+O'V-2G)^>6902"Q]W0&<0G$2.QPP+4E4&CI[IPX.<X'OI>02C
MR2Y]]I$7ZD5P66[-,""5.O<9'PPB,3#2:K>[L#XZS(Y]^H\7!Q52Q9H%F299
M9D<[/4><5_#CP;I71&HH0_#W?$2'\$HL!$/%.R1U0%]SXN=VLY-3/`)FT&ZY
M9BN1JM4QJT3C#%FLCXWO=!6-J:-*!:452A542BLGJ!36G^BJJ(4E3)/ZY(@H
MYG@4[4D?Z^U`PG?""T)Z/PBXI[5?GPNDFWX$SL>-OY'>^-/%3=FN5:&ZJ:4K
M@B:D3%H8X1<_MYK[L\Q!5L";HYDWEM%A%6+M,N`YMK)C+*,`>*P'"J_/),QI
M,7SA<>-'XF7RV^(9\*_H`/])_N&C=@=T$EY^QSUY'I6=.C%)I0RFC+47)/%B
M#=1E!&G18>X.X=\8%X@\XSJQNB^O6=1U?CQ>IFFD/<O*[/"]J=32YY-Y+"+(
M8!X1CYSA.'7<^$K3%0MGZ,L_$N.:LV*<6'KD4D&_,@>I/74^-WH_[=YTN:A5
M>*?RS^@\^@/:(+,!S3`!3IGY39S300V/:_TT<+W*Z:3*5;0-@J7#H*XJTW=$
MT,2-`.!9H8P#S/P;^+2G\<'Z/>UY`EDL(V5!3XGH#O7#TFS@:AKY#'5+%T:!
M0;(HJVH92^&!+2?178I8KA3SD>M,(Y?X.1:ZTM!@F1Z;$A>*3!AK]Z+U0Q<5
M*D@`3!$:A,*(]$67#\#X&,F3?2S7L]*$@WB/]3R+H6@G\VM6$F2D,6T%2RT@
M0O4:`4Q2.RSR)+-45EK559^<FC.]=CG.`6LH-927`>71&RSE/TN<R,Q.XSSC
M>L9MU4=B^S\ZFE[I:"K]*N%>N#OWPZ+]4JUHS84+6S1_2IK91YTP5PGSSWF:
M>TDI<)60_U+,TM>%_KJ-:Q%Q$VON[ZO;.!?*B6287>I<D[CJ0II5"=LU:^Y7
M+YFZ]HNFKK,&ZN:YCA=2"77&U;!XMV`#A],SOROP\[?'YN>^AT?6P>H'O]O&
M]J`+V&[Q//UIV!Y9W>YQ59#=7$W1YFO,=`)IKFID5TAW^_*!;G,[P4B\VH#E
MU>/J<>L;]SCKV4#\ZK26Q"]S#9ONW8M-A*_O]6ZYQ[);Q];A8;<L\EN&ZAJ<
M:\W92H:M9<:%OZ'`WF-)B*\K`WH`49]\E<K0CFVK?5R)*L:*V=D/Q=B2QK?1
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MNR:FRL3,,^]G;*:T>ON+\R1*6\5\?^^32.CF,'[`XHC[JB\BQ7HBOA?"S_H]
MI*U5TGX+_:DF`;H-C,.C:(R8\!$D(+%BD>A[@IJ9R,5]7[!/$#9#<:GG.R90
M/&V:U.,>M1)20Y$VBW"X&F(G(,_CO<!TAX^$(R05DRF+!4@3=FB(<$-;HV<Q
M[C@:I9"/2;0I1?`BPJ8XIB.+8CP,H^!!CO#$J=#NP(7_ZRXM$GLV!5'<H&XX
M,,[L*FRQ1\LE]0NEOBS(V<(FQTVVR4&(E+EA2]JD1!(Q"ML@8=\CH10).14^
M45A@.';!\`)_D+(_(]T5O3@3J]G@R?=\M(:F,!T/%$/V<2]($@\G^#D]:6'G
MB`..$C6,H`R%YP(K&D8)QMA.@]]QZ>&W#5#7AN(PB6X`!(K:YTZL^X@X,G*2
MD8HUA6FK&JY[T\1R)``O`I'V!G;I39&>TY@)[@PGC42W;#+S"7>RNU%&-:9+
M'G:125M/33$@9>4L&Y$!LQ1.,C<2(4A+3SR'&T58DRU%^&**"KU/D(%CEOB1
MX-3<1DM"[^2Q`9>^,CJBT)QWJ=<)]72A$RZPX1SB*](M[+.$WX/C*S@F0WN3
M71LX^=P$T<R/'4\*;5\2E7IB;`6%A>.FO0V6D).S&HEX&+B$(GYKB"(/J5V7
MKA9ILLN^YB`0NPC_U,$"&H`$=LH2J:>=Z/"6LWRVJ1DZ78FTDTYD\F+B#A%W
MR.L)W6E(=R6"5-4@<C^4("WJ6Y<"5RQE8;OU6M,3#[EI_2)&>)(?9>Z_;;]&
M/E"O&A7H5C5J"F&$8UK8Q$-8UPZ&0"M81#00IG=:'D`R>M(@`K*%_VA5`U8$
MH=`18\H;N!)3E-AT_R*.2W@C(T)``U.%7EW:9#`@%<I[BEZC8"]N'IO3F*3;
MV359(6QG#<R*`5P[LA4;F'%_E@;DP<^MYF$^2=K8K-"';-8EH$K-.@*8ZU9\
M'<F(LRN8?<0=D5`7)\72D@V<>;>@#V9\0?RO+'0H0`"!!"T"HU:9#D_WW$)E
MED5OS>YYUED04.\)EJM<KFX3PIY(/7*1$9BBFP/3++I+$Y,*A92HM(AD`)DK
M9$->F@F,+=:/@M%$.\?4B>L^3D!"MY7+P.5CW?(*(I]N`L;5`F5Z/,B)V&$Q
MXEH:70&A:?B+631#-G$&!@84T_JHJV)L\"6H_<3'-I-46C"86UJ@(^#4J>>Z
MTZ<U=Y/+NEHMS&/GB^S;/>&(S&5]X<@:ZJY9]<7>&DH-9=U0'KW'6?8KB?;^
MBO=()CH#L?7T$2D[5\L^;M6+A>\C6)4]77PUPC,(;^H8LS0FL?(5XE$0Q;@_
M4`4I>MD%W'3WI,:ZMIC-,V2UR'P6J++_5L1JA+W'G<072=D'VA5]D:11%_)_
MXD[49O+#EW+A>&I?A^V>)P*6(_$0\+9SEHP%CS91=_O4'Y*T[.KTH]IF,<ZR
M7\/X;L1WEUSXGH:$0UX]-Z>?]FOX"R+YYLO?IRY/;ML6OU<VA5\%:%OV<25N
M1[2WB.4WC7`U$G;;2XH0-V2.3U2-E7\K_W&FN/68.<=,>1_REFDKS0Y!VY//
M2W:%Y>#0.MQF'>X3S+=,,71%\[4[2]J0E<]^#ZW]XY7[ICU;*%UR5;HZ8;5]
M8'5:^U6PRVVVV]V465;(*$DQ5E[WE#*H?M-@*QY@6_86?S5K=4RWZ&TV9<B=
M)9E,Z2SYX,#J'E4OO%Y,%YB5RMQ^G.9<-;J;4((%9E7UFV0+W&XIKLW6=-1T
MU->QGWG3O&VU#K:9`#[MEVC+E*I^YW%*:\EZN:0'*K;5;:V\=_Y"`^JZG%]]
M`;@FILK$S#/ONOU9?4NBAE)#>0XHCTXWREZ*N?(MB8D63^OI!U-VII9]W(N_
M<U`YA#>UN5`:DZ@O2=18UQ:S(8;4ER0FO7Y]2:)ZI-67)'Z`2Q+TT_65V=;?
M9F^Y]>[J+]D=+^6>_M-:&BR(Y/4EB<7\M@^MSO$6*R571[6]S:K3C5V3V+Y!
M/DTY#@Y7_G7IQUEC?4_BB4(ZM(X.*W%/8INM:C9FO]L_)'^::ARM[-N?+9B^
MC&L2^U9[?XL_S/\$+:F^5=I+,H/2625JQJ93W/J>Q/KDU3VV;+L2;43;95JG
MKFC*W2HER*`:K?T-WR/>@+F6^Z*$;77V*[$@/;0K\>L"^JO*7)%X4HN]!295
M]9K.!2ZW%,7L-1TU'?4EB><]GCC:MPZ.*_.34\>K[TFL0;F?=IYB+XM-I3Q1
M:1_AO?QU[P)5/:*NR_O5M?@U,54F9IYY/V,#NR4-RVZ2GA)_)+B]='&';40(
M:A6ZDZ6MCW3++'&G>PE%NE<>=_0V63SD,0L<:O#CFOVR)5T_B*YT_RQKV@)_
M*+&@&UZAX5ZAI1'U[9-*):+834@JTV'(,G!F&QT-^9V@-D?8Y2["6;%OT,"G
M-E=`G!_XA0<J%YZFO\FVISG7`FN3V*GNWX<47D6!#W\[F@FE5J1+G_W&_21K
M>87/9GLV<3<(4<:^N&<\B8=!)$'&$D0T2$#\V(.+6C0![ZGE%PF&FBOU`]T?
M:91XL0RQ:9='7&$\`O4<:`[IWC[I5);IVL7#T,/^--A>:]G7C"K#3&\MZ<-P
MT(]4;3S0H,#5+9(`'>Q^1[H_0[2=]JKB,*FK>WPY0";.0FT=_[^]+W]NV\@2
M_E>PFDQM4D5*/$72DTR5+,N.9FQ9:\G)SO?+%$2"$F(0X."0K/WKOW=T-[IQ
MD"`(R93#K:V))9'=KU^_?O<1.4L;)T;A\$@YF='S@BG_2LXHXY%2KF_9*X&V
M;@1<CW*^EC$R[3^)&_+A:!_<O@BY-/_.<Q?P\F*Y3A*IF6JA`R`E.(2)!KHQ
MEK5]Q`RF&2QQ#Y#3$"&P<&@ZE6-`N[`?<705_`D^*4?(V?H@M1LG@K<7Q3R5
M$@"(',_#3RU#=^JH#W;_9KF\*YQFAEB5,^B"FS^<*9&4&NN&QP-F$<[:@/GX
M,?T#\`_D$6H2'+"6W!D49]'/\>`"A[QQY%T"MGR7!Z_9Z>M=A@%N-+-^=']*
MZ<.6>,)Q:L#>@$-%`H\\=),VG"81F(V`0;P=9(3^S/8"GP8LNA'-DH-E]77%
MP"P=RG2*H'7K^'`J8'XHNA'.T(F3D(?5T40T1!COGX&O)7^FD8_`;H&(%OQ2
M>4?$DG$@-U)4+!X38.)&CB(E'@OGB?E1B?EG\(4X##RY)E]J\>@Z>J7\/N5@
MOPC8'(T=1!);^<0+7O0CB0?GJQO1K66_SP]47V-6<P9M^>0QM;D'-`X243$&
M<_BK?1LZ`@;$E^LSS0`="JI#Z0DGY+>WA)?N!DF$2";!6?3T:1?%>_'+JQGL
MGT_>N,`)8GQY2_N1<:]-$#3H@M&>3HJ40.`#%_=%;"%]0K2#%H0\A._H[!_O
M0^AAI'<M'"<63Q2T)`84>8X&)4J,*0Y&I,-A!D+*P%+69-PX_BU=0`SM)!:1
M1XL;Z?J3':D/N4Q*+HM1D#JQ>MNLHN%/*6XT@($]3>]<YYX$*Q+KW!(C6V-]
M.IUX#_[,%8/U0H+UE<E=<VO3[#T_2HA+(SK$4-O2V78ZAQ.'8OCDFT^7%[AS
M_#M;Z&B*?^DC23/L$<?*HDB%=T:7QQQ,B:\DIA&;_`'<4\T[7`]M&:1_R\@*
M)64,:F.ZCM!+ZL`]`'DO[2C6MU!R)XMRGH(M#ZSV+=B$",B.`I_D@2YZM$LW
M-`G<4KP]"X?/1BTAV/"8@1I0O`QP5BLJ^.D%&5NW9#Y.1DP>6A]QD0<7IT>:
M%ZR>/!`;;8+R)Y5M@ODJ@7;OJ%FW\$`=MI#\6<F+P30$GH@*AV).D!?A/#(T
M,\5V`>PY%O.<#8&L<Y)K&@8,[$\P";*6U+N?!0[K/JDTY,7O<.MR<A,RQ>`2
M?#B2G3G,F2*<U"9I9DK-5[NY>0)*B78!DJ<J^6CP6WK-+#&)KX)N!TI.1'-6
MQ7N2P]4=X"%BX"B`0=(@MU*Z:TO37O&S18Q0YZ`E@F*GA.4'NU!0OE7&MF9V
M7I&Z&8+Q\CJ`_QB#;=^>7+W6M/"?I&YA,U;5(LS5Q$(LO::>'?(@<J)RM,K$
MH&@@HZD3QC8-;A57K=D7"V`8"=LQ*=[5^/.O2UO:63,WFGH!?C8BR5:\AA"F
M^$REH2%-$4V1I,43/[B)G/">F-6/[X$./*N/H[27"=,V6A!P;G50^-F9SX4!
M0KH[Z+Y(C/0+4MX),MOWT:"2AW!1IW478IZXT!)`:$9`NG#_/K$ZS>K,SU#M
M#@N4S/29`Y8`!CHXO[LL9S!.0>^4/2>IWP1G+,,2R,/U2=0ESAMY__$N*HZ)
M[Q0^!J!M1<\^&_!R,/<J!4K,H)>TK+ATZ-PA;[IWU*#SSZE5O&![(756V/0=
M=E4]RC590&`TCQZ)OJ@@'%RX)6RHQ1+XCY@`[CNQ'-?-]F_V`SP_N@A.J2*A
M0B'L*__6<Z02B_Q?W6P.++E&0-^/'X+42+Y)6'HZTX2>0Y8\X&K$SE,:Y9QB
MA+0&<F:0T)7(<4#?24^5/378R[?,VAF!OIC:+'&6__8*E&BKV6(]O/J";VA[
ML,01'Q<Z$GZKF#CHBV^1GA(0Y%-Q>!?ED:(8MNMU)D-\#O@>[$!)B2SF)$.1
M;$2I/D'$`(K/INQE'6/A=:,[FST?[%1#W29.&9SW>&B=V:'WF/(7ESU/`,?"
MC6/TWGY,YY;;4M\`T/1')`Z<Y5$&!E*NQC2![(I96Q'+*E-H-O!!KV!AZ2]^
M/DJB]JUM+U]=I:(D%:V7L,,4;O3:^1J_]H+IE[_C&C_+2`;]RKJV;V\!A@M0
MBZQV._T$EWJ6?T;N?)HZ#>Z=DU3/>:.DH]J>GC3\\,F9_W(`]G2[TVWC9?_[
MREFV^QWZ]\'?1;#ES<?3ZW]=GEEW\<*S+C^_?G]^:AVTCXY^[Y\>';VY?F/]
M[Z_7']Y;W<..=8TA`U*4;._HZ.SBP#JXB^/EJZ.CAX>'PX?^81#>'EU_.OJ*
M:W7QR^*?[5C[YN$LGAV4%[WF,=&SVE8-+&1V6"F0YC8H>H^OK/^^=A<@6R]`
M;'X*0/W^[Q;]H@7:@JNE=#08)^@=6E?G[R[.WYZ?GEQ<6R?O/IV=?3B[N+[:
MP6A`P5SY=*Q\5/H:F5$:+Q$9NM"_(S:%D4_8X?0NXR`+D)U)=X9D>ZX_0QW3
MF>U'R_]MWS1MO\M^EWW3M)7-,(Y-F7-]%SJ.]8$#'&=HL*3"YCGR4K:#_@*C
M,\T"_QU==+VN)RJ^9?4[K1TGAITXX7=#,77[Y*`-L=.$LL7!&F@-N9L'V]_8
M-KF(+[99TZ=@*D*#NG'4P,UNUVRGWYI,GC,7_T\$[:#;FCSG].%O"6V)*'[Z
M0M9K^XLSLY_@76V*=6T"2&LP>1G3,5O#X<OH3W'<&@U?1$$P0#IXZKEYSRRX
M+H)[.XS=':L0?Q'4`.)J_"(X0?<Y&S/5!W/<F@QK][GZ9B+JHTJDVIG7T^J-
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M__:U'3F>L8(LJ<BO<.Y/#P&`X-:A#&3:2ENE9657U]?5<_<!:-E;X,:9VI@P
M+].Q:6O7MTZ2VR2*5^'Z-K2I8)<AL+$11=OY.O42R@F7A<"B\J`H61)3O#T/
MMDU$M<42;R:,'_7Z.%F[W99%J_JWU#>T`JM(U>")^GMUX#B@7698!!,LQ2W+
MV2Y`K?A)X%].$KM37'F63&6IS3SQJ7V(Z@3RZ>*$4]3G0$181F'<[,6)JZ.>
MFWM$"17VK\*(.@55D]M\1KW'+WW7#6=4*^8ZHCI-XEIXCZFPELK#Y2N`K\V#
M)#0.:&,5(^?$BZ8&7(C$'Q>5]U:RQ)^Z8POS/#FIF?8H6(EJ`ERN0C(JY*DN
MDBAV[CK>C"[H+@'2QG(GAPLE@!I0.^+V%*JK!+ZZ&<``B+]YY+Q8/G>+?ZFJ
M*@V4XF>9*+$ZU==`MWX8=@X[*5$O7.!V6JTT%51H'\^>LD6UO?[C3A4#37,5
MU]3R`@5NI!XI8(A1DIA,@'^YM-V9@<$?>J/^X9`.)7$$/"%9@ID(Z)[:T9U6
M('F>HIBRE($)<%&$A*6D;B$.W9N$Z=IL5$&04>DXW@>^IJ*G*1\RG$Y>>(LJ
MN^SYW`4AA@6FV%>#:E'P?>0:8C!7T([M<NUW[#'&0F?J("\KJ*<E\A-EW[**
MR"S9%-!Q$2P6GMA8"\S%\"U.%,>GP@\,J?06J/U6\*P?NIU"0ETZYB..@8B<
M6#0/,N1"&#S:'C!&!?&-'7'GEX<@]&8/0#&RA@\=`02=(N^LJ)#EUIJ8E6S?
MBP(L0@2ER8WNJ(P2:QBQ-%@6^^IR%*CCXS0.C/H<D"P3@WV^D0M8I_J7#8ZZ
M"3<5<%3DJ.5/&Y7'MP'<0U%FS%'A7PK7N#QY=_;ZT]G)/[.?UFS(9RW5>%*5
MS/F*U7)$&2AM@0C@*4V_H&8&;`);A93J5J?\^2O\/)WP4G[G1'XGKWLQ77)9
M,"E=+7I=DB?@ZZ*/$-\"JO`=ENQ<9R<(G8%6I5OT#%05H@Y6`4@9C90>2(J#
MZ$Z6XE=`@*FS5CI^YBOJI=*6KYW8`33<)OYM9+U;W/Q:@IL"/?6=@S7ZCV4:
M)?4UD,@R82BY.1--4>!E&^MH[110M2S6^^PH<J@:E';)'%X)/0&\*%S66*VZ
M`VK.Q)QW6,!X=TK@<QW2HXE`(:MF2D@KQJ]$S0_]?K=(J*0J04HIMC`#I9D@
M]4';SVY@:A2$0E(><ONTK!\&O8+?IPM(&;/J=1%%%U^2!LG:AT.*LR'34JT9
MNR2$J`?#0<:'O?P^3)5$-<$4--0(]5?5,"-M*)-E+TKQD+*3<;P[Q/7[G>/+
M]A9%K:2,IA,F_4DM-`*"<51_&J-@6QU?[P\2.K(6>E4K,M$-I*!\7?:=40U`
M1)FU,-S,]C4:.`NP;KE#@-ZZ;$W;,F69R+6IIZ/6L8V;I<"UHGM)=6F3G8#T
MAG.YSF,I;$P/)V9[":H?5OT-U"&%&H1[SQQDPM0!C]H+^=K'@/O9`N'81-#^
MPK3_1S*[%?UA;H(D-CO_D/*-]8?WW#M/T0`L+._8I4IFOCD\LFKUD[:UL:FV
M6LD&70_CYCD`[)V[--L^W-&#XO,XL]Q59KO;D=:?]A;3]`#)M^+43&X5<0@A
M1ZB/X&+I!8^.J%IGTSUVG)#M\@55@>,\NS\"%ZDV]R=:1#2"B9WIG1]XP>UC
M^O>?E"*!C3D`)K;:4^95HO^NQ5`+Q5F4V$7]'F@+]6AN:8(00EW4&0;^O\+#
MUSJ]K9;"V*8$:]T+J$2G?XD,ZT?WT#GD/8KP+I]@"99^8A\@MQ##K@^/.6AU
MU!-T-PX5^8*!'W.'(Z-I!+*C+#<B1JF09'9["K/=[*A?EKD8OPRUH,E*T5+C
MWDA%M[.T`0^A+WL"8*&_IT.@:66TBREKRO"J(41@J`2_)N;D)CDH>!U4X:($
MV(CZ$C=0PAO2&($'NLP<61CU=$C)PW1*9OQYNR,U]6>IM9>33<SH`I3[4C7/
M8OD2VNBG:7NN$C'452O%!AT*G;38SM00N&"]!W':B^PQ;3J:MESQJ.$/,O,Y
M4&)L]""1;;B0TIC>^9(,\SCC+A+$$3JP&M"2@`$L)?*?4J\@ZO]#WC.]L]<B
M`.(0@BV2W%'O.Z:US.(7Q!WUS)=!U*.:D>F]R&!KWE?7,W)^FY8%YT>_7B"+
M[+$R!R2CI"L=9-'U3Z*)A)ZO*+ZP_U]+\@27G5)Q>6<Y"5*^OYC08N0AR9GG
M+&R7^'5ZRLQRJAF;]MG\80+5$"=/>06=SO0FG29$Y41=MGR6L'?G_8))=0'`
M+3)>J6Y'ND>1RK&)]4SUZ&*\Y'I_88_Q>QKTA=J_2J=1G;ZHLXSF&-0#'<CO
MR=6IOL9O5MQ+>JTE78KA?;*C"QN;^S'9,?@5\L@2(R6/1X'[#5OCG(1A`/1M
MSZQ/<GLYP!?/J/L#U$<S42N!HU0AFP*OB52/3XR8:*[+2"H-Q.VE]U9A0S)Y
M!)E$P3UU%E=02E57*$_*^C0<SL2NTN\L$A8VK"J2(LSM<XM\P;2LX#<(:<02
M.2?BTF8=3.#"7([E`TIY[*J^J>8]'EHG\:H^O*V\L6D:X0_`&7\8=@_[3^[(
MP*BV^@UEO%BRUX",*W/MT(X'EC/=!3OCC!.S,%B\4:!8*Z$R%:H5SCR!NLL[
M&\AF2N\&I)<$ZKV([OV8V\58"=N-H5V0:FO9T(0>!;6U]VJ$72+=W2<`*SE(
M?IB!#$.)[V6"Q:TT)M&2@8OV#7`AO:-TN:-?!#T+W(.;!Y);LI&WETIPG2,4
MAY?36P<&I'77UI1:TIJH11D&?^05M-`R3^:H!J,^E1@)"'IH.G<;&T5`5D0_
MQ%65QY256PQ$N!9/YN/)<&[@3]G*I7"R$P-18`,X$=]5`C`;:`:KWB18@EHT
M3=.BT(%T*&5CSAH.S.A;VF=Y`[*5?W?+&SRE"0Y+D;3#OGQNW2H;1I]$P.I0
M1H5N'*"GEOV#9*F+CZP#128:9-N>]O<!JB>*CXL;239B<I*A<:8"=9Q^S(5+
M?^@6IQUH(75\-SXPBC8J-KK;B-K)S;$;?G&\/;O7G6BXS(^HA:$G8"(1^5W0
MV>`)!P`0+#[<2W*+GY^?FVHIC@Y98LJJ0`?+K6&G/>P@JYR#?H.!+$JX4;Q/
M35]8)UW$$_CL$S.YBCE4/P=DB$`V9ZL(W`I.-$M3<L@#&23>C)B)%K`7,(N[
MI:M^"/2$#KD$.RUDAH'V`6)IS*`BSF>@B'@+'6'4J!%D0B5"85,W#3<4=&U%
M)4-\-9>`41!G69$60+X628*"(3U62WW)I,ZLS&LHHDO3&`;J_"A\U<7[M:P?
M>H5PH,K*6#`!*LD8&(N%C!25%6M\0)/&M.Y$)&E3:#ZHUGVHBEL_HOXGFX<:
M&7C7*;*NY2/^H!!E!E+/YY(2B,XH+8&E)%D.J0[$ZD%YAE*D2$I.>#':SMJ&
M1K,B'8H?AO"EB!R5);R>K^1A`FV@UY%=83./!\,!_%;2Q[,^-4QX$:NFAZU(
M#<OP1R.-*)>Z5IA*Q`C,Y1*)T2\JF:@T=4@R,9D^E+Z?]:Q1[^&>R1'ZH3LJ
M"M_R<Z=Q*7265I.)0#MCHEUF(AOKU2?3"R#E="A2EC2K301'A#]=>5^*3""@
MR%#UZY4#-$#"2#V7T[$B31VX2;4!09\YPU!SN#21[52FZPN'!B6YF-J^0`VB
M):L]:/M*'U>J6;?8BRR!S@QKD=C/XA5O0W\'$L^S,$F--%W2D!C/(I;=XJL>
MOCC6'4\KD5.CYFX8Q4#HMP%P($,AS+Q-8444&,9E%U"6IQB56@5D3$AWEZ[%
M&>N>O+]H?[KZ#9<#;75A'%,21*%F)B]1OXT[+;H%#,0.5Z&&)`;@=NHNU?`9
M:2+Y&R"M3-_+:79L>F92!B,1KF3FS,!S[+5(34XC6MEW]H_KZU/S5=EBG8*Z
M1]S97(HYG[;<IU-C.=$JG5=4=+QJ16.U-Z<9X(0`E@[%2`I19\9IS>Q1IG"&
MGU"W/YIEDG8AOY=EG;02#8[;'7Y>+]A?@?4+9U!)U)]O1X_BXV^1,EH67BA=
M(M[%3_SY,H57<_3G(LH*?B.4<J/B:D(58V>PGGREMX5N+O)?$/47$:8F(O\K
M(OA*$N20+E%6+/E^*L@8R,;T4[M7!V9-4+]>0)_ONTI0?[N`OJZ$K`KJ5U)]
M/)Q[)6XPXBE/PO,K+TM$[XG8F>KA$2@,9MD/2U'/G9/+T\?("7W?QGP`.-*N
MA?36A.0W-*T)ZWEKC@Z76G2T2HG1RQH0F`/+.$6J02)P,31!CBQ/-6TR5G1.
M4C4SI,T0+JTU*07:/17F$[@R#8EV)O.E.+,@FU.`[IK$FR.3BRDK4E,Z6YA8
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M%%`*KA"C@D_2AF**%(_%\F7HL2!R`!RMC1\&HSUV*#80"?',+EO!`N65'9HD
M(Z,'Y-:%[\^$=8&Q'A'H*TK,Z;2$.CB/V7'"BN'2`S$'JR$\I4D]G50!5^<7
M+@2-0U;!)K))TVV;2A\U8-:8V*M.%Z4.D[7[%'J;H@04TGMELP@:AJ_K46R9
MO+>OX*NG*<N7GWOU<@)\E+(U=;WL-Q)CV7G:+HIXNC6940HJFA-B=K^NV+A^
M3H%*`Y.8(N>R+X/*PFS014%M4=MC.`HKZ*)5GCBCSC`MV:#$`U>0(+[PM%QB
M2S+E-_YUZBQ%RL$ZO24]SP,^Y&[_L/O752<*DIAJ/V3.MCS=[EA<&P3:U>$K
ML"$SC*HA;F$75Z.Q*5<ATED26`0=`?F(*"8B,\A=W"0AUPC2Z,.(7+J49YG-
M$=)2>RRE.<%.P,,"*U65V%6L+$I#VV9^BLYX5=*G^/<\81+(^M`+"M3)\Z>D
MT2Z12<'#8%&G[E;D+#BL7#&CV4ADR;OC2*35[P*V<#(NN8*09<F``L<'6:-2
MVZ.S(\WS$?0;!ZJPO25Q7S%7*PT$\(S>LD=>4N$J^9<BEQKM441=&CL?-;HS
M2T4VE]A<4/NXXLB&&B3PAEHH<,TH%@X#=1DE`=4*O1B$%F+D+2@=HC3^FHU[
MJO8,A5T9:(\?1H6EI]G&#"H8"[3T`!="3@&*Q)*-X>>WEA(O$1Y@L4*J2&JT
MD@W:!/.Y"O<ZT5(()]NW\OUXZ,8RO5Q$<(V"?S*O>D:*Y?JW.G.F'ONA`_5N
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M[`UO:LX_*3RJ^BZP-9>42QHP=B#_)0YO=WU:1+IZR<%KJ7GO4WI#-A6RE.=`
M".K*E(V4?;R8!)&IN7/JZR44"0QS*,(MJ$BS9W\D+,PTWVHFU/-_CO!S+M-I
MTZF7D_:I6_&AZ+&B,<]RK%/0V>`9W9Z7(O-JMYR<_WP,'FSK5_O+E\#ZIQMB
M'[R=]G,6I92N<''6J5O14$('%6@I+UK)X_`T.&QA)YY#HU0E]SG3UY<&/-=`
M4-R5,`]%H3HDM(_25H3(\_YA+VU^3ER'`+?WQ>&T'DSIR;>$E&DMUS+5QT#2
MQ@E'L'E.OY:+4'Q;*KRH^[G4M!OTR$=_^DC"[MX-D\CLZ'/UFPZ14&#F[,5D
MWEWP$!2%D!&D\I(Z74/)U509^&-;MN=@IW+V%-3S`AB92)J0&2Z<+66F/9DE
MB.DFIW*)(D]QJCJ%#IH"$26<KL_"%#9?FB")_A?ZKR@_S]UPKL6CT9*"'\9I
M<@/J:J::*Y)1`-TW3A\TB`:4F6GHWJ`"`K`_[(ZF5](":@7]4(_`(L:5_XY,
MBS><A79Q(\(5S9O,Q,#\-I0AH%1RCHBB6EZBBZ])DB]N_)<&DTU57N3VCL:%
M>0-DMY<F\):E[;9D4F4VWSDJYAOXS$"OS2%F;0JT[LO-OXG=(=+K7%;AC1,_
MH"E6)";,2HQL_J%E]GU1;)OS^HB/Y9/U-D[4RWAF-".ED'Q5!T;R#AHDB,$B
M=>U9ILH=>-`G)0L!,W(IS7.C)"+6.F-X'"JKLX`7ID$":7#-@VF";@_:A.3I
M8=D[C);H1K[Q,.T_)@)$>X$R^,AWD67@*81F'[$<#NAJ,)%#2VSQ'=`\R>!2
M[FKG-O%8A%+!P[UT-A1(9N'_JRB=$>^&-B',N;A<JA1T*3-01!NAY>DIBU%6
M-,!UY1$LBKGD5VS#7YKX'E:YY[_%)2DMX?]6M9_H>$JQPJ&:#!`9$J%M-#(A
M]X<J?S6_&4<.QNU#F7_(EV^EN>N/!5\W'&<[Q7UJYKJN4L.$DT.]VX)$UWR?
M'_YKBC8JR=%;_R"01>H5HW/-43;,0RU*AY1ID!7R4+7>9+D.3&O21UG&H]%^
MLUEBYV:MGYA!9!;D$VZ9+5J>*9J[)Y1&JB?(ZO0^T:5BI5^.2)(V*='NL%B+
M9&"ZE]F9R%TXE.,%6^1::J@@1:`YQ[XZL[9HT,GY&5HP,?]"9$RBD(HSF!&2
M`ETK)#DISRWK7UGU"-F;Q^==@5DVL<JPN[;SCFA`HG7=F]I^Z3[QG5-RBUJJ
M)OG<"QN0K#CNUJZJ5:BD;#Q0X/,=0K]!TQ)AJ^VX]P?8N!V:C4LF6SN`-%N5
MSI;+W!*H*?0`:?'OBO,5=,-7:4#".V@8]02,LGUD<&]M05:FD*Q8*U.^#T-5
MN4P+N%03#)EV5^S]P"3KT);C#C@#L<TY,H1E!*G-9X`O"\?+G7N#"A$7L!5U
MHLI>*F)6W()YOW"-<*Z9,1,AO<B34A_?B?Q64::AR@'*%;9H<'"(B]5\^(@;
M"KLHZY"6Y5&I;BZZ7.&=2ISV6I2.F46>]!:UR%V'#418/L"U)M2I!'C=#`S5
M$,D+OL+=$DY15P9%2%(V'B`(W5L2G%E:SN&9E6]Q1FSW2C9:5@7'H)',,V6M
MGJ68?D[.&\%/JV,>6K*L509&<WX4=3.YX+B0$&R\J4>GR%($>D%/X=`3FD"\
MC42--*^BP..F9J&CKDF87(?RZ+(NE./.W&F!:<XHI"VM`$W!$B8!I]M+$N-E
M57<8F?W!*G_J64F%&NH0XO(]+WB0617Y<%D17Y`]+VX`,VBYP$>UUYPIM97>
MI9M'G138J!?M)N:.D]KSK-:*E"')9&S?*%@WL_Q-3J9;>P;4QIOAZS')J4O\
MXPU8M$4!^Y)W2^\1^!JF4[&V2@G]<TJ%G`'B(UD(FDA#Q2C=5;2,MWP7>+/=
M,;LVR$@3R-"BJ3F^X):)6YTL5K7QR/DJ"_M@J!>'^B0F@:5%@^;LDBR$1>T=
M\KDRZP>/C'OFW!?V0>;>/V`6)%TLXH\A#AX`0>^B6CH-VED7J%F8S'2F]0`7
MRDE)YZ_=H:@M#/G<=6DEJG0<<5B\H8*D`=,LRKKQ5IO\TM>4\XKQZ*="3T!.
MU+M1<?EJVNPL[W0C;FW:-JK)0!W'`>W08.OJ*%O!RC$<O8BT0A6JN=J?IZ]T
ML>JD%YX*EW%:<RKZJE6C06:LLOSTWLQ-D96H9D\:A[C3RR]%+>Z0M+*\DR^^
M#!LE!9^;%WM*/57W(N@.!J/TLVZS:!8_=2LSJU1ELAZ\IC)S^V;12EA_C\VB
MMVA1FQ.&[/KI'_9TS6-WGG!)C'NM\2@_014KJ=$(]!\_*O>PX(9X!SGW!VJ=
MAG;%CXILT!MZV!4L3V&)1QS"(5M>Z"LER;'E-J>L/R!2G=W;:3TZ.Q@*C$\O
M(1$H+5#-^DSQHY(S?*.#WZ'U%NL6M<I>Z0Q`5ZTFU474U;\/O'N'CJIZX,@X
M+YMR8G:D?BIAMD5*KL'/`+>8/Z-BBVF9@$LQ1QKYPP$KT.3<)54(`D^[#8,H
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MM]-/O':`\:[XC-S^W`>9Z5S;7POV(Q\7_/#)F?]R`-9WN]-MHW#Y-PB>=K]#
M_S[XNT#<FX^GU_^Z/+/NXH5G77Y^_?[\U#IH'QW]WC\].GIS_<;ZWU^O/[RW
MNH<=;N`A8D-'1V<7!];!71PO7QT=/3P\'#[T#X/P]NCZT]%77*N+7Q;_;,?:
M-P]G\>R@Z+++CMZWVE:58^](36D^>;=_:)U?G'[\<&9=G_SOV=73CR;?2MEF
M8X$25X3<<*S/AU>'5FQ_)4X(:$>#2)BPU,U3^CK4"#B?FE##5>&W9'K!/7O%
M5#P!"PR01?JH'BW@9'=8NX1?7Z$A'5IOTD;AO`0U`4[7H.W6K=,I8GW4%L`$
M-#V%Z%13U/9"<7/X:[<@'4T4%U&OT]U1S][("^Q,"(7Y-&AA<\R4KQ708(&]
M2P.(*6].%=1A,IVH11*>*B03MF7@2U,0&11^#<-'0.N#'?+T/UOH#:D>ICDE
MTF(`O`D)@QP>F%<'2.&.@8M,U=RF""?*/SA4?6AHF>A0D>1-TW>EVDU'Q!$;
M4B?48PP9\*AAKPXC?GF9A,M`^C4TND(,%>RB1>RI;":F(1B`&FH5Y;E?'!K%
M!3H>RGGE8.(OJV[.H&/03:G7D2-Q71&DNIOYW)VB2FE>G7S=Z*O$RP(-"M@Q
M_&20"84R;GAV"^R-^JT:($0OA3RZI%D!*F21$5\U#6WA[QGIVE3\5H@C4GHD
MI;!_8U9R2D2X!U_BP`=6-(\*/`(R@:+H,O0'KY$8NW*NS9V8](@*TJ])?,RR
M;,K@<)G&ROTNGXLXW,YP"+!5\W$1`+4`[UCH-W=F%,4EAQYVJRP@K0P+D-6A
MO5'1A%/1:;I[>+R&J;;8%P-:J:-&"`II)2\&'PY/4<-F!M@CC':^!WLG2"(:
M2X&:-3<5Z77ZG4/KHVK#P(/9HZ*!!.<82::T?<$'3H.9/I)'.#/P&:3TKT:U
MN1%Z;WG6I=%^(3\%M30NMZ3,8I$>-2<O=M2BJ"`5V64<)`57PD4$MD^)JI+E
MXPN?S_%1F`@5P7="JN!X.+>3C/-*PRAY]B<H"`2=+?W/Y-2CS=,^\,7@FA1$
MXZ/,+BI7C#6-9,<]*6`*KXM?7,%0;G3(%'[K2LQ\TSJZH+4*-QZO;+%!S%-P
MT8G2C=CU:B!OYLXLGE.'9R.3#%$M[*E,8`,S4VCKW6$=^EF,<LG4Z39/*#,$
M54TXV0V(ICG^P.X"]/P(^J/L<3%<5U:L8_1:IF8AKH7H9(<&10%7B\\\[Q<S
M%O%3-]*C(67J.I]=EA$6JH%$%M3ZG9T=B:^5.$I*4%C@Z(X[U^H@6S);Q+X/
M0G(YN[#EJK)..0?2D$Y</LY9`/RRV6^YBGB*#.!5IMA36+QG_TF`Q7QP@)?.
MN/,.>86^?_MWH-F_U9&PL];PX-#Z=/;N\_O/NV@(E_5NZ(SR7NIS=%:NKTK#
MCQFY?JKH!+/9L&PB0<5">`-Y>4H(8\<E<2O9Z["5"P(65CXNW&D89`<'ME3\
M!EFE2P50#Q9IR_@=["//%5L8=Q6.W_CNP7[,3Y8X3.&6C0-DHI^LD]8/*9K@
M<L&_4A;D85LR*8+%F6V=PB_2$8IE"22I!Y5T,Q;`OKT@D2#`0XF:UG#AS>P2
MH15GV10Q<DEMVB]5B9!+F8S<6RF]EK0D2N;KT$$E7G(%O5%116]:S:O;WT7$
M)<.H<O)ZI"=W*L/=CBEBX,J^JV(=&E^2'\^4IN-PRRJA>/*I*2N()C:@*T+D
M6LG3E?:RRIB@A0]Z87]1N39F7)BBFFG63PK*TD6IKD,3:>#0R7)S=#*YJ;R?
MA(%O3S2F+!VV`\>\HMZ;FL&&<1FAV;`=@:FZ&APEW1*%/I"U."C-,>=3$7/B
M!;(Q^LG64+8V%1>^LOU@[HHKY(/HL4I$JDO5XE*4:51LF/W*W9)^-._!$\J4
M;=W*YG)("H/#01YYLT3ICJ`<A32&!!N.23730-PU;BQ,J`?=S8EC#6,YAD<H
M629A&>\87WS@N3/VP*"%S'$XG`28]O&1G(#;9I*WH-P*%[.AJRNH+28QI#5Q
M.=Q+SR3VP?"O+6MP_%?ZW.2O+1GET2QN'4&2&`Q-GX]$&0345'3F+/$TW-->
M1.*Q?8O(%!)5&#<!F'4DD&AF3(".HX@<55@/C^%3-\(J0_Z<R(.Q149<[&!6
M5T2V*;8+!RN;<F"X_D7-;50]7PV36S_0!T*E,N7R0&F?QGV,J>Z%NCC8B<$C
MUO["[69Y>?I'F3SE@"1R58X)M_!*#Y$>0(`@E8<=;'"8]0B$SKWK/(@X9?H@
MJ#Q)5KJ1F<9^EHALO]`5OAR6==SAC)FFKFK]=GYF:%JL(,G2`UI54:HJ[4*V
MCNY"X8^&-3*6>."D,5;Q>@UA:IL16<^>?A$Q[N#!";D#7BC;[^B5P=R[`4TZ
M;+*'Y&T31*E9QZH4;!R`M,0>9UAVJU@A8Z&:><J6)[E.4/HAGW-6."H$0RO@
MRK*;$589<-:%P=5N;$_E(H'R1W8U9:D4,>$T,"WDP((,&P/_QBM:V,"AD@6Z
M0<C:0>223RCUAPA_&Z`';K)@^&IE%!B21JHS?*VA'OL6>-'?\\RY,6:4V]-I
MF(@F@TB_+2!UF]2R?"=,5JAY$G41SNRUE62[^?9%3@.+-]8TBZ@K;?5HD$0F
MX9-1D"P66(*N99X4W$6!8"V,&JZ//"J+0TU!%,0N"=U>^0Y%G_HR04ZL7V35
MI-[E.)VE0@U,1+I*D$0VMG_Y,?')\>?,?GKULE,L-,J<4G&6^6?"0RFUHK.G
M3=]^93%=3^&Q1L!%@5A^.>@<@``'?2VD?^*?EFAIB#\]N+/X[I>#;J?SUX,2
MG\PU[?ZK8\^R)X]#Y",$]DT0Q\$B7<*2'YG)+8:]OV8?$J(ZGJWZSN9?Z>YW
MV>_RY]B%?PZS3S+/)\8@PRJ\U*H`5CZ('SR$]O*7`_[O08;%8;(B<"GXQ;'I
M([TF"?6!!=,9"J;45[H]5$\-_05*U6:!_XXN6@+-(JG-,((D6WZU2(VV_M*A
M_S-QJA0+"_2)'2>&G3CA=T,QO9KX1)USIPEEBX-UOM>#[6]LLQ<M0\SE&GI6
MBW\=S![7:_'JG/;TRVV(W1->67^93AUG/B]C#D76D-XKI3M<?A6FBDMNT%=M
M_%6&"4JG,%JS'U/3]8T=VZ]2%.;LM.<CEOWG]I^K+7VKB=EM7M(%)>Y2DE;T
M!*_$\)[AWW]8_UDJRJ(/]UOCSN09^?I6P/9:_9<#;+?3&O2.7PJT2`>#IWU:
MSRS`/JH43=ECY1N*J#S"!ZW1N+\KO'$-H(,7`6AWV#H>CU\$I*-6=]QK^+45
M>*+%2VA:,U20/84TRRK^NJ9O(#*C]W-J7['2_RTN?7^._3EV5R=]CQ%J*OE(
M@Y'/\9JS.DH]_OGC9+1"5\ENBA_Y:7?/TFL-^M_/:8:MWO$*R?;"3M/MM_JC
M%2I%I>/LIG9,S22$9OR"7O[QZ+LAKL&VA+4[1^GWOJ<WO^U9]@KZ7B'<G^.[
M.,<W4]#1:8QII-]"-&_D./RQV^H,NKO'_3<[!"CAJQPR+^,0P]9PO(.6Q(;D
MU&\-16AV+X$SGVN*6_:!6\Z"!&//WX[M[P^S/TR#4ME,NRA*J3BBC&WS5RNJ
M$;[;G._1\6YDRNYWV727RF+M>TT@-!(RK>\V.4V6Y%BR$F?[4ZYGF2\_4^VU
MJ'VZPMJG?7[:,W^NA#D]O:E\:D=W+6Z_@`5ZL*'J2LWSW5EH.],DI"K7IS"I
MM[)Y!H-6YSD3%[:#=HB9*[6SL*I1R3-SD-^#\`L-6N&^&=^0513DO$W`JE\1
M]/A6S*"`C#NMP:!VPMLW8Q_75(;.#==VZN8'X]9XE2=D=VY^.&F-.K5SQ':2
M)6";,^P9^Z@:3.X*672[JT/LNT,6".FH-@%_8X9`/4MP#)X3FHU1J`?`3E%$
MKS4YKIV[^YR`CEJ32:,"HAFG3U$KR>I=#9^BL>0I37RC'4_\V2FU,+IU_"EH
MK]]_<\FAUEQR,T3L;(/)X:%U^O'#A_/K#V<7UU?6R<4;^/GB^OSBW=G%Z?ES
MS%^0D.`_:/KU>[@>GN]%N[F*B3T1&&NF=%\[7Q9N:%M%8#T53E)64_%?'W-=
M\[K'LJ.1/`":G9=A$(,=:KUV`[/=)77BG+L>=82;NO>NQ^V:;9SW:&.+.#'@
MV9BGPWU77F,?&NRUE*)(MI66+8.NDOD\\+[`-Q,_?H0?J8UNB#^'//CT=8!C
MP[AWV@?0>>WI70**KS"7@VS'O+[>KXG!=.?S2!Y!#*EV9OHIR*5MG7BGML_=
M/:_E%$R:V)1K1LJ?5+^@<=5V.KY''YZ4:8W4XO98V#C9G]ERIIH`B;;6P/(\
MYQ8>_<*-J*W<,G1M'77IX71A#XQU[LY$;U(Q_A2^Z<38Y,?U:<R:G+3,]Q9B
M6\'(P0G,<%AYQ7ZT!-J8/HI)>M2M*>'.EN'<"1W5PI`Z-MK<ZI(:2&%B[IV[
MC$1/)MI$;Q#)V&N)^9=_)-2)+'2G=]PD2E_O)L0FCBWQ7WEP=\$#GK";JV^G
M$\!N@P#[.E,[/)_^%0*F:>!L"W:BGQ&]3BSZ8\YM+Z)98@Z<+J*/,5#T49["
M-'668C25L+48I]B!#"=MFGVG^#HUJHL<YTL+FQX"??$P+$"1Z\R1LO](?.XK
M+7Y%JR=^.G%Z9B_L6S$"0\Y)<WU%`VG34=F/6]LXG;46&`#2)L`43H`FO/35
M'!<UX<8YU]XCS<1TN$E@^HC\2'1E*Z=$.><\0]9`FX^R.U4)"<-O%S0M^-8A
MG`DZP^&C(?]1<I[,*H=P--HNTT5S_`3'R_$1VKCJZ417O?5'(C,_I*(P]0H$
M1OF=T+!#FQ^U_E+4ZZ"6[8$5)8[^9^XCBW2";D8U>]T/_'8BTFO5#!\<A%#`
MA#9A-5DVPP^?MM$?_]J'OOJ1:_UR[]U`\"*),%-X8.-0'+]CMBET^<DBMO77
M1Q84*>S\5E'L</L^[0+5_(/"WM<I]8%@2\=_EY+)(I`->6=N!-B/RCKL"6)(
M`:$.;2E-Y,=)V):?4*P&V\&)9L'JF>H4F0[H+'EN#:LYJ(6N4;H^^SC.-\*>
M=@#]Y]B^>VGZ5Z^G]"]`9L%Y?D0D:]I&^A%=XRC5R5CWHO/"-Y'(J!U"9('U
M$<-+BP4)RCY^ZM>P?T:_TBY=Z2\?[*_6)0:MOM`6[T#I\;QH>F?/8^O_)2%.
MS9PY(<[=?`,4]CL0+@@I^K/C6V>'OQW2@TI7@0?C!_?,)]XM;GZ%XPNVW]*1
M\$&,=N`OF:H7PO?['1SU#N.!YP"RBT^;3@CZ[,*985=YZY/4SW153GTOOZ2!
M#/&VY=*`J^MT4KJ^(%A,QC5)X6U>M(EH_?N?\4\F,/0:Z172+'M0J,7T5B'V
MM:7%D.LHH#ZOP#5)!=7F<WHT@@75#E19>6J[_&!+\MWK!&Z,&8)H-WZ8)58Y
M686D)WU)BGN-%`.S.[@@N+37LU*#27!GYL88*HFV\RI%'C5F&N,MQS53-WWY
M'"+L:U\@;`MHNY42%/SZ_)JND:[&T-BUO67+?J%.9(^>/5UW(`?Q7>=N4$H@
M,2\I[;#-UT2SE.2<,'5;\J9:I2JDKG\2OG-MS$7L/MOJVGQ[Y:A1+"DGNPY!
MZ8\"2\R=6;'OFG40C[+/M<4N=34]8?U-*O4=H::.UDC_SNR%SU5][G%F'G9.
MO340CFU5<:RX'(8<DYZ!4Z.!7GDR&#YU,2%!5_'$<]2$EF<_1`E/EHNFH7N#
ME'`3W'.K630_L64K3X&'M\TL!)4QQYN+9<"F`]4'&!W0AI=Z'O!E)3=_.%,U
M2-[U<9"6C[.HQ7B%F$U4&Q6A4/:5QED'HJ-[F`!C+>`=N#/--@^M&WAGVO-,
M@2D8SB"PPM:<`I1''G(K9O%=ZFN+LZ6]1Y$E@"P8[5;%!O"#ONX?*&[]K+J\
MZRPA@M-.Y>WQ?"3ZTX,+P-TXH*+?VC0=A!\PB'=?&CE%N]P(OT]>]4R'<3$/
M=R)&K?)I!%'DRO&H_%Y!VDU=PH6:WP9<GN=JX`A+'-26HQ4<3`!70I0VQ1;O
M@H>F%XV]PS.S*>GF:'T<>.7>H:4AQ7<Z^HV&:>M@XJ73X&*Z1OC%-U"+A0RX
M`G7"H^O=056X:(!'D:S),VY-Q%"^&C<!QRDWMUYP@Y$O=6ZF&3F9.Z=+IPA*
MQW<;ZAJ^!>]>$#>8EH%_&XAQY/)YXN224$VB+]*50+ZT>*1'B.]5C)`1))BN
MU.(!J@2M<M2@DT=-3+@RSZ5`WJWFY!INL.,ZCW2)B\>9B/&G@#-GEJ"4)S,D
MY!D\1?0A-5>V9>B8->V9EL%8<=:][I>+[WCBHQ1#NF/$4(NM<UI'_G`N/2GZ
MX!YB]?@5FLI#/=4O3EQSD%3>:1Z)(7R9J4).;O^"';DS@OYZA&I&VV@:&[%]
M<[U*"S(OKT2=HF<_2J]$NH5Q-`RKH4*5@U\3/U^&SA_)S.7AG:"NE_O'A/`Q
MWQ!(I_C!<7PQ:BM$OKX[K^,D(ICR"$N156IU,+^3ZJID$BB@>>!@/2HE_1)E
MG_&LY).*[L0H9.$,"I#/\6QG6,SC.0NVA:YRC]']>*C;\C3\$<!.Y*S8$`Q1
M,CZEWB/8G,L&H.*N<&(Q)%;`)6?@S%8=T3P56%E)C+/`BOG%H<`HP8@;JL&-
M*W"XT?J&>I=.Y2AY,SH)Z&Q`N@896LF.*".!W;@W@B\P&#A3O@P?\/$/\'R^
M"`G8Z8__!ML<<D2K);5AFE+-6I%X8&XX:[/,"F"S6^5&->!,]<=T!"T-,T<.
M1I8KL62@ECL>0VIL(G"OG88'/^W.VS7<PCY-NIF1"LZCT?HE$^SQ+^/\7U;.
ML1;NZ>PLZW3@!8\!,R='%<XV!AD"_'69Q#QF.W($Q`\X,!AN);Q-U5T>8\Z>
M>WNV`+%-4\I0\H@F&R4C?/"O4SGF.PE)(\[XD;51/*J7G3EN5X-TLS27S?(K
MGB+5Y1-8+6$RC>E*`89/?*X3-93H^T]X.=827NJ@8T>\(/FTEV.<JWIU_>GS
MZ?7G3^<7[YX^S:6.'54<8>J([`)]UA^%:WQ?NBH=7<K-W;F,HI'CED;E\=]8
MYDB'.4A(D$H+3:9=!/>H:T7`'&2N@^1_[P4_3]5!:4,7N0IXW#SS)-\1]D#$
M<\';-S9/QM*W4,Z*5NF:K^6<N3=JSAS%+F68-YN4P!.>.9@B9J;2F/F4JLG?
MA--D5YQ#^E!$:'`!?!<1MZ#$`JFL(1I9J3.'E3$:1$P1OBCW%BRX#"RE:-OB
MPF"5=2X@'(&+>O9#$'X!9,.NJ-,9<PM[P[_NCAQ^DTK.2K,<\P,MR=GT0^^P
MEQ?+PD]G8+4MY12+3O3LY?JRZG/)Y-Q!(%M$K3_%.+N<0"XM,&/-0TL[U$;3
ML\S#Y<?;L_M#R>(,N9A`[,P-(X7/`QQ&3SCAVB<:2P9;1<(<6"P#7X[Y7/$(
MM=-J>@?3`)VO\#J%;UG.,U3CE5V^Z716V(KY8'^&.NS][*W]+OM=FMREI&3D
M)=;'&WKT1Y$-D.K/SUC%41/F'S^A`(]L+_K)"L*7!/D)1:>B/R7(W^L+.B5O
M#:LF+_%^9YC@R9/9X^`E07YI@UI]?1=BDL-+@OM$S$>VX_VCVKJ?B4#FCM]_
MO;,)SO)=GNU/TF[G*8Y9].:?JM]."7!%#N&J-=!G:]PPIO<C9\<W<.E;#HKJ
M3IYQ9DW3S4BW;7_Y#=`]>DYT;P6L<G+UGEZ@OZSVHB7$O!.-F/?GV)_CQ37X
M[G?6=!G9"\Z]X-P+SA<O.)MB<OONS_O#O.3#%#WO9EHT[4O'GBO0;ZM,,SJ8
M+`38,+%B'^;?A_GWN^QWV8?Y-X_B\OEVU\ENP+P/\[]$D+_;%Z2BMB_J$>W#
M^]^.4/:/:1?'E>S@*?>!_OTQ]X%^>>(=B5=,1L\X&N.;N\_WV-T')YKBK3L1
M?=V?8W^.?51_S\?W4O+%8/<[E9)-<;1]H'A_F)=\F*+G_713ENIT.ZG:A,;V
M_,=7;YRY@[V&SJD?TK7]U8F,YC$7KN]\H*CV&0:U_]WO7#E+=&$=6(GO\F<^
M7[TYP-D5[L+VHE\.VOV#O[>[_3[@_.>CLDTT$"X"'R>47N$\L=?8@P-C\(X?
M40>.,U$S_X[;!P$*3LSF00T`.QQUCE-@MP+G28YUC2V<:IRK.QKO]+G*&A.M
M/-2@W^WL\J%*+VO-N;J#X\DW.I=L50\+O7'N'2]84B.=!E[6I-?9]+**@7F"
M(]5]5;U1;[BK9ZKUHL:]\6!7#U3W-?5&XTU?T]HS_>Z@M@'"%_W`MPYVA@O\
M*VPW&'V&-:\#7#6)'=C!G>(JK@<_S2Z<^'T019=.J'UCX\?%^^2887>BG[-)
M")_CX)6>8,G)P43KO]R3KW^H9<?N?Y<77N7DQ\/!4YY\YKBO3G#0!C[[MYY]
M6ZV)(DUU^_DH]^UTT5-N\_06-'7;^Q?P&#CZ&^RN5FG]=KO;:_>[O$/94NEF
M;X)ILE`?N<3QAK.WU$NNTF[_T^>-2I<IVPF!V6`?_-^BG=0R^7T8B(UPA__;
M[DS@%^9>QE+YG:X?EQ4WZ';:_V,NC=]-5SSS8S=^/'5P=IIW#A3_]9_.8[6E
M@=2[J,"/!.R%2^5V8J)&.<=OX6,2XV@:ZARG;_O:QA;*SDGT<?[O?O?C-%[[
M!L\OWN(C'/6.)^.!`=**/7/P,?U^<I8!#9G#7L952>9?3F1L6[A4=L.WK@=/
M'6[Y-@@K(OYD.G4\;-D&]C)]7=_56"^[V26U%W[K!79<CNS./Q)_M9+9`3P/
MCH>C26_0U_?6EL_N_,FY)>W?CR]HZE"E<[Z_^-?[DP_6Y:\GGSZ<G)Y]OCX_
M/7E_U;+.+TX/]7W-Q;-;_Q9XB8\S^`@U%>_R(M`WR"R1W>%WQ_/^Z0</_I5C
M1X'OS,ZC*''".CN5+&4VW`4"H"S"2YYM+PAMQ?-YXTPKF$+];H_$U^IMM@.E
MFG(\'`B_P(:@8$+8^[1784.(Z<+_Y<`IWFIKB"J:XCU2+6M!E"P2\M!]Q%[E
MJ(.$SAV8%V"5L_,+M0]00C[.K^VOVV)NU!UDH=QD^R>"O1J.V]UAMT'@50]2
MS+<\!VMOZ<:VIXFF;7$-)O]@T#<A7KMI<T!6?-C=06_2V0[(*'+B:%ML]2=]
M4-=-0&CAS3:K=NI^M]/K]2MNUA#3Z@T'W?ZD8,]BOE!MZXK<:329#$>5M[ZW
M70^9^ML@O+(]Y\J9)B%'#IR;./VI*68^'`_[&3FW&01/!'XUW$[&Q^/A<T!_
M$?C3IL3G\6C4KPASNFV3@%:DVVZ_UQUO"2BZ\7`.`_SG[#^)>P]?PLD,\:D=
MAC@)^S?;2YQU*.U,UD#:'PV.34@K[=LHJ-6<T0#GN/N-(:VHK`R&D\ENX'0-
MH8X&_?[QTT#*C@?09D*<4/7&X?\V$G"==(;C406HBT%H"/A:\8=V[[C?%.#E
MTUJLKY'[RG>]7PYB4.4/-B?GH^:W*J/'@JV$LG9IAQ]#F@`U(Z(#I.2]K!6.
M<W9YE7/N=`X[77/PS9I-&X2R&!-/"R5[JTZ2^"[`C@"SC7!8XB#K4FS0I.;R
M'1L`K9+_O'G0R&_2",8&O?Z@#_^S`BK>;$N(JB-JT#L>CR:#8BK;`*)JOM<F
M$97SO&X'6Z,HJP);(XK&(&,+9M>ONWLUY6'0&VVV>];)4>A@J:L4@![3S6&C
M;,=ZH-5-HVA/CGOCIP6MGC8R&/2ZW6^$L[5.LWYWT*L'F\S!^P0:RRG\UXT;
M,OD'8],+6;K1UO!4?(%-P=.<C=X;'T_6P%1F\-8#JV*2S'@MJM:#=>_X25,Q
MDG&WVR^#2-]G.U@J6H'#48:5UX"E03=/;S(9K<1-Q:MJCGS&@W&W4P\B8%E3
ME[*OX-\\)A"S&!<8ROT_GKS7@/CKDPO:@&_]QEN"6DOF],?C\9:`GMFACR/%
MI=63R7NI@\Z,]=4#^=,Y'(]2*-?L61_`JCI%(82ZAOQD$%:ZY@+PNH>=WK=$
MX'H(.X?];ET(:;+EQ_F9F,C\"6SQCWZQ-Z<1];9G2M5-]C<A?^OB?.WWH$+-
MSGVP4F[=&\_AJ`IH4UMK2`/S=:_>K1G(JH;.ZD-6EGTN\FDM=P;&8>PLVIWA
M02/<O-/KF+&9-1#4!;=[T(B!,YYD[)LG`G=\L+T`ZHV..\\"[*`B;M>I'I/A
M%J209A.\#8,%NVX3X'(?>5)GX$>OG7D0.EJYT@?7#T(W?CS'1BM.%,-&YBK(
M6N+'#TY\AS[J>T=VJVK&BA],S-MYQA/L!NKJ>QGZF7#TGPYU-;T@_?[@^,^-
MN"V\-+W^:!=Q]Y1,ZGB4\;L^"[2U^4*WUUM%WD\$;LWXZ#"3*_=M4;N6=1RO
M(OX-H*5W\,F9.J"T8V'UMBZ4SG'&#5>XS5:05$-131"$,O.:NX\U\6K'13>5
MVVES<&K75A;J.>L!,E("SOU,/G,C_&V85>?7;KL-E/4817^<9VI;PXB)SQJ5
M-HK385['J`K`.L@SOLA&X!UTQJ/<BUF][S9@UB."86<XRHF+[8!<SP3K@5K(
MD:OLO0Y@RB#/)^TWTBQBF%-SJFW>!,RUT-P=#=;10TV0+T-G:;LS24V"28.F
MRNOEL[MKXKS7&Z\[0150&C].3:HG(??DITE?2T,=7;K'ZRA?V[(N=#51FDWZ
MV`@VJ80RJY$&5Q-(ZX[[6;B*-ZL!4ET=Z[B3=8@T!E*MRYOD1,#3HVB=.S13
MN[(I2!'H+?,Y,%$[=J*KY"9R9ZX=`D.%EQM,Z;?PEO\1N'[\&WP\"9WM*VZ.
MNUE5:@MHGN5@5?OB]+*\O[&#E8G9.BD>_6$GXVDL%:25MJV(G3%NO/&V@!9*
M2;L+O)D31FR3/T'1U[HMFP*P=J%8;0";JI<"9IRQ@=85F39?[SKI3S*I+NMA
MF`J%Y,H)[^&'J$$S:S0>#R89<$JVJP-5_;Y/QYFBH$;!JB4[CWO]3I;I/`>J
MULG/SFC2K0/6A1-CG/XR#.Y=V._U(_9R.???NC[0-'9`5'T/&XDH=S-U/M6W
M;P3L>OWO,L9]PS"S=&T<U>W>)&N%5@>@$<#KO:]N=S1\2JA%`*AQ=!_W)QD_
M174`&@&\GAUWW)UT)DV!G<8=&HK"#\<Y6DCWJ+K]%OGRF:84M;9O*AK<[-DW
MCZBNVC_P`TD>_!F9A]*(#WC<-[6`TNWJ0%6;.HX[@Z>#JF;8LMM]0IAJT](H
M4X9<$2K%<62_R$;\0]W.,,/P<OML`D9=\NF#O#AN#HQZ;NI.?YC)_G\:7*RS
M$ON]7KTK:5K@=(^/.\6`E+&^=:#49B_C42;ZN34H-051MY?QLCP=3M8*I=Z@
MORE22CH;O0U"Q[WUV=:>/EZ'MA_AG'%*^J>?/$H32N=@RB*O)^PHD'T%SP1[
M-8Q]]N'#'E8J_QIX6%3ZSG9]1/A'/^TB<A*Z$?SI#77/Y]V:+*\\[G0K86A;
M6+\!1FH[2;Y7A-1C5^.,/_0[0DA=MCGY9AC1G)H-UN5EFL*5[[0]1!4+%XOX
M=E6(GM1V&A9PAZK:=W7@MF%=3P]=S9R>K-+SS*A;"]]DM!U\ET$4AT[LA@XJ
M""+-#U.]FDM0'G0*<+AZW^T`K9G#-RE@*!N#>7UG^]?.8AF$=OAXOEC:;H@?
M10;J1%H$]1+K20-,C@AN?>2VY[XL^<N6E]4ZSK"(W3<#G'EJB8OKX&3ZGP00
M5=Y;KI&,I/%HD+FH#2!H!O1ZE5[=T3@34&\.\,L0'WS\>`E""PL6,(;:V"R9
M_G`R6`UWZ?:-@%T+W:-,+GQMF$.1"O;,7<"J[=LLK'5[@6T/ZU-T!,LUW5J]
M93/@5>_<U#AXH@_7%MWV)*1'C6^V`BT5-M-[9CW/\>KL6/>,W/VJX2:)VVQ1
ML3FB2)4M3)%M*$GG>#R>9-_(NCT;!+)BVZ-LY+0&D,'4<694I84/"R'X.#\M
M:4]>=R)<5FM:MVD5&,7<'X`C!$,##N;>4ZJ)Z%AASOM"20M:YM1+9C0V!/;X
MN*0:S$84PZQ#X$DA_E;(:21SY1MA!C5:6/"#C4-5X\>/\R>V%(Z[V=AY36B:
M/U+-7A&3T7$YC6]SH&)-N($.+-UQ+\?"RW=K`JZ*Z;O#?HYK5X5+*VC`))EF
M1%U_D,DF+MQE*T"JIA!F4E(K`5(TP3'?A&342#^:<:>?R;E8N7\]4(^;Z473
MRS6T?P)8>PTTHAD-)YD2UB<`M-],$YK>H#?:@@!B&^AN)AU:VOB;-\[<G;I;
M/^5V'[.VLH]HW:[-05G1==P?'Q]G=,)-H2S6#1K)SP&MVB3'XKTVAJ=>ADPO
MZP*K!$WCA1[=X;B7J6M;5SG1?#%'MS<:CZH!\5_M]ML@B/T@=BS0/A!%[3;_
MR7/]+Z_FXH_OX0?K*_TJ?EPZOQP`>`Z2RX'X;1AX\-N[.%Z^.CIZ>'@X_'H3
M>H=!>'O4ZW3Z1_CG(_S@`2TNE_>"J;$J_&S'02@7!>X#)_R+:I7&OP6-R?%4
M`[5_>S>>M'SK+-LM7+:[[;+CPF7'VRX[*%QVL.VRH\)E1]LN>URX[/&VR_8*
ME^UMNVR_<-E^T;+R69R$YO(@X>0B\,\U;T)\XFAN3^.V7%%^?0[V0H;&Q4;!
M+P?RR1+U?DO(NCL+V7AG(1OL+&2CG87L>&<AZ^TL9/T:D!E@A4X4).%4+5Y%
MQ&<!$JS4V/KKPH/?^[>@1/CMSU<XB-9O3^WHSHI02VG?H-(&.I"F'SHRB]DE
MAQ;\V?4ME4&1_AF#9W9DS0//"QZB5];/1\;Q6+$Q?X>:#?S^YR,\#?SC_P-0
M2P,$%`````@`5X=C/VJ68_K2"@``#(```!4`'`!A;&YY+3(P,3$P.3,P7V-A
M;"YX;6Q55`D``X4`LTZ%`+-.=7@+``$$)0X```0Y`0``Y5W?<^JX%7[O3/\'
MEWWI/A!"LO>VN9-TA_S:TLF],"'9V;>.8@M0UTA4DDG8O[Y'L@VVD8T,Y%JD
MDX<`/I*_HT\ZYT@ZLB]_?IN%W@)S01B]:G5/3EL>ICX+")U<M2+11L(GI.4)
MB6B`0D;Q58NRUL__^/.?+O_2;O]V_?C@!<R/9IA*S^<821QXKT1.O6OV2K'W
MA"83S#TM=T?12PA?7I;)Q1$;RU?$<7I_KWMZHOX^?6ZWDQM<(P$5PB5=P]E)
M-[X2$OK["USR`#T55ZVIE/,OG<[KZ^O)VPL/3QB?=,Y.3\\[J6`KEOSR)DA.
M^O4\E>UV?OOZ,/*G>(;:A"I]_74I58VI7/?BXJ*CKX*H(%^$+O_`?"1U>V[%
MY95*J&_M5*RM?FIWS]KGW9,W$;2@#3SODK,0/^*QIP%\D<LYD"/(;!XJX/JW
M*<?CJQ8*Z1)JZ'9/+\Y/5?D?KE&H]!M-,9:BY:F*GA_[*[RJ0(AF)SZ;==2U
M3D&^<]#[#Z$+4#G%DO@HK`NF4'AO9",)75CU9C$8#^:8:R)%CP8W;#;G>(JI
M(`O\P(1-L]6I[*#(;Y"8WH?LM2[(3+G]\42S&>++P7A$)I2,@1\J>[[/(BK!
MN`Q92'R"K0!:5K0_XDS]$X[C1K$!:"ZW-YX^&.(9?D)O5LV4D][[WK>)48?.
M>@?M+)=].F9\IGNP!9CJXGNC>\23*(QL6F4EN?<]8<S.B-3<ZA&L>Q_X2KM.
M7%GZ`.TA)(]\&7&HU:I5<O+)_<&"^E&H.7J`N^5PX#>):8"#%(FJQMI?)!41
MJ<HHW%[;6YD=^`S-$8`M!$\/GP0,Z$#'$4DM7ER-]]=GBJ*`P)4?8P<(D$/F
MYV"&RO4RGF^O!*7VKV,D7K23A=AF@M"\H]JQ@T,ITE]TR[9/NXFO_2'Y^=\/
M!+V0D$A@#!@<2>;_/F5A`*'+W7\CZ.'I/4/T@D.-Q*)(IP%%K*!7@LUTE![/
MXT;<3VN#C[E>LAGC)!(=H2R\JJT-[,[2\F/.9K;MF$!@Y>`9AV]7K9\@P(T$
M@&)S=4,5,[QB,IE*"'Z;H>,12T0H#NX0IS`:!;BV:*9:%P>W&+P*D09Z;`HU
M1M=V@FS@)X3]W3G",F`'$'GR7#`7>V$5TGW#<C`&=VQ@KW8-#E-96Y>$U^ZI
M<\0J'\VH5OE7%$;8P-RFB,/4;()-VOZS<TT_A+HPYSBH;'VCE,,$&/$ZZX@R
M7K8ZECFB2""'.FGY,^=:_C;I)H]X@6F$OS'J1URM:QAXJ)!U@94B`15PG35&
M:\Q4WL!_(BT9,8F[38H)\3$8J)M2-DQ"+G)@PGDL!JJ\]<L$76"@@+K$0A7)
M<#!.W1R^-H1LR!X%)QNH79X6\@@'5D:J0M9A5BI0.^LSDHT",41+M?M828E1
MT&T^C)"==2,](3+KP=G&3RXT`:I/%UC$*_-]VAN/H<V1Q&(4O0@2$,355$,(
MYNM?8=+Q+T:H_!7$(VZ<*.U97V/]+4].VL?VU,9=)SKD;(ZY7`Y#%&]3P?QQ
MKO3\ADWFH5K<,=*JP3H[[XJ5J3#1^>N.-7H!G;-&6.WQJRU(^*?ZQ0*%>E-2
MWB#.EX1.2I<^[<HUS$J)J[0$[VP8\XA]#*C!RZN5]/(A4B+G)BDE8)T=.;T`
M)B(:RA"1H$]OT)Q(%&:6V4U&RZ*0PTO8-O#=)6R!2*CZUSWC(QCR(^Q'7$?4
MM_A%KK]5N)RZ-;@YTFJKD5#ZMR.BM'*-UJZ8:Q&%%>B$JD_.475/*&C[0!88
M[(9$=$)`E5A3<XR]K8!C]&R#F\Y]W(LF,JF":Q]LG,H:Y=RT<25@T^'A&@<Z
M62*SQE-IOJJ$75B@*G)1A==J`7?."0-3MVPR(6$.`<_=VUPE)L+40:NT;89J
M5<K-X6,%O<YRSF6GD$_ZKDFFA7,`2:VKC-/N;AFGN5I_S&6@'CYIMLYI@8)^
M9Y89M>M;>&SLK6_B(:HD,[?QU'V:3KDUY))59-552C=FX@VHGBG'*"1_X."?
M,/4B=/(+(E2U]X"N0[P>)P(NW>H4[2$&>QA4Z/Y^MVK,6EF0GW,W[Z*]LVNE
M`'&=7&GH$(7KQ\!B`;*SJPIKD/>@9GR4(X*^LS:GUWC,.,X$I%\)U>$,S!,P
MQT*MR>=KB1=?OF(Y94%FRZ4T)O].=V^LVQB[=S[2_TY-X.R2,,34+%:83F)=
MDMC-9`W*91NCN(%AM+(TY<WA+-W:Q]7A?%N!YL;V-B5R;GT[5^ZE`JV[7HPX
M[:^5V0)%4??Y*<?N["@ZC-=UT%_:<U;'Z[D7?`WR6I9$OT:I_T=/9VP(]\E-
M.F\EM6N9QHBMZ(P;!*SA;C>.[8;:_Q=,`6T(G:T7S`@E0BKLBXH@8VN)YKDI
M]J64F:W0G75BCUA@:`:5T'*+%SAD.K>KG*0M\NY2M`6XLW9L9<@3J-?0U<;&
M<]REDB[/O`UPMU/1=F%7IVRA\!Z\+YG0>)_#7SYQ1`7R=9O30']+&`C^$\6>
M-EW$BA<,H1:.D<"W./Y?8X7V\+<^AK6^[]<:JRTKI[<;'XB?;+N-,%_`%Y$<
M1S+TI`K9YDUYN>VH@&W%T7?:52QY'%9AP^U\IPTW59^G*VQ\9\V8#VMMS.H5
M;VA_1*$;<K8@P/WU\EFH-)U[0A'UH9_VP*@LRLZZURG<G+7=@<+,5HNU@BYO
M@9F4B&?#.U)L+/R1*#8JZ.Q,9XB6VG@^L9X/#<!QZ<D64S).C<)-AMLU._$J
M8:>&>NXN.93HOXHG=AG$QL(?:1`;%71Y-IQ3LD\+1^[-\^)M95P;LA5=-C-]
MWJ95RJ)[[G83?'(>/+-LG9Q$MB*THO2'H+9"OY1D]QRN48WL(7-;:O-E/@JA
M>:U2&MTSN:,IXE@_.UVML<"\5+>1@;LRP2,DK$R5=''!/9:.)8=O=T[,*7W'
MX-LR9U.M3%Y._@B9VJ+1*KAT;P:QB3PYRI#&5L8C#5:DVE7T(=BV4S6UI14I
M5^YT@QCYQC.+K)@O+?LAR"[5+AWF[ATF!;U]C`.=^](7(E+'=`9C[?/%,P74
MH"7,J\E";S`80P&U+B)`+(S440!]=GV@U3-UB7>^GVO=J&)=//-0F?=LD1I[
M0`VO098?R[99A*PJ[5JOV&45LDJ_A.-S][Q'MG,KU-"%OR+U>@RY'(SK$;YK
M3<=(_JZZ)AWAPKG!?HOG'*N'F0$<^!SB)/6@-V-<DC_*IM%VQ5QCV")VL%/L
M'6SWYCMNU"^K!X/F7G:4HZ-<[,B:OUP1FT<:-)[1LAEUUGCJA%W)(R.TEFYI
M)%XQIESPE>M`L/HI6!9E7&-SYY#8]&PLM\?JW7B,?3D8W[WY4T0G^!%)/*#F
MC4L#N?6*'^5&;#T5CR/G4*\"#)F0'+PZUUEJ23ZO2*/ZLCS6;:5<&\L6EME*
MKY38BA7L!M>_/N;)MGU\;8VC;J<GI]V+3^?=LW)3[4X*^Q,8H2<\FS..^+(_
MFR/"E39*5RPRV@U5E,[44CZ;4/4<C#Y-7[EF?@3;06L_PCYS4/UKS'+?/ZW9
M\B6ZR1V2/&?H@U[;NR7"#YF(.%9)SW%%*ITY4Y6WKLO;>"/O`;4POVFW"/IL
M`W06Z>8K>@\'T#`O7<,Z+\**I;W\.WL/!Z;Z);QY="J?/97/?E0/AHH+>Z97
M^!X.[.I%O<56^ZG8:L57^AX.0^5+>HNX/A5Q94HGS],RO>3WD"V6>XEO$=_G
MS7;;>.GOY>I%]/#E?U!+`P04````"`!7AV,_E1O6NQP@``!(C@$`%0`<`&%L
M;GDM,C`Q,3`Y,S!?;&%B+GAM;%54"0`#A0"S3H4`LTYU>`L``00E#@``!#D!
M``#=77MOX\B1__^`^PZ=N0"9`>2Q/;.[E]G;32"_)LIZ;)\E;W81'`*::LG,
M4*1"4I[Q?OKKZ@<?(OM!2601P6(QEE15K%^SJE]57?W#G[^N0O),DS2(HQ]?
MG;X]>45HY,?S(%K^^&J3'GFI'P2O2)IYT=P+XXC^^"J*7_WY3__Y'S_\[NCH
M\FM&HSF=DU_.[J_)M?=(0W(=1)\?O902/Z%>QG[[$F1/Y"S^$E$R\Y9+F@CJ
MR\A[#-F'QQ?YXS1>9%^\A"IUR.G)6_COV^^.CN3SSIC<.6$_<0GOWIZ*7T+U
M2`8F2G]\]91EZ^^/C[]\^?+VZV,2OHV3Y?&[DY/WQXKPE:#\_FL:5*B_O%>T
MI\>_?+J>^D]TY1T%$<#W"RX0T\1W^N'#AV/^*R--@^]3SG\=^U[&F]>J%]%2
MP*<C178$7QV=OCMZ?_KV:SI_Q=J`D!^2.*3W=$&X`M]G+VOVKM)@M0Y!<?[=
M4T(7S5J$27(,_,<17<)+@R?\\8@]1#SAO^37KP@0/=Q/<BE<PB8]9J:R]+RU
M$!*"(1SG/,>]Z3>+,R_<14G)V)&F'^!=G7Y7UI3[2EW3[1?_H2)+,DDM.0#P
MMHJ>5+JDTA3X#98GF@(LE@L%L;%?$1B"^<9)(W(N:^&ECUR@:MYW)Z>GQS3,
M\@8_@F^.3D[5VY)?_V.:Q?[GISB<,X>__-<FR%[&CVF6>'ZFGL8Q\H[(RG"<
M`P"><5)%X26^DLG^M#2*I#CV8^;UZ^PH%.TNV!=)O'+32#X_=J'^1_@8;F.H
M`$AH&F\2G[9YKZPC?8Q3>EU6W[E%A4:LQV,L,!C0Z.AA^NI/988_$,I9OO]!
M>--AM0^[4UNPD'&6)<'C)H.!B&0QN6.C3Y21ORM9_[>-JS_7N`Z\QR`,LH"F
MYYL$U+*XAHD!QS7L$,JNH:?&<@V;1C4;DU0D+!C[]XS66I<81D1!&)@+C*-Y
MZ['"G1W=/9S@:9S%R#L`UW'0KVZ2D_'9Y'HRFUQ.R?CF@DQGM^<__>7V^N+R
M?LHZ[_]]F,Q^Q72LG3`5[(2MI4CC@#0$MQNG*<T<!QT-+8Y#&14O>T\C(9:K
M&)31#C`>Y^E_;&FCJZ`=UH@B='*RZ6$8L]V*.S5?NRTX&8'AW??K939MI]/+
MV13//,^]](D-+?`/C`?/7L@<)QUGYUZ2O`31\F<OW%`-0$=>'&-N!:QLXTZ,
MO9M^"ZWJ73ACXN,__Z/$/B)>1I0$PD5TXBQKF@3Q_#*:F]SE(`A]^(.6$5+V
M;;P@0H4.T4TS+\D0\#W291!%\/ZZ1>G0X76"$'ODEG,)E]G)(":AULGG=M?5
M7X/>)3$ST.SECKWYC!D*&,EZQ52ZH;KV-;/@-+<+C'+KF^A['T?LRM1<4[&,
M"&?B7IJSC0ACQ.IP]@##4=`"151'T9]C3*)GFF:@2#J)QHL%6[-[&4VGF\<T
MF`=>`LO_-(U]_BW#^=<XB+*?&?F&-:RF;?:4B>-:!VF(LN_M)1"OIQ0=MG',
MP1UL]*-,)SU:!J%2^UI+X_,\T"HW,)#V+XQK5<0ICN_'&^8;=]X+Q*,L<QT-
M,9(=&E6OV&4C9?^;%P8UZH8AB8FDSO>TT#8S=M)^+:A1#3S9T'D]0*6'J:-'
M,W,S@"U+;R;&,':3)DT6`_2D*3"(:/([8:!?US1**6*W?D$7E&DZOV?*GK-_
M@\QL]09Z'*NW`BA;O988*[QB4:AF.(J>=&;M)E?=65M@(()#ZZL8-O],HXUE
M*J,CQK;V)M6;3;U,B;=.<1Y7AS.@NHVD]B$4LS>_83!;=NAE%FPKU\,P=^L%
M_7!Z]FV=S)T[WV>"C7K)0]9Q`FG:`^CTW8%4^OV";3!=?POOJ-%CNX8&@&$,
MZ-@IW(RH41.3!7$&D_7T[]$M,20*@YM'HXS)]L%X`*.P9?CMW:IKSS:EU75B
MMM;=3KN*8LLSU"O:9]1/N@S//C3EDS128L7XM$I70WLU,KQYXGF\6L61M97K
M9$@).AIU*[DX6S3]I]TT*E#/7N!D(K]V)!)I1F22IAN*EXS12O-4:/[[D[<G
MIV3M)>198#A]]^WHY.0$_B?IDY=`(O$F>XJ3X#<Z_Q_RS;O1=W_\[]&';T[5
MKP$'S:.K\2;C1S@A-\7+R)39`UT]TH2\/QD1L&'.__Z;]Z-OWKVW\U]07[*?
M<O83U%WES6H3PO&XV^R))JP1UPE]HE$:/--)Y,<K>AVGZ0W-;A<S[ZM^?[&=
M%+0=Z%W`;NU+MQ&!L5O=7K^F_5\EA7`QI"*'"$'D-8AZP_,F8-[(Y"%N<!\8
M=LQA^Q78KT/`2P(N#\]G[VGF!1&=7WH)9,NE);79G#[P`]UJT841QS/=(96=
MT<[5N_^YJE2S/<5(%"=Y739'R?P&R\%VQE4&,1>4>)Y3/W:D@=M$.)03TDV>
M4*?JW?)U*NQSEAAG3>J,1"Q-TX8CW8/8,VD\9V=?AVO8T'=7C'#:'._$R>MR
MT\J^_<$7%"XVU^?V4AM$+D<YA[+'P[JAVV2:P>C%EYYW-)G"ZLYIVT?//(2=
M(!LT_>:0CA,KE-5&NX8L:K4-+C<.\BV#WOWI0#CDU@WC)W%"A`2QD4.8#,*%
M#,6_N#+I.-^'<6J9.M,0_$D'1>]'VQS#\)]FK>Q^4]M30_:?UCBDWP@^,M;B
MP/45L17;H@44PW!\I`K!YA^"&N%TD5D59T/"W3O?`T;5KX-&&+B^<%MLJ[>`
M7^$:CE<T@+&Y1HEE$/Y1T\?924J<0_*4-H"J[A+K`:&$45LN9)PXT8.M;98P
M#FQ8\R]GU2PA3[R5R]X(AKUF*<%S7+`8.=#]QF6I8B`?@)\X3NZK_H&_0MD9
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M&//R<%)%#70+#U9NL`.0:EJP@0$A(]BJ34,RL.#A^5$E+F5A>%G`>V*9%UQX
MGO&11LQC0P9B/%\%40"NFK%)H=DWK%PXWN$(INP?%A:\8W^UGM>UAQ[,X.PT
M*./DGVK4T"2<QK6!&'\<=AY_!S#=+,X<V="5*9&MN*YTHQT79'A=1:'#%<,B
MDH8_T>PIGI?JI&J:WI$7JVYL"V#5^K`.C)@O3"DA%)U$&64]AFX=IB?'+N?;
MK'YSI=XJ+=8BS*Q/K3]5/VO..7;>[[=65Y'GFWJ*`W$<@(T=[:Z*;DBP,"&-
M#DY0*@.%D0.O"VK[/@;W*EJ]!><7T,_TTZ*.;AK:N$$ZG/W17?9%,8OSEZ<(
MYW'$]-LP%>7,+H[2,[J($QE7F7E?:?HIB.*$S214E\H6C8>;>G6LP1`F<+TT
MLGX:V.GCL6?_3'GI4V<TH@MMV0,M-::!:)6OO\P:Z7X].%?<Y3KW-HVIOZ/D
M.4B9U1%F<ZH?S\#H$&.I-+.NSK=HD(;[)D4K0WR9`'';3E-QY2%*J!="FN)?
MXA!R4SYZ002JWD93ZF\2<7(X8?81+2_8QVAYQR_]LA0;ZNYQB!/L#INO-C7O
MX%FHI>)T"2'M4T@&F&74,KL(9W)O5<@AEVA(J40'3B%"'>O@.D(^#,_I_.SE
M(:5L"I=OY8[]+'@6SFU))-I!$-JHN2/DK:&UI12TW*,=-6V^MW(1QE]2`BU:
M"@%YN0B$U*1#P0,WY1"5*/+X0EZ#-#8O?4.**%(A<1!Y'./Y/S=RP36+[REX
M0!#2RM1O%A_&R;MY%%*MQPZ;K5(0LH/G]%\ULC,0]7IPQ:-@@,P?QH?12EU)
M^/EP#MM7=XS7E$G>E%#'':94\"W\S2\B7I=;<:-:T:F3[W5CARU$4GI!Q;^E
M9CGWU@&;AEJZL#8"T+9_6D+<VA%RY,:+-K;3L#X/>6*?X+!75+9.?KTDSR$K
MU4+K?SJR-SHE@+Q6(J"@;*DWDV(&,??03+[$'O`!E@]&08-:/CA`=E@^&*0,
M;/E@U=2Z?`B4A"$N']K#LRP?<H%#6SYH&N`JB#PV6=C?A8V"!N7"#I`=7-@@
M96`N;-74ZL(+)6&(+MP>GL6%<X%#<V%^-/B,S13FL`%)HY3'<36MI2-&JEYM
M5+U2P;J1LO\JU@8UZI6L@?CH$:A)F1QK[=E*^9LX.N(+0WZ47*+P#2@P5X%;
M=W8[3\YK?$-9\VD`F9=Z6TR].X>C1JYKGNV;X;'<9E=8P[D;OA$!W.!=RO+9
MP75T$@;D1&:05G=J9A_.UHE%Q29/RS-L=&:)TTVTA:'I,/BU]!(E%Z3K/#"=
M;^LF3N=FJO$-Q=$T@,SNM<6$F/?M'$+<.P8YL"6O`>)NP>[>IQQM53M$V!?G
MUIF#(.43>AG<:8SM(!9P]EYD5&SL_VL3))0A90IF+W<,!>0<0Y8Q/QFN::`V
M`I#*.K>&6*GP[,S==?[OWB]`EPW,='KRH$!&O(!X)&?F,1VJ.`>W4=JP4[SW
M5O/`1@D#Q-UB&D,9);2J'6)W?U"C1#NDAGR`IJC-X'RR8>MW[[WC@?FD`>)N
M00JD4W\M]7,SUZ:XQ(##$H<+1R`6]V2*LA$>_H%1_MD+828@#@%L+_TT#=9.
M!%(B_@XP*YGY+?CQ%L338!D%B\"'69O8PX0#'7$8^,S&9O1K=L8>_ED79'!D
M1@HXM8)6"4`Y<?8?D&JA5CU`53"3@ILH=O)W$$"X!,3X9KXM>!&D?ABGFX3:
MC-#,@GRNTP"C\7!G`SU&:,>BC&ZOF?&0@FD@)J4YL>QN8&T$X)A;>XAEXW/G
M[MT4VZI6,TQYI;200$HBAF>G4,T]$,K!M(&?UE_2"#IG=UMM*P3OTH'V4+>O
M(7"7@'(Q05OU&LO[2R%\8ZPBYI#VZX71"[?*DP_O3[A-PC=0Z00FK_Q*@EHF
MB:JOUUP&=*M9]A?7KYT>"CY8[+ZR>K/=PRC:E%LDEK9<)CFK94@5I9+S\K#C
M:JG;OI-!.FH)U^JW!X$WC_T-"&_*#^P(W^R)$F^Y3'C@@'@K6&+`[G[$'(T]
M:23OII?I972U#N,72DE"5YM(%J0A?NBE*5NF,`(O93\UMUA>B/1MW]V=KE[N
MSBVL%SC4+L_6!.TZ/9VT`79[9E7WZ?BD9-[O564/M^MKV1H*(GBRUSW$PW1_
M+3$>O@-<:EMMORZPO&))J?]V&3\?SVD@%BOLC^TU"OOJ'Y=L]IF]W-,EUR'*
M;KS5=K>G)^NW,[.I"UV4CJ:WCL>L0'TERTE)04N`N-^7?\X\BIGC))K3KS_1
M%RV@&AW6Z]<H7'W_6T0(!M"H@<X")#'AU(21]V4#%[)/G3&Q#5"J/_?_QIO4
M4R^Z_%NO[[?^X-IK520$:/I^ER(<=<FF]VS(,NB_18?W=AL5WG[-%2*4]]V@
M@?[%"V)R":M>1MZ7#8S9P^>@P%7H;5]9VO![_^^\44'UKBL_]OJ.&YY</P^B
M:`@0]?5&SS<)U!B["E+?"W]E2V>]8^M)^W_/-K75*]?1]?KVS4K4-W$%.1'T
M!!AZ=W0Q<?@;#<.?HOA+-*5>&D=TSN]<3AH@6NBQ)G,6`-5)G88887)GU$0W
MR0.FH\_`112;N+([Z==H?HY#MHCUDI>K(*3)=FJ=@0[+2#0*5XUCBPC!*!HU
MT!E#3DP$=<^+/M&#W=-UG$#\:9IYV49O"3IRM"6@4?VME6`C+<:"T*"(=ETH
M1YJ<B0BN?JV%6^@Y&]R6<:+?(-BBPK*-1F6K)E$A0;"$AN?K#("3$D7;[VN_
MVSR&@7\5QMYV[%=#@_7*&Q2MOO`2`<+KKCU=][(%(>&4/8\'\6H51WSCG!>9
M2&\W69IY$90*UW=H1B:TL<$!RM8(8>#`&">LZFA'"\XI8E,C(IA)B1NQQ`T;
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MF7>6%)Q#*I]5`J2!;.$92MFL!B#FDEDEA@$4=ZQIXUJG[5YO5_O!^"!@R#(U
M)J?8!8VS<[0#L7.]G4XQ8#KX74)AB%4%XF3F+5N9\>L)Q_RJ!^<V<1,VE"ZA
M#71S7^$B":E0U#[*-EPARUGSW&>^N!;W@HM+0?H^#L+0A9MYI3:;^DFSD#ZP
M[*$>$FG1,.W.BS@('N#1$6>M]SE%HA["_BC5,LQ_5@\:[I&2O5K)7,"\Z#("
MU4J5JHA%CY)0.'BQ8&-G_*6C&PX.<SAE`#9UR.-W*AL6:@?R$-4D6L3)RC.$
M?5KP(?23;0#E?:`+4[_]F[M&^@1G&*9EW+'$W?4-?58WZPY:;X>RE!Y%.NH5
M^Z8I.TM+B9?+KU$:G(%QNFK<B>D;GZ^WAG*6+R?&L0-QH,#-$BJTV+;0H'BS
M-1BT[LD>JJK:+$(>\3B(31ST2DV^YA*U]*^+RQ2=%W-:_J$LLBT`E77MC*PS
M:VL#Q?5B2;Y25C<GE$3TO238%Y^"4-\'0(QP/GM!"-MK5W$R]4(ZI?XFX0`N
MZ&-6?#)';EI+08I][@96>=N>*#OSN?:P:I:I)!RQN>!1RF20@FU$0$SE"Z1X
MT6'`?O*2SS0#$23-R8?H@6S!Z^_H=F76H?E:'9;=P?1X$+RJ`J"E*Q6\PW(>
M(Z:!><Q5$`49O0Z>81<I8XH&3#.Q`W]#=;YB8\+Q$C<HRC_<,?1X*4H2^Y3.
MTRN&"X[Z03KL[4)D9C]$<YJP&1.S*J;S.)HW7^\(EV_(?4%^:"CV/]^N>1JB
MYEUV_$RDJU?Z:$AE2;VU(.+M//K.3F=6;20,Y'X>.\C\E>^.KL.`:VO-S%?R
MK(8U4I7=#(`P9_KD9:#6R^VBO7WN*@V_0]L!?%-7M2/J_E[X!5TGU`]X!\G^
M#BG?E(_FXQ4<;OW-=.VU&RO.JVP#*]_YW`%/=YN@;@!J^Z$E-E@&2T:^<5-F
MQ9C+'P"2*-!GP-%GGG":)1L?_#I:,A3W-(31HK@XQKV8^&ZBL+*,=X>M'.T0
M>#MSO!T!-A0A+L1PLY6"2E<+]5!;7&5_E:X!;HS0-I%AQ/+UZA:A^SI-SY%Z
MG0(-79>@A&28_(YHI!B\L])07152>N*(BK*JA?(J$$`6<4(R1K<6X;8$NNB4
MBIMNX/L(KA![8E(IQ$/@&\IC]W](R5RU"<@3V83</<(B$@%B,R^(N+28*0."
M-_`IKI[WXRK`8,!&!J8H?[*H`=L6@4ANS)C*%:%@F@<`5$M3Z"47[,!VBG`Y
M$11&5]G4^E!I$RWR=41-BI="H':->X@*-FIJO-R^2&WO[>:_'7055]07E-K@
M3W\&S2.NI5"K-4YB8L`Q;3L$9=]NNF,F8[3L7]RXAY*(X=H'[8*JXVTU=S`[
M=E,]>WQ#T8.K.*'!,A(]DO\R2[PHA0M5^4*8?PI%6N3\GQMQ@]8-S6X7K`5:
MW?O9W^,1>Z,>F[?2MR&T:V=C:X\-N>VS(DNJ6K)#^O%K*-WQ9D2D%D2I04IZ
M\#EV21-2J,+/",.\GZF#L=&%V*BJQ7S58EDA=AA1A2)X9R]*X<"''RDP`C*'
M+PU(.O-X%]7KYP$%CU@/*RY>_@2Q_,1AT`0E-*DHSY;%Y"9^]I(L0%P$7RX6
MU&?>?_E5[#O<LTG3;=1\V;7&?=J)0+I2=0>8RJGVP=>9?[4$5"L;R-G!&)4`
M`A*(.DK&RUS!'R4Q&(YW,)A4P4PD3-B^ZW5_P9K25!MD.<,1YR`%"Q$\?/:!
M\4I:XRBI[DG5HXY4;VK[(E8K=A_OZ3.--M1<327?JI34Z*5@=M,^$=2]MW5I
M7\:L:8FPVR;.XLP+30WLK/(,),F9;U;>?N^U-S%NE#6O@2IMC9MONX/V81PM
MCS*:K%":7%F)[@I!>83:X;;$*I\Z>XW5K>R/QWS[XR#N6]=@-W(,[B;U[5EI
M"^T[ZX3,ZK:Z`!VC%]I/?;]R?_OKFSAC_WPS(M_R7[][@WARQO?AKE*FW%T<
M!J">I0RLB0'IE(P50GXVQEGWSMS`J.RV&4TWJQ7<_<+6)--@&06+P(?;/PL9
M1`D91*77/#12)!%9C,G(@1PPUX.HA<WMVG<?B6Y4UQB/'H+)7/)KD3_1[`GV
MDI]IFG>Q?XV#*/N9?6"(;'U2:RE(&TN[@<WWEO9#V=WV4FM8]<S$Y2;<#,,B
MK<F6%EMLP3_0=%F=_>V,K#/+:P/%G`T[!,LS3#&=!]26,@:W<K$/NGLAQ%C=
M.`W,QO7.(*Q3%N!LK-EI+FSAQ(D5-'4&581-6Z/I,'#JHKZNE*IDX_8FZ\/(
M+7?$TA3[06JH#JLV7W>O$GN@F:Z70/9X>D<3=18X\!F^BR#<Z&OH6KF09K)N
M8/*9:SL4W<U4K6K7@H*2`ZIXB:O21H1S<0N3?"C!SM90(`$IA/N'UN`5(DF"
M9Q>0(_*80YIW",FT65[Q<-W='#UT3];8CXNBU;!/<\_3>8OF-5O%HA_RUS3J
M%M5=*\EN..WKKC:_3(LGS!1G<'IOY4)+R/<YS\\%%=>`G=%%G-!2VO"G((H3
M7G(THTP=J$%:E:)94.MO7RC>F6B/0HWR=62/7!$BI!,AGI3DCTAY>VC$Y@=L
MSADG\R""/<A)1E?<]U:;4(:C>,*$N'**YTM`A>7*YB1;6OG!.E0Q1*85:\]0
M&)K`CF-C^"^-VZY\(9V?Q#/9+QL5K(X&(T?5RL99E@2/&U$D(HO)G8?7(;LB
M@+$/*W2*KJ.E"]LZX["50-+NVI?M=!BL-M\5%EI"3+A/H0Y+2BF0\_F=D@:]
MMK',&G;J['[H@4"L`E="0-"BMDUO;[B+$E7NB=+RYN<-/)3D3^6-QG^2=RE4
M;@?@CQZ1_.'R'@'Y>&R;Z;\]RZG::DW56>*YJ1-O3G-M/J2ANS1*E\P[4C6L
M&WI\G#'_`&AAN)U+$A*('%^1JP%_T(Y3F76]PU[G#9M&8\T)Y+XO9-L;&^J1
M;_V48H\;K30O3$H<%?,HW3[M<"[5Z_->K\Y?<JV2'NOQH?K'"PP3_,(0]NUZ
MI=_]40)@821%$"5CQ$?0;"0N#U&"L-[D_E#+=0/7DIECH]U@LTVN]JN"V/#B
M>IPCN_6B_[Z%'DN75K+)6I+`EA)`=:]:UDH"5NR[-<@B\KTSN@[CWFW@&*XI
M90N/$OLARY`=QCBO`U^.:5.:/+,/J=Q%T)BB@1['\*P`E)DY:]Z949E4K1\*
M\O/)D:+&VGEJJSLL0>0FDUQ.0LDR]DZA5ICRC#A![)+Y_.TN3K.$9FRH`=<\
MHQ%=!&RQ)<<A71C'A1.Q4H<;J$J1C79H.O,.-_6;#T95V8CB(XH18T*S&Y[S
M)R]9BIIYWYR<OO[\AI?7\Z(7L?\"VWY^?V=VFP-+>\?QM*$ZQ*7?SO@D&+;$
MY5D(;/[Y3T@/)L\B/YB\5EG`,V8/WIINLL#GMY"^[6:3R2V$\&\#UV2VW`5O
MXBBNQM[-!_M$CU+FRH.$DA'MO>V!Y[7<B'@CP[((74AN69-HO%@$8<"\,IUN
M'M-@'G@)9#6G:>SS;[=S[+5=2RX3#%(<+7WF^]:PU,T?,B+EQXQ(\2"Q8<&?
M1=3#\+RRRQ:"!AJNI]XE<H^-1RE^]D)M&#.G%"&:$>'$(QX!ZC]E;1_]4Z'_
M[T_>GIR2M9>09X'DV]')R0G\KXKD>!O6-2?!;XP'K#6*U0\!QRRV%C=9FK$_
M>`ELN)!MG='5(W/\]R<C`K-@D=A'??GM*?_V!&DF,?.^RDY+3HG,<P=&GN\6
MOY8<![;1MG,%5P1W2?P<I+S`,9O2[5OT5U-Z_&\T6#[!`1%FJ=Z2RII,(E28
MTODLAJC@)MM.IF3K-)@#W/$*:HIC"W4'\A&*G7?10'F5]$,*[[>\^N$UK]F_
M>@21S\C+F(D>#!Y#9C&1#Y(YR.,B!YG7%^1997>BA&'.C%+HN\\6\V2+E7.:
M4[*!%N.EVD6+U5*<>0'UQH1HG'+X/309U-%7K15M^`!7E)C3#)+9$QLF(4N<
M-R@/E(<^3P%E/]8;E:J$>6C45"3,SRG48@DB]K-(*8E%O?HL6/$*^HNFBG>R
MIKTHAE^K5M_S%MCLR8MF=+6.$R]YF:S67I#`NX2&IVEI/GHGBO3?4S]>1C`1
MF40J45]_J^)!GX"XI7;81H)AHP/QO0T<G>FN6;C"(TC^#%(\A(BGE+>/B'P.
M*1[$?B;Y81>$:G%]-Y>X5R-OKJ!H+M8L5.S=(&0(VJI)/T0)]4*`^I<XA/[Y
MHQ=$T"ZW41'W'2=L)ATM+_C19I$4I:KV&MNDJ?#QB!2/)/*9!!ZJ-BIAFI$_
MF<A'$_%LF3>&6?P8J4%+C;;DC16JQNHO`]6A54I59>J%:?+(K0;C].'3I_']
MK^3VBDPG'V\F5Y/S\<V,C,_/;Q]N9I.;C^3N]GIR/KF<XA1LVB<R70'T\?[R
M\M/ES:QW'(::-+:7,[DYO_UT26;C7_IO?DN]$W<0]Y<?'ZX?T/1W.M1OP\!>
MPZ?)C)L/&=]<D/-;[AN7-UB.<:C;Y"ZGL_N'\]G#/4.#.#U/EEXD;UYD;RAE
M?=?<D_7K[\0-8/SC[>(JB-@2(_#"*?N&BK=J+J9Q(-E(4_)#-DQE,GX(P?U/
MPP^G=7VP*-=F6R94,&FJ=LB_KYF.[#/[Q/Z`53'[\/]02P,$%`````@`5X=C
M/V.T]?:A$```N/T``!4`'`!A;&YY+3(P,3$P.3,P7W!R92YX;6Q55`D``X4`
MLTZ%`+-.=7@+``$$)0X```0Y`0``[5U?<]LV$G^_F?L.//?E^F#+3MK.)9-<
M1[;CGELGTMA.VGOJP"0DX4H!*DC:5C_]+4!2(D4``BU1)-%.'F))N^#^=A?_
M%HOEN^^?YZ'WB'E$&'U_='9R>N1AZK.`T.G[HR0Z1I%/R)$7Q8@&*&04OS^B
M[.C[?__];^_^<7S\R_GMC1<P/YEC&GL^QRC&@?=$XIEWSIXH]N[1=(JY)^D^
M4/00PH>'9?;C'9O$3XCC_/G>V>F)^/?M=\?'V0/.400-PD^RA5<G9^DO(:&_
M/<!/'DA/H_='LSA>O!T,GIZ>3IX?>'C"^'3PZO3T]2`G/$HIWSY'I$3]]#JG
M/1O\\O'FSI_A.3HF5.#UUURB&17?V9LW;P;R5R"-R-M(\M\P'\52GUOE\K04
MXM-Q3G8LOCH^>W7\^NSD.0J.0`>>]XZS$-_BB2<%>!LO%V"<B,P7H1!<?C?C
M>/+^"(5T"2V<G9V^>7TJ^+\Z1Z'`=S?#.(Z./-'0Y]OKE;R"(43S$Y_-!^*W
MP0;]8*_/'X,+T'B&8^*CL*XP&\P[2W87@PL+;XY&D]$"<VG(:$B#"S9?<#S#
M-"*/^(9%-FJKT]A>);]`T>PJ9$]UA2SP[2Y/,I\COAQ-[LB4D@G8A\9#WV<)
MC6%P&;.0^`1;"6C9T.X2%]J?<IPJQ49`-=_.\ES#0#S']^C92DTEZIV??9D-
MZN"L'T#/\?*:3AB?2P^V$,;,OK-TMWB:A(F-5E:4.S\3^NR<Q-*VL@=+[X.Y
MTLZ)C=Q[T$<4\\2/$PZM6FFE1)\]'X:D"`241KJ!QY4$P<\QI@$.<E%$.]83
M1M80B06/$-P[]E;C#OP-^@A@,(2I'OZ*H$<'<B&1M>*ES7C__$Q1$A#XY>MT
M!@290^:7Q`S%W,MX66&9E'*"G:#H0<ZRL+B9(K08"$4.<!A'^3=2M<>G9]ED
M^U7V]:\K@4>3*T)!,(+",8N(4-?P`12*_#A_;H@><"BEL60;M`!H&$6@5H/H
MFP0K(8N>,N1E@1'W\Z;@SY*;5%<Y&<5@(:?Q8W]&PI6'33B;UU%A)@13R\YX
M@/G[HU>PP$TB$(DM!+=8,P"8">8<!S<I<JVP4E)8JSZP"$O:-LUVD7"ALJW6
MJ]"U942UMY7-51&V&:LM.&$<)B78\+1C0K'.$M,`_/?A]X0\HE!.#/$%XGP)
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M9]D`9_'[:(R68K]@6$5K"#M@XVUK:HWD[EJ4)R!Z13]JH^IH>V%7G?#-C,6M
MF_8RD_T60%[`_\00MS#0=M^T!N$=W3NM$3]BFAC&81UAGXQ:EKR9+4WK%K4:
M@/LY\AJ&W+-3I_9#U8'H$Z-^C4&W2-X!P]9:#IO1.#_'RE'*TMP5VO[:N@*E
MF1FWY2'9/!;WSWXEX=T<BVM%H[H8?WJI;2VB3F>N#</C7'@)7G<,KZ1J+[QH
M:U"EV(Z&(T2^':-&*U9)NF_"JLR.KH>&04!2(&-$@FMZ@18$)H4"?E5<R8*I
M^S:V0>%H.&+H^\D\"47RYRB>85[*DT\3G$6V_"<<CR;WZ%D=6JS70@_\H2XD
M1R,;MSA&A.+@`^*4T&E4T`ML(XA/U'E4VYFZ[P(V*/:V^NZ8V:M:LEIW]\&L
M*JG_G`?\+SC8[]^&:CNBW/@[S^N=,O[P$9%0G(%>,7Z'0GR'_81+-5SBAWC]
MR7!@6+>%;F=;UD7CZAI?JP=C^-..K:-I7%:RNY/3<T4HB?$-+%1A(Q,C.B6`
M/561.NMV&T,WS;I-ZH;69NUDVZZNF:[S_959M$JZ3@_,&ID=W4_)S61A36(<
M=$W$?5N'F;"XD^ALO'&L#(9NN9_<'P,;P>QM@]6^B<<<+Q`)/CPOQ.5I@"H]
M>]O%)"NN3H_35@@.%P]Y-]B\.=_L??J-FB=9JZO+]6<ONUQ?:O7KOR[;_W6,
MO!G6JG^-P>((V;6#Q_(A*W2J$9>:"^1YW1CSNQFH>>NALIZQ^V%-6R1_"@^0
M6*-A$L]`JC_6X[W6\E6&OEF\BL#1`)8*]G44)=96SHG[:>%<>D</HU601TDL
M2R'*LDE6)BYQ]-/.)0B.!D,*V14UYFPKKNX;W0J&J^?+!?`6<[61NE>6UL[2
M^XZ,=,_"VCE:2]E#RV[,SLZEZE8`F^=F,WD/[:N:E7=/'.A"L*M.V=R-X-<K
MR\J2ZT=X;.*M'^*!0KW28SSQG`Y%P](SJDUE9-]:!<;L6FBC2W_"\3J?40%B
MX_=6#LU25Z'3+/AL*I]IH.U`$*^.(ZU.SO2('-WBWX)Y0+6B8N$E?L0AD^6T
M,OC*?%,C?5MVW^JVZTQ3H_R.ANQ^P!3T$P+H83`GE`C=Q-`;]';>RM%Y2V]%
MX&B/KBC(9N3N@3T5,N\K,->I;-(53N-204G5]UFWB,5)VWYBE)7!YF?\^E66
M!4]/[6Z!S-%H[-K1KT"9Z<;X(XYG+"C4L=0F'6[E:\L?K-V[G)"X%8^CJ[(U
MQE0/US3&8##5(*`G[9&M=1!<78B)I"VMFG0YJ`:&WIAZ&Q!'#U3KV-H%,V^W
M\,[S=J=6;^79*DV[30#[.KQZCB>,XT*:_4="I<SY8`<+I/W,_0T_O:<KRH/J
MR,UR0"O59'WY'%,\45X]UU+VVGD4>'8_-WZ3&IKBJ3B=V<RH[Y>:-@XI]G;\
MVJE>H-!'7G_"L%6WXNJIV:VPK39JAUC9'5A_-5S"W%5<V\;JBK9\IARC4*3>
M_(>%XAC_!T2HT,2(KJ\%#SF)X*=+^:;&,08L@:'Z37./ZI%7-:<$1_=E!AW7
M&\1[Y29&'!W;GU7?^"J^$1M,\1H]F10DWY0N,`$@J?7\&`B@A4D@+J;;YB[L
MN>T>3NA[UD`^L;5ZY707'U)G!;S8;73-M>$IC72D>CZD4T?GUD.[N)`NW>#%
M3J1O\$_J1GJ%N'R`H!C1KQC'9$K3F^#^\IXCT)0OG8`&\E.8ND3POR2-5N43
M?[K@@U9@I1CA2YS^7V.AO?]']VA%=3BE..K0>7G'_-(-='7BBUF!A$FLO+"P
ME:.'BR\K7`TEO+=3&]'/REC<8?X('Z+L;0@*>QMH>VII`Z*^K']^AM%M!EXY
MA`>A*<YN:LA+&I]AKKYG0AW@MAM.#(.<B#Z,Y9B9<ZB60_MMOX=^TH`6\O&C
M^<RI`U^8$>O$JY`]5>_&O'[1W1C1GB<;[-`EF!5(NQLO"O*6KK<(2<:</1*P
M[?E2^&UA&S"$-=%C&H4TI#N^H)$.='FMQ0IG`;5Q-3-!].GFTZ%38%[LP0<]
M\FGGA17YYB6Z9[?89]0G(2[!A2EJY^[?S&/ZZT_-Z,.=`KSY[JD<,E)-EQK"
MU@H!-MB?5N7)-)@=/>?;C*,4=)6]8\8P\-1A=MEGZNC!U=(+51VLRR5K4C--
M]&VY2_W^H'>"$J"=5S7*?+@.FGV<%F+-W^*I+,AJY0]V#;G@*'9(=YZ!^N)!
M0]]G"14U;9?Z0O+;>%SPBPHH=Z_V59'S!`>%G/.:SJ#C=L0M=/!<+<A65<+&
M6Z*M_*+"XX(W5$"YNL*T#PSL%"+M<^2C#LHFB@5TR"W2:T<[1M"-C?0X@F[$
MY4Z@"Z;%;.,_]']/",>@!^@*\7(<(BINK8E[:JJT1:&Z.LP=&S$L?']5V[<&
MRF:VL-T>,W8:*_KL&'50-I$9WR&WR%YML=M48FRDQU.)$5<S0?-NN\9.+M&Y
M$</"]^L[B*.5J@1ZD<`$_XE9\Q&%8F:USA^NQ]Z'(:,>HD9J`W3'#X;0.SA?
M0D>01?2M'6"#[]<6K_/N;GL%F+U5F%](OP(9>>RJ\1TR_1[C5*GA/]`V=Q2*
MB)X\NTE#M8675MH=H^MX70A8:L&Y^JX)6!'Y&`>R,HYX`X-XQ>)HDJ4I4\`,
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MMXP9*`76-EQJ*RLH&^6;+87]K;A<73]8*V!G+^G,!G0_Q<`[5\;[0!>5#E.E
MNS/.(OO&/8RB]WB^8!SQY?5\@0@72(4>1.VM%?*QV$@Q<6^'3:DH"GI-\Z(S
M8`?=T+.OUEUVO+TJJJ%S@L.5YDCF<]#`:')'`-^$^"+3+KWJ(0K,LI#XA8!9
M7JL#'-P[]BY)Y(<L2C@6A3O2AD1)CD)3WKHM;]58&]>,3>CN067GH7IE;\O8
MRI7^BD"FB_D&XM9Z^U8`JYO0EF9H,N)TB-Y8@#GE&)>6#^O.]ZK2^8H];LW8
MQAS'IXAF`<!UU9XT.#@N*&HTR7:@*%S7\S&]JW@_[;93OCH$("PM=CGD7.RB
MA%AK"YH&H%K<K;T$=)]67Q?`KH'\8+78#C`**&+2Z[[_>K/OI]1>2M[F"V?6
M4IG+-.BI6WU?CEUW-).W&.W=9H/*6W*<[T:7S$_$>"$NCL!Z0;PB:L+XO'2H
ME_<K47HNIR_^B6C@I<Q>D7LO)U`&\4R%[^WX7MZ5(NR?3-GC(,`D[47PQV;G
M@:]^31]^BZ>RD#.-/Z&YZJ1$3=9:">PZ6E^%0)40]%WE4+J_`!P<A=?0)9Y_
MPDNM\BMT/=1^!8/^R*%Y]><P[J%957I`Z>=>*;LLNC[1XW`Z'N<)M9>P7C0H
M>X.NEUK?P*`/DS>O_B'($PB9KD(T5843RK_W2MT;LALBS(=S\RM8C:'POQCQ
M*_A&=62@I>R5[K4H#('40ULA[89V=BC1]M@2)1R&VQ#-VR)]#4/!0?1COYZT
M5Y;0PS"\1>!0B\R?<1C^1-D3O<,H8A0'(@4$<X4UMM#WRB1;L!BJLQ_*+E]8
MF(`2^?**A)@K<U'4=#VT0P6#X3VE!]M\I9WV%B_$":&X?H%BY7QA)N^A-710
M#&^1.Y11I']<P-`Y95R_']Z@ZJ$)-A#DFF]EODXE&B</(?&O0H9445\%30^U
M7I(_UWF+4W,A!3.]-S9*XBA&5-P&TP]$1J8>6L4,*#>3=J8^0"#Z%D^3,%&<
MY7RS>9:34[:1^*I.P`)[_,@(C;_`!Y#1=$1;NX56\GO50MH=_M1A;NLHZ(5V
M7/6I&A!=.BP2HPA9J>J"R0033-7)3]]N]ML"MSPR*O.WDG.@A6-U3%N3OZ6W
M@F\7T9Q94:^!%M]T6=^6A;>(UP+I4I^^A=&+)[ZXTKI>$*U[\7?5V;=(WX)+
MEP0`<]WB4*0L6Y5ZJ\';1F_=*IY=GWU9,VWUW-KVS'OMRV"VVW??#02$!Q1A
M^/!_4$L#!!0````(`%>'8S]_>GV<-P4``*L?```1`!P`86QN>2TR,#$Q,#DS
M,"YX<V155`D``X4`LTZ%`+-.=7@+``$$)0X```0Y`0``[5E9;]LX$'Y?8/\#
M5T\ML+*LN`F0P&Z1HRT,>),@2;%]*VAI+!.E2"\/V_GW.Z0D6[[MM`&Z6"-`
M()$SWQS?\-"X_6&:<S(&I9D4G2!N-`,"(I$I$UDGL#JD.F$L^/#^]]_:?X3A
MUZN''DEE8G,0AB0*J(&43)@9DBLY$4">:):!:A`O>$^5!E6AD[C9<'^G9V%8
MPEU1C>HXY<5/&G$QHY,AY)2@9T)W@J$QHXLHFDPFC4FK(546G32;<?3UK]ZC
MEPL*P8MI7W&V(.Y&*H56Q(0V5"10R7,FOF\1=]-]]&\&OR)?>A.?GY]'?C8@
MAJH,S"W-08]H`C-QRL4SIWDCD3FBQW'SO-6L@-W<7H)""F'S]2ZG1D7F>001
M"H4H!8HER"0'1]0GJ?(;&%#+32?XQU+.!@S2@%!C%.M;`PL"5M1$YJE-S<QR
M/5&G43$9('&$M*D0TE"#=/MW-S(:,3&0Y2L.N$Q=*,GA"?TE[N'+0W=M`MQ<
M]`#:*)L8J[`D`\+23K`X-$.NL%,8,,&\#\V3YAD)R0W3"9?:*L"7!>UVM*RR
MC&:Q1._$>_\\4J`QGSZ^'@Z4VJ7(-LV$\L3R%RC./=NL5XY6.7UQJJ]EGC/C
M*D9?BO1:"H,9PMV`@2X2OTU@!PVGRS34L`@5*5E`.]*RL`(RRZVN:K]XV9'N
M=ZM5[_6.B:TE]J8\R+"6/V+QF><N;E0J]UX7V=XJL96"IB.@.BAKCZ[4"RA2
MPSK24J.EB_>/')[HM-IVZ@,[ZKZU7/>%+O'*QRS7LOS(,H&'?$*QNC,%_J)0
MYGO]U([,GRQGOH9"YC!'#NH<V#RGZOEN4,]XDDCKC\)[R=G\[-U3=@=+\0I+
M!2R1@T7"9LBD@CXR5V<.(RL*^FYP3?7P$Y>3BJBU4UMYB5ONN)@I^MN12$&X
MKR-\TLA`ZK^TYMB.,(=./#QY\T50FS*4>7OD:0-/=R-0WMWB\IICZ$/,,1M#
M3^HUY.V0W\[HR8L8G9LL[\0UH\19/1*]@>@KRMW'_>,0P.A[JC#4(1C<S'A!
M[);Y[43&\7Y$E@9(88&\6;#Q]LC;/KRMH6H7.WLNLV5V_E=LN'^NE?4``^(;
M51>N5=0)-,M'W#6X_-A0P:`3.(+"JO/T#<-M3'->B3C\+2TS3^ARADK#%015
MR0K*2B,-023NA`9O'?4^7.$Z,T[]OF:&.#OZ3T(Y>AK]M.`Y[1\:/*H`?\6H
M>P[_E<+%`CTTW*6:?J6@K^=6UH;>CNH]1GQ;[$&V,7*I#!$K7=D].JA%*[HG
M$X^W6_.V4,2L-L_#^"2,SQI3G5:^[NG*4KMZ'Q^\BGL+*SWG0LNYT(I?ZL*<
MC\-<J/0.=L%C:4@:F1Q'*3#?`@^;,0)L]&&MCGL(Y\K[61]0W?>16!UFE([V
MMKY6,0)N=#6RR9>R0>^//;<:O]U*X6[UCT8FW_VO(^X*B.>9M_IQZAY!/^#6
MAXMKB-?2&Q@#ER,'$OB0.L$/012;A?\IY2*7`@Q^&W;Q<'6G"B;!]C4N2NN0
M/BMI1Y4HGJ0YVF<<-T"W9(VR;A7[.5S=3*9/'CBUJNRN%7/]XEC&">@S\X-I
M^0P";\\<0[I,<SPRM7'&QG!08C:#_)=3TQ4)MRFD75%^88BLFKKLNQ"3P\IG
M+SQ:/E4QUQ.(,ZCS*NG;E*AMO=SE).PG^ZL%"`-0RI%2ZY^6\:R;^D4+^F]@
MV1!OYI=CK*P,W.]$4CP.\7-*?\%R?)*N(*T!+$Z6N/V+<7Q+;\&X#^1[4#6-
M*OZ?B[G`LP=Y-9[;47'PX.._4$L!`AX#%`````@`5X=C/V-#3P^N7P``J!P#
M`!$`&````````0```*2!`````&%L;GDM,C`Q,3`Y,S`N>&UL550%``.%`+-.
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`5X=C/VJ68_K2"@``#(```!4`
M&````````0```*2!^5\``&%L;GDM,C`Q,3`Y,S!?8V%L+GAM;%54!0`#A0"S
M3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%>'8S^5&]:['"```$B.`0`5
M`!@```````$```"D@1IK``!A;&YY+3(P,3$P.3,P7VQA8BYX;6Q55`4``X4`
MLTYU>`L``00E#@``!#D!``!02P$"'@,4````"`!7AV,_8[3U]J$0``"X_0``
M%0`8```````!````I(&%BP``86QN>2TR,#$Q,#DS,%]P<F4N>&UL550%``.%
M`+-.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`5X=C/W]Z?9PW!0``JQ\`
M`!$`&````````0```*2!=9P``&%L;GDM,C`Q,3`Y,S`N>'-D550%``.%`+-.
E=7@+``$$)0X```0Y`0``4$L%!@`````%``4`OP$``/>A````````
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
